MCRs to APIs: Tailoring Multicomponent Reactions for the Production of Pharmaceuticals by Heijden, G. van der
  
 
 
MCRs to APIs:  
Tailoring Multicomponent Reactions for the Production of 
Pharmaceuticals 
 
 
 
 
 
 
 
 
 
 
Gydo van der Heijden 
 
2018 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research leading to these results has received funding from the Innovative Medicines 
Initiative Joint Undertaking project CHEM21 under Grant Agreement No. 115360, 
resources of which are composed of financial contribution from the European Union’s 
Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind 
contribution. 
Printed by: Gildeprint 
Cover design by: John Braun 
ISBN: 978-94-6233-819-7 
VRIJE UNIVERSITEIT 
 
MCRs to APIs:  
Tailoring Multicomponent Reactions for the Production of 
Pharmaceuticals 
 
 
ACADEMISCH PROEFSCHRIFT 
ter verkrijging van de graad Doctor aan 
de Vrije Universiteit Amsterdam, 
op gezag van de rector magnificus 
prof.dr. V. Subramaniam, 
in het openbaar te verdedigen 
ten overstaan van de promotiecommissie 
van de Faculteit der Bètawetenschappen 
op donderdag 18 januari 2018 om 13.45 uur 
in de aula van de universiteit, 
De Boelelaan 1105 
 
door 
Gydo van der Heijden 
geboren te Zaandam 
  
 
promotor: prof.dr.ir. R.V.A. Orru 
copromotor: dr. E. Ruijter 
 
 
  
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table of Contents 
 
 
 List of Abbreviations 9 
Chapter 1 Isocyanide-Based Multicomponent Reactions in Total Synthesis 11 
Chapter 2 2-Bromo-6-isocyanopyridine as a Universal Convertible Isocyanide 
for Multicomponent Chemistry 
47 
Chapter 3 Metal-Free One-Pot α-Carboxylation of Primary Alcohols 79 
Chapter 4 Efficient Synthesis of Pipecolic Amides with a Highly 
Diastereoselective U-3CR 
99 
Chapter 5 An IMCR Approach Toward ACE Inhibitor Analogues 133 
Chapter 6 Conclusions & Outlook 151 
 Summary 167 
 Samenvatting 173 
 Acknowledgement 183 
 List of Publications 187 
 
 
 
 
8 
 
  
List of Abbreviations 
 
 
Å Ångström e.g. exempli gratia (for example) 
Ac acetyl ee enantiomeric excess 
ACE angiotensin-converting enzyme equiv equivalent 
AHA α-hydroxy acid et al. et alii (and others) 
API active pharmaceutical ingredient Fmoc fluoronylmethyloxycarbonyl 
aq. aqueous GBB Groebke-Blackburn-Bienaymé 
Ar aryl GC gas chromatography 
BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl h hour 
Bn benzyl HMDS bis(trimethylsilyl)amide 
Boc tert-butyloxycarbonyl HMPA hexamethylphosphoramide 
BOPCl bis(2-oxo-3-oxazolidinyl)phosphinic chloride HOMO highest occupied molecular orbital 
Bu butyl HPLC high pressure liquid chromatography  
CAN cerium ammonium nitrate HRMS high resolution mass spectrometry 
Cbz benzyloxycarbonyl HWE Horner-Wadsworth-Emmons 
CDI 1,1’-carbonyldiimidazole Hz hertz 
CSA camphorsulfonic acid i.e. id est (that is) 
d.r. diastereomeric ratio IMCR Isocyanide-based multicomponent 
dba dibenzylideneacetone  reaction 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene IR infrared 
DCE 1,2-dichloroethane J coupling constant 
DG directing group L ligand 
DiBAL di-isobutylaluminiumhydride LA Lewis acid 
DIPEA di-isopropylethylamine LDA lithium di-isopropylamide 
DKP diketopiperazine LG leaving group 
DMAP 4-dimethylaminopyridine LUMO lowest unoccupied molecular orbital 
DMF dimethylformamide M molar (concentration) 
DMP Dess-Martin periodinane m.p. melting point 
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 reaction TMS trimethylsilyl 
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1.1 Introduction 
In today’s world, the life expectancy of people continues to rise as a result of improved 
healthcare. However, the production of pharmaceuticals is very expensive and goes hand 
in hand with the generation of a vast amount of chemical waste. The pharmaceutical 
industry is one of the biggest contributors to the pollution of the environment with their 
use of hazardous chemicals and large amounts of toxic, flammable and volatile solvents. In 
fact, if you compare the pharmaceutical industry with the bulk or fine chemical industry, 
their product to waste ratio (also known as the E-factor) is approximately a hundred times 
higher.
1,2
 Since we can expect that the demand of pharmaceuticals will only increase in 
the near future, this can only significantly change by making the production process of 
medicines greener and more efficient. 
Ideally, the overall synthesis of medicines should consist of just a few reaction steps that 
are environmentally benign, proceed with full conversion/in 100% yield, are safe, simple 
and require only readily available starting materials (a concept known as the ‘ideal 
synthesis’
3
). Realistically, it is not possible to fulfill all of these requirements, but they can 
act as guidelines to contribute to a greener production. 
 
Figure 1. Linear vs multicomponent synthesis. 
Multicomponent reactions (MCRs) are increasingly appreciated as efficient synthetic tools 
to rapidly access complex products. Currently, most synthetic strategies for drug synthesis 
rely on linear synthesis, which is very inefficient with regard to the amount of waste, time 
and costs. MCRs, on the other hand, require only a single reaction step to create high 
molecular complexity from readily available starting materials (Figure 1).
4-8
 Furthermore, 
MCRs are generally carried out in green solvents under mild reaction conditions with high 
atom economy, thus aligning them with the criteria for an ideal synthesis.
9
 However, 
MCRs rely on reaction inputs with specific functional groups, thereby limiting the possible 
structural outcomes of these reactions. 
Linear 
+ + + 
Multicomponent 
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One of the most important inputs in MCR chemistry are isocyanides. Isocyanides are 
interesting compounds bearing a ‘reversed’ cyanide functionality of which the carbon 
atom has both a nucleophilic and electrophilic character. Its unique reactivity can be 
understood by examination of the frontier orbitals (Figure 2).
10
 The presence of a 
coefficient for the σ-orbital of the isocyanide carbon accounts for the nucleophilicity, 
whereas the electrophilicity can be rationalized by the significantly larger coefficient of the 
π*-orbital the carbon atom relative to the nitrogen atom. Additionally, the molecular 
orbitals are comparable with those of carbon monoxide (CO), explaining the similarities in 
the properties and reactivity of both reagents. Carbon monoxide is an excellent ligand for 
many transition metals and is often used in palladium catalyzed insertion reactions to 
introduce important carbonyl functionalities. Isocyanides can undergo similar Pd-catalyzed 
transformations by imidoylative cross-coupling reactions for the synthesis of interesting 
nitrogen containing heterocycles.
11,12 
 
Figure 2. Energy diagram of a nitrile, an isocyanide and carbon monoxide.10 
The nucleophilic and electrophilic character of isocyanides makes them excellent 
candidates for multicomponent chemistry. In 1921, Passerini was the first to describe an 
isocyanide-based multicomponent reaction (IMCR). He combined an isocyanide with an 
aldehyde and a carboxylic acid to obtain α-acyloxy amides (Scheme 1).
13
 The reaction 
proceeds best in aprotic solvents facilitating hydrogen bonding between the carboxylic 
acid and the aldehyde. The reaction conditions also suggest that a non-ionic concerted 
mechanism is more likely than a stepwise, ionic mechanism. After formation of the α-
adduct (4), a Mumm rearrangement takes place to form the α-acyloxy amide (5).  
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Scheme 1. The Passerini three-component reaction (P-3CR). 
Ugi and coworkers developed a closely related reaction. The introduction of an amine as 
the fourth reaction input results in a dipeptide scaffold (8, Scheme 2).
14
 This additional 
reaction input makes the reaction even more attractive for diversity-oriented synthesis 
(DOS).
15,16
 Interestingly, in contrast to the Passerini reaction, the Ugi reaction typically 
requires protic solvents, which also suggests a different reaction mechanism. The protic 
solvent is required for the formation of the imine (first step of the reaction mechanism) 
and also supports a stepwise ionic mechanism for the subsequent reaction steps. 
 
Scheme 2. The Ugi four-component reaction (U-4CR). 
Since the discovery of the Passerini and Ugi reactions many variations have appeared in 
the literature. The increasing knowledge about the chemistry of isocyanides has provided 
a huge boost in the applicability of IMCRs in both total synthesis and compound library 
generation. The convergent nature of these reactions makes them valuable tools for 
efficient total syntheses by shortening reactions routes avoiding the use of protection 
groups. In addition, IMCRs can give a great diversity of reaction products by simple 
variation of the starting material, which makes them very useful for the generation of 
compound libraries. The aim of this chapter is to highlight the broad range of possibilities 
that IMCRs (and variations thereof) can offer in a focused overview of their use in the 
synthesis of natural products and pharmaceuticals.  
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It is important to mention that IMCRs also have some limitations. One important 
drawback is that most IMCR-products have a similar backbone. This limitation can be 
overcome by the installation of smart functional groups in the IMCR inputs that allow 
post-modifications of the typical scaffold. Furthermore, most IMCRs generate a chiral 
center for which the stereocontrol is generally difficult. Another important limitation is 
the availability of the isocyanide input. Unlike other IMCR components, only few 
isocyanides are commercially available, especially with relevant functionalized side chains. 
In addition, the isocyanide input produces a very stable secondary amide in many IMCRs 
(such as the Ugi and Passerini
 
reaction). To address these limitations, the concept of a 
‘convertible’ or ‘universal’ isocyanide was introduced.
 
Ideally, this is a practical isocyanide 
which can be converted into any other functional group under mild conditions. Such a 
reagent should be versatile, easily synthesized and preferably recyclable, since the main 
part of the convertible isocyanide (everything but the carbon atom) does not end up in the 
final product. 
Over the past two decades a decent number of convertible isocyanides have appeared in 
the literature. The second part of this chapter provides an overview of the currently 
available convertible isocyanides and their applications in isocyanide chemistry to produce 
products beyond the traditional IMCR scope. 
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1.2 Isocyanide chemistry in total synthesis 
Traditionally, the use of isocyanides was not straightforward in organic chemistry. The 
reagents are considered difficult to handle due to their foul smell and tedious synthesis 
with strong dehydrating agents. Furthermore, their use in MCRs generally generates a 
stereocenter which is very difficult to control. Nowadays, many of these issues have been 
resolved and they have become a very useful addition to the organic chemist’s toolbox.    
1.2.1 Natural products 
Natural products are a rich source of inspiration for the development of new drugs.
17
 
Approximately 50% of recently developed drugs are inspired on natural products.
18
 
Modification of the natural products is often required to enhance the activity of the 
natural products or to provide them with properties for a desired drug (e.g. less side 
effects or better uptake by the human body). It is possible to modify the natural products 
that are obtained from natural resources, however these compounds are often very 
scarce and difficult to obtain in large quantities. Consequently, there is a need for efficient 
methods to synthesize these complex natural products. IMCRs can play an important role 
in achieving this goal. 
Tubulysin 
In this context, the highly convergent synthesis of tubugis (analogues of tubulysin) with 
the use of three different IMCRs as reported by the group of Wessjohann is a very elegant 
example (Scheme 3).
19
 Their synthetic approach consists of a late-stage Ugi four-
component reaction (U-4CR). Both the isocyanide (1) and aldehyde (2) input of this U-4CR 
do not alter the tubugis core structure and are introduced to create a small library of 
tubugi analogues (17). The required carboxylic acid (12) and amine (16) components are 
essential for the tubugis core structure and these inputs were in turn also synthesized by 
an IMCR. Carboxylic acid 12 was made with an Ugi-type reaction, starting from cyclic 
amine 9, trifluoroacetic acid and isocyanide 11 (also known as the Ugi three-component 
reaction (U-3CR)). The carboxylic acid moiety of 12 is found in the isocyanide input (11) 
protected as an OBO ester to avoid epimerization of the α-stereocenter.
20
 After the U-
3CR, basic hydrolysis of the piperidine-amide, followed by reductive amination and acid 
hydrolysis of the ortho-ester provided carboxylic acid 12 as a mixture of diastereomers. 
The diastereomers were readily separated by flash chromatography to obtain 12 as a 
single stereoisomer.   
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Scheme 3. Convergent synthesis of tubugis 17. 
The amine input (16) was synthesized on a multi-gram scale by a Passerini-Dömling 
reaction: a combination of a thiocarboxylic acid, an aldehyde and a Schöllkopf isocyanide 
(15) to form a thiazole in a single reaction step. Dömling and Wessjohann used this 
reaction before in the total synthesis of tubulysins U and V.
21
 Thiazole 16 was obtained 
after deprotection of the Boc-group in a 3:1 mixture of diastereomers. 
 
Entry Tubugi R1 R2 GI50 (nM) PC-3
a GI50 (nM) HT-29
b 
1 17a n-Bu H 0.23 ± 0.2
c 0.14 ± 0.02 
2 17b i-Pr H 0.29 ± 0.04 0.34 ± 0.07 
3 17c n-Bu Me 0.22 ± 0.01 0.23 ± 0.04 
4 Tubulysin A − − 0.21 ± 0.05 0.23 ± 0.06 
Table 1. Cytotoxic activity of the tubugis. aHuman prostate cancer cell line. bHuman colon 
cancer cell line. cSingle test.  
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With the methodology in hand, three different tubugis 17a-c were produced and their 
activity against two cancer cell lines was tested and compared to the parent compound 
tubulysin A. As shown in table 1, the tubugis have very comparable activity against both 
the human prostate cancer cell line PS-3 as the human colon cancer cell line HT-29. 
Advantageously, this methodology does not only make it very easy to obtain the desired 
scaffold, but it also allows diversifications in the search of even more potent analogues.  
Syringolin A 
Ichikawa and coworkers developed a very elegant synthetic route for the synthesis of the 
potent anti-cancer agent Syringolin A.
22
 The key-step in their synthetic approach was an 
intramolecular Ugi four-center three-component reaction (U-4C-3CR) to construct the 
conformationally restricted 12-membered macrocycle (Scheme 4). The IMCR involves the 
combination of isocyano aldehyde 19, which was synthesized in 12 steps from L-valine, 
2,4-dimethoxybenzylamine (20) as an ammonia equivalent and urea carboxylic acid 21. 
The components were mixed and refluxed for 36 hours in CH2Cl2 to form macrolactam 22 
in 32% yield over two steps after removal of the silyl protecting group. Dehydration of the 
secondary alcohol and complete deprotection finalizes the total synthesis of Syringolin A 
(23), which was obtained as a single diastereomer. No trace of other diastereomers was 
observed or isolated after the U-4C-3CR, which suggests that the intramolecular Ugi 
proceeded fully diastereoselectively.  
 
Scheme 4. Key U-4C-3CR macrocyclization step for the synthesis of Syringolin A. 
The authors underline the importance of the late stage convergent approach, since 
modifications to the carboxylic acid components provided analogues with higher activity 
than the parent compound (Syringolin A) with the help of structure-based drug design. In 
addition, this methodology allows for the installation of substituents that increase 
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membrane permeability. These modifications also showed a very positive influence on the 
cytotoxic activity.  
1.2.2 Commercial drugs 
In order to reduce the amount of chemical waste produced by the pharmaceutic industry, 
shorter and more efficient methods are required for the production of drugs. A higher 
synthetic efficiency directly correlates with the production costs of the medicines, which is 
beneficial for both the company and the patients. Isocyanide chemistry plays an important 
role in this process, highlighted by the large number of examples published in the last 
decades.  
Bicalutamide 
Isocyanide chemistry is not just limited to the traditional Ugi and Passerini reactions. They 
effectively serve as an inspiration for the development of new types of reactions with 
isocyanides. Ross et al. describe the use of a Passerini-type reaction for the synthesis of 
bicalutamide 26 (sold on the market name Casodex®, Scheme 5).
23
 Replacement of the 
carboxylic acid input with the Lewis acid TiCl4 leads to the formation of α-hydroxy amides 
(instead of the α-acyloxy amides from the P-3CR).
24
 Both inputs for the synthesis of 
bicalutamide were easily obtained from commercial starting materials. The isocyanide was 
made from the corresponding aniline and the sulfonyl ketone 25 was prepared by the 
oxidation of 1-((4-fluorophenyl)thio)propan-2-one with mCPBA. The lack of stereocontrol 
in the IMCR is not problematic for Casodex®, since it is sold as the racemate.  
 
Scheme 5. Synthesis of bicalutamide with a Passerini-type reaction. 
Salbutamol 
Similar to the bicalutamide-strategy, our group developed a variation of the P-3CR to 
produce β-amino alcohols,
25
 a privileged structural motif that is present in many 
important drugs (e.g. salbutamol and propranolol). In this reaction sequence, the 
carboxylic acid component of the Passerini reaction is replaced with SiCl4 together with a 
catalytic amount of HMPA, which leads to the formation of α-trichlorosilyloxy imidoyl 
chlorides (like 28) as intermediates (Scheme 6).
26,27
 The intermediate can subsequently be 
reduced with ammonia borane complex to obtain the target β-amino alcohols. The 
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reaction sequence proved very effective for the preparation of the antiasthmatic drug 
salbutamol acetate 29 from protected aldehyde 27 and tert-butyl isocyanide. In this case 
racemic salbutamol was synthesized; however, the reaction sequence is readily upgraded 
to a catalytic asymmetric version with the use of chiral HMPA analogues. 
 
Scheme 6. Synthesis of rac-salbutamol. 
(R)-Lacosamide 
Perhaps one of the most interesting industrial examples is the large scale synthesis (for 
the production of >50 kg) of (R)-Lacosamide (34) by Wehlan and coworkers from Sanofi 
with the application of an U-4CR (Scheme 7).
28
 Many chemists are sceptic about the use of 
IMCRs on an industrial scale, especially due to the difficult handling of the isocyanide (they 
typically have a foul smell and their preparation requires harsh conditions) and poor 
stereocontrol. However, Wehlan et al. show very attractive chemical solutions for these 
obstacles in the preparation of (R)-lacosamide (34).    
 
Scheme 7. Scalable synthesis of (R)-Lacosamide with an U-4CR. 
They developed an efficient one-pot procedure for the synthesis of benzyl isocyanide from 
benzylamine (Scheme 8). First benzylamine was formylated by treatment with ethyl 
formate and the resulting formamide (36) was dehydrated with mesyl chloride in the 
presence of pyridine in toluene.
29
 After removal of the salts, they obtained the isocyanide 
as a toluene solution in essentially quantitative yield. This procedure minimizes the 
Isocyanide-Based Multicomponent Reactions in Total Synthesis 
 
 
21 
possible exposure to the strong odor of the isocyanide and avoids the use of very strong 
or toxic dehydrating agents like POCl3 or triphosgene. 
 
Scheme 8. One-pot synthesis of benzylisocyanide. 
The second main issue of the Ugi reaction is the poor stereocontrol. The authors solved 
this problem by the use of (S)-4-methoxyphenethylamine (31) as chiral amine auxiliary. 
After optimization of the Ugi reaction, mainly by varying the reaction temperature, they 
obtained the Ugi product in 95% yield with a 69:31 diastereomeric ratio in favor of the 
desired (S,R)-diastereomer 33. The high crystallinity of the unwanted (S,S)-diastereomer 
made it possible to obtain the desired diastereomer (33) in high purity in a gratifying 55% 
overall yield after several crystallizations. The challenging removal of the chiral auxiliary 
was achieved by treatment with formic acid in the presence of anisole. The addition of 
anisole provided control over the formation of byproducts resulting from the 4-
methoxybenzyl cation. Anisole traps the reactive cation to form a mixture of para and 
ortho-bis-4-methoxyphenyl ethane (37 and 38 respectively, Figure 3). The non-polar side 
products were readily removed by extraction with methylcyclohexane to obtain (R)-
lacosamide in >99.9% purity and 99.9% ee. 
 
Figure 3. Para and ortho bis-4-methoxyphenyl ethane. 
Telaprevir 
As mentioned several times in this chapter, the Ugi reaction generally suffers from a lack 
of stereocontrol. However, the issue can be circumvented with the use of “smart” chiral 
inputs, which can induce diastereoselectivity. Our group used an interesting variation of 
this strategy in the total synthesis of the hepatitis C drug telaprevir 44.
30
 The key-step of 
the synthetic strategy is a diastereoselective U-3CR which combines bicyclic imine 40, 
carboxylic acid 41 and isocyanide 42 (Scheme 9). The reason for the high 
diastereoselectivity is embedded in the imine input. The second ring of the bicyclic imine 
sterically blocks the back side of the imine, which causes the isocyanide to attack mainly 
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from the convex side.
31
 Bicyclic imine 40 was obtained by the enzymatic oxidation of 
corresponding pyrrolidine 39 with the genetically engineered monamine oxidase N (MAO-
N D5) in excellent ee (94%).
32
  
Scheme 9. Synthesis of telaprevir with a very diastereoselective Ugi reaction. 
The carboxylic acid input (41) was obtained according to an improved literature procedure 
with straightforward peptide coupling reactions.
33
 The isocyanide (42) was synthesized 
from commercial (S)-2-amino-1-pentanol (45) in three steps (Scheme 10). First the amine 
of (S)-2-amino-1-pentanol was formylated, followed by oxidation of the primary alcohol 
with Dess-Martin periodinane resulting in the corresponding aldehyde with acetic acid as 
byproduct. Addition of cyclopropyl isocyanide 46 directly after the oxidation as the third 
reagent for the P-3CR provided α-acetyloxy amide 47. Careful dehydration of the 
formamide provided isocyanide 42 without epimerization at the α-carbon. Even though 
three relatively large substrates were combined, the U-3CR proceeded smoothly to afford 
telaprevir precursor 43. Finally, basic methanolysis of the acetate and subsequent 
oxidation of the resulting alcohol provided telaprevir in a total of only 11 steps. 
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Scheme 10. Synthesis of isocyanide 42 with a P-3CR. 
Praziquantel 
As a final example, Dömling et al. discribe a very efficient method for the synthesis of 
praziquantel (52), an anti-schistosomiasis drug.
34,35
 The disease is caused by parasitic 
flatworms and spreads quickly among children from developing countries in Africa. 
Importantly, praziquantel is currently the only available treatment for this disease. 
Especially for the people in Africa, cheaper medicins resulting from a more efficient 
synthesis are essential. The method from the group of Dömling comprises a high yielding 
Ugi reaction followed by an acid-catalyzed N-acyl iminium Pictet-Spengler reaction. The 
development of an asymmetric Pictet-Spengler reaction for this system was not required, 
because Praziquantel is sold as a racemate.  
 
Scheme 11. Synthesis of Praziquantel by a Ugi-Pictet-Spengler sequence. 
The authors use the advantage of the convergent nature of the reaction to produce a large 
number of derivatives of Praziquantel. A simple replacement of the aldehyde or carboxylic 
acid input rapidly creates a diverse set of new analogues.
35
 Additionally, the group of Qiao 
discovered that changes in the aromatic ring of the isocyanide input can enhance the 
activity of the analogue compared to the parent drug in vitro.
36
 However, none of these 
compounds performed better than Praziquantel in the in vivo studies. 
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1.3 Convertible isocyanides 
The previous section demonstrated the inspiring use of isocyanides in the synthesis of 
pharmaceuticals and natural products. For these target compounds, there is hardly a 
better synthetic strategy imaginable. However, they generally have a similar molecular 
skeleton, e.g. a dipeptide for Ugi products. As pointed out in the introduction, many 
convertible isocyanides have recently been developed to address the diversity limitations 
of the IMCR products. These isocyanides rely on two different cleavage strategies: (i) 
isocyanides that can directly be converted after the IMCR and (ii) isocyanides that require 
activation before cleavage (Scheme 12). 
The first group of isocyanides generally has a simple design, which makes their synthesis 
relatively straightforward. The group can be subdivided into (a) isocyanides that are 
converted under acidic conditions and (b) isocyanides that are converted under basic 
conditions. The conversion reactions are typically harsh, which limits the number of 
different functional groups that can be introduced. However, since the resulting amides of 
these isocyanides do not require a multistep activation, they have the advantage that the 
conversion of the secondary amide can generally be performed in the same pot as the 
IMCR. 
The second group of isocyanides is based on activation of the secondary amide to a much 
better leaving group (like an N-acyl indole or pyrrole). This activation requires additional 
(sometimes difficult) reaction steps and/or a relatively complex (hence synthetically 
challenging) isocyanide. Afterwards the conversion potential is much greater, meaning 
milder reaction conditions and introduction of a broader range of functional groups. 
 
Scheme 12. Direct and indirect convertible isocyanides. 
The second part of this chapter describes the potential of convertible isocyanides in 
organic chemistry by presenting an overview of the recently developed convertible 
isocyanides and their application in IMCR chemistry. 
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1.3.1 Direct convertible isocyanides 
Direct convertible isocyanides which are converted under acidic conditions rely on the 
ability of the IMCR product to form a münchnone intermediate (57, Scheme 13). If the 
target secondary amide is activated (by e.g. protonation), the tertiary amide can undergo 
an intramolecular cyclization to generate münchnone intermediate 57, which is stabilized 
by the formation of aromatic oxazolium 58. The münchnone intermediate is readily 
trapped by a nearby nucleophile, which generally is the (thio)alcoholic solvent in which 
the activation takes place.  
 
Scheme 13. Conversion of the convertible isocyanide via a münchnone intermediate. 
1-Cyclohexenyl isocyanide (Armstrong) 
Already in 1963, Ugi described the use of 1-cyclohexenyl isocyanide (59) in the U-4CR and 
its subsequent deprotection to the primary amide.
37
 It was not until 1995 that Armstrong 
realized the potential of this isocyanide.
38,39
 Armstrong showed that treatment of the Ugi 
products of 1-cyclohexenyl isocyanide (60) with anhydrous HCl in a protic solvent 
(generated by reacting AcCl with the solvent) leads to N-acyliminium species 61. This 
reaction intermediate is not hydrolyzed to the primary amide under these conditions, but 
cyclized to the above-mentioned münchnone (57). The münchnone is subsequently 
trapped by the solvent, leading to various esters and thioesters.
38,40
 Since most of the Ugi 
reactions proceed very well in MeOH as solvent, both the Ugi reaction and the subsequent 
cleavage to the methyl ester can be carried out in one pot with similar yields. 
Interestingly, when formic acid was used as acid input (R
1
 = H), methanolysis of the 
formamide is faster than the formation of the münchnone intermediate leading to the 
aminoacetamide, hence showing the importance of the münchnone intermediate for the 
functioning of the convertible isocyanide.  
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Scheme 14. The use of 1-cyclohexenyl isocyanide as direct convertible isocyanide. 
Armstrong validated the existence of the münchnone intermediate by trapping it with an 
acetylenic dipolarophile (Scheme 15). A [3+2] cycloaddition between an electron-deficient 
alkyne and the 1,3-dipole then results in the formation of intermediate 63, which rapidly 
undergoes a retro-Diels-Alder type aromatization to form pyrroles 64 with the expulsion 
of CO2. 
 
Scheme 15. Trapping of the munchnone intermediate with acetylenic dipolarphiles. 
Since the discovery of 1-cyclohexenyl isocyanide, many applications of this reagent have 
appeared in the literature. For example, it has been used in the synthesis of several 1,4-
dibenzodiazepine-2,5-diones by a cyclization reaction
40,41
 and in the total synthesis of 
Motuporin.
42
 Furthermore, due to the volatility of the isocyanide, several variations of the 
isocyanide have been synthesized to improve its applicability, like the 4-tert-butyl and 4-
phenyl derivatives.
43
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2-Isocyanophenyl benzoate (Pirrung) 
One of the widely discussed disadvantages of isocyanides is their repugnant smell. 
Therefore, Pirrung and coworkers developed a set of convertible isocyanides with a very 
delegate odor due to the presence of an ester functionality (68).
44,45
 Furthermore, the 
isocyanides are made from benzoxazole 65, without the use of strong or poisonous 
dehydrating agents, such as POCl3 or triphosgene (Scheme 16). Deprotonation of 
benzoxazole 65 with n-BuLi leads to the formation of lithiate 66, which is in equilibrium 
with isocyanophenolate 67. The phenolate is then trapped with an acylchloride to provide 
the isocyano ester (68).  
 
Scheme 16. Synthesis of isocyanide 68. 
The conversion mechanism of the amide resulting from this isocyanide is similar to that of 
1-cyclohexenyl isocyanide (59). The secondary amide is activated in acidic media to form 
an N-benzoxazolium amide intermediate (71), which can undergo an intramolecular 
cyclization to form the münchnone intermediate (Scheme 17). The authors showed that 
the intermediate can be trapped by MeOH to form methyl esters (as exemplified in 
Scheme 17) or acetylenic dipolarphiles to form pyrroles (not shown). In addition, the 
reagent was used for the synthesis of azepinediones
46
 and 2,5-diketopiperazines
47
 by 
trapping the münchnone with an internal nucleophile.  
 
Scheme 17. Utility of 68 as convertible isocyanide. 
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The electronic properties of the acyl group in the convertible isocyanide (R
4
) have a 
notable influence on the rate of the reaction. Electron-withdrawing groups should 
facilitate the formation of intermediate 70, while electron-donating groups favor the 
formation of the benzoxazolium intermediate (71). Experimental results clearly indicate 
shorter reaction times for electron-donating groups, which suggests that the formation of 
the benzoxazolium 71 is the rate-determining step.  
Trityl isocyanide (Cioc) 
Recently our group showed the application of triphenylmethyl (trityl) isocyanide (73) in 
IMCR chemistry.
48
 Trityl isocyanide is a very versatile reagent, which can be employed as a 
cyanide source or used as a convertible isocyanide depending on the reaction conditions. 
When the reagent is applied in the U-4CR it results in the trityl amide, which is easily 
deprotected to the primary amide (76) under acidic conditions due to the high stability of 
the trityl cation (Scheme 18). Interestingly, in some cases the reaction does not stop at 
this stage, but continues to (partially) form a münchnone intermediate after the expulsion 
of ammonia. The münchnone intermediate is trapped by water resulting in the carboxylic 
acid (77, X = O). The ratio of carboxylic acid and primary amide obtained depends on the 
propensity of the Ugi product to form the münchnone intermediate. Electron-withdrawing 
groups of the tertiary amide (R
1
 or R
3
) hamper the intramolecular cyclization due to 
reduction of the amides nucleophilicity. 
 
Scheme 18. Application of trityl isocyanide in the U-4CR. 
The importance of the münchnone intermediate for the convertibility of the secondary 
amide is more evident when isocyanide 73 is used in the P-3CR  (Scheme 19). The Passerini 
product does not contain the tertiary amide, which is crucial for the formation of the 
münchnone. Consequently, the Passerini products are selectively converted to the 
primary amides (80) after treatment with TFA. 
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Scheme 19. Use of trityl isocyanide in the P-3CR. 
Finally, the utility of trityl isocyanide was tested in the Groebke-Blackburn-Bienaymé 
(GBB) reaction (Scheme 20). The GBB reaction combines amidines (81), aldehydes and 
isocyanides to obtain imidazo[1,2-a]pyridines (like 83), which is an important scaffold from 
a medicinal chemistry point of view. The GBB products with trityl isocyanide (83) were 
readily deprotected under mildly acidic conditions to the free amines (84).  
 
Scheme 20. Use of trityl isocyanide in the GBB-deprotection sequence. 
There is a big difference in deprotection strategies with these compounds in comparison 
with the Ugi and Passerini-type products. For Ugi-type products, the convertible 
isocyanide is used as a ‘C’-synthon, while for the GGB reaction the nitrogen atom is also 
incorporated in the product. Consequently, the GGB deprotection depends on the 
formation of a stabile carbocation as the leaving group. More generally applied 
isocyanides for the deprotection of the 3-amino group of GBB products are tert-butyl 
isocyanide
49-53
 and 1,1,3,3-tetramethylbutyl isocyanide (Walborsky’s reagent).
54-56
 In 
contrast to this procedure using trityl isocyanide, the deprotection conditions of the other 
GBB products are typically very harsh. 
Chapter 1
 
 
30 
n-Butyl isocyanide (non-designer isocyanide) 
Not all convertible isocyanides require a clever design in order to facilitate conversion at 
the secondary amide center. In 2009, Hulme describes the use of n-butyl isocyanide (the 
most widely available isocyanide in the US) for the synthesis of triazadibenzoazulenones
57
 
(not shown) and 1,4-benzodiazepine-2,4-diones 89
58
 (Scheme 21). This reaction relies on 
the formation of a thermodynamically favorable product by the use of very harsh reaction 
conditions, like high temperatures or microwave irradiation. The choice of the isocyanide 
is in this case irrelevant (in other words: it would work with any other isocyanide) and 
therefore Hulme coined them ‘non-designer’ convertible isocyanides. 
 
Scheme 21. Synthesis of 1,4-benzodiazepine-2,4-diones with the use of the non-designer n-butyl isocyanide. 
1-Isocyano-4-methoxy-2-nitrobenzene (Martens) 
The secondary amides resulting from the above described direct convertible isocyanides 
are all cleaved under acidic conditions. However, there are also direct convertible 
isocyanides which are cleaved under basic conditions. These isocyanides are designed in 
such a way that the resulting negatively charged leaving group is stabilized by strong 
electron-withdrawing groups. An interesting example is 1-isocyano-4-methoxy-2-
nitrobenzene (90), which is developed by the group of Martens (Scheme 22).
59,60
 The nitro 
group greatly enhances electrophilicity of the amide and at the same time also stabilizes 
the resulting leaving group after basic cleavage to the carboxylic acid (92). The presence of 
the 4-methoxy group makes the isocyanide sufficiently nucleophilic for Ugi-type chemistry 
and also enhances the stability of the isocyanide. 
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Scheme 22. Use of isocyanide 90 in the U-4CR and subsequent basic cleavage. 
The authors described the application of isocyanide 90 for the synthesis of several N-
terminal protected PNA monomers by a combination of the Ugi-4CR and basic hydrolysis 
with the use of LiOH or KOH at elevated temperatures.   
2-isocyano-2,2-dimethylethyl)-alkyl-carbonates (Ugi) 
In 1999, Ugi and coworkers reported (β-isocyano-ethyl)-alkyl-carbonates (93) as new class 
of convertible isocyanides.
61
 These isocyanides are synthesized similarly to Pirrung’s 
isocyanides (Scheme 16) starting from the corresponding oxazolidines. These convertible 
isocyanides have a very clever mode of action. After the U-4CR, the secondary amide (94) 
is deprotonated with KOtBu leading to oxazolidine amide 96 promoted by the Thorpe-
Ingold effect (Scheme 23). The alkoxylate which is expelled during this process can now 
attack the activated amide to form the corresponding ester (97).   
 
Scheme 23. Application of 93 as convertible isocyanide. 
Ugi and coworkers conducted the U-4CR with several of their convertible isocyanides and 
successfully obtained the corresponding esters in moderate to good yields (31-85%, R
4
 = 
Me, Et, Bn or allyl). Interestingly, when the phenyl carbonate version of the isocyanide is 
used (R
4
 = Ph), the resulting phenolate is not nucleophilic enough to open the N-
acyloxazolidinone intermediate 96.
62
 In fact, intermediate 96 can now be used in a 
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subsequent reaction with another nucleophile to functionalize the secondary amide. 
Fukuyama et al. used this isocyanide for the synthesis of n-dodecyl thioesters by trapping 
intermediate 96 with dodecyl thiolates.
63,64
 Consequently, 2-isocyano-2,2-dimethylethyl)-
phenyl-carbonate (93, R
4
 = Ph) can be considered as the first indirect convertible 
isocyanide.  
1.3.2 Indirect convertible isocyanides 
The direct convertible isocyanides, as shown in the previous section, have some clear 
advantages. They are rapidly converted towards a handful of functional groups (generally 
(thio)esters and carboxylic acids) and for most isocyanides this can even be done in the 
same pot as the IMCR. The second class of convertible isocyanides, the indirect convertible 
isocyanides, contain a synthetic handle, which allows activation of the secondary amide to 
a much better leaving group (e.g. an indolyl or pyrrolyl amide). The activation does require 
one or more chemical steps, but afterwards many different chemical transformations are 
available. This section provides an overview of the most interesting indirect convertible 
isocyanides to highlight their synthetic design and their broad post-modification potential.   
1-Benzyloxy-2-isocyanobenzene (Borthwick) 
One of the first reported indirect convertible isocyanides is 1-benzyloxy-2-
isocyanobenzene (98), was developed by the group of Borthwick from GlaxoSmithKline 
(Scheme 24).
65-67
 The OBn-group is incorporated in the isocyanide to serve as a synthetic 
handle for follow-up activation. After the Ugi reaction, the resulting secondary amide was 
converted into the activated N-acyl 2-benzoxazolinone 100, by hydrogenolytic cleavage of 
the benzyl group followed by reaction with 1,1-carbonyldiimidazole (CDI). 
 
Scheme 24. Activation of 1-benzyloxy-2-isocyanobenzene as indirect convertible isocyanide. 
Borthwick applied this method in the synthesis of a wide range of atosiban derivatives 
(Scheme 25). Atosiban (104; R
1 
= 2,6-dimethylpyridin-3-yl, R
2
 = (S)-sec-butyl, R
3
,R
4
 = 
morpholine) is an oxytocin antagonist used as a drug for the prevention of preterm labor. 
However, atosiban can only be administered by infusion, which makes long-term 
maintenance treatment impossible. Therefore, there is a considerable interest in the 
development of atosiban analogues that can be dosed orally. 
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Scheme 25. Application of 98 in the synthesis of a wide range of atosiban derivatives. 
Borthwick and coworkers were able to obtain the (3R,6R)-diketopiperazine (DKP) skeleton 
with the use of Cbz-protected amino acid 101 and amino ester 102 as inputs for the U-4CR 
(Scheme 25). Hydrogenation of the Cbz-group results in the formation of the desired DKP 
and simultaneous deprotection of the benzyl group for the formation of the activated 
amide (103) after treatment with CDI. The acyl benzoxazolinone was readily hydrolyzed by 
addition of water and the resulting carboxylic acid was coupled with different amides after 
activation of the carboxylic acid with BOPCl. The authors recognized that they activated 
the same amide twice in order to synthesize the desired DKP 104. Addition of several 
primary and secondary amides directly to the acyl benzoxazolinone 103 successfully 
resulted in the formation of the desired amides (104) in higher overall yields and 
diastereoselectivity.  
1-(2,2-Dimethoxyethyl)-2-isocyanobenzene (Kobayashi, Wessjohann) 
In 2007, Kobayashi
68
 and Wessjohann
69
 independently developed 1-(2,2-dimethoxyethyl)-
2-isocyanobenzene (105) as a convertible isocyanide. Their strategy relies on the 
formation of an indolyl amide (107), which is known to be susceptible to chemical 
transformations under mild conditions. The dimethoxyacetal is the synthetic handle that 
can be cleaved with aqueous acid after which direct cyclization occurs to form the desired 
indolyl amide 107 (Scheme 26). 
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Scheme 26. Activation of isocyanide to the N-acylindole. 
The group of Kobayashi showed the application of the isocyanide in a U-4C-3CR using 
levulinic acid and p-methoxybenzylamine. Subsequent addition of acid provided the 
corresponding γ-lactam indolyl amides. The synthetic utility of convertible isocyanide 105 
was demonstrated by converting the indolyl amide (107) into a variety of functional 
groups, like a carboxylic acid, an ester, a thioester (62) and a primary amide (108) (Scheme 
27).
70,71
 Noteworthy, addition of sodium borohydride results in the selective single 
reduction to the aldehyde (109), presumingly due to the formation of a stabile N,O-
hemiacetal. Furthermore, Kobayashi showed various synthetic applications with γ- and δ-
lactam indolyl amides as intermediate.
68,72-75
  
 
Scheme 27. Convertibility of N-acylindole 107. 
The group of Wessjohann reported the use of isocyanide 105 in the U-4CR with a more 
diverse set of different carboxylic acids, aldehydes and amines. The Ugi products were 
successfully converted to the activated indolyl amides, followed by transformation to the 
corresponding acids, methyl esters and a set of different secondary and primary amides.
69
 
Furthermore, the use of isocyanide 105 in the Passerini (Scheme 28) and Ugi-Smiles 
reactions (not shown) was demonstrated. Notably, by a clever choice of reaction 
conditions, they were able to chemoselectively transform the indolyl amides of the 
Passerini products to different functional groups selectively with or without cleavage of 
the ester. In addition, Wessjohann showed the application of isocyanide 105 in the 
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synthesis of DKPs with an intramolecular cyclization reaction.
76
 Finally, the value of the 
isocyanide was also acknowledged in the field of polymer chemistry for the synthesis of 
functionalized heterocyclic monomers.
77,78 
 
Scheme 28. Application of isocyanide 105 in the P-3CR.  
2-Nitrophenyl isocyanide (Kobayashi) 
Shortly after the development of isocyanide 105, Kobayashi published 2-nitrophenyl 
isocyanide (114) which has a slightly different cleavage mechanism (Scheme 29).
79
 This 
indirect convertible isocyanide requires reduction of the nitro group. Then diazotization of 
the resulting aniline followed by a cyclization of the amide nitrogen on the diazonium salt 
results in the formation of N-acyl benzotriazole 116. The acyl benzotriazole has some 
advantages over the acyl indole type amides. Firstly, the synthesis of the isocyanide is 
much more straightforward compared to isocyano acetal 105. Secondly, the electron-
withdrawing properties of the two additional nitrogen atoms enhances both the reactivity 
of the amide carbonyl and the leaving group capability of the benzotriazole (compared to 
the indole) after nucleophilic attack. On the other hand, activation of Ugi product 115 
requires two reaction steps of which the chemistry is less specific for activation of the 
secondary amide.  
 
Scheme 29. Activation of 2-nitrophenyl isocyanide to the benzotriazole (116). 
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The group of Kobayashi tested the utility of 2-nitrophenyl isocyanide in the synthesis of γ-
lactams with an U-4C-3CR followed by the activation of the secondary amide to give N-acyl 
benzotriazoles 117. The benzotriazole is a highly activated leaving group and only requires 
a catalytic amount of Et3N (0.1 equiv) together with different nucleophiles such as 
alcohols, thiols and amines (Scheme 30).
80,81
 In this case, NaBH4 fully reduced the amide to 
the corresponding primary alcohol (120). However, addition of a Grignard nucleophile to 
117 selectively provided the corresponding ketone (not shown). Moreover, isocyanide 114 
was used by the group of Carreira in the synthesis of an important precursor of Massadine 
via an U-3CR.
82
 
 
Scheme 30. Convertibility of the benzotriazole amide 117. 
4-Isocyanopermethylbutane-1,1,3-triol (Wessjohann) 
In 2012, the group of Wessjohann developed 4-isocyanopermethylbutane-1,1,3-triol (IPB) 
121 as an indirect convertible isocyanide (Scheme 31).
83,84
 The design of their isocyanide 
was inspired by the work of Fukuyama, who described the formation of acyl pyrroles from 
the trimethoxybutyl amide (like 122) under relatively mild acidic conditions.
85
 The pyrrolyl 
amides (123) are suitably activated amides for follow-up transformations, similar to the 
above-mentioned indolyl amides. IPB (121) was effective in the U-4CR and tolerates a set 
of chemically diverse inputs. The subsequent conversion to the pyrrolyl amides under the 
acidic conditions developed by Fukuyama (10% CSA and 10% quinolone at reflux) tolerates 
many different nitrogen protection groups, such as Boc, Cbz and Fmoc. However, some 
inputs showed partial thermal decomposition, which was resolved by stirring the Ugi 
products in 5% TFA at room temperature for 1 hour for cleaner conversion to the products 
(123). 
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Scheme 31. Activation of isocyanide 121 to the pyrrolyl amide. 
The utility of the post transformation of the U-4CR products was tested with pyrrolyl 
amide 124 as benchmark (Scheme 32). Typical transformation to different primary, 
secondary or tertiary amides (126) as well as to the carboxylic acid and (methyl) ester 
(125) proceeded satisfyingly. In addition, reduction with NaBH4 afforded aldehyde 127, 
which was too reactive for proper isolation. Instead, the aldehyde was further reduced to 
the primary alcohol (128) or transformed into trans-alkene 129 by a Horner-Wadsworth-
Emmons (HWE) olefination.  
 
Scheme 32. Convertibility of pyrrolyl amide 124. 
(Z)-1-Bromo-2-(2-isocyanovinyl)benzene (Zhu) 
Very recently, Zhu et al. published a set of vinyl isocyanides as novel class of convertible 
isocyanides (Scheme 33).
86
 Especially (Z)-1-bromo-2-(2-isocyanovinyl)benzene (133) has 
promising features, mostly due to its stability and non-volatility. These isocyanides were 
synthesized based on an old procedure from Fehlhammer in 1985,
87
 which consists of the 
preparation of isocyanomethylphosphonium salt 131 from trimethylsilylmethyl isocyanide 
(130). Wittig reactions with different aldehydes led to the production of the vinyl 
isocyanides in different E/Z ratios (ranging from excellent Z or E selectivity to very poor 
selectivity) depending on the electronic properties of the aldehyde. The synthesis of the 
desired isocyanide 133 with 2-bromobenzaldehyde proceeded with excellent Z selectivity 
(E/Z = 2/98).  
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Scheme 33. Preparation of vinyl isocyanide 133 by a Wittig reaction. 
The authors present the utility of their isocyanide in an U-4CR with propionic acid, benzyl 
amine and 3-phenylpropanal 134 (Scheme 34). The secondary amide of Ugi product 135 
has similar electronic properties as the Ugi products produced with Armstrong’s 
isocyanide (Scheme 14). Addition of a strong acid in the presence of an alcohol or thiol 
leads to the formation of the corresponding (thio)ester (136) via the münchnone 
intermediate. For this reason the isocyanide can be considered as a direct convertible 
isocyanide. However, the isocyanide can also be transformed into an N-acylindole (137), 
the same reactive intermediate as Kobayashi’s isocyanide (Scheme 26), with an 
intramolecular Buchwald-Hartwig-type coupling. Therefore the isocyanide can also be 
classified as an indirect convertible isocyanide.  
   
 
Scheme 34. Application of vinyl isocyanide 133 as direct and indirect convertible isocyanide. 
1.3.3 Resin bound convertible isocyanides 
The previous section described many different (both direct and indirect) convertible 
isocyanides, making it possible to overcome the traditional limitations of IMCR chemistry. 
Unfortunately, all these isocyanides share a common disadvantage, i.e. the larger part of 
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the convertible isocyanide is discarded after the post-transformation and effectively only 
the carbon-atom of the isocyanide is incorporated in the final product.  
This disadvantage can be turned into an advantage by linking the isocyanide to a solid 
support. For solid phase synthesis, it is required to install a cleavable linker in order to 
remove the desired product from the solid-phase material after completing the reaction 
sequence. When a convertible isocyanide is attached to a solid support, the resulting 
reactive secondary amide directly functions as the “cleavable linker”. An additional 
advantage is of course the ease of purification of the Ugi-products avoiding the use of 
time consuming flash chromatography. To this end, several resin-bound convertible 
isocyanides have appeared in the literature in the last decades (Figure 4).
88-92
 
 
Figure 4. Resin bound convertible isocyanides. 
In 2002, Kennedy reported a very inspiring example demonstrating the application of 
resin-bound convertible isocyanide 142, based on the convertible isocyanide developed by 
Ugi (Scheme 23).
92
 Kennedy used the resin-bound isocyanide for the synthesis of large 
compound library (>80 examples) of different 2,5-diketopiperazines 144 and 1,4-
benzodiazepine-2,5-diones 146 in parallel in a 80-wells plate (Scheme 35). These results 
convincingly demonstrate the efficiency of resin-bound convertible isocyanides for the 
generation of large compound libraries for lead discovery programs.  
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Scheme 35. General strategy for the synthesis of 2,5-diketopipeazines and 1,4-benzodiazepine-2,5-diones. 
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1.4 Conclusion 
IMCRs are excellent tools for the organic chemist as illustrated by the examples in this 
chapter. Their convergent nature efficiently shortens the number of reaction steps in total 
synthesis, whereas their broad substrate tolerance offers great opportunities for the 
synthesis of large compound libraries for drug discovery. In addition, many variations of 
the traditional IMCRs have been introduced to gain excess to multiple different IMCR 
scaffolds.  
The disadvantages of the isocyanide chemistry, i.e. the commercial availability of the 
isocyanides and the limited scaffold diversity of the IMCRs, are overcome by the 
introduction of convertible isocyanides. Convertible isocyanides facilitate the 
diversification of the IMCR products at the normally chemically inert secondary amide. 
The possible transformations are limitless and can proceed under various different 
conditions, depending on the type of convertible isocyanide (e.g. direct or indirect). 
Consequently, the scope of the IMCRs is greatly enhanced in terms of synthetic complexity 
and scaffold diversity. 
1.5 Scope and outline of this thesis 
From the introductory chapter, it becomes clear that IMCRs play a considerable role in the 
improvement of the synthesis of drug-like molecules and compound libraries. With the 
use of convertible isocyanides, the potential of the IMCRs is greatly enhanced. However, 
the current set of convertible isocyanides generally suffers from some severe 
disadvantages, including the stability/handling of the isocyanide, its multistep and/or 
tedious synthesis or the difficult and/or harsh post-transformation conditions. 
The research described in this thesis involves the development of 2-bromo-6-
isocyanopyridine as a novel convertible isocyanide and its use for the short and efficient 
synthesis of pharmaceuticals and bioactive compounds. Chapter 2 will describe the design 
of 2-bromo-6-isocyanopyridine as a novel convertible isocyanide. The reagent combines 
the advantages of direct and indirect convertible isocyanides. To demonstrate the utility of 
the reagent, a large set of chemically different U-4CR products were synthesized. These 
Ugi products were subjected to different post-transformations to show the broad 
convertibility. Finally, the extremely potent narcotic carfentanil was synthesized using this 
methodology as a showcase example. In chapter 3, the use of 2-bromo-6-isocyanopyridine 
in an oxidation-Passerini-hydrolysis sequence is described. This method provides direct 
access to valuable α-hydroxy acids (AHAs) from the corresponding primary alcohols.  
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For most IMCRs one of the major challenges is control in the stereoselectivity of the 
reaction. Chapter 4 describes the combination of the enzymatic oxidation of 4-substituted 
piperidines with monoamine oxidase N (MAO-N) to the corresponding Δ
1
-piperideines 
with a highly diastereoselective Ugi three-component reaction (U-3CR) generating 
pharmaceutically relevant pipecolic amides. This methodology was combined with the 
convertible isocyanide chemistry in the efficient synthesis of the anticoagulant 
argatroban. This methodology was further explored with the use of enzymatically 
desymmetrized 1,2-substituted pyrroles in Chapter 5. A diastereoselective U-3CR with the 
resulting imine, together with 2-bromo-6-isocyanopyridine and different carboxylic acids 
leads to the synthesis of valuable ACE-inhibitor analogues after hydrolytic cleavage of the 
activated secondary amide. Finally, Chapter 6 provides an outlook of the potential of 2-
bromo-6-isocyanopyridine for the synthesis of pharmaceuticals. For example, the drug 
Valsartan would be an ideal target for the convertible isocyanide or it can be used in the 
synthesis of new penicillin analogues with the use of protected amino aldehydes. 
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2-Bromo-6-isocyanopyridine as a Universal Convertible 
Isocyanide for Multicomponent Chemistry 
 
 
 
Abstract: In this chapter, the development of 2-isocyanopyridines as novel convertible 
isocyanides for multicomponent chemistry is reported. Comparison of twelve 
representatives of this class revealed 2-bromo-6-isocyanopyridine as the optimal reagent 
in terms of stability and synthetic efficiency. It combines sufficient nucleophilicity with 
good leaving group capacity of the resulting amide moiety under both basic and acidic 
conditions. To demonstrate the practical utility of this reagent, an efficient two-step 
synthesis of the potent opioid carfentanil is presented. 
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Introduction 
Drug discovery relies heavily on high-throughput screening of large compound collections 
which, in turn, requires efficient parallel synthesis methodologies for effective coverage of 
biological activity space. Isocyanide-based multicomponent reactions (IMCRs) such as the 
Ugi four-component reaction (U-4CR, Scheme 1) are of tremendous importance in this 
area because of their high efficiency and variability.
1
 Clever design of inputs with various 
reactivity handles opens possibilities for post modification of the IMCR products to 
generate arrays of new scaffolds such as heterocycles and macrocycles.
2 
 
Scheme 1. Applications of a convertible isocyanide in the U-4CR. 
One important drawback of IMCRs is the limited commercial availability of many 
isocyanides, particularly with biologically relevant functional groups, compared to the 
exceedingly wide availability of other IMCR components (carboxylic acids, 
ketones/aldehydes, and amines).
3
 In addition, the isocyanide input generally results in a 
very stable secondary amide, which makes further synthetic manipulation at this site 
challenging. 
 
Figure 1. Selected examples of convertible isocyanides I-VIII. 
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Already in 1962, Ugi and Rosendahl described the use of cyclohexenyl isocyanide (I, R = H, 
Figure 1) in the U-4CR and subsequent conversion of the product to a primary amide. In 
1995, Armstrong introduced the concept of a convertible isocyanide (Scheme 1).
4
 In the 
ideal case, this (universal) isocyanide can substitute all other isocyanides, since it can be 
converted after the IMCR into any other functional group, e.g. another amide, a 
(thio)ester, or a carboxylic acid. As a result, the synthesis, purification and handling of 
custom isocyanides can be avoided, while a host of functional groups can be introduced by 
post-MCR transformations, greatly expanding the molecular diversity of the products 
beyond the typical secondary amides. Over the past two decades several convertible 
isocyanides have been developed
5
 (Figure  1), but all suffer from limitations such as: (a) 
preparation of the isocyanides requires lengthy, tedious synthetic routes; (b) the 
isocyanides themselves are unstable/difficult to handle; (c) after the IMCR, the conversion 
to different functional groups is rather limited; (d) functional groups in the isocyanide 
moiety are incompatible with various standard manipulations; (e) the IMCR requires a 
workup before cleavage of the secondary amide; (f) cleavage of the convertible 
isocyanides requires a tedious multistep transformation. In light of our continued interest 
in the application of isocyanide-based reactions, we embarked on the quest of finding a 
truly practical convertible isocyanide which is sufficiently nucleophilic to react with a 
broad range of other inputs in various IMCRs, but also generates an electrophilic amide 
carbonyl upon the IMCR. We envisioned that 2-isocyanopyridines could be suitable 
candidates as the resulting N-2-pyridyl amide is a good leaving group under both basic and 
acidic conditions (Scheme 2). 
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Scheme 2. Proposed cleavage of N-pyridyl amides under basic and acidic conditions. 
Basic cleavage would lead to a negatively charged aminopyridine species in which the 
charge is stabilized by the pyridine ring, whereas protonation of the pyridine ring 
enhances both the leaving group capability of the amine and the electrophilicity of the 
amide (potentially via münchnones as described by Armstrong).
4b
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Results and Discussion 
Although there are scattered reports on the synthesis,
6
 dimerization
7
 and metal 
complexes
8
 of 2-isocyanopyridines, their use in IMCRs is limited to only three examples.
9
 
Given their proposed potential as convertible isocyanides, we set out to synthesize a set of 
nineteen monosubstituted 2-isocyanopyridines from the corresponding commercial 2-
aminopyridines (Figure 2).  
 
Figure 2. Representative set of isocyanopyridines (6) as potential convertible isocyanides. 
Electron withdrawing functional groups will enhance the leaving group capability of the 
resulting pyridinyl amide under basic conditions (Scheme 2), by stabilization of the 
negatively charged amino pyridine leaving group. However, strongly electron withdrawing 
groups like nitro (6k) or cyano (6l) groups reduce the stability of the isocyanide. In these 
cases the isocyanide carbon atom becomes too electrophilic, making it prone to attack by 
external nucleophiles like water or to polymerization. The electron-poor 2-
isocyanopyridines (marked in red in Figure 2) proved to be unstable during workup and 
showed signs of rapid polymerization. Furthermore, the very electron-poor isocyano-
pyrimidines (6p and 6q) displayed the same problems. Fortunately, the other 2-
isocyanopyridines, bearing methyl or halogen substituents, did provide stable isocyanides, 
generally as easily handled solids. Finally, we were curious to see whether the 
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isoelectronic 4-isocyanopyridines (6r and 6s) could also function as convertible 
isocyanides, since they should have similar leaving group capabilities. However, these 
isocyanides showed also rapid degradation during workup. 
The remaining twelve stable candidates were then reacted with isovaleraldehyde, 
benzylamine, and acetic acid to afford Ugi products 7b-o. Compounds 7b-o were 
subsequently subjected to mild hydrolysis conditions (5 equiv aq. NaOH, MeOH, rt) to give 
carboxylic acid 8a and their conversion was followed by gas chromatography.
10
 The 
results, summarized in Table 1, clearly indicate that 2-bromo-6-isocyanopyridine (6o) is 
the optimal isocyanide in all respects (ease of synthesis, reactivity in the U-4CR, and 
hydrolysis of the resulting secondary amide).  
 
Entry 6 R 7 Yield 7 Yield 8aa 
1 6b 3-CH3 7b 66% 48% 
2 6c 3-Br 7c 41% 63% 
3 6d 4-CH3 7d 66% 52% 
4 6e 4-Br 7e 65% 95% 
5 6f 5-CH3 7f 58% 21% 
6 6g 5-F 7g 58% 23% 
7 6h 5-Cl 7h 62% 73% 
8 6i 5-Br 7i 76% 81% 
9 6j 5-CF3 7j 15% n.d. 
10 6m 6-CH3 7m 62% 55% 
11 6n 6-Cl 7n 65% 95% 
12 6o 6-Br 7o 70% 96% 
Table 1. Selection of the optimal convertible isocyanide. aYield 
determined by GC. 
Isocyanide 6o is a stable solid and easy to handle in IMCRs. However, due to its reactivity, 
the reagent suffers from slow degradation when stored for extended periods of time at 
room temperature. In order to serve as useful new reagent and universal reagent in 
IMCRs, the compound does require long-term stability. We investigated the stability of the 
isocyanide by monitoring its degradation with NMR at different temperatures (Figure 3). 
Isocyanide 6o was fully decomposed after storage for four months at room temperature 
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and showed some degradation when stored at 4 °C. Gratifyingly, the isocyanide does not 
show any degradation when properly stored at −20 °C. 
 
Figure 3. Stability of isocyanide 6o at different temperatures. 
To evaluate the applicability of isocyanide 6o in the U-4CR, we reacted it with a set of 
chemically diverse amines, aldehydes and carboxylic acids (Scheme 3) under standard Ugi 
conditions (MeOH, rt, 48 h). Pleasingly, all examined combinations provided the Ugi 
products 9a-k in moderate-to-excellent yields (39-92%). Reactions with (hetero)aromatic 
carboxylic acids (to give 8c and 8d) and aromatic aldehydes (to give 8f-h) gave low 
conversion under the standard reaction conditions. However, the yields were greatly 
improved using the more activating solvent 2,2,2-trifluoroethanol (TFE).
11  
We then converted Ugi products 9a-k to the corresponding carboxylic acids under mildly 
basic conditions. Carboxylic acids are the most versatile intermediates, since standard 
methodologies allow their further elaboration to e.g. (thio)esters and amides. In most 
cases, the hydrolysis proceeded very cleanly in quantitative yield at room temperature 
(8a-g). For sterically more demanding substrates (8h-k), higher temperatures (up to 50 °C) 
and/or longer reaction times were required. Notably, the mild hydrolysis conditions 
tolerate a variety of functional groups. As expected, however, esters are saponified (8k). 
Since both the Ugi and the hydrolysis reaction require the same solvent, we envisioned a 
one-pot IMCR/hydrolysis procedure (MeOH, rt; then 5 equiv aq. NaOH). To our delight, we 
rt, 4 months 
 
 
 
4 °C, 4 months 
 
 
 
−20 °C, 6 months 
Chapter 2
 
 
54 
obtained the hydrolyzed Ugi product 8a in similar yield as the two-step procedure (67% vs. 
70%). Advantageously, 8a could be purified by simple acid-base extraction, thereby 
avoiding the need for flash chromatography. 
Scheme 3. Applicability of isocyanide 6I in the U-4CR. aDeprotection requires elevated temperatures (50 °C) or 
prolonged reaction time. bThe methyl ester was also hydrolyzed under the reaction conditions. PCB = p-
chlorobenzyl; PCP = p-chlorophenyl; PMB = p-methoxybenzyl. 
Next, we investigated the transformation of the secondary amide of 9a(7o) into other 
functionalities. Switching from NaOH to NaOMe under anhydrous conditions furnished the 
corresponding methyl ester 10a (Table 2, entry 2). To our delight, addition of 5 equivalents 
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of n-butylamine or pyrrolidine provided the corresponding secondary and tertiary amide 
10b and 10c, respectively (entries 3 and 4). However, the use of a less nucleophilic 
secondary amine (morpholine, entry 5) or more sterically demanding amine (α-(S)-methyl-
benzylamine, entry 6)) did not provide the desired product. 
 
Entry NuH Product Yield (%) Cond.a 
1 H2O 8a 99 A 
2 MeOH 10a 80 A 
3 n-BuNH2 10b 61 A 
4 Pyrrolidine 10c 70 A 
5 Morpholine 10d 0b A 
6 α-(S)-methyl-benzylamine 10e 0b A 
7 H2O 8a 99 B 
8 MeOH 10a 99 B 
9 n-BuOH 10f 99 B 
10 i-PrOH 10g 99 B 
11 3-butyn-1-ol 10h 65c B 
12 EtSH 10i 86d B 
13 BnSH 10j 39e B 
14 indole 10k 0f B 
Table 2. Substitution of the 2-pyridylamido group by various 
nucleophiles. aReaction conditions: (A) NaOMe (5 equiv) in MeOH, 3 Å 
MS, 50 °C, 24 h; (B) NuH (5 equiv), HCl (5 equiv), CH2Cl2/Et2O, room 
temperature, 16 h. bOnly the methyl ester was observed in 1H NMR. 
cTwo equiv of the corresponding alcohol were used. dEtSH was used as 
a co-solvent. e3 Å MS were added to the reaction mixture. fOnly the 
carboxylic acid was observed in 1H NMR. 
As proposed in Scheme 2, protonation should enhance the electrophilicity of the amide as 
well as the leaving group capability of the pyridylamine. As envisioned, performing the 
acid-mediated conversion in the presence of 5 equivalents of non-basic nucleophiles such 
as water (entry 7), alcohols (entries 8-11) or thiols (entries 12-13) provided the 
corresponding carboxylic acid, ester or thioester respectively in good to excellent yields 
(36-99%). Notably, thioesters are versatile intermediates with great potential in chemical 
biology used for native chemical ligation (NCL).
12
 Our Ugi/thioesterification method can 
provide easy access to synthetic peptide thioesters bearing various labels. The generality 
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of this approach is an important synthetic advantage. Furthermore, even less nucleophilic 
alcohols, such as 3-butyn-1-ol (entry 11), in only moderate excess (2 equiv) afford the 
corresponding ester in reasonable yield. Unfortunately, the use of carbon nucleophiles 
(e.g. indole, entry 14) did not lead to the desired ketones.  
To evaluate the potential of convertible isocyanide 6o in other IMCRs, we reacted it with 
acetic acid and either isobutyraldehyde or n-hexanal to give the corresponding Passerini 
products 11a and 11b in 98% and 81% yield, respectively (Scheme 4). Subsequent 
hydrolysis quantitatively afforded the α-hydroxycarboxylic acids 12a and 12b. 
 
Scheme 4. Synthesis of α-hydroxycarboxylic acids via Passerini reaction of 6o. 
Moreover, the isocyanide was introduced to other IMCRs like the Ugi-Smiles reaction and 
the Groebke-Blackburn-Bienaymé (GBB) reaction, showing its broad applicability (Scheme 
5). Unfortunately, conversion of these IMCR products was not straightforward. The Ugi-
Smiles products (13) did not show clean conversion to the free carboxylic acid after basic 
hydrolysis. Presumingly, a retro Smiles rearrangement took place under these conditions 
to end up with the amino acid, which is easily lost during the aqueous workup. 
Furthermore, the GBB product does not contain the required secondary amide, making 
the post-transformations impossible. 
 
Scheme 5. Application of isocyanide 6o in the Ugi-Smiles and GBB reaction. 
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An additional advantage of 6o over most other convertible isocyanides is the fact that the 
N-substituent remains intact after conversion of the IMCR product. This offers 
opportunities for overall recyclability by recovery of the 2-aminopyridine. Thus, we 
performed a full recovery cycle starting from 2-amino-6-bromopyridine (5o; Scheme 6). 
After quantitative N-formylation, the dehydration with phosphoryl chloride was 
incomplete, but the majority of the unreacted formamide (15o) was recovered. The U-4CR 
leading to 7o/9a proceeded optimally with a slight excess of 6o, and unreacted 6o was 
quantitatively recovered. In the final methanolysis, 5o was isolated in 91% yield. 
Combination of the various recovered fractions led to an overall recovery of 83%, making 
our novel reagent the first recyclable convertible isocyanide. 
 
Scheme 6. Recyclability of 6-bromo-2-isocyanopyridine (6o). 
  
Chapter 2
 
 
58 
As a demonstration of the practicality of our new reagent, we applied it to the efficient 
synthesis of carfentanil (18).
13
 This synthetic opioid, which is approximately 100,000 times 
more potent than morphine,
14
 is plausibly accessible via the U-4CR of 6o, commercial 
ketone 16, aniline and propionic acid followed by methanolysis (Scheme 7). To our delight, 
the U-4CR smoothly afforded 17 in excellent yield (92%). Acidic methanolysis (AcCl/MeOH, 
45 °C) then gave carfentanil (18) in near-quantitative yield (98%). 
 
Scheme 7. Synthesis of the potent opioid carfentanil. 
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Conclusions 
In conclusion, we have successfully developed 2-bromo-6-isocyanopyridine as a novel 
convertible isocyanide (Figure 4). Compared to existing convertible isocyanides, our 
reagent performs better in terms of accessibility, convertibility of the IMCR primary 
scaffold, and regeneration/recycling. The most important advantage is the facile and 
versatile diversification of IMCR products at a site that is relatively chemically inert: the 
secondary amide originating from the isocyanide input in Ugi-type reactions can be 
converted (in the same pot) to a diverse set of functional groups under two sets of 
complementary reaction conditions. Thus, we believe that this novel reagent has 
unmatched synthetic potential and can play an important part in applications of  
multicomponent reactions. 
 
Figure 4. 6-Bromo-2-isocyanopyridine: a universal convertible isocyanide. 
  
New reagent 
Easy to handle 
Good convertibility 
Easily accessible 
Recyclable 
Versatile 
Mild transformations 
Broadly applicable 
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Experimental Section 
General Remarks 
Unless stated otherwise, all solvents and commercially available reagents were used as purchased. Powder 3 Å 
and 4 Å molecular sieves were purchased from Sigma Aldrich and activated before use. GC yield and conversion 
analysis was performed using a Shimadzu GC2010 equipped with a Zebron ZB-1 capillary column (30 m x 0.25 
mm) with dodecane as internal standard. Infrared (IR) spectra were recorded neat using a Shimadzu FTIR-8400s 
spectrophotometer and wavelengths are reported in cm-1. Nuclear magnetic resonance (NMR) spectra were 
recorded on a Bruker Avance 500 (125.78 MHz for 13C) or Bruker Avance 400 (100.62 MHz for 13C) using the 
residual solvent as internal (1H: δ 7.26 ppm, 13C{1H}: δ 77.00 ppm for CDCl3, 
1H: δ 2.50 ppm, 13C{1H}: δ 39.52 ppm 
for DMSO-d6 and 
1H: δ 3.31 ppm, 13C{1H}: δ 49.00 ppm for MeOD-d4). Chemical shifts (δ) are given in ppm and 
coupling constants (J) are quoted in hertz (Hz). Resonances are described as s (singlet), d (doublet), t (triplet), q 
(quartet), bs (broad singlet) and m (multiplet) or combinations thereof. Melting points were recorded on a Büchi 
M-565 melting point apparatus and are uncorrected. Electrospray Ionization (ESI) high-resolution mass 
spectrometry was carried out using a Bruker micrOTOF-Q instrument in positive ion mode (capillary potential of 
4500 V). Flash chromatography was performed on Silicycle Silia-P Flash Silica Gel (particle size 40-63 μm, pore 
diameter 60 Å) using the indicated eluent. Thin Layer Chromatography (TLC) was performed using TLC plates 
from Merck (SiO2, Kieselgel 60 F254 neutral, on aluminium with fluorescence indicator) and compounds were 
visualized by UV detection (254 nm) and KMnO4 stain. 
 
General synthetic procedures 
General procedure I: Synthesis of 2-formamidopyridines (15). 
Unless stated otherwise: In a flame-fried roundbottom flask equipped with a reflux condenser formic acid (41 
mmol, 2.05 equiv) was added dropwise to acetic anhydride (40 mmol, 2.0 equiv) and the resulting mixture 
refluxed at 65 °C for 2-3 hours. The mixture was cooled to room temperature and slowly added to a cold solution 
of a 2-aminopyridine (5, 20 mmol, 1.0 equiv) in anhydrous THF (50 mL) at 0 °C. After 1 h, the reaction was 
allowed to warm up to rt and stirred for 2-3 more hours. The solvent and excess of acetic acid were evaporated 
and the residue was redissolved in EtOAc. The crude mixture was washed with a saturated NaHCO3 and the 
water layer was extracted with EtOAc (2×). The organic layers were combined, washed with brine and dried over 
Na2SO4. The solvent was evaporated to furnish the corresponding formamide (15). 
General procedure II: Synthesis of 2-isocyanopyridines (6). 
Unless stated otherwise: To a flame dried 3-neck flask a 2-formamidepyridine (S1, 10 mmol, 1.0 equiv) was 
added and dissolved in anhydrous CH2Cl2 (30 mL). Then, Et3N (60 mmol, 6.0 equiv) was added and the solution 
was cooled to −78 °C. POCl3 (11.5 mmol, 1.15 equiv) in anhydrous CH2Cl2 (5 mL) was added dropwise to the 
mixture. After 1h, the mixture was warmed up to 0 °C and stirred overnight. The crude reaction mixture was 
carefully quenched with saturated NaHCO3 (25 mL). The layers were separated and the water layer was extracted 
with CH2Cl2 (2×). The organic layers were combined and washed with brine, dried over Na2SO4 and concentrated. 
The residue was purified by flash chromatography (CH2Cl2) to afford the 2-isocyanopiridine 6. The product was 
stored in the freezer at −18 °C. 
General procedure III: The Ugi reaction. 
An amine (1.0 mmol, 1.0 equiv) and an aldehyde (1.0 mmol, 1.0 equiv) were dissolved in MeOH or TFE (3 mL) and 
prestirred for 2 hours at room temperature. A carboxylic acid (1.5 mmol, 1.5 equiv) and 2-bromo-6-
isocyanopyridine (6l, 220 mg, 1.2 mmol, 1.2 equiv) were added subsequently. Additional solvent (1 mL) was 
added and the reaction mixture stirred for 48 hours at room temperature. The solvent was removed under 
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reduced pressure and the crude mixture was purified by flash chromatography (cyclohexane : EtOAc) to yield Ugi 
products 7/9 as foamy solids. 
General procedure IV: Hydrolysis of the Ugi products.  
Unless stated otherwise: An Ugi product (9, 0.1 mmol, 1.0 equiv) was dissolved in MeOH (0.75 mL) and 2M NaOH 
(0.25 mL, 5.0 equiv) was added. The resulting mixture was stirred for 48 hours at room temperature. The crude 
mixture was acidified to pH 1 with 1M HCl and extracted with EtOAc. The organic layer was washed with 1M HCl 
and with brine, dried over Na2SO4 and concentrated under reduced pressure to yield the corresponding 
carboxylic acid 8. Note: rotamers could be observed in the NMR data. 
General procedure V: Transacylation under basic conditions. 
To a flame dried Schlenk 3 Å MS, NaOMe in MeOH (0.5M, 5 mL, 2.5 mmol, 5.0 equiv) and a nucleophile (2.5 
mmol, 5.0 equiv) were added and predried for 1 hour under nitrogen atmosphere. The Ugi product 2-(N-
benzylacetamido)-N-(6-bromopyridin-2-yl)-4-methylpenta-namide (7l, 209 mg, 0.5 mmol, 1.0 equiv) was added 
and the mixture was stirred for 24 h at 50 °C. The crude mixture was cooled to 0 °C and acidified at once to pH 1 
with 6M HCl and extracted with EtOAc. The organic layer was washed with 1M HCl and brine, dried over Na2SO4 
and concentrated under reduced pressure. The crude mixture was purified by flash chromatography 
(cyclohexane : EtOAc) to yield the corresponding products 10. 
General procedure VI: Transacylation under acidic conditions. 
Unless stated otherwise: The Ugi product 2-(N-benzylacetamido)-N-(6-bromopyridin-2-yl)-4-methyl-pentanamide 
(7l, 209 mg, 0.5 mmol, 1.0 equiv) was dissolved in CH2Cl2 (2 mL) and HCl in Et2O solution (1M, 2.5 mL, 2.5 mmol, 
5.0 equiv) was added. Subsequently, the nucleophile (2.5 mmol, 5.0 equiv) was added and the resulting mixture 
was stirred for 16 hours at room temperature. The crude mixture was acidified to pH 1 with 1M HCl and 
extracted with CH2Cl2. The organic layer was washed with 1M HCl and brine, dried over Na2SO4 and concentrated 
under reduced pressure to yield the corresponding products 10. 
General procedure VII: The Passerini reaction. 
An aldehyde (1.0 mmol, 1.0 equiv) was dissolved in CH2Cl2 (3 mL), acetic acid (86 µL, 1.5 mmol, 1.5 equiv) and 2-
bromo-6-isocyanopyridine (6l, 201 mg, 1.1 mmol, 1.1 equiv) were added subsequently. Additional CH2Cl2 (1 mL) 
was added and the resulting mixture was stirred for 48 hours at room temperature. The solvent was removed 
under reduced pressure and the crude mixture was purified by flash chromatography (cyclohexane : EtOAc) to 
yield the Passerini products 11. 
General procedure VIII: Hydrolysis of the Passerini products. 
A Passerini product (11, 0.2 mmol, 1.0 equiv) was dissolved in MeOH (0.9 mL) and 10M NaOH (0.1 mL, 1 mmol, 
5.0 equiv) was added. The resulting mixture stirred at room temperature for 48 hours. A small portion of water 
was added to the crude reaction mixture. The water later was washed with EtOAc (2×), acidified to pH 1 with 1M 
HCl and extracted with EtOAc (4×). The organic layer was dried over Na2SO4 and concentrated under reduced 
pressure to yield the corresponding α-hydroxy carboxylic acids 12. 
General procedure IX: The Ugi-Smiles reaction. 
Under nitrogen atmosphere benzylamine (109 µL, 1.0 mmol, 1.0 equiv) and isovaleraldehyde (108 µL, 1.0 mmol, 
1.0 equiv) were dissolved in the MeOH (3 mL) and prestirred for 2 hours at room temperature. The nitrophenol 
(1.5 mmol, 1.5 equiv) and 2-bromo-6-isocyanopyridine (220 mg, 1.2 mmol, 1.2 equiv) were added subsequently. 
Additional MeOH (1 mL) was added and the resulting mixture was refluxed for 72 hours. The solvent was 
removed under reduced pressure and the crude mixture was purified by column chromatography (cyclohexane : 
EtOAc) to yield the Ugi-Smiles-product as a foamy solid. 
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N-(6-bromopyridin-2-yl)formamide (15o).  
Following general procedure I on a 300 mmol scale with 2-amino-6-bromopyridine (5l, 51.9 
g, 300 mmol, 1.0 equiv) the formamide S1l was obtained as a white solid (59.9 g, 298 
mmol, 99%). Two rotamers were present on NMR timescale (R1 : R2 = 1 : 0.5). m.p.: 140-144 
°C. 1H NMR (CDCl3, 500 MHz) δ 9.32 (d, J = 10.5 Hz, 0.5H), 8.85 (bs, 0.5H), 8.71 (bs, 1H), 
8.53 (s, 1H), 8.19 (d, J = 8.0 Hz, 1H), 7.59 (t, J = 8.0 Hz, 1H), 7.51 (t, J = 8.0 Hz, 0.5H), 7.27-7.23 (m, 1.5H), 6.83 (d, J 
= 8.0 Hz, 0.5H). 13C NMR (CDCl3, 125 MHz) δ 162.6 (CH), 159.4 (CH), 150.7 (Cq), 150.6 (Cq), 140.9 (CH), 140.5 (CH), 
139.2 (Cq), 124.1 (CH), 123.7 (CH), 113.4 (CH), 109.3 (CH). IR (neat): νmax (cm
-1) = 3055 (w), 1686 (s), 1562 (s), 
1439 (s), 1397 (s), 1294 (s), 1238 (m), 1157 (s), 1132 (s), 792 (m), 715 (s), 517 (s). HRMS (ESI): m/z calculated for 
C6H6BrN2O [M + H]
+ 200.9658, found 200.9656. 
 
2-Isocyano-3-methylpyridine (6a). 
Following general procedure II with N-(3-methylpyridin-2-yl)formamide (S1a, 1.36 g, 10 mmol, 1.0 
equiv) the isocyanide was obtained as an off-white crystalline solid (520 mg, 4.4 mmol, 44%). m.p.: 
67 °C. 1H NMR (CDCl3, 500 MHz) δ 8.32 (d, J = 4.0 Hz, 1H), 7.67 (d, J = 7.5 Hz, 1H), 7.29 (dd, J = 7.5 
Hz, 4.7 Hz, 1H), 2.44 (s, 3H). 13C NMR (CDCl3, 125 MHz) δ 165.2 (Cq), 147.0 (CH), 140.3 (Cq), 139.4 (CH), 130.3 (Cq), 
124.6 (CH), 17.9 (CH3). IR (neat): νmax (cm
-1) = 3053 (w), 2122 (s), 1572 (s), 1115 (s), 804 (s), 633 (s), 534 (s), 498 
(s), 413 (s), 401 (s). HRMS (ESI): m/z calculated for C7H7N2 119.0604 [M + H]
+, found 119.0609. 
 
3-Bromo-2-isocyanopyridine (6b). 
Following general procedure II with N-(3-bromopyridin-2-yl)formamide (S1b, 2.01 g, 10 mmol, 1.0 
equiv) the isocyanide was obtained as a light-brown powder (1.39 g, 7.6 mmol, 76%). Degradation 
point: 64 °C. 1H NMR (CDCl3, 500 MHz) δ 8.43 (d, J = 4.0 Hz, 1H), 8.04 (d, J = 8.0 Hz), 7.29 (dd, J = 
8.0, 4.8 Hz, 1H). 13C NMR (CDCl3, 125 MHz) δ 168.2 (Cq), 147.9 (CH), 142.0 (CH), 139.7 (Cq), 125.6 
(CH), 117.2 (Cq). IR (neat): νmax (cm
-1) = 3043 (s), 2120 (s), 1564 (s), 1416 (s), 1030 (s), 804 (s), 497 (s), 411 (s), 
401 (s). HRMS (ESI): m/z calculated for C6H4BrN2 [M + H]
+ 182.9552, found 182.9552. 
 
2-Isocyano-4-methylpyridine (6c). 
Following general procedure II with N-(4-methylpyridin-2-yl)formamide (S1c, 1.36 g, 10 mmol, 1.0 
equiv) the isocyanide was obtained as a dark brown powder (177 mg, 1.5 mmol, 15%). Degradation 
point: 51 °C. 1H NMR (CDCl3, 500 MHz) δ 8.33 (d, J = 4.7 Hz, 1H), 7.19-7.18 (m, 2H), 2.40 (s, 3H). 
13C 
NMR (CDCl3, 125 MHz) δ 163.2 (Cq), 150.6 (Cq), 149.3 (CH), 140.4 (Cq), 125.7 (CH), 121.9 (CH), 20.8 
(CH3). IR (neat): νmax (cm
-1) = 3053 (w), 2122 (s), 1603 (s), 1404 (s), 837 (s), 496 (s), 451 (s), 413 (s), 401 (s). 
HRMS (ESI): m/z calculated for C7H7N2 [M + H]
+ 119.0604, found 119.0613. 
 
4-Bromo-2-isocyanopyridine (6d). 
Following general procedure II with N-(4-bromopyridin-2-yl)formamide (S1d, 2.01 g, 10 mmol, 1.0 
equiv) the isocyanide was obtained as a light brown powder (842 mg, 4.6 mmol, 46%). Degradation 
point: 76 °C. 1H NMR (CDCl3, 500 MHz) δ 8.33 (d, J = 5.0 Hz, 1H), 7.56 (d, J = 6.6 Hz, 1H), 7.54 (s, 1H). 
13C NMR (CDCl3, 125 MHz) δ 165.7 (Cq), 150.2 (CH), 140.6 (Cq), 134.5 (Cq), 128.2 (CH), 124.7 (CH). IR 
(neat): νmax (cm-1) = 3075 (w), 2133 (s), 1564 (s), 1381 (s), 837 (s), 633 (s), 498 (s), 451 (s), 418 (s), 401 (s). HRMS 
(ESI): m/z calculated for C6H4BrN2 [M + H]
+ 182.9552, found 182.9555. 
 
2-Isocyano-5-methylpyridine (6e). 
Following general procedure II with N-(5-methylpyridin-2-yl)formamide (S1e, 1.36 g, 10 mmol, 
1.0 equiv) the isocyanide was obtained as an orange-brown powder (697 mg, 5.9 mmol, 59%). 
m.p.: 62 °C. Degradation point: 69 °C. 1H NMR (CDCl3, 500 MHz) δ 8.29 (s, 1H), 7.59 (d, J = 8.0 Hz, 
1H), 7.24 (d, J = 8.1 Hz, 1H), 2.38 (s, 3H). 13C NMR (CDCl3, 125 MHz) δ 163.0 (Cq), 149.9 (CH), 139.0 (CH), 138.1 
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(Cq), 135.0 (Cq), 120.7 (CH), 18.2 (CH3). IR (neat): νmax (cm
-1) = 3057 (w), 2127 (s), 1578 (s), 1474 (s), 1034 (s), 833 
(s), 633 (s), 536 (s), 525 (s), 494 (s), 413 (s), 401 (s). HRMS (ESI): m/z calculated for C7H7N2 119.0604 [M + H]
+, 
found 119.0609. 
 
5-Fluoro-2-isocyanopyridine (6f). 
Following general procedure II with N-(5-fluoropyridin-2-yl)formamide (S1f, 1.40 g, 10 mmol, 
1.0 equiv) the isocyanide was obtained as a dark brown powder (0.330 g, 2.7 mmol, 27%). The 
product readily degrades at room temperature. Therefore, many impurities are visible in the 1H 
NMR. Degradation point: 67 °C. 1H NMR (CDCl3, 500 MHz) δ 8.35 (s, 1H), 7.55-7.51 (m, 1H), 7.41-
7.36 (m, 1H). 
 
5-Chloro-2-isocyanopyridine (6g). 
Following general procedure II with N-(5-chloropyridin-2-yl)formamide (S1g, 1.57 g, 10 mmol, 
1.0 equiv) the isocyanide was obtained as a light brown powder (499 mg, 3.6 mmol, 36%). 
Degradation point: 86 °C. 1H NMR (CDCl3, 500 MHz) δ 8.45 (s, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.33 
(d, J = 8.5 Hz, 1H). 13C NMR (CDCl3, 125 MHz) δ 165.5 (Cq), 148.8 (CH), 138.5 (CH), 138.1 (Cq), 133.1 (Cq), 122.1 
(CH). IR (neat): νmax (cm-1) =3051 (w), 2125 (s), 1572 (s), 1452 (s), 1115 (s), 1014 (s), 842 (s), 496 (s), 401 (s). 
HRMS (ESI): m/z calculated for C6H4ClN2 139.0058 [M + H]
+, found 139.0064. 
 
5-Bromo-2-isocyanopyridine (6h). 
Following general procedure II with N-(5-bromopyridin-2-yl)formamide (S1h, 2.01 g, 10 mmol, 
1.0 equiv) the isocyanide was obtained as a yellow brown powder (1.15 g, 6.3 mmol, 63%). 
Degradation point 105 °C. 1H NMR (CDCl3, 500 MHz) δ 8.56 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.28 
(d, J = 8.2 Hz, 1H). 13C NMR (CDCl3, 125 MHz) δ 165.6 (Cq), 150.9 (CH), 141.3 (CH), 138.6 (Cq), 122.4 (CH), 121.5 
(Cq). IR (neat): νmax (cm
-1) = 3049 (w), 2125 (s), 1566 (s), 1456 (s), 1450 (s), 1365 (s), 1094 (s), 1011 (s), 841 (s), 
494 (s). HRMS (ESI): m/z calculated for C6H4BrN2 [M + H]
+ 182.9552, found 182.9544. 
 
2-Isocyano-5-(trifluoromethyl)pyridine (6i). 
Following general procedure II with N-(5-(trifluoromethyl)pyridin-2-yl)formamide (S1i, 1.33 
g, 7.0 mmol, 1.0 equiv) the isocyanide was obtained as a dark brown powder (514 mg, 2.99 
mmol, 43%). The product readily degrades at room temperature. Therefore, many impurities 
are visible in the 1H NMR. 1H NMR (CDCl3, 500 MHz) δ 8.82 (s, 1H), 8.11 (d, J = 8.1 Hz, 1H), 7.53 (d, J = 8.1 Hz, 1H). 
 
2-Isocyano-6-methylpyridine (6j). 
Following general procedure II with N-(6-methylpyridin-2-yl)formamide (S1j, 1.36 g, 10 mmol, 
1.0 equiv) 2-isocyano-4-methylpyridine was obtained as a dark brown powder (709 mg, 6.0 
mmol, 60%). Degradation point: 49-51 °C. 1H NMR (CDCl3, 500 MHz) δ 7.68 (t, J = 7.8 Hz, 1H), 
7.22 (d, J = 7.8 Hz, 1H), 7.16 (d, J = 7.8 Hz, 1H) 2.55 (s, 3H). 13C NMR (CDCl3, 125 MHz) δ 163.1 (Cq), 159.6 (Cq), 
139.6 (Cq), 138.7 (CH), 124.4 (CH), 118.3 (CH), 18.3 (CH3). IR (neat): νmax (cm
-1) = 3078 (w), 2130 (s), 1595 (s), 
1450 (s), 796 (s), 633 (s), 538 (s), 496 (s), 401 (s). HRMS (ESI): m/z calculated for C7H7N2 119.0604 [M + H]
+, found 
119.0609. 
 
 6-Chloro-2-isocyanopyridine (6k). 
Following general procedure II with N-(6-chloropyridin-2-yl)formamide (S1k, 1.57 g, 10 mmol, 
1.0 equiv) 6-bromo-2-isocyanopyridine was obtained as a green powder (804 mg, 5.8 mmol, 
58%). Degradation point: 68 °C. 1H NMR (CDCl3, 500 MHz) δ 7.78 (t, J = 8.0 Hz, 1H), 7.43 (d, J = 
8.0 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H). 13C NMR (CDCl3, 125 MHz) δ 165.9 (Cq), 151.1 (Cq), 141.0 (CH), 139.2 (Cq), 
125.8 (CH), 119.8 (CH). IR (neat): νmax (cm-1) = 3082 (w), 2124 (s), 1574 (s), 1427 (s), 1163 (s), 989 (s), 864 (s), 
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802 (s), 532 (s), 498 (s), 413 (s), 401 (s). HRMS (ESI): m/z calculated for C6H4ClN2 139.0058 [M + H]
+, found 
139.0063. 
 
6-Bromo-2-isocyanopyridine (6l). 
Following general procedure II with N-(6-bromopyridin-2-yl)formamide (13, 2.01 g, 10 mmol, 
1.0 equiv) 6-bromo-2-isocyanopyridine was obtained as a green powder (1.30 g, 7.1 mmol, 
71%). Degradation point: 88 °C. 1H NMR (CDCl3, 500 MHz) δ 7.69 (t, J = 8.0 Hz, 1H), 7.59 (d, J = 
8.0 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H). 13C NMR (CDCl3, 125 MHz) δ 166.1 (Cq), 141.2 (CH), 140.6 (Cq), 139.3 (Cq) 
129.6 (CH), 120.1 (CH). IR (neat): νmax (cm-1) = 3056 (w), 2131 (s), 1570 (s), 1431 (s), 989 (s), 802 (s), 631 (s), 538 
(s), 503 (s), 496 (s), 436 (s), 405 (s). HRMS (ESI): m/z calculated for C6H4BrN2 [M + H]
+ 182.9552, found 182.9546. 
2-(N-benzylacetamido)-4-methyl-N-(3-methylpyridin-2-yl)pentanamide (7a). 
Following general procedure III with 2-isocyano-3-methylpyridine (6a, 142 mg, 1.2 mmol, 
1.2 equiv) the Ugi product was obtained as a light-brown oil (233 mg, 0.66 mmol, 66%). 
Flash chromatography: (EtOAc). 1H NMR (CDCl3, 500 MHz) δ 8.92 (bs, 1H), 8.30 (d, J = 3.9 
Hz, 1H), 7.51 (d, J = 7.4 Hz, 1H), 7.37-7.20 (m, 5H), 7.06 (t, J = 6.0 Hz, 1H), 5.19 (t, J = 7.5 
Hz, 1H), 4.65 (s, 2H), 2.29 (s, 3H), 2.21 (s, 3H), 1.97 (m, 1H), 1.58 (m, 1H), 1.46 (m, 1H), 
0.88- 0.86 (m, 6H). 13C NMR (CDCl3, 125 MHz) δ 173.6 (Cq), 169.0 (Cq), 149.3 (Cq), 146.0 (CH), 139.4 (CH), 137.1 
(Cq), 128.8 (CH), 127.3 (CH), 126.8 (Cq), 126.0 (CH), 121.2 (CH), 57.1 (CH), 49.5 (CH2), 36.9 (CH2), 25.2 (CH), 22.9 
(CH3), 22.4 (CH3), 22.2 (CH3), 17.9 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 1674 (m), 1448 (s), 1420 (s), 633 (s), 
534 (s), 496 (s), 401 (s). HRMS (ESI): m/z calculated for C21H28N3O2 [M + H]
+ 354.2176, found 354.2193. 
 
2-(N-benzylacetamido)-N-(3-bromopyridin-2-yl)-4-methylpentanamide (7b). 
Following general procedure III with 3-bromo-2-isocyanopyridine (6b, 220 mg, 1.2 
mmol, 1.2 equiv) the Ugi product was obtained as a dark yellow oil (172 mg, 0.41 mmol, 
41%). Flash chromatography: (EtOAc). 1H NMR (CDCl3, 500 MHz) δ 9.11 (bs, 1H), 8.43 (d, 
J = 4.1 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.38-7.18 (m, 5H), 6.97 (dd, J = 7.6, 4.5 Hz, 1H), 
5.22 (t, J = 6.5 Hz, 1H), 4.63 (s, 2H), 2.14 (s, 3H), 2.01 (m, 1H), 1.58 (m, 1H), 1.46 (m, 1H), 
0.92 (d, J = 5.0 Hz, 3H), 0.88 (d, J = 5.0 Hz, 3H). 13C NMR (CDCl3, 125 MHz) δ 173.6 (Cq), 168.7 (Cq), 148.6 (Cq), 
147.3 (CH), 141.3 (CH), 137.0 (Cq), 128.8 (CH), 127.4 (CH), 126.1 (CH), 121.2 (CH), 111.6 (Cq), 57.3 (CH), 49.5 (CH2), 
36.5 (CH2), 25.2 (CH), 22.9 (CH3), 22.4 (CH3), 22.3 (CH3). IR (neat): νmax (cm
-1) = 2956 (w), 1628 (m), 1497 (s), 
1431 (m), 633 (s), 534 (s), 498 (s), 405 (s). HRMS (ESI): m/z calculated for C20H25BrN3O2 [M + H]
+ 418.1125, found 
418.1130. 
 
2-(N-benzylacetamido)-4-methyl-N-(4-methylpyridin-2-yl)pentanamide (7c). 
Following general procedure III with 2-isocyano-4-methylpyridine (6c, 142 mg, 1.2 mmol, 
1.2 equiv) the Ugi product was obtained as an off-white (233 mg, 0.66 mmol, 66%). Flash 
chromatography: (cyclohexane : EtOAc = 2:1). m.p.: 106 °C. 1H NMR (CDCl3, 500 MHz) δ 
9.03 (bs, 1H), 8.14 (d, J = 4.8 Hz, 1H), 7.82 (s, 1H), 7.28-7.17 (m, 5H), 6.84 (d, J = 4.6 Hz, 
1H), 5.22 (t, J = 7.2 Hz, 1H), 4.66 (d, J = 17.5 Hz, 1H), 4.60 (d, J = 17.5 Hz, 1H), 2,31 (s, 3H), 
2.14 (s, 3H), 1.95 (m, 1H), 1.56-1.45 (m, 2H), 0.88 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 125 
MHz) δ 173.2 (Cq), 169.5 (Cq), 151.2 (Cq), 149.5 (Cq), 147.6 (CH), 137.0 (Cq), 128.8 (CH), 127.3 (CH), 126.0 (CH), 
120.9 (CH), 114.6 (CH), 56.8 (CH), 49.2 (CH2), 36.8 (CH2), 25.2 (CH), 22.8 (CH3), 22.3 (CH3), 22.3 (CH3), 21.3 (CH3). 
IR (neat): νmax (cm-1) = 2957 (w), 1697 (s), 1630 (m), 1568 (s), 1414 (s), 633 (s), 523 (s), 498 (s), 407 (s). HRMS 
(ESI): m/z calculated for C21H28N3O2 [M + H]
+ 354.2176, found 354.2185. 
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2-(N-benzylacetamido)-N-(4-bromopyridin-2-yl)-4-methylpentanamide (7d). 
Following general procedure III with 4-bromo-2-isocyanopyridine (6d, 220 mg, 1.2 
mmol, 1.2 equiv) the Ugi product was obtained as a yellow solid (272 mg, 0.65 mmol, 
65%). Flash chromatography: (cyclohexane : EtOAc = 1:1). m.p.: 111 °C. 1H NMR (CDCl3, 
500 MHz) δ 9.21 (bs, 1H), 8.19 (s, 1H), 8.10 (d, J = 5.0 Hz , 1H), 7.27 – 7.22 (m, 5H), 7.17 
(d, J = 6.6 Hz, 1H), 5.17 (t, J = 6.8 Hz, 1H), 4.66 (d, J = 17.5 Hz, 1H), 4.57 (d, J = 17.5 Hz, 
1H), 2.18 (s, 3H), 1.94 (m, 1H), 1.52 (m, 2H), 0.88 (m, 6H). 13C NMR (CDCl3, 125 MHz) δ 
173.4 (Cq), 169.6 (Cq), 151.9 (Cq), 148.5 (CH), 136.6 (Cq), 134.1 (Cq), 128.8 (CH), 127.5 (CH), 126.2 (CH), 123.0 (CH), 
117.1 (CH), 56.8 (CH), 49.4 (CH2), 36.6 (CH2), 25.1 (CH3), 22.8 (CH3), 22.4 (CH3), 22.3 (CH3). IR (neat): νmax (cm
-1) = 
2957 (w), 1628 (s), 1560 (s), 1396 (s), 633 (s), 536 (s), 498 (s), 401 (s). HRMS (ESI): m/z calculated for C20H25BrN3O2 
[M + H]+ 418.1125, found 418.1128. 
 
2-(N-benzylacetamido)-4-methyl-N-(5-methylpyridin-2-yl)pentanamide (7e). 
Following general procedure III with 2-isocyano-5-methylpyridine (6e, 142 mg, 1.2 
mmol, 1.2 equiv) the Ugi product was obtained as a yellow solid (205 mg, 0.58 mmol, 
58%). Flash chromatography: (cyclohexane : EtOAc = 2:1). m.p.: 90 °C. 1H NMR (CDCl3, 
500 MHz) δ 8.98 (bs, 1H), 8.10 (s, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.44 (d, J =  8.4 Hz, 1H), 
7.26-7.16 (m, 5H), 5.22 (m, 1H), 4.65 (d, J = 17.5 Hz, 1H), 4.59 (d, J = 17.5 Hz, 1H), 2.27 
(s, 3H), 2.13 (s, 3H), 1.92 (m, 1H), 1.55-1.48 (m, 2H), 0.88 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.7 Hz, 3H). 13C NMR 
(CDCl3, 125 MHz) δ 173.2 (Cq), 169.2 (Cq) 149.0 (Cq), 147.8 (CH), 138.5 (CH), 137.0 (Cq), 129.0 (Cq), 128.7 (CH), 
127.3 (CH), 126.0 (CH), 113.5 (CH), 56.7 (CH), 49.2 (CH2), 36.8 (CH2), 25.1 (CH), 22.7 (CH3), 22.4 (CH3), 22.4 (CH3), 
17.8 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 1630 (m), 1522 (s), 1385 (s), 1298 (s), 633 (s), 534 (m), 498 (s). 
HRMS (ESI): m/z calculated for C21H28N3O2 [M + H]
+ 354.2176, found 354.2193. 
 
2-(N-benzylacetamido)-N-(5-fluoropyridin-2-yl)-4-methylpentanamide (7f). 
Following general procedure III with 5-fluoro-2-isocyanopyridine (6f, 147 mg, 1.2 
mmol, 1.2 equiv) the Ugi product was obtained as an off-white solid (207 mg, 0.58 
mmol, 58%). Flash chromatography: (cyclohexane : EtOAc = 3:1). m.p.: 112 °C. 1H 
NMR (CDCl3, 500 MHz) δ 9.17 (bs, 1H), 8.16 (s, 1H), 7.98 (dd, J = 9.1, 3.8 Hz, 1H), 7.37 
(m, 1H), 7.28-7.17 (m, 5H), 5.21 (m, 1H), 4.67 (d, J = 17.5 Hz, 1H), 4.60 J = 17.5 Hz, 1H), 
2.20 (3H), 1.96 (m, 1H), 1.56-1.53 (m, 2H), 0.91 (m, 6H). 13C NMR (CDCl3, 125 MHz) δ 173.4 (Cq), 169.1 (Cq) 156.2 
(d, J = 250 Hz, Cq), 147.4 (Cq), 136.7 (Cq) 135.5 (d, J = 25 Hz, CH), 128.8 (CH), 127.5 (CH), 126.1 (CH), 124.8 (d, J = 
20 Hz, CH), 114.6 (CH), 56.7 (CH), 49.3 (CH2), 36.6 (CH2), 25.1 (CH), 22.7 (CH3), 22.4 (CH3), 22.4 (CH3). IR (neat): 
νmax (cm-1) = 2959 (w), 1630 (s), 1526 (s), 1472 (s), 1391(s), 633 (s), 534 (s), 498 (s). HRMS (ESI): m/z calculated 
for C20H25FN3O2 [M + H]
+ 358.1925, found 358.1932. 
 
2-(N-benzylacetamido)-N-(5-chloropyridin-2-yl)-4-methylpentanamide (7g). 
Following general procedure III with 5-chloro-2-isocyanopyridine (6g, 166 mg, 1.2 
mmol, 1.2 equiv) the Ugi product was obtained as an orange solid (232 mg, 0.62 
mmol, 62%). Flash chromatography: (cyclohexane : EtOAc = 4:1). m.p.: 112 °C. 1H 
NMR (CDCl3, 500 MHz) δ 9.16 (bs, 1H), 8.24 (s, 1H), 7.92 (d, J = 8.9 Hz, 1H), 7.58 (d, J = 
8.8 Hz), 7.26-7.15 (m, 5H), 5.18 (m, 1H), 4.65 (d, J = 17.4 Hz, 1H), 4.57 (d, J = 17.4 Hz, 
1H), 2.18 (s, 3H), 1.94 (m, 1H), 1.56-1.51 (m, 2H), 0.89-0.87 (m, 6H). 13C NMR (CDCl3, 125 MHz) δ 173.4 (Cq), 169.4 
(Cq) 149.5 (Cq), 146.6 (CH), 137.6 (CH) 136.6 (Cq), 128.8 (CH), 127.5 (CH), 126.6 (Cq), 126.1 (CH), 114.5 (CH), 56.8 
(CH), 49.4 (CH2), 36.5 (CH2), 25.1 (CH), 22.7 (CH3), 22.4 (CH3), 22.4 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 1628 
(m), 1522 (m), 1375 (s), 1292 (s), 633 (s), 538 (s), 498 (s). HRMS (ESI): m/z calculated for C20H25ClN3O2 [M + H]
+ 
374.1630, found 374.1633. 
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2-(N-benzylacetamido)-N-(5-bromopyridin-2-yl)-4-methylpentanamide (7h). 
Following general procedure III with 5-bromo-2-isocyanopyridine (6h, 220 mg, 1.2 
mmol, 1.2 equiv) the Ugi product was obtained as a brown solid (318 mg, 0.76 
mmol, 76%). Flash chromatography: (cyclohexane : EtOAc = 3:1). m.p.: 110 °C. 1H 
NMR (CDCl3, 500 MHz) δ 9.20 (bs, 1H), 8.34 (s, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.73 (d, J 
= 8.7 Hz, 1H), 7.27-7.17 (m, 5H), 5.20 (t, J = 6.7 Hz, 1H), 4.67 (d, J = 17.4 Hz, 1H), 4.59 
(d, J = 17.4 Hz, 1H), 2.20 (s, 3H), 1.95 (m, 1H), 1.57-1.54 (m, 2H), 0.91-0.89 (m, 6H). 13C NMR (CDCl3, 125 MHz) δ 
173.4 (Cq), 169.4 (Cq), 149.9 (Cq), 148.9 (CH), 140.4 (CH), 136.6 (Cq), 128.8 (CH) 127.5 (CH), 126.1 (CH), 115.1 (CH), 
114.5 (Cq), 56.8 (CH), 49.4 (CH2), 36.5 (CH2), 25.1 (CH), 22.7 (CH3), 22.4 (CH3), 22.4 (CH3). IR (neat): νmax (cm
-1) = 
2957 (w), 1626 (m), 1518 (m), 1367 (s), 1290 (s), 633 (s), 523 (m), 498 (s), 413 (s), 403 (s). HRMS (ESI): m/z 
calculated for C20H25BrN3O2 [M + H]
+ 418.1125, found 418.1138. 
 
2-(N-benzylacetamido)-4-methyl-N-(5-(trifluoromethyl)pyridin-2-yl)pentanamide (7i). 
Following general procedure III with 2-isocyano-5-(trifluoromethyl)pyridine (6i, 207 
mg, 1.2 mmol, 1.2 equiv) the Ugi product was obtained as a solid (61 mg, 0.15 
mmol, 15%). Flash chromatography: (cyclohexane : EtOAc = 4:1). m.p.: 93-94 °C. 1H 
NMR (CDCl3, 500 MHz) δ 9.47 (bs, 1H), 8.56 (s, 1H), 8.08 (d, J = 8.7 Hz, 1H), 7.85 (d, J 
= 8.7 Hz, 1H), 7.28-7.17 (m, 5H), 5.21 (m, 1H), 4.68 (d, J = 17.4 Hz, 1H), 4.59 (d, J = 
17.4 Hz, 1H), 2.23 (s, 3H), 1.97 (m, 1H), 1.60-1.55 (m, 2H), 0.92 (m, 6H). 13C NMR (CDCl3, 125 MHz) δ 173.5 (Cq), 
169.8 (Cq) 153.8 (Cq), 145.4 (q, J = 3.7 Hz, CH), 136.5 (Cq), 135.3 (q, J = 3.7 Hz, CH), 128.8 (CH), 127.6 (CH), 126.2 
(CH), 123.5 (q, J = 270 Hz, Cq), 122.3 (q, J = 31 Hz, Cq), 113.2 (CH), 56.9 (CH), 49.5 (CH2), 36.5 (CH2), 25.1 (CH), 22.7 
(CH3), 22.4 (CH3), 22.4 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 1626 (m), 1520 (s), 1325 (s), 908 (s), 731 (s), 633 
(s), 532 (s), 496 (s). HRMS (ESI): m/z calculated for C21H25F3N3O2 [M + H]
+ 408.1893, found 408.1909. 
 
2-(N-benzylacetamido)-4-methyl-N-(6-methylpyridin-2-yl)pentanamide (7j). 
Following general procedure III with 2-isocyano-6-methylpyridine (6j, 142 mg, 1.2 
mmol, 1.2 equiv) the Ugi product was obtained as an off-white solid (219 mg, 0.62 
mmol, 62%). Flash chromatography: (cyclohexane : EtOAc = 2:1). m.p.: 84 °C. 1H NMR 
(CDCl3, 500 MHz) δ 8.84 (bs, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.30-
7.18 (m, 5H), 6.88 (d, J = 7.5 Hz, 1H), 5.28 (m, 1H), 4.68 (d, J = 17.6 Hz, 1H), 4.62 (d, J = 
17.6 Hz, 1H), 2.46 (s, 3H), 2.16 (s, 3H), 1.93 (m, 1H), 1.57-1.48 (m, 2H), 0.91-0.81 (m, 6H). 13C NMR (CDCl3, 125 
MHz) δ 173.1 (Cq), 169.2 (Cq), 157.0 (Cq), 150.4 (Cq), 138.3 (CH), 137.1 (Cq), 128.8 (CH), 127.3 (CH), 126.0 (CH), 
119.2 (CH), 110.7 (CH), 56.5 (CH), 49.0 (CH2), 36.8 (CH2), 25.1 (CH), 24.0 (CH3), 22.8 (CH3), 22.4 (CH3), 22.3 (CH3). 
IR (neat): νmax (cm-1) = 2957 (w), 1630 (m), 1454 (s), 633 (s), 536 (s), 498 (s), 403 (s). HRMS (ESI): m/z calculated 
for C21H28N3O2 [M + H]
+ 354.2176, found 354.2182. 
 
2-(N-benzylacetamido)-N-(6-chloropyridin-2-yl)-4-methylpentanamide (7k). 
Following general procedure III with 6-chloro-2-isocyanopyridine (6k, 166 mg, 1.2 
mmol, 1.2 equiv) the Ugi product was obtained as a brown solid (243 mg, 0.65 mmol, 
65%). Flash chromatography: (cyclohexane : EtOAc = 7:1). m.p.: 100 °C. 1H NMR 
(CDCl3, 500 MHz) δ 8.98 (bs, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.58 (t, J = 7.9 Hz, 1H), 7.30-
7.18 (m, 5H), 7.04 (d, J = 7.6 Hz, 1H), 5.23 (m, 1H), 4.67 (d, J = 17.4 Hz, 1H), 4.60 (d, J = 
17.4 Hz, 1H), 2.20 (s, 3H), 1.94 (m, 1H), 1.57-1.52 (m, 2H), 0.91 (m, 6H). 13C NMR (CDCl3, 125 MHz) δ173.2 (Cq), 
169.5 (Cq) 151.0 (Cq), 149.0 (Cq), 140.5 (CH), 136.7 (Cq), 128.8 (CH), 127.5 (CH), 126.1 (CH), 119.7 (CH), 112.0 (CH), 
56.5 (CH), 49.2 (CH2), 36.7 (CH2), 25.1 (CH), 22.7 (CH3), 22.4 (CH3), 22.3 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 
1628 (s), 1572 (s), 1435 (s), 1157 (s), 633 (s), 536 (s), 498 (s), 424 (s), 413 (s), 403 (s). HRMS (ESI): m/z calculated 
for C20H25ClN3O2 [M + H]
+ 374.1630, found 374.1632. 
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2-(N-benzylacetamido)-N-(6-bromopyridin-2-yl)-4-methylpentanamide (7l). 
Following general procedure III with 6-bromo-2-isocyanopyridine (6l, 220 mg, 1.2 
mmol, 1.2 equiv) the Ugi product was obtained as a brown solid (293 mg, 0.70 mmol, 
70%). Flash chromatography: (cyclohexane : EtOAc = 7:1). m.p.: 116 °C. 1H NMR 
(CDCl3, 500 MHz) δ 9.06 (bs, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 7.27-
7.14 (m, 6H), 5.27 (m, 1H), 4.67 (d, J = 17.4 Hz, 1H), 4.60 (d, J = 17.4 Hz, 1H), 2.18 (s, 
3H), 1.92 (m, 1H), 1.54-1.48 (m, 2H), 0.88 (m, 6H). 13C NMR (CDCl3, 125 MHz) δ 173.1 (Cq), 169.5 (Cq) 151.2 (Cq), 
140.1 (CH), 139.3 (Cq), 136.8 (Cq), 128.8 (CH), 127.4 (CH), 126.1 (CH), 123.4 (CH), 112.3 (CH), 56.4 (CH), 49.1 (CH2), 
36.8 (CH2), 25.1 (CH), 22.7 (CH3), 22.3 (CH3), 22.3 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 1624 (s), 1566 (s), 1429 
(s), 1388 (s), 1155 (s), 633 (s), 530 (s), 496 (s), 403 (s). HRMS (ESI): m/z calculated for C20H25BrN3O2 [M + H]
+ 
418.1125, found 418.1139. 
 
N-benzyl-N-(2-((6-bromopyridin-2-yl)amino)-2-oxoethyl)acetamide (9b). 
Following general procedure III in MeOH with benzylamine (109 µL, 1.0 mmol, 1.0 
equiv), paraformaldehyde (45 mg, 1.0 mmol, 1.0 equiv) and acetic acid (86 µL, 1.5 
mmol, 1.5 equiv) the Ugi product was obtained as an orange solid (140 mg, 0.39 
mmol, 39%). Flash chromatography: (cyclohexane : EtOAc = a gradient of 10:1 to 8:1). 
m.p.: 191°C. Two rotamers were present on NMR timescale (R1 : R2 = 1 : 0.2). 1H NMR (CDCl3, 500 MHz) δ 8.69 
(bs, 1H), 8.22 (bs, 0.2H), 8.12 (d, J = 8.1 Hz, 0.2H), 8.08 (d, J = 7.7 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1.2H), 7.38-7-26 (m, 
3.6H), 7.20 (dd, J = 4.9, 2.7 Hz, 2.4H), 4.70 (s, 2.4H), 4.14 (s, 2H), 4.04 (s, 0.4H), 2.30 (s, 3H), 2.19 (s, 0.6H). 13C 
NMR (CDCl3, 125 MHz) δ 172.4 (Cq), 167.4 (Cq), 151.0 (Cq), 140.4 (CH), 139.3 (Cq), 135.3 (Cq), 129.1 (CH), 128.9 
(CH), 128.5 (CH), 128.1 (CH), 127.9 (CH), 126.6 (CH), 123.7 (CH), 112.4 (CH), 53.4 (CH2), 51.6 (CH2), 50.6 (CH2), 
49.9 (CH2), 21.8 (CH3) 21.4 (CH3). IR (neat): νmax (cm
-1) = 3227 (w), 3040 (w), 1701 (s), 1623 (m), 1568 (s), 1431 
(s), 1155 (s), 1128 (s), 789 (s), 729 (s). HRMS (ESI): m/z calculated for C16H17BrN3O2 [M + H]
+ 362.0499, found 
362.0485. 
 
N-benzyl-N-(1-((6-bromopyridin-2-yl)amino)-4-methyl-1-oxopentan-2-yl)benzamide (9c). 
Following general procedure III in TFE with benzylamine (109 µL, 1.0 mmol, 1.0 
equiv), 3-methylbutyraldehyde (108 µL, 1.0 mmol, 1.0 equiv) and benzoic acid (183 
mg, 1.5 mmol, 1.5 equiv) the Ugi product was obtained as an light-brown solid (384 
mg, 0.80 mmol, 80%). Flash chromatography: (cyclohexane : EtOAc = 10:1). m.p.: 
102-103 °C. 1H NMR (CDCl3, 500 MHz) δ 9.38 (bs, 1H), 7.78-6.97 (m, 13H), 5.04 (m, 
1H), 4.75 (d, J = 15.0 Hz, 1H), 4.47 (m, 1H), 1.96 (m, 2H), 1.72 (m, 1H), 0.99 (m, 6H). 13C NMR (CDCl3, 125 MHz) δ 
174.1 (Cq), 169.4 (Cq), 151.1 (Cq), 139.9 (CH), 139.2 (Cq), 135.8 (Cq), 135.2 (Cq), 130.3 (CH), 128.6 (CH), 128.4 (CH), 
127.6 (CH), 127.5 (CH), 123.2 (CH), 112.3 (CH), 57.5 (CH), 51.5 (CH2), 36.3 (CH2), 24.9 (CH), 22.9 (CH3), 22.0 (CH3). 
IR (neat): νmax (cm-1) = 3252 (w), 2955 (w), 1697 (s), 1564 (s), 1522 (m), 1431 (s), 1155 (s), 787 (s), 698 (m). 
HRMS (ESI): m/z calculated for C25H27BrN3O2 [M + H]
+ 480.1281, found 480.1272. 
 
N-benzyl-N-(1-((6-bromopyridin-2-yl)amino)-4-methyl-1-oxopentan-2-yl)thiophene-2-carboxamide (9d). 
Following general procedure III in TFE with benzylamine (109 µL, 1.0 mmol, 1.0 
equiv), 3-methylbutyraldehyde (108 µL, 1.0 mmol, 1.0 equiv) and thiophene-2-
carboxylic acid (192 mg, 1.5 mmol, 1.5 equiv) the Ugi product was obtained as a 
brown solid (398 mg, 0.82 mmol, 82%). Flash chromatography: (cyclohexane : 
EtOAc = a gradient of 10:1 to 7:1). m.p.: 120 °C. The spectra contain minor 
amounts of EtOAc. 1H NMR (CDCl3, 500 MHz) δ  9.18 (bs, 7.83 (d, J = 8.1 Hz, 1H), 7.51 (d, J = 2.5 Hz, 1H), 7.46-7.41 
(m, 2H), 7.27-7.17 (m, 6H), (t, J = 4.4 Hz, 1H), 5.04 (d, J = 17.1 Hz, 1H), 5.02 (t, J = 7.3 Hz, 1H), 4.82 (d, J = 16.8 Hz, 
1H), 1.99 (m, 1H), 1.75 (m, 1H), 1.61 (m, 1H), 0.90 (m, 6H).13C NMR (CDCl3, 125 MHz) δ 169.3 (Cq), 166.7 (Cq), 
151.2 (Cq), 140.1 (CH), 139.4 (Cq), 137.1 (Cq), 136.5 (Cq), 130.8 (CH), 130.0 (CH), 128.7 (CH), 127.7 (CH), 127.3 (CH), 
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127.2 (CH), 123.6 (CH), 112.5 (CH), 59.2 (CH), 51.5 (CH2), 37.1 (CH2), 25.2 (CH). 22.6 (CH3), 22.5 (CH3). IR (neat): 
νmax (cm-1) = 3240 (w), 2957 (w), 1697 (s), 1562 (s), 1517 (s), 1427 (s), 1387 (s), 1155 (s), 1120 (s), 727 (s). HRMS 
(ESI): m/z calculated for C23H25BrN3O2S [M + H]
+ 486.0845, found 486.0831. 
 
 N-(6-bromopyridin-2-yl)-2-(N-(4-chlorobenzyl)pivalamido)-4-methyl-pentanamide (9e). 
Following general procedure III in MeOH with (4-chlorophenyl)-methanamine 
(122 µL, 1.0 mmol, 1.0 equiv), 3-methylbutyraldehyde (108 µL, 1.0 mmol, 1.0 
equiv) and pivalic acid (153 mg, 1.5 mmol, 1.5 equiv) the Ugi product was 
obtained as a yellow solid (287 mg, 0.58 mmol, 58%). Flash chromatography: 
(cyclohexane : EtOAc = a gradient of 12:1 to 7:1). m.p.: 117 °C. 1H NMR (CDCl3, 
500 MHz) δ 9.04 (bs, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.22-
7.13 (m, 6H), 4.89 (d, J = 16.3 Hz, 1H), 4.66 (t, J = 7.4 Hz, 1H), 4.56 (d, J = 16.3 Hz, 1H), 1.85 (m, 1H), 1.69 (m, 1H), 
1.54 (m, 1H), 1.38 (s, 9H), 0.91 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6, 3H). 13C NMR (CDCl3, 125 MHz) δ 180.3 (Cq), 
169.8 (Cq), 151.2 (Cq), 140.0 (CH), 139.3 (Cq), 134.7 (Cq), 133.6 (Cq), 128.9 (CH), 128.8 (CH), 123.3 (CH), 112.3 (CH), 
59.1 (CH), 49.9 (CH2), 40.2 (Cq), 36.7 (CH2), 28.9 (CH3), 24.9 (CH), 22.8 (CH3), 22.3 (CH3). IR (neat): νmax (cm
-1) = 
2957 (w), 1701 (s), 1562 (s), 1431 (s), 1155 (s), 787 (s). HRMS (ESI): m/z calculated for C23H30BrClN3O2 [M + H]
+ 
494.1204, found 494.1201. 
 
2-(N-benzylacetamido)-N-(6-bromopyridin-2-yl)-2-phenylacetamide (9f). 
Following general procedure III in TFE with benzylamine (109 µL, 1.0 mmol, 1.0 
equiv), benzaldehyde (102 µL, 1.0 mmol, 1.0 equiv) and acetic acid (86 µL, 1.5 mmol, 
1.5 equiv) the Ugi product was obtained as an off-white solid (317 mg, 0.73 mmol, 
73%). Flash chromatography: (cyclohexane : EtOAc = 4:1). m.p.: 158-159 °C. 1H NMR 
(CDCl3, 500 MHz) δ 8.23 (bs, 1H), 8.20 (d, J = 8.3 Hz, 1H), 7.53 (t, J = 8.3 Hz, 1H), 7.34 (m, 2H), 7.27 (m, 3H), 7.18 
(m, 4H), 6.98 (d, J = 7.3 Hz, 2H), 6.12 (s, 1H), 4.75 (d, J = 17.6 Hz, 1H), 4.53 (d, J = 17.6, 1H), 2.17 (s, 3H). 13C NMR 
(CDCl3, 125 MHz) δ 172.8 (Cq), 168.6 (Cq), 151.1 (Cq), 140.5 (CH), 139.2 (Cq), 137.1 (Cq), 133.3 (Cq), 130.1 (CH), 
129.2 (CH), 129.1 (CH), 128.4 (CH), 127.0 (CH), 126.0 (CH), 123.6 (CH), 112.3 (CH), 63.9 (CH), 50.5 (CH2), 22.4 
(CH3). IR (neat): νmax (cm
-1) = 3238 (w), 3030 (w), 1703 (s), 1634 (s), 1568 (s), 1431 (m), 1153 (s), 698 (m), 631 (s), 
530 (s), 500 (s). HRMS (ESI): m/z calculated for C22H21BrN3O2 [M + H]
+ 438.0812, found 438.0804. 
 
N-(2-((6-bromopyridin-2-yl)amino)-2-oxo-1-phenylethyl)-N-(4-methoxy-phenethyl)propionamide (9g). 
Following general procedure III in TFE with 2-(4-methoxyphenyl)-ethanamine  (147 
µL, 1.0 mmol, 1.0 equiv), benzaldehyde (102 µL, 1.0 mmol, 1.0 equiv) and 
propionic acid (112 µL, 1.5 mmol, 1.5 equiv) the Ugi product was obtained as an 
orange solid (346 mg, 0.70 mmol, 70%). Flash chromatography: (cyclohexane : 
EtOAc = 8:1). m.p.: 152 °C.  1H NMR (CDCl3, 500 MHz) δ  8.23 (bs, 1H), 8.21 (d, J = 
8.2 Hz, 1H), 7.52 (t, J = 7.9 Hz, 1H), 7.50-7.41 (m, 5H), 7.17 (d, J = 7.7 Hz, 1H), 6.78-6.74 (m, 4H), 6.19 (s, 1H), 3.75 
(s, 3H), 3.45 (m, 2H), 2.62-2.43 (m, 3H), 2.10 (m, 1H), 1.20 (t, J = 7,3 Hz, 3H). 13C NMR (CDCl3, 125 MHz) δ 175.0 
(Cq), 168.9 (Cq), 158.2 (Cq), 151.2 (Cq), 140.4 (CH), 139.2 (Cq), 133.9 (Cq), 130.2 (CH), 130.1 (Cq), 129.4 (CH), 129.3 
(CH), 129.2 (CH), 123.5 (CH), 113.9 (CH), 112.3 (CH), 63.5 (CH), 55.2 (CH3), 48.1 (CH2), 35.4 (CH2), 26.7 (CH2), 9.4 
(CH3). IR (neat): νmax (cm
-1) = 3238 (w), 2937 (w), 1705 (m), 1618 (s), 1568 (s), 1512 (s), 1431 (s), 1153 (s), 787 
(m). HRMS (ESI): m/z calculated for C25H27BrN3O3 [M + H]
+ 496.1130, found 496.1123. 
 
  
2-Bromo-6-isocyanopyridine as a Universal Convertible Isocyanide for Multicomponent Chemistry 
 
 
69 
N-(6-bromopyridin-2-yl)-2-(4-chlorophenyl)-2-(N-propylacetamido)-acetamide (9h). 
Following general procedure III in TFE with propylamine (82 µL, 1.0 mmol, 1.0 equiv), 
4-chlorobenzaldehyde (141 mg, 1.0 mmol, 1.0 equiv) and acetic acid (86 µL, 1.5 
mmol, 1.5 equiv) the Ugi product was obtained as an off-white solid (327 mg, 0.77 
mmol, 77%). Flash chromatography: (cyclohexane : EtOAc = 4:1). m.p.: 166 °C. 1H 
NMR (CDCl3, 500 MHz) δ 8.81 (bs, 1H), 8.17 (d, J = 8.0 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 
7.33 (bs, 4H), 7.17 (d, J = 7.5, 1H), 6.11 (s, 1H), 3.25 (t, J = 8.0 Hz, 2H), 2.25 (s, 3H), 
1.45 (m, 1H), 1.05 (m, 1H), 0.69 (t, J = 7.0 Hz, 3H). 13C NMR (CDCl3, 125 MHz) δ 172.1 
(Cq), 168.6 (Cq), 151.2 (Cq), 140.4 (CH), 139.3 (Cq), 135.0 (Cq), 132.8 (Cq), 131.0 (CH), 123.6 (CH), 112.3 (CH), 62.6 
(CH), 49.2 (CH2), 23.0 (CH2), 21.8 (CH3) 11.1 (CH3). IR (neat): νmax (cm
-1) = 2968 (w), 1703 (m), 1616 (m), 1566 (s), 
1533 (m), 1427 (s), 1391 (s), 1300 (m), 1155 (s), 1128 (s), 789 (s), 731 (s), 548 (s). HRMS (ESI): m/z calculated for 
C18H20BrClN3O2 [M + H]
+ 424.0422, found 424.0418. 
 
2-(N-benzylacetamido)-N-(6-bromopyridin-2-yl)-2-cyclohexylacetamide (9i). 
Following general procedure III in MeOH with benzylamine (109 µL, 1.0 mmol, 1.0 
equiv), cyclohexanecarbaldehyde (121 µL, 1.0 mmol, 1.0 equiv) and acetic acid (86 
µL, 1.5 mmol, 1.5 equiv) the Ugi product was obtained as an off-white solid (396 mg, 
0.89 mmol, 89%). Flash chromatography: (cyclohexane : EtOAc = a gradient of 10:1 to 
6:1). The spectra contain minor amounts of EtOAc. m.p.: 90 °C. 1H NMR (CDCl3, 500 
MHz) δ 9.26 (bs, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.21-7.12 (m, 6H), 4.78 (m, 1H), 4.68 (d, J = 
17.2 Hz, 1H), 4.61 J = 17.2 Hz, 1H), 2.28 (m, 1H), 2.17 (s, 3H), 1.75-1.60 (m, 6H), 1.20-1.14 (m, 2H), 1.03-0.99 (m, 
2H). 13C NMR (CDCl3, 125 MHz) δ 173.2 (Cq), 168.8 (Cq), 151.2 (Cq), 140.2 (CH), 139.3 (Cq), 136.7 (Cq), 128.7 (CH), 
127.3 (CH), 126.1 (CH), 123.5 (CH), 112.4 (CH), 60.4 (CH), 50.1 (CH2), 35.6 (CH), 30.2 (CH2), 28.9 (CH2), 26.2 (CH2), 
25.6 (CH2), 25.5 (CH2), 22.4 (CH3). IR (neat): νmax (cm
-1) = 3198 (w), 2924 (w), 1628 (s), 1568 (s), 1431 (s), 773 
(m), 631 (s),534 (m), 494 (s), 405 (s). HRMS (ESI): m/z calculated for C22H27BrN3O2 [M + H]
+ 444.1281, found 
444.1266. 
 
2-(N-benzylpropionamido)-N-(6-bromopyridin-2-yl)-3,3-dimethyl-butanamide (9j). 
Following general procedure III in MeOH with benzylamine (109 µL, 1.0 mmol, 1.0 
equiv), pivaldehyde (110 µL, 1.0 mmol, 1.0 equiv) and propionic acid (112 µL, 1.5 
mmol, 1.5 equiv) the Ugi product was obtained as a white solid (395 mg, 0.92 
mmol, 92%). Flash chromatography: (cyclohexane : EtOAc = 10:1). m.p.: 160 °C. 1H 
NMR (CDCl3, 500 MHz) δ 8.69 (bs, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.37 (t, J = 7.8 Hz, 
1H), 7.18-7-04 (m, 6H), 5.36 (bs, 1H), 5.19 (d, J = 17.5 Hz, 1H), 4.74 (d, J = 17.5 Hz, 1H), 2.39 (m, 1H), 2.22 (m, 1H), 
1.14 (s, 9H), 1.10 (t, J = 7.3 Hz, 3H). 13C NMR (CDCl3, 125 MHz) δ 176.7 (Cq), 168.3 (Cq), 150.8 (Cq), 140.2 (CH), 
139.2 (Cq), 138.1 (Cq), 128.6 (CH), 126.7 (CH), 125.3 (CH), 123.6 (CH), 112.4 (CH) 49.6 (CH2), 36.7 (Cq),  27.6 (CH3), 
27.4 (CH2), 9.8 (CH3). IR (neat): νmax (cm
-1) = 2960 (w), 1630 (s), 1566 (s), 1529 (m), 1431 (s), 1389 (s), 1153 (s), 
1128 (s), 789 (s), 731 (s). HRMS (ESI): m/z calculated for C21H27BrN3O2 [M + H]
+ 432.1281, found 432.1267. 
 
Methyl 3-(N-(1-((6-bromopyridin-2-yl)amino)-3,3-dimethyl-1-oxobutan-2-yl)acetamido)propanoate (9k). 
Following general procedure III in MeOH on a 3.0 mmol scale with β-alanine methyl 
ester (309 mg, 3.0 mmol, 1.0 equiv), pivaldehyde (330 µL, 3.0 mmol, 1.0 equiv) and 
acetic acid (216 µL, 3.75 mmol, 1.25 equiv) the Ugi product was obtained as an off-
white solid (910 mg, 2.20 mmol, 73%). Flash chromatography: (cyclohexane : EtOAc 
= 2:1). The spectra contain minor amounts of EtOAc. m.p.: 187-188 °C. 1H NMR 
(CDCl3, 500 MHz) δ 9.60 (bs, 1H), 8.17 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.19 
(d, J = 7.5 Hz, 1H), 5.31 (bs, 1H), 4.17 (m, 1H), 3.85 (m, 1H), 3.65 (s, 3H), 2.63-2.56 (m, 2H), 2.34 (s, 3H), 1.11 (s, 
9H). 13C NMR (CDCl3, 125 MHz) δ 172.8 (Cq), 171.3 (Cq), 169.1 (Cq), 151.3 (Cq), 140.4 (CH), 139.5 (Cq), 123.7 (CH), 
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112.6 (CH), 60.4 (CH2), 51.9 (CH), 36.5 (Cq), 34.6 (CH2), 27.8 (CH3), 21.9 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 
1735 (s), 1628 (s), 1568 (s), 1431 (s), 1153 (s), 764 (m), 631 (s), 534 (m), 498 (s), 401 (s). HRMS (ESI): m/z 
calculated for C17H25BrN3O4 [M + H]
+ 414.1023, found 414.1017. 
 
2-(N-benzylacetamido)-4-methylpentanoic acid (8a). 
Following general procedure IV with 2-(N-benzylacetamido)-N-(6-bromopyridin-2-yl)-4-
methylpentanamide (7l, 42 mg, 0.1 mmol, 1.0 equiv) the corresponding carboxylic acid was 
obtained as an off-white solid (26 mg, 0.1 mmol, 100%). m.p.: 90 °C. Two rotamers were 
present on NMR timescale (R1 : R2 = 1 : 0.3). 1H NMR (CDCl3, 500 MHz) δ 11.40 (bs, 1.3H), 7.42-
7.18 (m, 6.5H), 5.05 (d, J = 15.6 Hz, 0.3H), 4.75-4.70 (m, 2H), 4.51 (d, J = 17.3 Hz, 1H), 4.42 (m, 
0.3H), 4.22 (d, J = 15.6 Hz, 0.3H), 2.30 (s, 0.9H), 2.17 (s, 3H), 1.92 (m, 1H), 1.73 (m, 0.3H), 1.65-1.49 (m, 2.3H), 
1.36 (m, 0.3H), 0.89 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.5 Hz, 0.9H), 0.75 (d, J = 6.6 Hz, 3H), 0.59 (d, J = 6.7 Hz, 0.9H). 
13C NMR (CDCl3, 125 MHz) δ 175.4 (Cq), 174.4 (Cq), 173.3 (Cq), 173.0 (Cq), 138.2 (Cq), 136.5 (Cq), 128.8 (CH), 128.1 
(CH), 127.8 (CH), 127.6 (CH), 126.9 (CH), 126.6 (CH), 59.5 (CH), 57.2 (CH), 51.7 (CH2), 47.5 (CH2), 38.4 (CH2), 38.1 
(CH2), 25.2 (CH), 24.4 (CH), 22.2 (CH3), 22.2 (CH3), 22.2 (CH3), 22.0 (CH3), 22.0 (CH3), 21.7 (CH3). IR (neat): νmax 
(cm-1) = 2955 (w), 1735 (s), 1718 (s), 729 (s), 632 (s), 546 (s), 501 (s). HRMS (ESI): m/z calculated for C15H22NO3 [M 
+ H]+ 264. 1594, found 264.1603. 
 
2-(N-benzylacetamido)acetic acid (8b). 
Following general procedure IV with N-benzyl-N-(2-((6-bromopyridin-2-yl)amino)-2-
oxoethyl)acetamide (9b, 36 mg, 0.10 mmol, 1.0 equiv) the corresponding carboxylic acid was 
obtained as an off-white solid (21 mg, 0.10 mmol, 100%). Two rotamers were present on NMR 
timescale (R1 : R2 = 1 : 0.4). 1H NMR (CDCl3, 500 MHz) δ 8.60 (bs, 1.4H), 7.39-7.19 (m, 7H), 4.66 
(s, 0.8H), 4.63 (s, 2H), 4.09 (s, 2H), 3.94 (s, 0.8H), 2.25 (s, 3H), 2.16 (s, 1.2H). 13C NMR (CDCl3, 125 MHz) δ 172.7 
(Cq), 172.6 (Cq), 172.3 (Cq), 172.1 (Cq), 136.31 (Cq), 135.4 (Cq), 129.1 (CH), 128.7 (CH), 128.4 (CH), 128.0 (CH), 127.7 
(CH), 126.7 (CH), 53.0 (CH2), 49.5 (CH2), 48.8 (CH2), 47.1 (CH2), 21.3 (CH3), 21.1 (CH3). IR (neat): νmax (cm
-1) = 2927 
(w), 1732 (m), 1599 (m), 1431 (m), 1201 (m), 633 (s), 532 (m), 498 (s), 403 (s). HRMS (ESI): m/z calculated for 
C11H14NO3 [M + H]
+ 208.0968, found 208.0964. 
 
2-(N-benzylbenzamido)-4-methylpentanoic acid (8c). 
Following general procedure V with N-benzyl-N-(1-((6-bromopyridin-2-yl)amino)-4-methyl-
1-oxopentan-2-yl)benzamide (9c, 48 mg, 0.10 mmol, 1.0 equiv) the corresponding carboxylic 
acid was obtained as a brown oil (33 mg, 0.10 mmol, 100%). Two rotamers were present on 
NMR timescale (R1 : R2 = 1 : 0.7). 1H NMR (CDCl3, 500 MHz) δ 10.45 (bs, 1.7H), 7.59-7.16 (m, 
17H), 5.19 (d, J = 14.3 Hz, 0.7H), 4.69 (d, J = 15.6 Hz, 1H), 4.49 (m, 1.7H), 4.21 (d, J = 14.6 Hz, 
0.7H), 4.14 (m, 1H), 2.19 (m, 1H), 1.83-1.52 (m, 3.1H), 1.30 (m, 1H), 0.98-0.82  (m, 6H), 0.60-0.40 (m, 4.2H). 13C 
NMR (CDCl3, 125 MHz) δ 176.0 (Cq), 175.5 (Cq), 173.7 (Cq), 173.6 (Cq), 138.3 (Cq), 135.8 (Cq), 135.7 (Cq), 135.2 (Cq), 
130.3 (CH), 130.1 (CH), 129.7 (CH), 128.8 (CH), 128.4 (CH), 128.3 (CH), 128.1 (CH), 127.9 (CH), 127.4 (CH), 127.0 
(CH), 126.6 (CH), 60.6 (CH), 58.7 (CH), 54.6 (CH2), 47.4 (CH2), 38.2 (CH2), 29.7 (CH2), 25.4 (CH), 24.2 (CH), 22.4 
(CH3), 22.2 (CH3), 21.4 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 1713 (m), 1593 (m), 1447 (m), 1246 (m), 733 (m), 
633 (s), 536 (s), 494 (s), 403 (s). HRMS (ESI): m/z calculated for C20H24NO3 [M + H]
+ 326.1751, found 326.1748. 
 
N-benzyl-N-(thiophene-2-carbonyl)leucine (8d). 
Following general procedure V with N-benzyl-N-(1-((6-bromopyridin-2-yl)amino)-4-
methyl-1-oxopentan-2-yl)thiophene-2-carboxamide (9d, 49 mg, 0.10 mmol, 1.0 equiv) the 
corresponding carboxylic acid was obtained as a yellow oil (33 mg, 0.10 mmol, 100%). 1H 
NMR (CDCl3, 500 MHz) δ 10.35 (bs, 1H), 7.49 (s, 1H), 7.47-7.30 (m, 6H), 7.00 (s, 1H), 4.99 
(d, J =16.5 Hz, 1H), 4.79 (bs, 1H), 4.16 (bs, 1H), 2.17 (m, 1H), 1.65 (m, 2H), 0.91-0.63 (m, 
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6H). 13C NMR (CDCl3, 125 MHz) δ 175.8 (Cq), 166.4 (Cq), 136.9 (Cq), 129.5 (CH), 128.8 (CH), 127.8 (CH), 127.4 (CH), 
127.2 (CH), 60.0 (CH), 38.3 (CH2), 29.7 (CH2), 25.3 (CH), 22.5 (CH3), 22.1 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 
1715 (s), 1591 (m), 1522 (s), 1425 (m), 1352 (m), 1319 (m), 1245 (m), 1173 (m), 968 (m), 908 (m), 858 (m), 729 
(s). HRMS (ESI): m/z calculated for C18H22NO3S [M + H]
+ 332.1315, found 332.1305. 
 
N-(4-chlorobenzyl)-N-pivaloylleucine (8e). 
Following general procedure V with N-(6-bromopyridin-2-yl)-2-(N-(4-
chlorobenzyl)pivalamido)-4-methylpentanamide (9e, 50 mg, 0.10 mmol, 1.0 equiv) the 
corresponding carboxylic acid was obtained as a brown oil (34 mg, 0.10 mmol, 100%). 
1H NMR (CDCl3, 500 MHz) δ 7.34 (d, J = 7.4 Hz, 1H), 7.28 (d, J = 7.4 Hz, 1H), 4.91 (d, J = 
16.5 Hz, 1H), 4.55 (d, J = 15.0 Hz, 1H), 3.49 (m, 1H), 2.19 (m, 1H), 1.59 (m, 1H), 1.43 (m, 
1H), 1.34 (s, 9H), 0.86 (d, J = 6.5 Hz, 1H), 0.73 (d, J = 6.5 Hz, 1H). 13C NMR (CDCl3, 125 
MHz) δ 179.6 (Cq), 174.7 (Cq), 129.0 (CH), 128.9 (CH), 60.6 (CH), 39.3 (CH2), 38.7 (Cq), 29.7 (CH2), 28.4 (CH3), 25.4 
(CH), 22.8 (CH3), 22.0 (CH3). IR (neat): νmax (cm
-1) = 2959 (w), 1734 (m), 1716 (m), 1636 (m), 1493 (s), 1182 (m), 
790 (m), 516 (s), 430 (s). HRMS (ESI): m/z calculated for C18H27ClNO3 [M + H]
+ 340.1674, found 340.1650. 
 
2-(N-benzylacetamido)-2-phenylacetic acid (8f). 
Following general procedure V with 2-(N-benzylacetamido)-N-(6-bromopyridin-2-yl)-2-
phenylacetamide (9f, 44 mg, 0.1 mmol, 1.0 equiv) the corresponding carboxylic acid was 
obtained as a yellow-brown solid (28 mg, 0.1 mmol, 100%). m.p.: 130 °C. 1H NMR (CDCl3, 500 
MHz) δ 10.40 (bs, 1H), 7.37-7.17 (m, 8H), 6.99 (m, 2H), 5.92 (s, 1H), 4.68 (d, J = 17.6 Hz, 1H), 
4.45 (d, J = 17.6 Hz, 1H), 2.13 (s, 3H). 13C NMR (CDCl3, 125 MHz) δ 173.8 (Cq), 173.4 (Cq), 136.7 (Cq), 133.5 (Cq), 
129.9 (CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 127.1 (CH), 126.1 (CH), 62.6 (CH), 50.6 (CH2), 22.1 (CH3). IR (neat): 
νmax (cm-1) = 2922 (w), 1732 (m), 1597 (m), 1418 (m), 1204 (m), 729 (s), 698 (s), 634 (s), 530 (s), 496 (s), 401 (s). 
HRMS (ESI): m/z calculated for C17H18NO3 [M + H]
+ 284.1281, found 284.1274. 
2-(N-(4-methoxyphenethyl)propionamido)-2-phenylacetic acid (8g). 
Following general procedure V with N-(2-((6-bromopyridin-2-yl)amino)-2-oxo-1-
phenylethyl)-N-(4-methoxyphenethyl)propionamide (9g, 50 mg, 0.10 mmol, 1.0 equiv) the 
corresponding carboxylic acid was obtained as an off-white solid (34 mg, 0.10 mmol, 100%). 
Two rotamers were present on NMR timescale (R1 : R2 = 1 : 0.14). 1H NMR (CDCl3, 500 MHz) 
δ 10.71 (bs, 1.14H), 7.42 (m, 5.7H), 6.75 (m, 4.56H), 6.03 (s, 1H), 5.74 (s, 0.14H), 3.75 (s, 
3.42H), 3.65 (m, 0.14H), 3.42 (m, 1H), 3.35 (m, 1H), 3.17 (m, 0.14H), 2.75 (m, 0.14H), 2.58 (m, 1H), 2.50-2.31 (m, 
2.28H), 2.13 (m, 1H), 1.92 (m, 0.14H), 1.16 (t, J =7.0 Hz, 3.42H). 13C NMR (CDCl3, 125 MHz) δ 175.6 (Cq), 174.0 (Cq), 
158.2 (Cq), 133.9 (Cq), 129.9 (Cq), 129.8 (CH), 129.4 (CH), 128.9 (CH), 113.9 (CH), 62.5 (CH), 55.2 (CH3), 48.4 (CH2), 
35.2 (CH2), 26.6 (CH2), 9.4 (CH3). IR (neat): νmax (cm
-1) = 2937 (w), 1736 (m), 1610 (m), 1512 (s), 1421 (m), 1246 
(s), 1178 (s), 1157 (s), 1036 (m), 727 (m), 702 (s). HRMS (ESI): m/z calculated for C20H24NO4 [M + H]
+ 342.1700, 
found 342.1687. 
 
2-(4-Chlorophenyl)-2-(N-propylacetamido)acetic acid (8h). 
Following general procedure V at 50 °C with N-(6-bromopyridin-2-yl)-2-(4-chlorophenyl)-2-(N-
propylacetamido)-acetamide (9h, 43 mg, 0.10 mmol, 1.0 equiv) the corresponding carboxylic 
acid was obtained as a colorless oil (27 mg, 0.10 mmol, 100%). Two rotamers were present on 
NMR timescale (R1 : R2 = 1 : 0.1). 1H NMR (CDCl3, 500 MHz) δ 10.15 (bs, 1.1H), 7.99 (d, J =7.5 
Hz, 0.1H), 7.42 (d, J = 7.5 Hz, 0.1H), 7.30 (m, 4H), 5.67 (s, 1H), 5.54 (s, 0.1H), 3.37 (m, 0.1H), 
3.24 (m, 1H), 3.12 (m, 1H), 3.02 (m, 0.1H), 2.20 (s, 3.3H), 1.45 (m, 1.1H), 1.14 (m, 1.1H), 0.73 (t, 
J = 7.3 Hz, 3H), 0.63 (m, 0.3H). 13C NMR (CDCl3, 125 MHz) δ 172.8 (Cq), 172.7 (Cq), 172.4 (Cq), 
170.1 (Cq), 140.1 (Cq), 134.6 (Cq), 132.8 (Cq), 131.5 (CH), 130.8 (CH), 130.2 (CH), 128.8 (CH), 127.9 (Cq), 64.1 (CH), 
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62.1 (CH), 49.9 (CH2), 47.3 (CH2), 29.7 (CH2), 22.6 (CH2), 22.2 (CH3), 21.4 (CH3), 11.3 (CH3), 11.1 (CH3). IR (neat): 
νmax (cm-1) = 2968 (w), 1734 (m), 1595 (s), 1493 (s), 1421 (m), 1194 (m), 1092 (s), 1016 (s), 734 (m). HRMS (ESI): 
m/z calculated for C13H17ClNO3 [M + H]
+ 270.0891, found 270.0886. 
 
2-(N-benzylacetamido)-2-cyclohexylacetic acid (8i). 
Following general procedure V at 50 °C with 2-(N-benzylacetamido)-N-(6-bromopyridin-2-yl)-
2-cyclohexylacetamide (9i, 44 mg, 0.10 mmol, 1.0 equiv) the corresponding carboxylic acid 
was obtained as an off-white solid (29 mg, 0.10 mmol, 100%). Two rotamers were present on 
NMR timescale (R1 : R2 = 1 : 0.2). 1H NMR (CDCl3, 500 MHz) δ 10.78 (bs, 1.2H), 7.38-7.11 (m, 
6H), 4.74 (d, J = 16.8 Hz, 1H), 4.67 (d, J = 15.5 Hz, 0.2H), 4.60 (d, J = 15.5 Hz, 0.2H), 4.40 (d, J = 
16.8 Hz, 1H), 3.99 (d, J = 11.0 Hz, 0.2H), 3.87 (d, J = 10.5 Hz, 1H), 2.32 (m, 1H), 2.26 (s, 0.6H), 2.20 (s, 3H), 1.93 (m, 
0.2H), 1.81-1.56 (m, 4.8H), 1.48 (m, 0.2H), 1.36-1.04 (m, 4.6H), 1.01-0.68 (m, 2.4H). 13C NMR (CDCl3, 125 MHz) δ 
174.7 (Cq), 173.5 (Cq), 172.5 (Cq), 171.8 (Cq), 137.9 (Cq), 135.2 (Cq), 129.0 (CH), 128.1 (CH), 128.0 (CH), 127.9 (CH), 
126.8 (CH), 126.7 (CH), 70.6 (CH), 66.2 (CH), 55.4 (CH2), 46.2 (CH2), 36.7 (CH), 36.0 (CH), 30.3 (CH2), 30.1 (CH2), 
29.7 (CH2), 29.3 (CH2), 26.1 (CH2), 26.0 (CH2), 25.6 (CH2), 25.5 (CH2), 25.3 (CH2), 22.6 (CH3), 22.3 (CH3). IR (neat): 
νmax (cm-1) = 2926 (m), 1728 (m), 1601 (s), 1450 (s), 1421 (m), 1240 (m), 1184 (m), 910 (m), 729 (s), 696 (s). 
HRMS (ESI): m/z calculated for C17H24NO3 [M + H]
+ 290.1751, found 290.1733. 
 
2-(N-benzylpropionamido)-3,3-dimethylbutanoic acid (8j). 
Following general procedure V at 50 °C with 2-(N-benzylpropionamido)-N-(6-bromopyridin-
2-yl)-3,3-dimethylbutanamide (9j, 43 mg, 0.10 mmol, 1.0 equiv) the corresponding 
carboxylic acid was obtained as a white solid (28 mg, 0.10 mmol, 100%). 1H NMR (CDCl3, 
500 MHz) δ 7.35 (t, J = 7.3 Hz, 2H), 7.28 (d, J = 7.3 Hz, 1H), 7.16 (d, J = 7.3 Hz, 2H), 4.96 (d, J 
= 17.0 Hz, 1H), 4.40 (d, J = 17.0 Hz, 1H), 4.29 (bs, 1H), 2.37 (m, 2H), 1.12 (m, 12H). 13C NMR 
(CDCl3, 125 MHz) δ 178.2 (Cq), 171.4 (Cq), 136.0 (Cq), 129.1 (CH), 127.8 (CH), 126.0 (CH), 36.9 (CH2), 29.7 (Cq), 28.4 
(CH3), 28.0 (CH2), 9.5 (CH3). IR (neat): νmax (cm
-1) = 2961 (w), 1733 (m), 1604 (m), 1465 (m), 1452 (m), 1213 (m), 
1163 (s), 966 (m), 731 (s), 696 (s). HRMS (ESI): m/z calculated for C16H24NO3 [M + H]
+ 278.1751, found 278.1742. 
 
2-(N-(2-carboxyethyl)acetamido)-3,3-dimethylbutanoic acid (8k). 
Following general procedure V at 50 °C with 3-(N-(1-((6-bromopyridin-2-yl)amino)-3,3-
dimethyl-1-oxobutan-2-yl)acetamido)propanoate (9k, 41 mg, 0.10 mmol, 1.0 equiv) the 
corresponding carboxylic acid was obtained as a white solid (25 mg, 0.10 mmol, 100%). Two 
rotamers were present on NMR timescale (R1 : R2 = 1 : 0.5). 1H NMR (MeOD, 500 MHz) δ 4.26 
(bs, 0.5H), 3.95 (m, 1H), 3.63 (m, 2H), 2.82-2.58 (m, 3H), 2.17 (s, 4.5H), 1.14 (s, 4.5H), 1.10 (s, 
9H). 13C NMR (MeOD, 125 MHz) δ 175.6 (Cq), 174.9 (Cq), 174.9 (Cq), 174.1 (Cq), 172.5 (Cq), 
172.2 (Cq), 69.6 (CH), 69.5 (CH), 42.9 (CH2), 37.1 (CH2), 36.6 (CH2), 34.6 (CH2), 33.2 (Cq), 30.8 (Cq), 28.5 (CH3), 28.3 
(CH3), 22.7 (CH3), 21.7 (CH3). IR (neat): νmax (cm
-1) = 2962 (w), 1717 (m), 1607 (m), 1419 (m), 1367 (s), 1209 (m), 
1165 (s), 797 (s), 540 (m). HRMS (ESI): m/z calculated for C11H20NO5 [M + H]
+ 246.1336, found 246.1327. 
Methyl 2-(N-benzylacetamido)-4-methylpentanoate (10a). 
Following general procedure VIII with methanol (101 µL, 2.5 mmol, 5.0 equiv) methyl 2-(N-
benzylacetamido)-4-methylpentanoate was obtained as a colorless oil (126 mg, 0.46 mmol, 
91%). Flash chromatography: (cyclohexane : EtOAc = 1:2). Or following general procedure IX 
with methanol (101 µL, 2.5 mmol, 5.0 equiv) methyl ester was obtained as a slightly yellow 
oil (139 mg, 0.5 mmol, 100%). Two rotamers were present on NMR timescale (R1 : R2 = 1 : 
0.35). 1H NMR (CDCl3, 500 MHz) δ  7.42-7.17 (m, 6.75H), 4.95 (t, J = 7.0 Hz, 1H), 4.66 (d, J = 17.6 Hz, 1.35H), 5.51 
(d, J = 17.6 Hz, 1.35H), 4.41 (dd, J = 8.5, 6.1 Hz, 0.35H), 3.60 (s, 3H), 3.49 (s, 1.05H), 2.28 (s, 1.05H), 2.13 (s, 3H), 
1.86-1.74 (m, 1.35H), 1.66 (m, 0.35H), 1.54 (m, 2H), 1.41 (m, 0.35H), 0.90 (m, 4.05H), 0.79 (d, J = 6.3 Hz, 3H), 0.71 
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(d, J = 6.7 Hz, 1.05H). 13C NMR (CDCl3, 125 MHz) δ 172.2 (Cq), 171.9 (Cq), 171.7 (Cq), 171.3 (Cq), 138.0 (Cq), 137.0 
(Cq), 128.6 (CH), 128.1 (CH), 128.0 (CH), 127.4 (CH), 127.0 (CH), 126.4 (CH), 58.8 (CH), 55.6 (CH), 52.1 (CH3), 51.9 
(CH3), 50.5 (CH2), 46.2 (CH2), 38.3 (CH2), 29.6 (CH2), 25.1 (CH), 24.3 (CH), 22.4 (CH3), 22.4 (CH3), 22.2 (CH3), 22.2 
(CH3), 22.1 (CH3), 21.9 (CH3). IR (neat): νmax (cm
-1) = 2955 (m), 1738 (s), 1649 (s), 1410 (s), 1200 (s), 729 (s), 633 
(s), 498 (s). HRMS (ESI): m/z calculated for C16H24NO3 [M + H]
+ 278.1751, found 278.1742. 
 
2-(N-Benzylacetamido)-N-butyl-4-methylpentanamide (10b). 
Following general procedure VIII with butylamine (247 µL, 2.5 mmol, 5.0 equiv) the 
corresponding amide was obtained as a colorless oil (97 mg, 0.31 mmol, 61%). Flash 
chromatography: (cyclohexane : EtOAc = 3:1). Two rotamers were present on NMR 
timescale (R1 : R2 = 1 : 0.1). 1H NMR (CDCl3, 500 MHz) δ 7.32 (t, J = 7.5 Hz, 2H), 7.26 (t, J = 7.5 
Hz, 1H), 7.17 (d, J = 7.5 Hz, 2H), 6.56 (bs, 1H), 5.04 (m, 1H), 4.65 (d, J = 17.8 Hz, 1H), 4.59 (d, 
J = 17.8 Hz, 1H), 3.23-3.11 (m, 2H), 2.06 (s, 3H), 1.84 (m, 1H), 1.51-1.34 (m, 4H), 1.33-1.28 (m, 2H), 0.92 (t, J = 7.5 
Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 125 MHz) δ 172.9 (Cq), 170.6 (Cq), 137.5 
(Cq), 128.6 (CH), 127.2 (CH), 125.9 (CH), 55.7 (CH), 48.9 (CH2), 38.9 (CH2), 37.0 (CH2), 31.4 (CH2), 25.1 (CH), 22.8 
(CH3), 22.4 (CH3), 22.3 (CH3), 20.0 (CH2), 13.7 (CH3). IR (neat): νmax (cm
-1) = 3298 (m), 2957 (m), 1630 (s), 1547 (s), 
633 (s), 532 (s), 498 (s). HRMS (ESI): m/z calculated for C19H31N2O2 [M + H]
+ 319.2380, found 319.2369. 
 
N-Benzyl-N-(4-methyl-1-oxo-1-(pyrrolidin-1-yl)pentan-2-yl)acetamide (10c). 
Following general procedure VIII with pyrrolidine (209 µL, 2.5 mmol, 5.0 equiv) the 
corresponding amide was obtained as an off-white solid (111 mg, 0.35 mmol, 70%). Flash 
chromatography: (cyclohexane : EtOAc = 3:1). Two rotamers were present on NMR 
timescale (R1 : R2 = 1 : 0.16). 1H NMR (CDCl3, 500 MHz) δ 7.39-7.08 (m, 5.8H), 5.58 (t, J = 7.0 
Hz, 1H), 5.08 (d, J = 15.0 Hz, 0.16H), 4.73 (d, J = 17.5 Hz, 1H), 4.68 (d, J = 17.5 Hz, 1H), 4.27 
(m, 0.16H), 4.05 (d, J = 15.0 Hz, 0.16H), 3.71 (m, 1H), 3.51 (m, 1H), 3.35 (m, 1H), 3.21 (m, 0.32H), 3.12 (m, 0.16H), 
3.00 (m, 1H), 2.70 (m, 0.16H), 2.35 (m, 0.16H), 2.27 (s, 0.48H), 2.07 (s, 3H), 2.00-1.69 (m, 5.64H), 1.63-1.41 (m, 
2.32H), 0.99-0.80 (m, 6.96H). 13C NMR (CDCl3, 125 MHz) δ 171.9 (Cq), 170.7 (Cq), 168.9 (Cq), 166.0 (Cq), 138.4 (Cq), 
138.0 (Cq), 128.4 (CH), 128.4 (CH), 127.8 (CH), 126.9 (CH), 126.8 (CH), 125.8 (CH), 57.8 (CH), 52.1 (CH), 47.9 (CH2), 
46.4 (CH2), 45.7 (CH2), 45.6 (CH2), 45.4 (CH2), 45.1 (CH2), 39.2 (CH2), 38.6 (CH2), 25.9 (CH2), 25.6 (CH2), 24.8 (CH), 
24.6 (CH), 24.0 (CH2), 23.4 (CH3), 23.4 (CH2), 22.9 (CH3), 22.6 (CH3), 22.3 (CH3), 21.8 (CH3), 21.7 (CH3). IR (neat): 
νmax (cm-1) = 2955 (m), 1636 (s), 1439 (m), 1408 (m), 698 (m), 621 (m). HRMS (ESI): m/z calculated for 
C19H29N2O2 [M + H]
+ 317.2224, found 317.2200. 
 
Butyl N-acetyl-N-benzylleucinate (10e). 
Following general procedure IX with butanol (229 µL, 2.5 mmol, 5.0 equiv) the corresponding 
ester was obtained as a yellow oil (160 mg, 0.5 mmol, 100%). Two rotamers were present on 
NMR timescale (R1 : R2 = 1 : 0.4). 1H NMR (CDCl3, 500 MHz) δ 7.34-7.12 (m, 7H), 4.80 (t, J = 6.6 
Hz, 1H), 4.65 (m, 1.4H), 4.43 (m, 1.4H), 4.37 (m, 0.4H), 4.00 (m, 1H), 3.93 (m, 1.4H), 3.76 (m, 
0.4H), 2.23 (s, 1.2H), 2.06 (s, 3H), 1.82-1.75 (m, 1.4H), 1.56-1.43 (m, 5.6H), 1.33-1.24 (m, 
2.8H), 0.89-0.83 (m, 8.4H), 0.73 (d, J = 6.5 Hz, 3H), 0.65 (d, J = 6.7 Hz, 1.2H). 13C NMR (CDCl3, 125 MHz) δ 171.8 
(Cq), 171.7 (Cq), 171.5 (Cq),170.8 (Cq), 137.9 (Cq), 137.0 (Cq), 128.5 (CH), 128.0 (CH), 127.8 (CH), 127.3 (CH), 126.8 
(CH), 126.3 (CH), 65.1 (CH2), 64.7 (CH2), 58.9 (CH), 56.00 (CH2), 50.6 (CH2), 46.3 (CH2), 38.3 (CH2), 38.1 (CH2), 30.3 
(CH2), 30.1 (CH2), 25.0 (CH), 24.3 (CH), 22.2 (CH3), 22.1 (CH3), 22.0 (CH3), 21.9 (CH3), 21.8 (CH3), 18.9 (CH2), 18.9 
(CH2), 13.5 (CH3), 13.5 (CH3). IR (neat): νmax (cm
-1) = 2957 (m), 1734 (s), 1653 (s), 633 (s), 536 (s), 498 (s). HRMS 
(ESI): m/z calculated for C19H30NO3 [M + H]
+ 320.2220, found 320.2206. 
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Isopropyl N-acetyl-N-benzylleucinate (10f). 
Following general procedure IX with 2-propanol (190 µL, 2.5 mmol, 5.0 equiv) the 
corresponding ester was obtained as a slightly yellow oil (153 mg, 0.5 mmol, 100%). Two 
rotamers were present on NMR timescale (R1 : R2 = 1 : 0.4). 1H NMR (CDCl3, 500 MHz) δ 
7.40-7.15 (m, 7H), 4.94 (qq, J = 6.3, 6.3 Hz, 1H), 5.89-5.80 (m, 1.8H), 4.70 (d, J = 17.5 Hz, 
1H), 4.47 (d, J = 17.5 Hz, 1H), 4.33 (t, J = 6.3 Hz, 0.4H), 4.28 (d, J = 15.5 Hz, 0.4H), 2.56 (s, 
1,2H), 2.09 (s, 3H), 1.84 (m, 1H), 1.73 (m, 0.4H), 1.64-1.35 (m, 2.8H), 1.21 (d, J = 6.0 Hz, 6H), 1.19 (d, J = 6.0 Hz, 
1.2H), 1.13 (d, J = 6.0 Hz, 1.2H), 0.88 (m, 4.2H), 0.78 (d, J = 6.5 Hz, 3H), 0.67 (d, J = 6.5 Hz, 1.2H). 13C NMR (CDCl3, 
125 MHz) δ 172.0 (Cq), 171.9 (Cq), 171.2 (Cq), 170.5 (Cq), 138.4 (Cq), 137.4 (Cq), 128.7 (CH), 128.2 (CH), 127.9 (CH), 
127.4 (CH), 126.9 (CH), 126.5 (CH), 69.3 (CH), 68.6 (CH), 59.5 (CH), 56.5 (CH), 50.8 (CH2), 46.8 (CH2), 38.6 (CH2), 
25.3 (CH), 24.5 (CH), 22.5 (CH3), 22.4 (CH3), 22.3 (CH3), 22.3 (CH3),  22.2 (CH3), 22.0 (CH3), 21.7 (CH3), 21.6 (CH3), 
21.5 (CH3). IR (neat): νmax (cm
-1) = 2957 (m), 1730 (s), 1653 (s), 1410 (m), 1177 (m), 1105 (s), 968 (m), 727 (s), 
698 (s). HRMS (ESI): m/z calculated for C18H28NO3 [M + H]
+ 306.2064, found 306.2051. 
 
But-3-yn-1-yl N-acetyl-N-benzylleucinate (10g). 
Following general procedure IX with 3-butyn-1-ol (75 µL, 1.0 mmol, 2.0 equiv) the 
corresponding ester was obtained after purification by flash chromatography 
(cyclohexane : EtOAc = 4:1) as a colorless oil (102 mg, 0.32 mmol, 65%). Two rotamers 
were present on NMR timescale (R1 : R2 = 1 : 0.35). 1H NMR (CDCl3, 500 MHz) δ 7.42-
7.18 (m, 6.75H), 4.77 (t, J = 7.0 Hz, 1H), 4.75 (m, 1.35H), 4.50 (m, 1.35H), 4.41 (t, J = 7.0 
Hz, 0.35H), 4.13 (m, 2H), 4.03 (m, 0.35H), 3.87 (m, 0.35H), 2.48 (m, 2H), 2.39 (m, 0.70H), 2.29 (s, 1H), 2.12 (s, 3H), 
1.99 (s, 1.05H), 1.98 (0.35H), 1.89 (m, 1H), 1.78 (m, 0.35H), 1.71-1.38 (m, 2.7H), 0.89 (d, J = 6.5 Hz ,4.05H), 0.78 
(d, J = 6.5 Hz, 3H), 0.73 (d, J = 6.5 Hz, 1.05H). 13C NMR (CDCl3, 125 MHz) δ 171.9 (Cq), 171.8 (Cq), 171.4 (Cq),170.7 
(Cq), 138.1 (Cq), 137.1 (Cq), 128.7 (CH), 128.2 (CH), 128.1 (CH), 127.6 (CH), 127.0 (CH), 126.6 (CH), 80.1 (Cq), 70.2 
(CH), 69.8 (CH), 62.8 (CH2), 62.6 (CH2), 58.9 (CH), 56.2 (CH), 51.1 (CH2), 46.3 (CH2), 38.4 (CH2), 38.2 (CH2), 25.2 
(CH), 24.4 (CH), 22.5 (CH3), 22.4 (CH3), 22.4 (CH3), 22.3 (CH3), 22.2 (CH3), 22.0 (CH3), 18.8 (CH2), 18.7 (CH2). IR 
(neat): νmax (cm-1) = 3279 (m), 2957 (m), 1736 (s), 1647 (s), 1410 (m), 1240 (m), 1171 (m), 729 (s), 698 (s), 638 
(m), HRMS (ESI): m/z calculated for C19H26NO3 [M + H]
+ 316.1907, found 316.1892. 
 
S-Ethyl 2-(N-benzylacetamido)-4-methylpentanethioate (10h). 
Following general procedure IX with ethanethiol (cosolvent), the corresponding thioester was 
obtained after purification by flash chromatography (cyclohexane : EtOAc = 6:1) as a yellow oil 
(132 mg, 0.43 mmol, 86%). Two rotamers were present on NMR timescale (R1 : R2 = 1 : 0.4). 1H 
NMR (CDCl3, 500 MHz) δ 7.42-7.18 (m, 7H), 5.30 (t, J = 7.0 Hz, 1H), 5.10 (d, J = 15.5 Hz, 0.4H), 
4.70 (d, J = 17.5 Hz, 1H), 4.44 (d, J = 17.5 Hz, 1H), 4.40 (t, J = 7.0 Hz, 0.4H), 4.02 (d, J = 15.5 Hz, 
0.4H), 2.85 (m, 2.8H), 2.29 (s, 1.2H), 2.13 (s, 3H), 1.80 (m, 1.4H), 1.54 (m, 1.4H), 1.43 (m, 1H), 1.3 (m, 0.4H), 1.23 
(m, 4.2H), 0.88 (d, J = 6.5 Hz, 3H), 0.84 (d, J = 6.5 Hz, 1.2H), 0.74 (d, J = 6.5 Hz, 3H), 0.53 (d, J = 6.5 Hz, 1.2H). 13C 
NMR (CDCl3, 125 MHz) δ 199.4 (Cq), 199.2 (Cq), 172.4 (Cq), 171.9 (Cq), 138.5 (Cq), 137.3 (Cq), 128.7 (CH), 128.3 
(CH), 127.8 (CH), 127.4 (CH), 127.0 (CH), 126.2 (CH), 66.9 (CH), 62.1 (CH), 50.2 (CH2), 47.7 (CH2), 38.3 (CH2), 37.8 
(CH2), 25.3 (CH), 24.5 (CH), 23.6 (CH2), 23.4 (CH2), 22.4 (CH3), 22.4 (CH3), 22.3 (CH3), 21.8 (CH3), 14.4 (CH3). IR 
(neat): νmax (cm-1) = 2957 (m), 1681 (m), 1655 (s), 1402 (s), 972 (m), 727 (s), 698 (s). HRMS (ESI): m/z calculated 
for C17H26NO2S [M + H]
+ 308.1679, found 308.1659. 
The synthesis of S-benzyl 2-(N-benzylacetamido)-4-methylpentanethioate (10i). 
Following general procedure IX with phenylmethanethiol (294 µL, 2.5 mmol, 5.0 equiv) and 4 
Å MS. The corresponding thioester was obtained after purification by column 
chromatography (cyclohexane : EtOAc = 6:1) as a yellow oil (67 mg, 0.18 mmol, 36%). Two 
rotamers were present on NMR timescale (R1 : R2 = 1 : 0.4). 1H NMR (CDCl3, 500 MHz) δ 7.29-
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7.11 (m, 14H), 5.24 (m, 1H), 5.05 (d, J = 15.5 Hz, 0.4H), 4.63 (d, J = 17.6, 1H), 4.36 (m, 1.4H), 4.03 (m, 3.2H), 2.21 
(s, 1.2H), 2.06 (s, 3H), 1.81-1.70 (m, 1.4H), 1.54-1.36 (m, 2.8H), 0.82 (d, J = 6.5 Hz, 3H), 0.77 (d, J = 6.5 Hz, 1.2H), 
0.67 (d, J = 6.6 Hz, 3H), 0.46 (d, J = 6.6 Hz, 1.2H). 13C NMR (CDCl3, 125 MHz) δ 198.9 (Cq), 198.6 (Cq), 172.3 (Cq), 
171.8 (Cq), 138.3 (Cq), 137.1 (Cq), 136.9 (Cq) 136.6 (Cq), 128.8 (CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 128.5 (CH), 
128.2 (CH), 127.8 (CH), 127.4 (CH), 127.4 (CH), 127.2 (CH), 127.0 (CH), 126.14 (CH), 66.8 (CH), 62.2 (CH), 50.3 
(CH2), 47.8 (CH), 38.2 (CH2), 37.8 (CH2), 33.5 (CH2), 33.3 (CH2), 25.2 (CH), 24.4 (CH), 22.4 (CH3), 22.3 (CH3), 22.3 
(CH3), 22.2 (CH3), 22.2 (CH3), 21.7 (CH3). IR (neat): νmax (cm
-1) = 2957 (m), 1684 (s), 1655 (s), 1240 (s), 606 (s), 579 
(s), 459 (s). HRMS (ESI): m/z calculated for C22H28NO2S [M + H]
+ 370.1835, found 370.1821. 
 
1-((6-Bromopyridin-2-yl)amino)-3-methyl-1-oxobutan-2-yl acetate (11a). 
Following general procedure VI with isobutyraldehyde (91 µL, 1.0 mmol, 1.0 equiv) the 
Passerini product was obtained as an off-white solid (309 mg, 0.98 mmol, 98%). Flash 
chromatography: (cyclohexane : EtOAc = 6:1). m.p.: 99 °C. 1H NMR (CDCl3, 500 MHz) δ 
8.29 (bs, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 
5.17 (d, J = 4.5 Hz, 1H), 2.36-2.29 (m, 1H), 2.24 (s, 3H), 1.02 (d, J = 3.8 Hz, 3H), 0.99 (d, J 
= 3.6 Hz, 3H). 13C NMR (CDCl3, 125 MHz) δ 169.7 (Cq), 168.2 (Cq), 150.5 (Cq), 140.7 (CH), 139.3 (Cq), 124.1 (CH), 
112.5 (CH), 78.1 (CH), 31.0 (CH3), 21.0 (CH), 18.6 (CH3), 17.1 (CH3). IR (neat): νmax (cm
-1) = 3296 (w), 1743 (m), 
1708 (s), 1566 (s), 1519 (m), 1429 (s), 1389 (m), 1232 (m), 789 (m). HRMS (ESI): m/z calculated for C12H16BrN2O3 
[M + H]+ 315.0339, found 315.0314. 
 
1-((6-Bromopyridin-2-yl)amino)-1-oxooctan-2-yl acetate (11b). 
Following general procedure VI with heptanal (140 µL, 1.0 mmol, 1.0 equiv)  the 
Passerini product was obtained as a dark yellow oil (288 mg, 0.81 mmol, 81%). Flash 
chromatography: (cyclohexane : EtOAc = 7:1). 1H NMR (CDCl3, 500 MHz) δ 8.35 (bs, 
1H), 8.20 (d, J = 8.0 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 7.25 (d, J = 7.5 Hz, 1H), 5.26 (t, J = 
6.0 Hz), 2.23 (s, 3H), 1.90 (m, 2H), 1.37-1.27 (m, 8H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR 
(CDCl3, 125 MHz) δ 169.6 (Cq), 168.7 (Cq), 150.6 (Cq), 140.7 (CH), 139.3 (Cq), 124.1 (CH), 112.6 (CH), 74.1 (CH), 32.0 
(CH2), 31.5 (CH2), 28.8 (CH2), 24.6 (CH2), 22.5 (CH2), 21.1 (CH3), 14.0 (CH3). IR (neat): νmax (cm
-1) = 2928 (w), 1717 
(m), 1568 (s), 1431 (s), 787 (m), 631 (s), 536 (s), 498 (s). HRMS (ESI): m/z calculated for C15H22BrN2O3 [M + H]
+ 
357.0808, found 357.0800. 
 
2-Hydroxy-3-methylbutanoic acid (12a). 
Following general procedure VII with 1-((6-bromopyridin-2-yl)amino)-3-methyl-1-oxobutan-2-yl 
acetate  (11a, 63 mg, 0.2 mmol, 1.0 equiv) the α-hydroxy acid was obtained as a white solid (24 
mg, 0.2 mmol, 100%). 1H NMR (CDCl3, 500 MHz) δ 4.15 (d, J = 3.4 Hz, 1H), 2.16 (m, 1H), 1.05 (d, J 
= 7.0 Hz, 1H), 0.91 (d, J = 7.0 Hz, 1H). 13C NMR (CDCl3, 125 MHz) δ 179.3 (Cq), 74.8 (CH), 31.9 (CH), 
18.8 (CH3), 15.9 (CH3). 
 
2-Hydroxyoctanoic acid (12b). 
Following general procedure VII with N-(6-bromopyridin-2-yl)-2-hydroxyoctanamide  (11b, 72 
mg, 0.2 mmol, 1.0 equiv) the α-hydroxy acid was obtained as a white solid (32 mg, 0.2 mmol, 
100%). 1H NMR (CDCl3, 500 MHz) δ 4.28 (dd, J = 7.5, 4.2 Hz, 1H), 1.87 (m, 1H), 1.72 (m, 1H), 
1.47-1.41 (m, 8H) 0.88 (t, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 125 MHz) δ 179.6 (Cq), 70.2 (CH), 
34.2 (CH2), 31.6 (CH2), 28.9 (CH2), 24.7 (CH2), 22.5 (CH2), 14.0 (CH3). 
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The synthesis of 2-(benzyl(4-nitrophenyl)amino)-N-(6-bromopyridin-2-yl)-4-methyl-pentanamide (13a). 
Following general procedure VIII with 4-nitrophenol (209 mg, 1.5 mmol, 1.5 
equiv) the Ugi-Smiles product was obtained as a yellow solid (99.5 mg, 0.20 
mmol, 20%). Purification by flash chromatography: (cyclohexane : EtOAc = 
9:1). 1H NMR (CDCl3, 500 MHz) 8.17 (bs, 1H), 8.12 (d, J = 9.4 Hz, 2H), 8.04 (d, J 
= 8.2 Hz, 1H), 7.51 (t. J = 8.0 Hz, 1H), 7.38-7.18 (m, 6H), 6.82 (d, J = 9.4 Hz, 
2H), 4.82 (d, J = 17.2 Hz, 1H), 4.67 (d, J = 17.2 Hz, 1H), 4.51 (m, 1H), 2.15 (m, 1H), 1.70 (m, 2H), 0.96 (d, J = 6.2 Hz, 
3H), 0.91 (d, J = 6.2 Hz, 3H). 13C NMR (CDCl3, 125 MHz) δ 169.5 (Cq), 152.9 (Cq), 150.5 (Cq), 140.6 (CH), 139.3 (Cq), 
139.2 (Cq), 136.5 (Cq), 129.1 (CH), 127.7 (CH), 126.6 (CH), 126.1 (CH), 124.1 (CH), 113.0 (CH), 112.2 (CH), 62.5 
(CH), 52.3 (CH2), 37.9 (CH2), 25.5 (CH), 22.6 (CH3), 22.5 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 1699 (s), 1595 
(m), 1506 (s), 1431 (s), 1315 (s), 1115 (s), 785 (s), 631 (s), 498 (m), 478 (s). HRMS (ESI): m/z calculated for 
C24H26BrN4O3 [M + H]
+ 497.1183, found 497.1178. 
 
The synthesis of 2-(benzyl(2-nitrophenyl)amino)-N-(6-bromopyridin-2-yl)-4-methyl-pentanamide (13b). 
Following general procedure VIII with 2-nitrophenol (209 mg, 1.5 mmol, 1.5 equiv) 
the Ugi-Smiles product was obtained as a yellow foamy solid (169 mg, 0.34 mmol, 
34%). Purification by flash chromatography (cyclohexane : EtOAc): a gradient of 
6:1 to 4:1. The spectra contain minor amounts of EtOAc and cyclohexane. 1H NMR 
(CDCl3, 500 MHz) δ  9.19 (bs, 1H), 8.16 (d, J = 8.1 Hz, 1H), 7.71 (dd, J = 8.1 Hz, 1.5 
Hz, 1H), 7.53 (t, J = 7.9 Hz, 1H), 7.43-7.39 (m, 1H), 7.24-7.14 (m, 7H), 7.13 (t, J = 7.2 Hz, 1H), 4.39 (d, J = 14.7 Hz, 
1H), 4.19 (d, J = 14.7 Hz, 1H), 3.92 (dd, J = 9.1 Hz, 4.9 Hz, 1H), 2.01 (m, 1H), 1.63 (m, 1H), 1.48 (m, 1H), 0.83 (m, 
6H). 13C NMR (CDCl3, 125 MHz) δ 170 (Cq), 151.1 (Cq), 146.2 (Cq), 141.9 (Cq), 140.3 (CH), 139.6 (Cq), 136.1 (Cq), 
132.9 (CH), 128.6 (CH), 128.4 (CH), 127.5 (CH), 125.8 (CH), 125.7 (CH), 124.4 (CH), 123.7 (CH), 112.2 (CH), 67.2 
(CH), 53.9 (CH2), 38.0 (CH2), 25.4 (CH), 23.0 (CH3), 21.0 (CH3). IR (neat): νmax (cm
-1) = 2957 (w), 1703 (m), 1566 
(s), 1508 (s), 1431 (s), 1387 (s), 783 (m), 631 (s), 534 (s), 494 (s), 478 (s). HRMS (ESI): m/z calculated for 
C24H25BrN4NaO3 [M + Na]
+ 519.1002, found 519.0095. 
 
The synthesis of 2-(benzyl(2,4-dinitrophenyl)amino)-N-(6-bromopyridin-2-yl)-4-methyl-pentanamide (13c). 
Following general procedure VIII with 2,4-dinitrophenol (276 mg, 1.5 mmol, 
1.5 equiv)  the Ugi-Smiles product was obtained as a yellow foamy solid (423 
mg, 0.78 mmol, 78%). Purification by flash chromatography (cyclohexane : 
EtOAc): a gradient of 9:1 to 8:1. The spectra contain minor amounts of 
EtOAc. m.p.: 107 °C. 1H NMR (CDCl3, 500 MHz) δ 8.64 (s, 1H), 8.64 (bs, 1H), 
8.16 (m, 2H), 7.55 (t, J = 7.9 Hz, 1H), 7.33-7.20 (m, 6H), 4.67 (d, J = 15.8 Hz, 1H), 4.56 (d, J = 15.8 Hz, 1H), 4.04 (m, 
1H), 2.05 (m, 1H), 1.85 (m, 1H), 1.61 (m, 1H), 0.92 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 125 
MHz) δ 168.8 (Cq), 150.6 (Cq), 147.9 (Cq), 140.6 (Cq), 140.55 (CH), 140.1 (Cq), 139.8 (Cq), 134.9 (Cq), 129.0 (CH), 
128.1 (CH), 127.9 (CH), 127.6 (CH), 124.2 (CH), 122.9 (CH), 122.8 (CH), 112.3 (CH), 66.6 (CH), 52.1 (CH2), 39.1 
(CH2), 25.2 (CH), 22.6 (CH3), 22.0 (CH3). IR (neat): νmax (cm
-1) = 2959 (w), 1701 (s), 1603 (m), 1516 (m), 1431 (s), 
1337 (m), 1126 (m), 739 (m), 498 (m), 478 (s), 428 (s). HRMS (ESI): m/z calculated for C24H24BrN5NaO5 [M + Na]
+ 
564.0853, found 564.0838. 
 
The synthesis of N-(6-bromopyridin-2-yl)-2-isobutyl-6-methylimidazo[1,2-a]pyridin-3-amine (14). 
The isovaleraldehyde (81 µL, 0.75 mmol, 1.5 equiv) and 2-amino-5-methylpyridine (54 mg, 
0.5 mmol, 1 equiv) were dissolved in MeOH (3 mL). Then, 2-bromo-6-isocyanopyridine (110 
mg, 0.6 mmol, 1.2 equiv) was added followed by a solution of perchloric acid in MeOH (1M, 
50 µL, 0.05 mmol, 0.1 equiv) and the resulting mixture stirred for 16h at room temperature. 
The reaction mixture was diluted with CH2Cl2 (30 mL) and the organic layer was washed with 
saturated NaHCO3 and brine. The organic layer was dried with Na2SO4, filtered and 
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concentrated under reduced pressure. The product was purified by column chromatography (EtOAc : 
cyclohexane = 3:2) to afford the title compound as a light-brown solid (135 mg, 0.38 mmol, 75%). m.p.: 97 °C. 1H 
NMR (CDCl3, 500 MHz) δ 7.60 (bs, 1H), 7.47 (d, J =9.0 Hz, 1H), 7.25 (s, 1H), 7.20 (t, J =8.0 Hz, 1H), 7.02 (d, J =9.0 
Hz, 1H), 6.85 (d, J =7.5 Hz, 1H), 5.88 (d, J =8.0 Hz, 1H), 2.50 (d, J =7.0 Hz, 2H), 2.25 (s, 3H), 2.09 (m, 1H), 0.83 (d, J 
=6.5 Hz, 6H). 13C NMR (CDCl3, 125 MHz) δ 158.0 (Cq), 142.6 (Cq), 141.9 (Cq), 140.4 (CH), 140.2 (Cq), 127.6 (CH), 
121.7 (Cq), 119.8 (CH), 118.4 (CH), 116.7 (CH), 116.2 (Cq), 104.3 (CH), 36.2 (CH2), 28.5 (CH), 22.5 (CH3), 18.2 (CH3). 
IR (neat): νmax (cm-1) = 2955 (m), 1582 (s), 1508 (m),  1429 (s), 1384 (m), 1155 (s), 1128 (m), 906 (s), 800 (m), 777 
(m), 727 (s). HRMS (ESI): m/z calculated for C17H20N4 [M + H]
+ 359.0866, found 359.0851. 
 
N-(6-bromopyridin-2-yl)-1-phenethyl-4-(N-phenylpropionamido)piperidine-4-carboxamide (17). 
Aniline (182 µL, 2.0 mmol, 1 equiv) and 1-phenethyl-4-piperidone (13, 407 mg, 
2.0 mmol, 1 equiv) were dissolved in TFE (5 mL). Then, 3 Å MS (500 mg) were 
added and the resulting mixture was stirred overnight at room temperature 
before adding propionic acid (299 µL, 4.0 mmol, 2 equiv). Lastly, after one hour, 
2-bromo-6-isocyanopyridine (6l, 439 mg, 2.4 mmol, 1.2 equiv) was added and the 
mixture stirred for 24 hours. The reaction mixture was filtered and washed with 
EtOAc. The filtrate was washed with sat. NaHCO3 (2×) and with Brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product 
was purified with flash chromatography (cyclohexane : EtOAc = 1:1) to yield an 
off-white solid (982 mg, 1.83 mmol, 92%). m.p.: 151 °C. 1H NMR (CDCl3, 500 MHz) δ 8.82 (bs, 1H), 8.25 (d, J = 8.0 
Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.55 (m, 3H), 7.33 (d, J = 6.0 Hz, 2H), 7.28-7.10 (m, 6H), 2.84-2.69 (m, 4H), 2.60-
2.40 (m, 6H), 1.92 (q, J = 7.5 Hz, 2H), 1.81 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H). 13C NMR (CDCl3, 125 MHz) δ 175.2 (Cq), 
171.6 (Cq), 151.6 (Cq), 140.3 (CH), 140.0 (Cq), 139.2 (Cq), 139.0 (Cq), 130.5 (CH), 129.5 (CH), 128.8 (CH), 128.5 (CH), 
128.3 (CH), 125.9 (CH), 123.3 (CH), 112.3 (CH), 64.4 (Cq), 60.1 (CH2), 50.0 (CH2), 33.6 (CH2), 33.5 (CH2), 29.6 (CH2), 
9.1 (CH3). IR (neat): νmax (cm
-1) = 1701 (s), 1649 (s), 1562 (s), 1512 (s), 1429 (s), 1381 (s), 1286 (m), 1254 (m), 
1126 (s), 727 (s), 700 (s), 575 (m). HRMS (ESI): m/z calculated for C28H32BrN4O2 [M + H]
+ 535.1703, found 
535.1699. 
 
Carfentanil (18).  
Acetyl chloride (89 µL, 1.25 mmol, 5 equiv) was added to a solution of N-(6-bromopyridin-
2-yl)-1-phenylethyl-4-(N-phenylpropionamido)-piperidine-4-carboxamide (17, 134 mg, 
0.25 mmol, 1 equiv) in MeOH (3 mL). The resulting mixture stirred overnight at 45 °C. 
Then, saturated aqueous NaHCO3 and EtOAc were added. The layers were separated and 
the water layer was extracted with EtOAc (3×). The organic layers were combined and 
concentrated under reduced pressure. The crude product was purified with flash 
chromatography (cyclohexane : EtOAc = 1:1) to yield a slightly yellow oil (97 mg, 0.246 
mmol, 98%). 1H NMR (CDCl3, 500 MHz) δ 7.39 (m, 3H), 7.32 (d, J = 7.5 Hz, 2H), 7.23 (t, J = 
7.5 Hz, 2H), 7.14 (m, 3H), 3.79 (s, 3H), 2.71 (m, 4H), 2.53 (m, 2H), 2.44 (t, J = 11.5 Hz, 2H), 
2.31 (d, J = 13.0 Hz, 2H), 1.87 (q, J = 7.5 Hz, 2H), 1.86 (t, J = 12.0 Hz, 2H), 0.94 (t, J = 7.5 Hz, 3H). 13C NMR (CDCl3, 
125 MHz) δ 174.0 (Cq), 173.8 (Cq), 140.1 (Cq), 139.2 (Cq), 130.5 (CH), 129.2 (CH), 128.6 (CH), 128.5 (CH), 128.2 
(CH), 125.9 (CH), 62.7 (Cq), 60.3 (CH2), 52.0 (CH3), 49.8 (CH2), 33.6 (CH2), 33.5 (CH2), 28.9 (CH2), 9.0 (CH3). HRMS 
(ESI): m/z calculated for C24H31N2O3 [M + H]
+ 395.2329, found 395.2324.  
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Metal-Free One-Pot α-Carboxylation of Primary Alcohols 
 
 
 
Abstract: In this chapter, the development of an efficient metal-free procedure for the 
formal α-carboxylation of primary alcohols is described. The method involves a one-pot 
oxidation/Passerini/hydrolysis sequence and provides access to α-hydroxy acids bearing a 
broad range of functional groups. A minor modification to the reaction conditions extends 
the range of accessible products to α-hydroxy esters. 
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Introduction 
α-Hydroxy acids (AHAs) are common structural motifs in biologically active 
compounds
1
 and play a considerable role in the cosmetic industry.
2
 Furthermore, 
owing to their enhanced acidity and aqueous solubility they have many applications 
in organic chemistry; they can e.g. serve as chiral ligands,
3
 resolving agents,
4
 and 
building blocks for total synthesis.
1,5
 Finally, they are common monomers in 
polymerization reactions
6
 and unnatural (depsi)peptides.
7 
Consequently, numerous 
(bio)synthetic strategies have been developed to access this key motif. 
The most common methods include diazotization of amino acids and subsequent 
hydrolysis of the resulting α-lactone,
6b,8
 addition of HCN
9
 or CHBr3
10
 to aldehydes followed 
by harsh hydrolysis, (enzymatic) reduction of the prochiral α-ketocarboxylic acids
11
 and 
selective oxidation of diols (Scheme 1).
12
 Other syntheses of AHAs include the nucleophilic 
addition to glycidic acid
8b
 or glyoxylic acid
13
 and the recently reported palladium-catalyzed 
C-H activation of lactic acid derivatives.
14
 However, many of these methods suffer from 
low yields or limited accessibility of starting materials, require multistep transformations 
and/or rely on highly toxic and hazardous inputs such as cyanides. From a synthetic 
perspective, the direct α-carboxylation of primary alcohols represents a highly desirable 
entry into AHAs. However, to the best of our knowledge, no such method has been 
developed to date.
 
 
Scheme 1. Various methods to synthesize AHAs. 
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In the previous chapter, we describe the development of 2-bromo-6-isocyanopyridine as a 
novel convertible isocyanide and its utility in the Ugi four-component reaction (U-4CR).
15
 
The resulting N-pyridyl amides were readily hydrolyzed under mildly basic conditions 
(MeOH:H2O, NaOH, rt) to the corresponding carboxylic acids (Scheme 2). We envisioned 
that application of isocyanide 7 in the Passerini reaction (P-3CR) would afford α-acyloxy 
amides 8, which would be converted to the desired α-hydroxy acids after basic hydrolysis. 
 
Scheme 2. Application of 2-bromo-6-isocyanopyridine (7) in the U-4CR and P-3CR. 
Oxidation of primary alcohols with hypervalent iodine oxidants
16
 provides the 
corresponding aldehydes typically with one or two equivalents of acetic acid as a by-
product, representing two of the three required components for the P-3CR (Scheme 3).
17
 
Addition of convertible isocyanide 7 to the reaction mixture followed by basic hydrolysis in 
the same pot provides direct access to the desired AHAs, constituting a formal α-
carboxylation of primary alcohols. 
 
Scheme 3. The oxidation/Passerini/hydrolysis sequence. 
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Results and Discussion 
To explore this envisioned strategy, we started our investigation with 2-
phenylethanol (6a) as the benchmark substrate and Dess-Martin periodinane as the 
acetic acid liberating oxidant (Scheme 4). The execution of the reaction sequence is 
very straightforward: the reagents were added consecutively after completion of 
the previous reaction step without removal of solvents or other workup strategies. 
The conversion to the corresponding α-hydroxy acid proceeded very efficiently, 
although the purification of the desired product proved problematic. Reduction and 
basic hydrolysis of DMP resulted in the formation of 2-iodosobenzoic acid, which 
was inseparable from the product by standard purification methods. 
 
Scheme 4. The oxidation/Passerini/hydrolysis sequence with DMP as oxidant. 
A logical alternative for DMP avoiding the isolation issue is PhI(OAc)2 in 
combination with TEMPO as a catalyst. Pleasingly, the reaction still produced the 
desired α-hydroxy acid with an exceedingly simple purification method: an acid-
base extraction. Our next goal was to explore the scope of the primary alcohol in 
this reaction. For practical reasons the P-3CR was stirred over the weekend (60 h), 
however the Passerini reaction is generally much faster and these long reaction 
times are not required (Scheme 4, 1a).  
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Scheme 5. Scope of the α-carboxylation. aThe reaction time of the P-3CR 
was shortened to 12 h. bThe reaction was carried out on a 10 mmol scale. 
cBasic hydrolysis of the Passerini intermediate required an elevation of the 
reaction temperature up to 65 °C. dThe product was obtained as a 10:1 
mixture with the exocyclic alkene isomer. eTLC indicated unselective 
oxidation with PhI(OAc)2/TEMPO. 
fThe product contained about 20% of 1n 
as a contamination. 
Primary alcohols with unfunctionalized saturated and unsaturated aliphatic sidechains are 
good substrates for the reaction sequence (1a-f; Scheme 5). Even the structurally complex 
monoterpene nopol (6f) provided the desired AHA 1f in very good yield. The product 
Chapter 3
 
 
84 
however revealed traces of isomerization to the exocyclic alkene, which likely occurred 
after oxidation to the aldehyde to form the thermodynamically favored α,β-unsaturated 
aldehyde. Notably, inputs with protected alcohols (6g) and amines (6h and 6i) were 
converted with good efficiency and even alkyl chloride 6j proved to be a suitable substrate 
for the reaction sequence. Unfortunately, indole derivative 6k and thiophene derivative 6l 
proved to be incompatible substrates due to unselective oxidation leading to complex 
mixtures. Heterocycles that are less sensitive to oxidation, like the tetrahydropyran-4-
methanol (6m) were cleanly converted to the corresponding AHA (1m).  
However, for 1c and 1m heating was required during the hydrolysis step in order to get to 
full conversion, most likely because of the steric bulk of the side chain. AHA 1n was 
obtained in good yield starting from the corresponding keto-alcohol, underlining the full 
chemoselectivity of the P-3CR for the aldehyde. Finally, AHA 1o (derived from the 
corresponding diol 6o) was also obtained in reasonable yield, showing the 
chemoselectivity of the initial oxidation for the primary alcohol over the secondary 
(benzylic) alcohol, although 1n was observed as an impurity. Notably, the reaction can be 
successfully scaled up to 10 mmol (1a, Scheme 5). 
Generally, many different aldehyde inputs are accepted in the P-3CR. However, we 
discovered that conjugated aldehydes, like α,β-unsaturated aldehydes and aromatic 
aldehydes (resulting from the oxidation of allylic and benzylic alcohols respectively) are 
poorly converted into the corresponding Passerini product. The isocyanide does not seem 
sufficiently nucleophilic for these stabilized aldehydes. In order to enhance the 
electrophilicity of the aldehydes, we experimented with the addition of several different 
Lewis acids (LAs) after the oxidation of the primary alcohol (using geraniol (6p) as the 
benchmark alcohol, Table 1). Unfortunately, only traces of the Passerini product were 
observed and the isocyanide was mainly converted to the formamide. Apparently, the 
Lewis acids rather coordinate to the pyridine nitrogen of isocyanide 7, thereby enhancing 
the electrophilicity of the isocyanides carbon atom, making it more sensitive for hydrolysis 
to the corresponding formamide. 
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Entry LA Yield (%) 
1 No catalyst 0 
2 FeCl3 <5 
3 CuCl2 <5 
4 ZnCl2 <5 
Table 1. Addition of Lewis acids to the P-3CR. 
As described in chapter 2, the U-4CR products with 2-bromo-6-isocyanopyridine as the 
isocyanide input are also readily converted under acidic conditions to the corresponding 
esters. As for many convertible isocyanides,
18
 acidic conversion relies on the propensity of 
the diamide structure of the Ugi product (8, Scheme 2) to form a münchnone 
intermediate, which plays a key role in the convertibility to other functional groups. 
Passerini products, however, do not contain this structural handle. Therefore, we 
wondered if acidic alcoholysis of the intermediate Passerini products (10) would be viable 
regardless of the R
1
 and R
2
 substituents. 
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Scheme 6. Synthesis of α-hydroxy esters. aStage 3: 10 equiv of AcCl and 40 °C were used. 
bStage 3: 10 equiv of AcCl and 80 °C was used. 
To our delight, we discovered that replacement of the basic hydrolysis for acidic 
methanolysis in our reaction sequence provided the desired methyl α-hydroxy ester of our 
benchmark substrate in high yield (11a, Scheme 6). The method proved to be general and 
also showed clean conversion for more functionalized inputs (11b, 11c and 11d). 
Furthermore, also butanol and isopropanol were found to be compatible alcohol inputs 
(11e and 11f), although somewhat harsher reaction conditions are required. 
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Figure 1. Chiral catalysts for the P-3CR. 
With this new method in hand, we pursued the catalytic asymmetric version of the 
reaction. In the past few years several chiral Lewis acid catalysts for enantioselective 
Passerini reactions have appeared in the literature (Figure 1).
19 
The quest for 
enantioselective Passerini reaction was initiated by the group of Dömling.
19a
 After a large 
screening of chiral catalysts, they discovered that Ti-taddol complex 12 worked best in 
terms of yield and ee. Next, Schreiber et al. found out that Cu-pybox complex 13 provided 
enantio-enriched Passerini products for specific chelating aldehydes.
19b
 Finally, the group 
of Wang and Zhu discovered that Al-salen complex 14 proved to be a more general 
catalyst for the P-3CR, however only aliphatic aldehydes are accepted.
19c
 Very recently the 
group of Liu and Tan described phosphoric acid 15 as a general and efficient catalysts for 
the Passerini reaction.
19d
 To evaluate the potential of the combination of isocyanide 7 with 
chiral catalysts, we decided to use the commercial available Al-salen complex 15 to 
evaluate the potential for chiral induction in this Passerini reaction.  
According to the results of Wang and Zhu
19c
 the carboxylic acid input also influences the 
outcome (in terms of ee) of the reaction. Thus four different acids were used to make the 
racemic standards (Table 2, entries 1-4). The results nicely demonstrate that the acidity of 
the carboxylic acid positively correlates with the yield of the reaction. The initial test with 
the Al-salen complex (15) showed some induction (entry 5), although in poor yield and ee. 
Unfortunately, further optimization of the reaction conditions by changing the carboxylic 
acid input (entries 6 & 8), the catalyst loading (entry 9) and reaction temperature (entry 
10) did not provide any satisfying results. Changing the solvent from toluene to CH2Cl2 
showed some improvement in terms of ee, but the yield was still unsatisfactory. Since a 
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rise in temperature typically has a drastic influence on the ee, we reasoned a reduction of 
the reaction temperature could enhance the stereoselectivity. However, the already 
disappointing yields were only further reduced at lower temperatures. As a consequence 
we decided to stop the investigation at this point.     
 
Entry R Product Solvent Cat. (mol%) Temp. (°C) Yield (%) ee (%) 
1 Me 17a CH2Cl2 -- rt 82 -- 
2 t-Bu 17b CH2Cl2 -- rt 71 -- 
3 CH2Cl 17c CH2Cl2 -- rt 84 -- 
4 Ph 17d CH2Cl2 -- rt 86 -- 
5 Me 17a Toluene 10 −10 25 26 
6 CH2Cl 17c Toluene 10 −10 43 <5 
7 Me 17a CH2Cl2 10 −10 29 28 
8 Ph 17d Toluene 10 −10 30 15 
9 Me 17a Toluene 20 −10 55 5 
10 Me 17a Toluene 10 rt 44 <5 
Table 2. Investigation to the stereocontrolled P-3CR with isocyanide 7.  
Conclusions 
In conclusion, this chapter describes the one-pot α-carboxylation of primary alcohols by an 
efficient oxidation/Passerini/hydrolysis reaction sequence. The relatively mild reaction 
conditions tolerate a broad range of functional groups. Finally, the methodology was 
effectively extended to the synthesis of α-hydroxy esters by a minor modification of the 
reaction sequence. 
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Experimental Section 
General Remarks 
Unless stated otherwise, all solvents and commercially available reagents were used as purchased. All reaction 
were performed under air, unless stated otherwise. Infrared (IR) spectra were recorded neat using a Shimadzu 
FTIR-8400s spectrophotometer and wavelengths are reported in cm-1. Nuclear magnetic resonance (NMR) 
spectra were recorded on a Bruker Avance 500 (125.78 MHz for 13C) or Bruker Avance 400 (100.62 MHz for 13C) 
using the residual solvent as internal (1H: δ 7.26 ppm, 13C{1H}: δ 77.00 ppm for CDCl3, 
1H: δ 2.50 ppm, 13C{1H}: δ 
39.52 ppm for DMSO-d6 and 
1H: δ 3.31 ppm, 13C{1H}: δ 49.00 ppm for MeOD-d4). Chemical shifts (δ) are given in 
ppm and coupling constants (J) are quoted in hertz (Hz). Resonances are described as s (singlet), d (doublet), t 
(triplet), q (quartet), bs (broad singlet) and m (multiplet) or combinations thereof. Chiral HPLC was recorded 
using a LC10VP with a SCL-10A VP system controller, LC-10AT VP liquid chromatograph, SPD-M10A VP diode 
array detector and CTO-10AC VP column oven from Shimadzu. Melting points were recorded on a Büchi M-565 
melting point apparatus and are uncorrected. Electrospray Ionization (ESI) high-resolution mass spectrometry 
was carried out using a Bruker micrOTOF-Q instrument in positive ion mode (capillary potential of 4500 V). Flash 
chromatography was performed on Silicycle Silia-P Flash Silica Gel (particle size 40-63 μm, pore diameter 60 Å) 
using the indicated eluent. Thin Layer Chromatography (TLC) was performed using TLC plates from Merck (SiO2, 
Kieselgel 60 F254 neutral, on aluminium with fluorescence indicator) and compounds were visualized by UV 
detection (254 nm) and KMnO4 stain. 
 
Synthesis of the non-commercial primary alcohols (6) 
6-(Benzyloxy)hexan-1-ol (6g): 
1,6-Hexanediol (1.18 g, 10 mmol, 1 equiv) was dissolved in anhydrous DMF (30 mL) 
and cooled to 0 °C. Then, NaH (60%, 460 mg, 11.5 mmol, 1.15 equiv) was added 
portion-wise and the mixture was allowed to warm up to room temperature and stirred for 30 minutes. The 
reaction mixture was cooled to 0 °C and benzyl bromide (1.19 mL, 10 mmol, 1 equiv) was added drop-wise and 
allowed to warm up to room temperature. After 16h, the mixture was concentrated and partitioned between 
water and EtOAc. The organic layer was washed with saturated NH4Cl and brine, dried with Na2SO4, filtered, 
concentrated and purified with flash chromatography (cyclohexane/EtOAc = 4:1) to obtain 6-(benzyloxy)hexan-1-
ol as a colorless oil (930 mg, 4.45 mmol, 45%). RF = 0.25 (cyclohexane/EtOAc = 4:1 v/v); 
1H NMR (CDCl3, 500 
MHz): δ 7.39 – 7.27 (m, 5H), 4.52 (s, 2H), 3.59 (t, J = 6.7 Hz, 2H), 3.49 (t, J = 6.6 Hz, 2H), 2.56 (bs, 1H), 1.68 – 1.62 
(m, 2H), 1.59 – 1.54 (m, 2H), 1.44 – 1.35 (m, 4H); 13C NMR (CDCl3, 125 MHz): δ 138.5 (Cq), 128.4 (CH), 127.7 (CH), 
127.5 (CH), 72.9 (CH2), 70.3 (CH2), 62.6 (CH2), 32.6 (CH2), 29.7 (CH2), 26.0 (CH2), 25.6 (CH2). 
 
N-(6-Hydroxyhexyl)-4-methylbenzenesulfonamide (6h): 
6-Amino-1-hexanol (1.00 g, 8.5 mmol, 1.0 equiv) and trimethylamine (2.1 mL, 15 
mmol, 1.7 equiv) were dissolved in CH2Cl2 (100 mL) and cooled to 0 °C. Then, tosyl 
chloride (1.91 g, 10 mmol, 1.2 equiv) was added portion-wise. After 1 h, the mixture was allowed to warm up to 
room temperature and stirred for 16 h. The reaction was quenched with water and the layers were separated. 
The organic layer was dried with Na2SO4, filtered, concentrated and purified with flash chromatography 
(cyclohexane/EtOAc, 1:1) to obtain N-(6-hydroxyhexyl)-4-methylbenzenesulfonamide as a white solid (900 mg, 
3.3 mmol, 39%). RF = 0.30 (cyclohexane/EtOAc = 1:1); 
1H NMR (CDCl3, 500 MHz): δ 7.74 (d, J = 8.3 Hz, 2H), 7.30 (d, 
J = 8.0 Hz, 2H), 5.20 (bs, 1H), 3.58 (t, J = 6.6 Hz, 2H), 2.90 (t, J = 7.0 Hz, 2H), 2.42 (s, 3H), 2.13 (bs, 1H), 1.52 –1.43 
(m, 4H), 1.31 – 1.25 (m, 4H); 13C NMR (CDCl3, 125 MHz): δ 143.4 (Cq), 136.9 (Cq), 129.7 (CH), 127.1 (CH), 62.6 
(CH2), 43.1 (CH2), 32.4 (CH2), 29.4 (CH2), 26.2 (CH2), 25.2 (CH2), 21.6 (CH3). 
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Benzyl (6-hydroxyhexyl)carbamate (6i):  
6-Amino-1-hexanol (1.17 g, 10 mmol, 1 equiv) and sodium carbonate (2.33 g, 22 
mmol, 2.2 equiv) were dissolved in THF/H2O (1:1, 30 mL) and cooled to 0 °C. Benzyl 
chloroformate (1.56 mL, 11 mmol, 1.1 equiv) was added and the reaction mixture was allowed to warm to room 
temperature. After 16 hours, the product was extracted with EtOAc (3×). The combined organic layers were 
washed with brine, dried with Na2SO4, filtered and concentrated to obtain benzyl (6-hydroxyhexyl)carbamate as 
a white solid (2.38 g, 9.5 mmol, 95%). 1H NMR (CDCl3, 500 MHz): δ 7.36 – 7.28 (m, 5H), 5.07 (m, 2H), 4.95 (bs, 
1H), 3.59 (t, J = 6.6 Hz, 2H), 3.17 (m, 2H), 2.11 (bs, 1H), 1.55 – 1.46 (m, 4H), 1.42 – 1.31 (m, 4H); 13C NMR (CDCl3, 
125 MHz): δ 156.6 (Cq), 136.7 (Cq), 128.6 (CH), 128.5 (CH), 128.1 (CH), 66.6 (CH2), 62.6 (CH2), 40.9 (CH2), 32.6 
(CH2), 30.0 (CH2), 26.4 (CH2), 25.4 (CH2). 
 
1-(2-((6-Hydroxyhexyl)oxy)phenyl)ethan-1-one (6n): 
2-Hydroxyacetophenone (1.8 mL, 15 mmol, 1 equiv), TBAI (0.277 g, 0.75 mmol, 
0.05 equiv) and K2CO3 (2.49 g, 18 mmol, 1.2 equiv) were dissolved in anhydrous 
DMF (30 mL). 6-chlorohexanol (2.00 mL, 15 mmol, 1 equiv) was added and the 
temperature was raised to 100 °C. After 7h, the reaction mixture was cooled to 
room temperature and stirred overnight. The mixture was concentrated and partitioned between water and 
EtOAc. The water layer was extracted with EtOAc (2×) and the combined organic layers were washed with brine, 
dried with Na2SO4, filtered, concentrated and purified with flash chromatography (cyclohexane/EtOAc = 3:2) to 
yield 1-(2-((6-hydroxyhexyl)oxy)phenyl)ethan-1-one as a red oil (2.62 g, 11.1 mmol, 74%). RF = 0.23 
(cyclohexane/EtOAc = 3:2 ); 1H NMR (CDCl3, 500 MHz): δ 7.72 (dd, J = 7.7, 1.8 Hz, 1H), 7.43 (m, 1H), 6.95 (m, 2H), 
4.05 (t, J = 6.4 Hz, 2H), 3.65 (t, J = 6.5 Hz, 2H), 2.62 (s, 3H), 1.86 (m, 2H), 1.72 (s, 1H), 1.61 – 1.43 (m, 6H); 13C NMR 
(CDCl3, 125 MHz): δ 200.3 (Cq), 158.6 (Cq), 133.8 (CH), 130.5 (CH), 128.3 (Cq), 120.5 (CH), 112.3 (CH), 68.4 (CH2), 
62.9 (CH2), 32.7 (CH2), 32.2 (CH3), 29.3 (CH2), 26.2 (CH2), 25.6 (CH2); IR (neat): νmax (cm
-1) = 3396 (w), 2935 (m), 
1668 (s), 1592 (s), 1450 (s), 1294 (s), 1236 (s), 756 (s), 594 (m); HRMS (ESI): m/z calculated for C14H20NaO3 [M + 
Na]+ 259.1305, found 259.1307. 
 
6-(2-(1-Hydroxyethyl)phenoxy)hexan-1-ol (6o): 
1-(2-((6-Hydroxyhexyl)oxy)phenyl)ethan-1-one (1.06 g, 4.46 mmol, 1 equiv) was 
dissolved in MeOH (15 mL) and cooled to 0 °C. Then, NaBH4 (0.28 g, 7.5 mmol, 1.7 
equiv) was added portion-wise and the resulting mixture stirred for 2h at 0 °C. 
The mixture was quenched with sat. NH4Cl and MeOH was evaporated. Water 
was added and the product was extracted with EtOAc (2×). The combined organic layers were washed with brine 
and dried with Na2SO4, filtered and concentrated to obtain 6-(2-(1-hydroxyethyl)phenoxy)hexan-1-ol as a 
colorless oil (965 mg, 4.05 mmol, 91%). 1H NMR (CDCl3, 500 MHz): δ 7.32 (dd, J = 7.5, 1.6 Hz, 1H), 7.22 (dt, J = 8.1, 
1.7 Hz, 1H), 6.95 (dt, J = 7.5, 0.9 Hz, 1H), 6.86 (dd, J = 8.0, 0.5 Hz, 1H), 5.09 (q, J = 6.5 Hz, 1H), 4.02 (t, J = 6.3 Hz, 
2H), 3.65 (t, J = 6.5 Hz, 2H), 2.09 (s, 2H), 1.84 (m, 2H), 1.63 – 1.43 (m, 9H); 13C NMR (CDCl3, 125 MHz): δ 156.1 
(Cq), 133.4 (Cq), 128.4 (CH), 126.3 (CH), 120.8 (CH), 111.3 (CH), 67.9 (CH2), 66.9 (CH), 62.9 (CH2), 32.7 (CH2), 29.4 
(CH2), 26.2 (CH2), 25.6 (CH2), 23.0 (CH3); IR (neat): νmax (cm
-1) = 3352 (w), 2933 (m), 1601 (w), 1490 (m), 1450 
(m), 1236 (s), 1076 (s), 752 (s); HRMS (ESI): m/z calculated for C14H22NaO3 [M + Na]
+ 261.1461, found 261.1459. 
 
Synthesis of the α-hydroxy acids (1) 
General procedure I: The oxidation/Passirini/hydrolysis sequence  
PhI(OAc)2 (339 mg, 1.05 mmol, 1.05 equiv) and TEMPO (15.6 mg, 0.1 mmol, 0.1 equiv) were added to the alcohol 
(1 mmol, 1 equiv) in CH2Cl2 (3 mL) and the resulting mixture stirred for 4 hours at room temperature. 
Subsequently, 2-bromo-6-isocyanopyridine (228 mg, 1.25 mmol, 1,25 equiv) was added and the resulting mixture 
stirred for 60 hours (generally over weekend). Then, MeOH (1 mL) and NaOH (10M, 0.5 mL, 5 mmol, 5 equiv) 
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were added and the resulting biphasic mixture stirred for another 24 h. Next, the layers were separated and the 
water layer was washed with CH2Cl2 (2×). The organic layers were combined and extracted with NaOH (1M, 1×). 
Both water layers were combined, acidified with HCl (12M) to pH 1 and saturated with NaCl. Finally, the water 
layer was extracted with EtOAc (3×). The organic layers were combined, dried with Na2SO4, filtered and 
concentrated to obtain the title product generally as a slowly solidifying oil. 
 
2-Hydroxy-3-phenylpropanoic acid (1a): 
Prepared according to general procedure I on a 5 mmol scale: from 2-phenylethenol (598 
µL, 5 mmol).  Yield: 606 mg, 3.6 mmol, 73%. 1H NMR (CDCl3, 500 MHz): δ 7.38 – 7.22 (m, 
5H), 4.51 (dd, J = 7.2, 4.2 Hz, 1H), 3.20 (dd, J = 14.0, 4.2 Hz, 1H), 2.99 (dd, J = 14.0, 7.3 Hz, 
1H); 13C NMR (CDCl3, 125 MHz): δ 178.5 (Cq), 136.1 (Cq), 129.6 (CH), 128.6 (CH), 127.2 (CH), 
71.1 (CH), 40.2 (CH2); IR (neat): νmax (cm
-1) = 3035 (w), 1718 (s), 1088 (s), 909 (m), 732 (s), 729 (s); HRMS (ESI): 
m/z calculated for C9H9O3 [M – H] 165.0557, found 165.0559. 
 
2-Hydroxynonanoic acid (1b): 
Prepared according to general procedure I from 1-octanol (157 µL, 1 mmol). Yield: 
115 mg, 0.66 mmol, 66%. 1H NMR (CDCl3, 500 MHz): δ 9.00 – 6.00 (bs, 2H), 4.26 (dd, 
J = 7.6, 4.2 Hz, 1H), 1.82 (m, 1H), 1.68 (m, 1H), 1.42 (m, 2H), 1.27 (m, 8H), 0.86 (t, J = 
6.7 Hz, 3H); 13C NMR (CDCl3, 125 MHz): δ 180.1 (Cq), 70.4 (CH), 34.2 (CH2), 31.9 
(CH2), 29.4 (CH2), 29.2 (CH2), 24.9 (CH2), 22.8 (CH2), 14.2 (CH3); IR (neat): νmax (cm
-1) = 3390 (w), 2925 (m), 1704 
(s), 1227 (m), 1202 (m), 1128 (s), 1085 (s), 917 (m); HRMS (ESI): m/z calculated for C9H17O3 [M – H] 173.1183, 
found 173.1185. 
 
2-hydroxy-3,3-dimethylbutanoic acid (1c): 
Prepared according to general procedure I from 2,2-dimethylpropan-1-ol (88 mg, 1 mmol). The 
reaction mixture was heated to 65 °C after addition of aqueous NaOH. Yield: 87 mg, 0.66 mmol, 
66%. 1H NMR (CDCl3, 500 MHz): δ 8.00 – 6.50 (bs, 2H), 3.91 (s, 1H), 1.01 (s, 9H); 
13C NMR (CDCl3, 
125 MHz): δ 178.6 (Cq), 78.2 (CH), 35.2 (Cq), 25.7 (CH3); IR (neat): νmax (cm
-1) = 3378 (w), 2959 
(m), 1713 (s), 1217 (m), 1078 (s), 1022 (m), 702 (m); HRMS (ESI): m/z calculated for C6H11O3 [M – H] 131.0714, 
found 131.0711. 
 
2-Hydroxyhept-6-enoic acid (1d): 
Prepared according to general procedure I from hex-5-en-1-ol (120 µL, 1 mmol). Yield: 
120 mg, 0.84 mmol, 84%. 1H NMR (CDCl3, 500 MHz): δ 7.70 – 6.30 (br, 2H), 5.78 (m, 1H), 
5.00 (m, 2H), 4.28 (dd, J = 7.6, 4.2 Hz), 2.09 (m, 2H), 1.85 (m, 1H), 1.70 (m, 2H), 1.55 (m, 
2H); 13C{1H} NMR (CDCl3, 125 MHz): δ 179.9 (Cq), 138.2 (CH), 115.2 (CH2), 70.3 (CH), 33.6 
(CH2), 33.4 (CH2), 24.1 (CH2); IR (neat): ν max (cm
-1) = 2927 (w), 1717 (s), 1213 (m), 1089 (m), 1089 (s), 909 (s); 
HRMS (ESI): m/z calculated for C7H11O3 [M – H] 143.0714, found 143.0712. 
 
2-Hydroxy-4-methylpent-4-enoic acid (1e): 
Prepared according to general procedure I from 3-methyl-3-buten-1-ol (101 µL, 1 mmol). 
Yield: 91 mg, 0.70 mmol, 70%. 1H NMR (CDCl3, 500 MHz): δ 7.20 – 6.20 (br s, 2H), 4.92 (s, 1H), 
4.86 (s, 1H), 4.39  (dd, J = 8.8, 3.9 Hz, 1H), 2.61 (dd, J = 14.2, 3.6 Hz, 1H), 2.40 (dd, J = 14.2, 8.8 
Hz, 1H), 1.80 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ 178.6 (Cq), 140.8 (Cq), 114.7 (CH2), 68.8 
(CH), 42.5 (CH2), 22.4 (CH3); IR (neat): νmax (cm
-1) = 2918 (w), 1714 (m), 1436 (w), 1218 (w), 1095 (m), 894 (m); 
HRMS (ESI): m/z calculated for C6H9O3 [M – H] 129.0557, found 129.0558. 
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3-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl)-2-hydroxypropanoic acid (1f):  
Prepared according to general procedure I from (-)-nopol (171 µL, 1 mmol). Yield: 187 
mg, 0.89 mmol, 89%. The product exist as a 1:1 mixture of 2 diastereoisomers and 
contains about 9% of the exocylic (side) product. 1H NMR (CDCl3, 500 MHz): δ 5.42 (bs, 
1H), 4.29 (dd, J = 8.4, 3.8 Hz, 0.5H), 4.25 (dd, J = 7.7, 4.2 Hz, 0.5H), 2.55 (m, 1H), 2.37 (m, 
2H), 2.25 (m, 2H), 2.09 (m, 2H), 1.27 (s, 3H), 1.15 (m, 1H), 0.85 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ 179.1 (Cq), 
179.1 (Cq) ,143.3 (Cq), 142.9 (Cq), 121.8 (CH), 121.7 (CH), 68.8 (CH), 68.6 (CH), 46.0 (CH), 45.4 (CH), 41.8 (Cq), 41.8 
(Cq), 40.7 (CH2), 40.6 (CH2), 38.2 (Cq), 38.0 (Cq), 31.9 (CH2), 31.8 (CH2), 31.8 (CH2), 31.6 (CH2), 26.3 (CH3), 26.3 (CH3), 
21.3 (CH3), 21.2 (CH3); IR (neat): νmax (cm
-1) = 2920 (m), 1718 (s), 1217 (m), 1083 (s), 907 (s), 731 (s); HRMS (ESI): 
m/z calculated for C12H17O3 [M – H] 209.1183, found 209.1186. 
 
7-(Benzyloxy)-2-hydroxyheptanoic acid (1g): 
Prepared according to general procedure I from 6-(benzyloxy)hexan-1-ol (208 mg, 
1 mmol). Yield: 184 mg, 0.73 mmol, 73%. 1H NMR (CDCl3, 500 MHz): δ 7.38 – 7.28 
(m, 5H), 4.53 (s, 2H), 4.23 (dd, J = 7.6, 4.2 Hz, 1H), 3.51 (t, J = 6.6 Hz, 2H), 1.83 (m, 
1H), 1.69 – 1.64 (m, 3H), 1.48 – 1.39 (m, 4H); 13C NMR (CDCl3, 125 MHz): δ 178.6 
(Cq), 138.1 (Cq), 128.5 (CH), 127.9 (CH), 127.8 (CH), 72.9 (CH2), 70.3 (CH2), 70.2 (CH), 34.0 (CH2), 29.4 (CH2), 25.8 
(CH2), 24.7 (CH2); IR (neat): νmax (cm
-1) = 2941 (br), 2862 (br), 1724 (s), 1448 (m), 1211 (m), 1001 (s), 748 (s), 696 
(s) ; HRMS (ESI): m/z calculated for C14H19O4 [M – H] 251.1289, found 251.1300. 
 
2-Hydroxy-7-((4-methylphenyl)sulfonamido)heptanoic acid (1h): 
Prepared according to general procedure I from N-(6-hydroxyhexyl)-4-
methylbenzenesulfonamide (258 mg, 0.95 mmol). Yield: 270 mg, 0.86 mmol, 90%. 
1H NMR (CDCl3, 500 MHz): δ 7.72 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 6.70 – 
5.50 (bs, 2H), 5.19 (bs, 1H), 4.25 (dd, J = 7.1, 4.0 Hz, 1H), 2.90 (m, 2H), 2.41 (s, 3H), 1.78 (m, 1H), 1.66 (m, 1H), 
1.49 – 1.25 (m, 6H); 13C NMR (CDCl3, 125 MHz): δ 178.5 (Cq), 143.6 (Cq), 136.8 (Cq), 129.9 (CH), 127.2 (CH), 70.1 
(CH), 43.0 (CH2), 33.8 (CH2), 29.3 (CH2), 26.0 (CH2), 24.2 (CH2), 21.7 (CH3); IR (neat): νmax (cm
-1) = 3274 (w), 2934 
(w), 1717 (m), 1429 (w), 1321 (m), 1153 (s), 1090 (s), 908 (s), 813 (s), 727 (s), 663 (s), 546 (s); HRMS (ESI): m/z 
calculated for C14H20NO5S [M – H] 314.1068, found 314.1082. 
7-(((Benzyloxy)carbonyl)amino)-2-hydroxyheptanoic acid (1i): 
Prepared according to general procedure I from benzyl (6-
hydroxyhexyl)carbamate (251 mg, 1 mmol). Yield: 168 mg, 0.57 mmol, 57%. m.p. 
76 °C; 1H NMR (CDCl3, 500 MHz): δ 7.33 (m, 5H), 5.15 –  5.08 (m, 2H), 4.22 (dd, J 
= 6.9, 3.8 Hz, 3H), 3.17 (m, 2H), 1.82 (m, 1H), 1.69 (m, 1H), 1.53 – 1.33 (m, 6H); 
13C{1H} NMR (CDCl3, 125 MHz): δ 178.4 (Cq), 156.9 (Cq), 136.5 (Cq), 128.7 (CH), 128.3 (CH), 128.1 (CH), 70.1 (CH), 
67.0 (CH2), 40.8 (CH2), 33.9 (CH2), 29.8 (CH2), 26.1 (CH2), 24.2 (CH2); IR (neat): νmax (cm
-1) =  3327 (m), 2929 (w), 
1681 (s), 1545 (s), 1271 (s), 1130 (m), 1075 (w), 727 (w), 698 (w); HRMS (ESI): m/z calculated for C14H20NO5 [M – 
H] 294.1347, found 294.1356. 
 
7-Chloro-2-hydroxyheptanoic acid (1j): 
Prepared according to general procedure I from 6-chlorohexanol (134 µL, 1 mmol). 
Yield: 117 mg, 0.65 mmol, 65%. m.p.: 54 °C; 1H NMR (CDCl3, 500 MHz): δ 8.00 – 6.00 
(bs, 2H), 4.28 (dd, J = 7.6, 4.1 Hz, 1H), 3.53 (t, J = 6.7 Hz, 2H), 1.88 – 1.69 (m, 4H), 1.53 
– 1.43 (m, 4H); 13C NMR (CDCl3, 125 MHz): δ 179.9 (Cq), 70.2 (CH), 45.0 (CH2), 34.0 
(CH2), 32.4 (CH2), 26.6 (CH2), 24.2 (CH2); IR (neat): νmax (cm
-1) = 2934 (w), 1714 (s), 1216 (m), 1103 (s), 912 (m), 
730 (s); HRMS (ESI): m/z calculated for C7H12ClO3 [M – H] 179.0480, found 179.0488. 
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2-Hydroxy-2-(tetrahydro-2H-pyran-4-yl)acetic acid (1m): 
Prepared according to general procedure I from (tetrahydro-2H-pyran-4-yl)methanol: (116 
mg, 1 mmol). The reaction mixture was heated to 50 °C after addition of aqueous NaOH. 
Yield: 142 mg, 0.89 mmol, 89%. 1H NMR (CDCl3, 500 MHz): δ 4.13 (d, J = 3.9 Hz, 1H), 4.11 – 
4.04 (m, 2H), 3.48 – 3.39 (m, 2H), 2.05 (m, 1H), 1.76 – 1.60 (m, 3H), 1.50 – 1.42 (m, 1H); 13C 
NMR (CDCl3, 125 MHz): δ 177.4 (Cq), 73.6 (CH), 67.9 (CH2), 67.7 (CH2), 39.0 (CH), 28.6 (CH2), 26.4 (CH2); IR (neat): 
νmax (cm-1) = 3375 (w), 2951 (m), 2854 (m), 1720 (s), 1234 (s), 1105 (s), 1083 (s), 1018 (m), 881 (m), 544 (s); 
HRMS (ESI): m/z calculated for C7H11O4 [M – H] 159.0663, found 159.0668. 
 
7-(2-Acetylphenoxy)-2-hydroxyheptanoic acid (1n): 
Prepared according to general procedure I from 1-(2-((6-
hydroxyhexyl)oxy)phenyl)ethan-1-one: (236 mg, 1 mmol). Yield: 179 mg, 0.64 
mmol, 64%. 1H NMR (CDCl3, 500 MHz): δ 7.72 (dd, J = 7.8, 1.8 Hz, 1H), 7.42 (dt, 
J = 6.9, 1.8 Hz, 1H), 6.95 (m, 2H), 4.27 (dd, J = 7.5, 4.2 Hz, 1H), 4.05 (t, J = 6.3 Hz, 
2H), 2.63 (s, 3H), 1.90 – 1.84 (m, 3H), 1.74 (m, 1H), 1.59 – 1.50 (m, 4H); 13C 
NMR (CDCl3, 125 MHz): δ 201.1 (Cq), 178.9 (Cq), 158.6 (Cq), 134.1 (CH), 130.5 (CH), 128.1 (Cq), 120.5 (CH), 112.4 
(CH), 70.2 (CH), 68.4 (CH2), 34.0 (CH2), 32.1 (CH3), 29.1 (CH2), 26.1 (CH2), 24.6 (CH2); IR (neat): νmax (cm
-1) = 2935 
(w), 1722 (s), 1668 (s), 1595 (s), 1450 (s), 1294 (s), 1236 (s), 1163 (m), 757 (s); HRMS (ESI): m/z calculated for 
C15H19O5 [M – H] 279.1238, found 279.1251. 
 
2-Hydroxy-7-(2-(1-hydroxyethyl)phenoxy)heptanoic acid (1o): 
Prepared according to general procedure I from 6-(2-(1-
hydroxyethyl)phenoxy)hexan-1-ol (238 mg, 1 mmol). Yield: 157 mg, 0.65 mmol, 
65%. The product is obtained as a 5:1 mixture with 1n. 1H NMR (CDCl3, 500 
MHz): δ 7.72 (dd, J = 7.7, 1.8 Hz, 0.2H), 7.46 – 7.41 (m, 0.2H), 7.29 (dd, J = 7.5, 
1.4 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 6.97 – 6.92 (m, 1H), 6.85 (t, J = 7.5 Hz, 1H), 
6.60 – 5.50 (br, 2H), 5.20 – 5.05 (m, 1H), 4.23 (dd, J = 7.0, 3.4 Hz, 1.2H), 4.00 (m, 2.4H), 2.63 (s, 0.6H), 1.83 (m, 
3.6H), 1.72 (m, 1.2H), 1.51 (m, 7.8H); 13C NMR (CDCl3, 125 MHz): δ 178.5 (Cq), 158.6 (Cq), 156.0 (Cq), 134.0 (CH), 
132.6 (Cq), 130.5 (CH), 128.6 (CH), 126.3 (CH), 120.8 (CH), 120.4 (CH), 112.4 (CH), 111.3 (CH), 70.1 (CH), 70.1 (CH), 
68.4 (CH2), 67.9 (CH2), 67.8 (CH2), 67.2 (CH), 34.0 (CH2), 34.0 (CH2), 33.9 (CH2), 32.1 (CH3), 29.1 (CH2), 26.1 (CH2), 
24.6 (CH2), 24.6 (CH2), 22.7 (CH3); IR (neat): νmax (cm
-1) = 2938 (w), 1723 (m), 1599 (m), 1490 (m), 1234 (s), 1075 
(s), 907 (s), 727 (s); HRMS (ESI): m/z calculated for C15H21O5 [M – H] 281.1394, found 281.1406. 
Synthesis of the α-hydroxy acids (1) 
General procedure II: Synthesis of  α-hydroxy esters (11) 
PhI(OAc)2 (339 mg, 1.05 mmol, 1.05 equiv) and TEMPO (15.6 mg, 0.1 mmol, 0.1 equiv) were added to the alcohol 
(1 mmol, 1 equiv) in CH2Cl2 (3 mL) and stirred for 4 hours at room temperature. Subsequently 2-bromo-6-
isocyanopyridine (228 mg, 1.25 mmol, 1,25 equiv) was added and the resulting mixture stirred for 60 hours. 
Then, MeOH (3 mL) and AcCl (357 µL, 5 mmol, 5 equiv) were added. After 24 hours, the mixture was 
concentrated and purified by flash chromatography (cyclohexane/EtOAc) to obtain the title compound. 
 
Methyl 2-hydroxy-3-phenylpropanoate (11a): 
Prepared according to general procedure II from 2-phenylethanol (120 µL, 1 mmol). 
Purified by flash chromatography using cyclohexane/EtOAc (4:1) and obtained as a 
colorless oil. Yield: 155 mg, 0.86 mmol, 86%. RF = 0.40 (cyclohexane/EtOAc = 4:1); 
1H NMR 
(CDCl3, 500 MHz): δ 7.33 – 7.22 (m, 5H), 4.48 (m, 1H), 3.77 (s, 3H), 3.13 (dd, J = 13.9, 4 Hz, 
1H), 2.98 (dd, J = 13.9, 6.9 Hz, 1H); 13C NMR (CDCl3, 125 MHz): δ 174.6 (Cq), 136.4 (Cq), 129.5 (CH), 128.4 (CH), 
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126.9 (CH), 71.3 (CH), 52.5 (CH3), 40.5 (CH2); IR (neat): νmax (cm
-1) = 3384 (w), 1729 (s), 1659 (s), 1437 (m), 1203 
(s), 1093 (s), 746 (m), 699 (s); HRMS (ESI): m/z calculated for C10H12NaO3 [M + Na]
+ 203.0679, found 203.0682. 
 
Methyl 7-(benzyloxy)-2-hydroxyheptanoate (11b): 
Prepared according to general procedure II from 6-(benzyloxy)hexan-1-ol (187 
mg, 0.9 mmol). Purified by flash chromatography using cyclohexane/EtOAc (4:1) 
and obtained as a yellow oil. Yield: 153 mg, 0.64 mmol, 64%. RF = 0.25 
(cyclohexane/EtOAc = 4:1); 1H NMR (CDCl3, 500 MHz): δ 7.38 – 7.28 (m, 5H), 4.52 
(s, 2H), 4.20 (m, 1H), 3.79 (s, 3H), 3.48 (t, J = 6.6 Hz, 2H), 2.86 (bs, 1H), 1.82 (m, 1H), 1.70 – 1.62 (m, 3H), 1.51 – 
1.38 (m, 4H); 13C NMR (CDCl3, 125 MHz): δ 175.9 (Cq), 138.7 (Cq), 128.4 (CH), 127.7 (CH), 127.6 (CH), 73.0 (CH2), 
70.4 (CH), 70.3 (CH2), 52.6 (CH3), 34.4 (CH2), 29.7 (CH2), 26.0 (CH2), 24.7 (CH2); IR (neat): νmax (cm
-1) = 2940 (w), 
2863 (w), 1734 (s), 1455 (w), 1210 (m), 1092 (s), 736 (s), 697 (s); HRMS (ESI): m/z calculated for C15H22NaO4 [M + 
Na]+ 289.1404, found 289.1410. 
 
Methyl 2-hydroxy-7-((4-methylphenyl)sulfonamido)heptanoate (11c): 
Prepared according to general procedure II from N-(6-hydroxyhexyl)-4-
methylbenzenesulfonamide (272 mg, 1 mmol). Purified by flash chromatography 
using cyclohexane/EtOAc (1:1) and obtained as a yellow oil. Yield: 218 mg, 0.62 
mmol, 62%. RF = 0.30 (cyclohexane/EtOAc = 1:1); 
1H NMR (CDCl3, 500 MHz): δ 
7.71 (d, J = 8.2 Hz, 2H), 7.26 (d, J = 8.2 Hz, 2H), 5.16 (bs, 1H), 4.13 (dd, J = 7.6, 4.1 Hz, 1H), 3.72 (s, 3H), 3.01 (bs, 
1H), 2.86 (m, 2H), 2.38 (s, 3H), 1.67 (m, 1H), 1.53 (m, 1H), 1.43 – 1.38 (m, 2H), 1.34 – 1.22 (m, 4H); 13C NMR 
(CDCl3, 125 MHz): δ 175.7 (Cq), 143.3 (Cq), 136.9 (Cq), 129.7 (CH), 127.1 (CH), 70.3 (CH), 52.5 (CH3), 43.0 (CH2), 
34.0 (CH2), 29.3 (CH2), 26.1 (CH2), 24.2 (CH2), 21.5 (CH3); IR (neat): νmax (cm
-1) = 3292 (w), 2943 (w), 1731 (s), 
1321 (s), 1153 (s), 1091 (s), 910 (s), 813 (s), 727 (s), 549 (s); HRMS (ESI): m/z calculated for C15H23NNaO5S [M + 
Na]+ 352.1189, found 352.1181. 
 
Methyl 7-(((benzyloxy)carbonyl)amino)-2-hydroxyheptanoate (11d): 
Prepared according to general procedure II from benzyl (6-
hydroxyhexyl)carbamate (251 mg, 1 mmol). Purified by flash chromatography 
using cyclohexane/EtOAc (1:1) and obtained as a yellow oil. Yield: 140 mg, 0.45 
mmol, 45%. RF = 0.33 (cyclohexane/EtOAc = 1:1); 
1H NMR (CDCl3, 500 MHz): δ 7.34-7.29 (m, 5H), 5.07 (s, 2H), 
4.86 (bs, 1H), 4.17 (m, 1H), 3.76 (s, 3H), 3.17 (m, 2H), 2.93 (bs, 1H), 1.75 (m, 1H), 1.62 (m, 1H), 1.51 – 1.30 (m, 
6H); 13C NMR (CDCl3, 125 MHz): δ 175.8 (Cq), 156.5 (Cq), 136.7 (CH), 128.6 (CH), 128.2 (CH), 128.2 (CH), 70.3 (CH), 
66.7 (CH2), 52.6 (CH), 41.0 (CH2), 34.2 (CH2), 29.9 (CH2), 26.4 (CH2), 24.5 (CH2); IR (neat): νmax (cm
-1) = 3359 (w), 
2938 (w), 1688 (s), 1541 (m), 1455 (m), 1235 (s), 1131 m), 697 (s); HRMS (ESI): m/z calculated for C16H23NNaO5 
[M + Na]+ 332.1468, found 332.1468. 
 
Butyl 2-hydroxy-3-phenylpropanoate (11e): 
Prepared according to general procedure II from 2-phenylethanol (120 µL, 1 mmol). The 
mixture was heated after addition of anhydrous BuOH and AcCl (714 µL, 10 mmol, 10 
equiv) to 40 °C. Purified by flash chromatography using cyclohexane/EtOAc (6:1) and 
obtained as a colorless oil. Yield: 167 mg, 0.75 mmol, 75%. RF = 0.28 (cyclohexane/EtOAc = 
6:1); 1H NMR (CDCl3, 500 MHz): δ 7.34 – 7.24 (m, 5H), 4.46 (m, 1H), 4.17 (m, 2H), 3.14 (dd, J = 14.0, 4.5 Hz, 1H), 
2.99 (dd, 14.0, 7.0 Hz, 1H), 2.91 (bs, 1H), 1.65 (p, J = 7.5 Hz, 2H), 1.39 (h, J = 7.5 Hz, 2H), 0.97 (t, J = 7.5 Hz, 3H); 13C 
NMR (CDCl3, 125 MHz): δ 174.3 (Cq), 136.4 (Cq), 129.5 (CH), 128.4 (CH), 126.9 (CH), 71.3 (CH), 65.6 (CH2), 40.6 
(CH2), 30.6 (CH2), 19.1 (CH2), 13.7 (CH3); IR (neat): νmax (cm
-1) = 3475 (br), 2958 (m), 1730 (s), 1454 (m), 1267 
(m), 1195 (s), 1091 (s), 746 (m), 698 (s); HRMS (ESI): m/z calculated for C13H18NaO3 [M + Na]
+ 245.1148, found 
245.1154. 
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Isopropyl 2-hydroxy-3-phenylpropanoate (11f):  
Prepared according to general procedure II from 2-phenylethanol (120 µL, 1 mmol). The 
mixture was heated after addition of anhydrous i-PrOH and AcCl (714 µL, 10 mmol, 10 
equiv) to 80 °C. Purified by flash chromatography using cyclohexane/EtOAc (6:1) and 
obtained as a colorless oil. Yield: 131 mg, 0.63 mmol, 63%. RF = 0.33 (cyclohexane/EtOAc = 
6:1); 1H NMR (CDCl3, 400 MHz): δ 7.33 – 7.24 (m, 5H), 5.07 (septet, J = 6.0 Hz, 1H), 4.41 (m, 1H), 3.13 (dd, J = 
14.0, 4.8 Hz, 1H), 2.97 (dd, J = 14.0, 6.4 Hz, 1H), 2.82 (bs, 1H), 1.26 (m, 6H); 13C NMR (CDCl3, 100 MHz): δ 173.7 
(Cq), 136.4 (Cq), 129.6 (CH), 128.3 (CH), 126.8 (CH), 71.2 (CH), 69.6 (CH), 40.5 (CH2), 21.7 (CH3); IR (neat): νmax 
(cm-1) = 3475 (br), 2958 (m), 1728 (s), 1454 (m), 1197 (s), 1091 (s), 744 (m), 698 (s); HRMS (ESI): m/z calculated 
for C12H16NaO3 [M + Na]
+ 231.0992, found 231.0995.  
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Efficient Synthesis of Pipecolic Amides with a Highly 
Diastereoselecive U-3CR 
 
 
Abstract: In this chapter, a highly diastereoselective U-3CR between electronically diverse 
isocyanides, carboxylic acids and 4-substituted Δ
1
-piperideines is described. The required 
piperidines are generated by an efficient two-step procedure involving alkylation of 4-
picoline and subsequent reduction of the pyridine ring. The piperidines can be both 
chemically oxidized to the corresponding racemic Δ
1
-piperideines or biocatalytically to the 
optically enriched Δ
1
-piperideines with novel MAO-N derivatives. To demonstrate the 
potential of this methodology, we show the utility of the U-3CR, in combination with our 
novel convertible isocyanide in the synthesis of the anticoagulant argatroban.  
 
manuscript in preparation 
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Introduction 
In the past decades, isocyanide based multicomponent reactions (IMCRs) have proven 
their value as useful tools for the generation of structurally diverse compound libraries.
1-3
 
In chapters 2 and 3, we have introduced 2-bromo-6-isocyanopyridine as useful reagent to 
address the traditional limitations in the scaffold diversity of the IMCR products. 
Nevertheless, there is still a general drawback regarding IMCRs, i.e. the difficult 
stereocontol. Most IMCRs, like the Ugi and Passerini reactions, generate a chiral center 
which is generally difficult to control. A very important accomplishment within the field of 
IMCRs is the development of novel methods to gain stereocontrol (e.g. for the Passerini
4-7
 
and the ‘acid-less’ Ugi reaction
8
) with the use of cleverly designed (organo)catalysts. 
However, for one of the most widely used IMCRs – the Ugi four-component reaction (U-
4CR) – there is no general method available.
9
 
A different approach to control the stereochemical outcome of the Ugi reaction is the use 
of chiral starting materials. Unfortunately, the diastereoselectivity in Ugi reactions is 
generally very poor. In view of stereocontrol, chiral isocyanides and carboxylic acids show 
very poor stereochemical induction and typically result into 1:1 diastereomeric mixtures.
10
 
Moreover, aldehyde inputs have similar problems with the additional disadvantage that 
the α-carbon is sensitive toward epimerization.
11
 However, the combination of two 
different functional groups in a single (chiral) reactant provides much higher stereo-
control, especially in the formation of (macro)cycles.
12-14
 In addition, chiral amine and 
imine inputs are generally able to transfer their chiral information.
15-19
 
Recently, our group reported an elegant method to induce stereoselectivity in the Ugi 
reaction using chiral bicyclic imines (2) for the synthesis of prolyl peptides (5, Scheme 1).
20
 
The strategy was based on the combination of a biocatalytic desymmetrization of 3,4-
substituted meso-pyrrolidines (1) with monoamine oxidase N (MAO-N) to the 
corresponding imines (2)
21
 with a highly diastereoselective Ugi three-component reaction 
(U-3CR).
20
 The diastereoselectivity arises from the steric bulk present in the 1-pyrroline 
skeleton. This methodology provides access to a large set of chemically interesting prolyl 
peptides (5), including the hepatitis C virus NS3 protease inhibitor telaprevir (6).
22
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Scheme 1. MAO-MCR sequence with 3,4-substituted pyrrolidines. 
Obviously, prolyl peptides are desirable building blocks for medicinal chemistry, due to the 
high occurrence of proline in proteins and oligopeptides. Moreover, the structurally 
related homo-analogues of the prolyl peptides, the pipecolic amides, are common 
structural motifs in bioactive compounds.
23-25
 Especially 4-substituted pipecolic acid 
derivatives represent an important class of compounds. A large part of this class consists 
of bioactive 2,4-cis substituted pipecolic amides or acids, such as the potent HIV inhibitor 
palanivir
26
 and the NMDA antagonist selfotel
27,28
 (Figure 1). Additionally, trans-pipecolic 
acid derivatives are key motifs in for example antitumor agents and the thrombin inhibitor 
argatroban.
29
 
 
Figure 1. Bioactive 4-substituted pipecolic acid derivatives. 
The bioactive pipecolic amide derivatives are generally obtained from non-commercial 
pipecolic acids, which are synthetically challenging targets.
30
 This prompted us to 
investigate the MAO-IMCR methodology for the desymmetrization of the prochiral 4-
substituted piperidines (10) followed by a U-3CR of the resulting cyclic imines (11, Scheme 
2).  
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Scheme 2. The MAO-MCR sequence. 
There is some literature evidence that Δ
1
-piperideines (11) are good substrates for IMCR 
chemistry, e.g. for the synthesis of pipecolic acids
31
 and acyldepsipeptide antibiotics.
32,33
 
Furthermore, the group of El Kaïm has shown that 4-benzyl Δ
1
-piperideine is a good 
substrate for the Ugi-Smiles reaction.
34
 In order for our envisioned MAO-IMCR reaction 
sequence to be successful, good enzymatic activity towards the 4-substituted piperidines 
and a high diastereoselectivity in the subsequent U-3CR are required.  
 
Results and discussion 
Initial screening of a small set of chemically diverse 4-substituted piperidines with MAO-N 
clearly showed activity for 4-alkyl substituted piperidines in contrast to other substituents 
(such as aryl groups or substituents linked via a heteroatom). These results are in 
agreement with earlier observations on the substrate profile of MAO-N. The active site of 
the enzyme lies within a hydrophobic pocket.
35
 To further investigate the 4-alkyl 
piperidine scope of various MAO-N variants, synthesis of a larger set of 4-alkyl piperidines 
was required, since these piperidines are not commercially available. 
Initially we set out to synthesize the 4-alkyl piperidines (13) by Wittig reaction with N-Cbz 
piperidone (13) and different alkylphosphonium halides (Scheme 3). The resulting alkenes 
were reduced under hydrogen atmosphere in the presence of palladium on charcoal, 
which directly provided the free 4-alkyl piperidines (10) as foul smelling liquids. This route 
generated only a small set of inputs in disappointing yields (20-45%). 
 
Scheme 3. Synthesis of 4-alkyl piperidines 15 from N-Cbz piperidone 13. 
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In order to create a larger library of 4-alkyl piperidines, we decided to use a different 
synthetic approach. The strategy involved the alkylation of 4-picoline (15)
36,37
 with 
different alkyl bromides followed by hydrogenation of the 4-alkyl pyridines (16) in the 
presence of catalytic PtO2 (Table 1).
38,39
 The alkylation proceeded very efficiently with 
linear alkyl bromides (entries 2-4) and secondary alkyl bromides (entry 5) to produce the 
4-alkyl pyridines (16b-f) in high yields. In addition, double alkylation with alkyl dibromides 
and two equivalents of LDA directly provided 4-cyclopentyl- and 4-cyclohexylpyridine (16h 
and 16i, entries 7-8), albeit in lower yields. 
 
entry 16 R 10 yield 16 (%) yield 10 (%) 
1 16b Et 10b --
a 100 
2 16c n-Pr 10c 97 100 
3 16d n-Bu 10d 97 100 
4 16e n-Pentyl 10e 90 100 
5 16f i-Bu 10f 86 100 
6 16g t-Bu 10g --a 93c 
7 16h c-pentyl 10h 24b 99 
8 16i c-hexyl 10i 25b 92 (94)d 
Table 1. Two-step synthesis of 4-alkyl piperidines 10 from 4-picoline. aThe corresponding piperidine is 
commercially available. bThe cyclic side-groups are generated by a double alkylation with dibromides. c0.10 equiv 
of PtO2 were used. 
d4-phenylpyridine was used as starting material in the reduction step. 
 
The hydrogenation of the pyridines (16) was performed with PtO2 as catalyst in the 
presence of HCl to obtain the piperidines (10) as odorless HCl salts (a significant advantage 
compared to the foul smelling liquids). Reduction of pyridines is generally performed 
under elevated hydrogen pressure and reaction temperature, however we discovered that 
atmospheric hydrogen pressure at room temperature worked just as effectively to provide 
all piperidinium salts (10b-i) in near quantitative yields (entries 1-8). Interestingly, the use 
of 4-phenylpyridine as the starting material for the hydrogenation also provided 4-
cyclohexyl piperidine 10i in similar yield through reduction of the conjugated phenyl 
ring.
40
 
 
With a set of 4-alkyl piperidines (10) in hand, racemic imines 11 were synthesized as 
racemic standards for the determination of the enantioselectivity of the 
biotransformation. Synthesis of the Δ
1
-piperideines (11) was accomplished by chlorination 
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of the piperidines with NCS followed by elimination of HCl with ethanolic KOH (Scheme 
4).
41
 
1
H NMR analysis of the resulting products indicated that the imines were not stable 
and rapidly formed diastereomeric mixtures of trimers (17). 
 
Scheme 4. Synthesis of the racemic Δ1-piperideines 11. 
To validate if the trimers are still reactive inputs for the U-3CR, we reacted the obtained 
mixtures of trimers and racemic imines (11) with a set of different isocyanides (4) and 
carboxylic acids (3, Scheme 5). To our delight, the pipecolic amides were obtained in 
generally excellent yields, indicating that the trimerization is reversible under acidic 
conditions. More importantly, the pipecolic amides were obtained as single 
diastereomers, independently of the size of the alkyl-group on the piperidine ring. X-ray 
structural analysis of compound 12q indicated the expected trans-configuration of the 
pipecolic amides (Figure 2). All other pipecolic amides 12 were assigned to have the same 
2,4-trans-configuration by similarity and comparison of 
1
H NMR coupling constants. The 
scope of the reaction is very broad in terms of both the isocyanide and carboxylic acid 
input. Different types of aliphatic isocyanides were accepted, including the α-acidic methyl 
isocyanoacetate to give 12e and 12m, albeit in slightly lower yields compared to the other 
inputs. The carboxylic acid component can be varied widely, ranging from aromatic, 
benzylic and aliphatic substituents. The more congested pivalic acid proved to be an 
advantageous input for NMR analysis. Most U-3CR products appear as rotamers on the 
NMR spectra due to hindered rotation of the tertiary amide bond. The steric bulk of the 
tert-butyl strongly disfavors one of the possible amide configurations, which greatly 
simplifies the NMR analysis. 
 
Figure 2. Crystal X-ray structure of compound 12q with displacement ellipsoids drawn at 50% probability level. 
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Scheme 5. Scope of the highly diastereoselective U-3CR. 
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The diastereoselectivity of the U-3CR is determined in one of the first steps of the reaction 
mechanism, more specifically the attack of the isocyanide on the carbon of the protonated 
imine (Scheme 6). The Δ
1
-piperideine (11) is preferably present in the half-chair 
conformation with the alkyl substituent pseudo-equatorially positioned. The isocyanide (4) 
has two options: an attack from the bottom side (an equatorial attack) which leads to an 
unfavored twist-boat conformation (19a) or an attack from the top (axial attack) which 
leads directly to a favored chair conformation (18). Consequently, the kinetic barrier for an 
axial attack is much lower than for an equatorial attack, providing exclusively the trans-
product.
42,43
   
 
Scheme 6. Mechanism of the initial isocyanide attack on iminium species 11. 
With the establishment of the feasibility of the U-3CR with Δ
1
-piperideine inputs, we 
focused on the biocatalytic conversion of the piperidines with engineered MAO-N. Turner 
et al. reported great success with the MAO-N D5 variant for the enantioselective oxidation 
of 3,4-substituted pyrrolidines (2).
21
 Due to the trimeric character of the imines, the 
conversion and ee of the desymmetrization was measured by derivatization of the 
resulting imines to the corresponding α-amino nitriles (20) with a cyanide donor (KCN or 
TMSCN). Unfortunately, MAO-N D5 proved a poor catalyst for biotransformation of the 4-
substituted piperidines (10). To enhance the activity, the biocatalysts were subjected to a 
round of directed evolution with MAO-N D5 as the parent leading to five new mutants 
(D12A-E). For most substrates the activity increased significantly, however the sterically 
demanding substrates (10e-j) were generally not accepted. To develop a variant with a 
broader substrate tolerance, another round of directed evolution was performed. This 
time MAO-N D9 was used as parent enzyme resulting in two new variants: D13A-B. 
All substrates were screened with the new variants and the best results are presented in 
Table 2. The results clearly indicate that smaller piperidines (10a-d) are better accepted by 
the D12 mutants (entries 1-4), while the sterically more demanding substrates (10e-j) are 
better converted by the D13 mutants (entries 5-8). 4-Cyclohexylpiperidine (10i) does not 
show any conversion, which shows the sensitivity for the size of the substrates. 
Unfortunately, there is no clear relationship between the size and shape of the R-
substituent and the corresponding conversion and ee. 
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entry 20 R variant conversion (%) ee (%) 
1 20a Me D12A 
D12C 
>99 
98 
57 
49 
2 20b Et D12A 
D12B 
>99 
9 
−24 
>99 
3 20c n-Pr D12A 
D12B 
40 
69 
93 
92 
4 20d n-Bu D12D 
D13A 
D13B 
>99 
77 
89 
86 
87 
78 
5 20e n-Pentyl D9 
D13B 
>99 
>99 
87 
87 
6 20f i-Bu D13A 
D13B 
55 
88 
92 
88 
7 20g t-Bu D12A 
D12E 
D13B 
67 
56 
48 
83 
88 
99 
8 20h c-pentyl D13A 
D13B 
55 
70 
92 
87 
9 20i c-hexyl D13A 
D13B 
-- 
-- 
-- 
-- 
10 20j i-Pr D5 
D13B 
>99 
>99 
20 
−10 
Table 2. Enzymatic oxidation of 4-alkyl piperidines 10 with different MAO-N variants. 
 
To establish the stereopreference of the MAO-N mutants, biocatalytically produced 
enantioenriched 11a was reacted with benzyl isocyanide and 4-phenylbutyric acid (22) 
followed by acidic hydrolysis to give the known amino acid 23. Comparison of the optical 
rotation of 23 with literature values of (−)-23 by our collaborators in Manchester led to a 
preliminary assignment of the R,R-configuration to the main enantiomer.
44
 
 
Scheme 7. Determination of the absolute stereochemistry of 23. 
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As a demonstration of the full potential of our MAO-MCR strategy, we applied our 
methodology to the synthesis of argatroban (27). The drug acts as anticoagulant by 
competitively inhibiting the enzyme thrombin. Mitsubishi reported the synthesis of 
argatroban in the patent literature starting from the optically pure 4-methylpipecolic ester 
25 (Scheme 8).
45
 The synthesis is straightforward and involves a linear sequence of 
standard protections/deprotections and peptide coupling reactions. However, the 
synthesis of optically pure synthon 25 requires a six-step synthesis from 2,4-
dimethylpyridine (24) including a resolution by crystallization with L-tartaric acid.  
 
Scheme 8. Synthesis of argatroban by Mitsubishi. 
In 2001, Cossy et al. reported an improved synthesis of argatroban with a similar strategy 
as Mitsubishi (Scheme 9).
46
 They circumvented the troublesome enantioselective 
synthesis of the pipecolic ester by using the readily accessible racemic pipecolic ester 30. 
They rationalized that they could separate the diastereoisomers after coupling to 
protected L-arginine 26. The racemic pipecolic ester 30 was made by α-lithiation of N-Boc 
4-methylpiperidine (28). The resulting lithiate was quenched with benzyl chloroformate to 
obtain 29 with high diastereoselectivity in favor of the trans-diastereomer (up to 95:5).
47
 
Subsequently, the Boc group was removed under acidic conditions to obtain pipecolic 
ester 30 in an overall yield of 34%. Then, the pipecolic ester was coupled to protected 
arginine 26. At this stage, the diastereomers were separable by flash chromatography to 
give optically pure N-Boc 31 in 17% yield from 26. After acidic cleavage of the Boc group, 
the resulting amine was sulfonylated by treatment with 3-methylquinolinesulfonyl 
chloride (32) in the presence of Et3N. Finally, hydrogenation of the quinoline ring and 
reductive cleavage of the benzyl ester and the nitro group provided argatroban in 77% 
yield over the last 2 steps. 
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Scheme 9. Synthesis of Argatroban by Cossy et al. 
We envisinoned a more convergent MAO-MCR strategy, which required the following 
components for the U-3CR: a protected arginine (33) as carboxylic acid input, the (R)-
configured 4-methyl-Δ
1
-piperideine ((R)-11a) from the biocatalytic oxidation as imine 
input, and an isocyanide of which the resulting secondary amide can be converted to the 
carboxylic acid after the U-3CR. The obvious candidate for this transformation is our novel 
reagent 2-bromo-6-isocyanopyridine (34).
48
  
 
Scheme 10. Retrosynthesis of argatroban with the use of the MAO-MCR sequence. 
In order for the U-3CR to work, a less basic guanidine is required. Initially, we designed our 
synthetic approach with Nω-nitro-L-arginine 26 as starting input, which has several 
advantages. Firstly, the nitro group is much smaller than most other protection groups 
improving the overall atom economy. Secondly, the nitro group is one of the strongest 
electron-withdrawing groups, which completely deactivates the guanidine, resulting in 
higher yields in the U-3CR. Finally, the nitro group can be removed in the final reaction 
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step simultaneously with the reduction of the quinolone ring. However, we discovered 
that the nitro guanidine (35) shows signs of degradation during the basic hydrolysis of the 
activated amide (Scheme 11). 
1
H NMR and HPLC-MS analysis indicated several products 
(such as 36 and 37) in which the nitro guanidine group of 35 was hydrolyzed. Therefore, 
we favored the double Cbz protected arginine 39 as starting input, which can also be 
removed at the final hydrogenation reaction. 
 
Scheme 11. Hydrolysis of the nitro arginine group. 
Unfortunately, we discovered at this point that the biocatalytic oxidation of 4-methyl 
piperidine did not provide the desired (R)-enantiomer of 11a, but the (S)-enantiomer. 
Assignment of the absolute configuration by comparison of the specific optical rotation 
with literature values (Scheme 7) can be very unreliable for compounds with a very small 
specific rotation, e.g. due to the presence of impurities with much higher specific rotation. 
Therefore, we sought a chemical alternative to make the desired (R)-4-methyl-Δ
1
-
piperideine ((R)-11a) to circumvent the biocatalytic oxidation.  
Since there are no chemical (non-enzymatic) catalysts that can enantioselectively oxidize 
the 4-substituted piperidines (11) to the corresponding imines, we developed a different 
synthetic approach to obtain the desired enantiomer (R)-11a (Scheme 12). We started 
with the synthesis of enantiomerically enriched lactam 43 by the copper-catalyzed 
enantioselective conjugate reduction of α,β-unsaturated lactam 42 as described by 
Buchwald.
49
 The α,β-unsaturated lactam 42 was synthesized by a conjugate addition of p-
anisidine (39) to methyl vinyl ketone (38). An intramolecular Knoevenagel condensation 
followed by a retro-Claisen decarboxylation provided lactam 39 in 80% yield over 3 steps. 
The conjugate reduction in de presence of CuCl and (R)-T-BINAP as chiral ligand provided 
(R)-lactam 43 in high yield (90%) and ee (90%). X-ray crystallographic analysis established 
the desired (R)-configuration of 43. Oxidative cleavage of the p-methoxyphenyl group with 
ceric ammonium nitrate (CAN) resulted in the unprotected lactam. According to the 
literature, related cyclic lactams can be reduced to the corresponding imines by treatment 
with the Schwartz’s reagent and reacted in the same pot with a carboxylic acid and 
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isocyanide to obtain the U-3CR products.
50
 Unfortunately, treatment of 4-methyl-2-
piperidone with zirconocene chloride hydride did not gave any conversion to the desired 
imine ((R)-11a), however we mainly recovered the starting material. In order to selectively 
reduce the lactam to imine (R)-11a, we required a slight detour. The lactam was first 
protected with a Boc group, followed by reduction of the amide with DiBAL to give the 
hemiaminal, which dehydrated during workup to the cyclic enamine. Finally, deprotection 
of the Boc group with TFA should provide imine (R)-11a. However, addition of the U-3CR 
components after deprotection of the Boc group resulted in a disappointing yield of the 
Ugi product (about 10%). Possibly, the imine is in equilibrium with the corresponding 
enamine and can irreversibly form di- and trimers and/or other oligomers by a Henry-type 
reaction.
51,52 
Scheme 12. Chemical synthesis of imine (R)-11a. X-ray structure of 43 with displacement ellipsoids drawn at 50% 
probability level. 
In order to validate our synthetic approach, we decided to continue our route with 
racemic imine (±)-11a and separate the diastereoisomers at a later stage (Scheme 13). The 
route starts with double Cbz protected 44 as the arginine input of the reaction sequence. 
The Boc group was removed by treatment with TFA and the resulting amine was 
sulfonylated with 3-methyl-8-quinolinesulfonyl chloride (32) in the presence of DIPEA to 
furnish carboxylic acid 46 in nearly quantitative yield. Compound 46 was combined with 
convertible isocyanide 34 and racemic imine (±)-11a to afford U-3CR product 47 as a 1:1 
mixture of diastereomers. The resulting 47 was subjected to several separation methods 
(e.g. crystallization, flash and semi-preparative chromatography), however we were 
unable to separate the diastereomers, which led us to continue with the diastereomeric 
mixture. The activated amide of 47, resulting from the 2-bromo-6-isocyanopyridine, was 
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hydrolyzed with aqueous NaOH. Interestingly, the Cbz groups appear sensitive to these 
reaction conditions, resulting in the quantitative removal of one of the Cbz groups and 
partial removal of the other. At this stage, we managed to separate minor quantities of 
the diastereoisomers by semi-preparative chromatography to obtain the desired 
stereoisomer. Finally, the quinolone ring was reduced and the remaining Cbz-group was 
removed by a hydrogenation reaction with Pd/C to obtain argatroban (27). In order to 
determine an accurate yield for the last two transformations, the reactions were repeated 
on a bigger scale with the diastereomeric mixture of 47 without separation of the 
diastereomers after the basic hydrolysis. Gratifyingly, 27 was obtained as a mixture of four 
diastereoisomers in high yield.  
  
Scheme 13. Synthesis of argatroban with the diastereoselective U-3CR. 
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Conclusion and Outlook 
In conclusion, we have developed an efficient and highly diastereoselective U-3CR to make 
pipecolic amides. The starting materials of this reaction are 4-substituted Δ
1
-piperideines, 
which can be made from the corresponding 4-substituted piperidines. The piperidines 
were synthesized by an alkylation of 4-picoline followed by hydrogenation of the pyridine 
ring with hydrogen and catalytic PtO2 in the presence of HCl. The piperidines were 
chemically oxidized to the racemic Δ
1
-piperideines. Additionally, we investigated the 
potential biocatalytic oxidation of the piperidines with MAO-N to obtain the optically pure 
imines. Even though the initial results showed only poor conversion and 
enantioselectivity, the results were significantly improved by directed evolution of the 
known D5 and D9 derivatives. The Δ
1
-piperideines proved very effective inputs for the U-
3CR in combination with chemically diverse isocyanides and carboxylic acids leading to a 
wide variety of biologically interesting pipecolic amides. As a demonstration of the 
potential of the U-3CR, we used our methodology in combination with our recently 
developed convertible isocyanide 2-bromo-6-isocyanopyridine to synthesize the 
anticoagulant Argatroban.  
In the near future we plan to use biocatalytically oxidized Δ
1
-piperideines in the U-3CR to 
obtain enantiomerically enriched pipecolic amides. Furthermore, we will separate the 
diastereomers of U-3CR product in the synthetic route to argatroban on a larger scale with 
semi-preparative HPLC in combination with a chiral column to obtain larger quantities of 
argatroban.  
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Experimental Section 
General Remarks 
Unless stated otherwise, all solvents and commercially available reagents were used as purchased. All reaction 
were performed under air, unless stated otherwise. Infrared (IR) spectra were recorded neat using a Shimadzu 
FTIR-8400s spectrophotometer and wavelengths are reported in cm-1. Nuclear magnetic resonance (NMR) 
spectra were recorded on a Bruker Avance 500 (125.78 MHz for 13C) or Bruker Avance 400 (100.62 MHz for 13C) 
using the residual solvent as internal (1H: δ 7.26 ppm, 13C{1H}: δ 77.00 ppm for CDCl3, 
1H: δ 2.50 ppm, 13C{1H}: δ 
39.52 ppm for DMSO-d6 and 
1H: δ 3.31 ppm, 13C{1H}: δ 49.00 ppm for MeOD-d4). Chemical shifts (δ) are given in 
ppm and coupling constants (J) are quoted in hertz (Hz). Resonances are described as s (singlet), d (doublet), t 
(triplet), q (quartet), bs (broad signal) and m (multiplet) or combinations thereof. Chiral HPLC was recorded using 
a LC10VP with a SCL-10A VP system controller, LC-10AT VP liquid chromatograph, SPD-M10A VP diode array 
detector and CTO-10AC VP column oven from Shimadzu. Data was processed using Shimadzu Labsolutions. Semi-
preparative reverse phase HPLC was recorded using a LC20 with a CBM-20A communications bus module, LC-
20AT liquid chromatograph, SPD-M20A diode array detector, SIL-20A auto sampler, CTO-20AC column oven and 
a FRC-10A fraction collector from Shimadzu. Melting points were recorded on a Büchi M-565 melting point 
apparatus and are uncorrected. Electrospray Ionization (ESI) high-resolution mass spectrometry was carried out 
using a Bruker micrOTOF-Q instrument in positive ion mode (capillary potential of 4500 V). Flash 
chromatography was performed on Silicycle Silia-P Flash Silica Gel (particle size 40-63 μm, pore diameter 60 Å) 
using the indicated eluent. Thin Layer Chromatography (TLC) was performed using TLC plates from Merck (SiO2, 
Kieselgel 60 F254 neutral, on aluminium with fluorescence indicator) and compounds were visualized by UV 
detection (254 nm) and KMnO4 stain. 
 
A synthetic strategy towards 4-substituted piperidinium salts (10) 
General procedure I: Synthesis of 4-alkylpyridines  
A flame dried three-neck round bottom flask under N2 atmosphere was charged with a solution of 
diisopropylamine (5.0 mL, 35.7 mmol, 1.55 equiv) in anhydrous THF (100 mL). The reaction mixture was cooled to 
−78 °C and a solution of n-butyllithium (1.6 M in hexanes, 21.6 mL, 34.5 mmol, 1.5 equiv) was added dropwise. 
After 10 min, the solution was warmed to 0 °C and stirred for another 20 min. The solution was cooled again to 
−78 °C and 4-picoline (2.24 mL, 23 mmol, 1.0 equiv) in anhydrous THF (15 mL) was added dropwise. The resulting 
mixture stirred for 1 h resulting in a dark red solution. Then the alkyl bromide (23 mmol, 1 equiv) in anhydrous 
THF (10 mL) was added dropwise at −78 °C. After stirring for 1 h, the temperature was allowed to warm up to 
room temperature and stirred overnight. The reaction mixture was quenched with saturated NH4Cl(aq) (50 mL). 
The layers were separated and the water layer was extracted with EtOAc (3×). The organic layers were combined, 
washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product 
was purified by flash column chromatography providing the liquid alkylpyridines.  
Synthesis of 4-propylpyridine (16c) 
 Prepared according to general procedure I using bromoethane (1.72 mL, 23 mmol, 1 equiv). Flash 
chromatography (cyclohexane/EtOAc = 3:2) provided the product as a yellow liquid (2.69 g, 22.2 mmol, 
97%). RF = 0.37 (cyclohexane/EtOAc = 1:1); 
1H NMR (CDCl3, 500 MHz): δ 8.39 (d, J = 5.9 Hz, 2H), 7.01 (d, 
J = 5.9 Hz, 2H), 2.49 (t, J = 7.5 Hz, 2H), 1.56 (tq, J = 7.5, 7.5 Hz, 2H), 0.86 (t, J = 7.5 Hz, 3H) ppm; 13C NMR 
(CDCl3, 125 MHz): δ 151.3 (Cq), 149.3 (CH), 123.7 (CH), 37.0 (CH2), 23.2 (CH2), 13.5 (CH3) ppm; IR (neat): 
νmax (cm-1) = 2960, 2933, 2871, 1600, 1413, 1220, 794, 626, 445; HRMS (ESI): m/z calculated for C8H12N [M+H]
+ 
122.0964, found 122.0969. 
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Synthesis of 4-butylpyridine (16d) 
Prepared according to general procedure I using 1-bromopropane (2.09 mL, 23 mmol, 1 equiv). 
Flash chromatography (cyclohexane/EtOAc = 3:1) provided the product as a yellow liquid (3.01 g, 
22.3 mmol, 97%). RF = 0.23 (cyclohexane/EtOAc = 3:1); 
1H NMR (CDCl3, 500 MHz): δ 8.39 (d, J = 5.8 
Hz, 2H), 7.02 (d, J = 5.8 Hz, 2H), 2.51 (t, J = 7.5 Hz, 2H), 1.52 (tt, J = 7.5, 7.5 Hz, 2H), 1.26 (tq, J = 7.5, 
7.5 Hz, 2H), 0.85 (t, J = 7.5 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 151.5 (Cq), 149.4 (CH), 123.7 
(CH), 34.7 (CH2), 32.2 (CH2), 22.0 (CH2), 13.6 (CH3) ppm; IR (neat): νmax (cm
-1) = 2965, 2931, 2860, 
1600, 1413, 993, 804, 733, 630, 582, 526, 501; HRMS (ESI): m/z calculated for C9H14N [M+H]
+ 136.1121, found 
136.1121. 
Synthesis of 4-pentylpyridine (16e) 
Prepared according to general procedure I using 1-bromobutane (2.47 mL, 23 mmol, 1 equiv). Flash 
chromatography (cyclohexane/EtOAc = 5:1) provided the product as a yellow liquid (3.07 g, 20.6 
mmol, 90%). RF = 0.45 (cyclohexane/EtOAc = 2:1); 
1H NMR (CDCl3, 500 MHz): δ 8.49 (bs, 2H), 7.10 
(bs, 2H), 2.59 (t, J = 7.5 Hz, 2H), 1.62 (p, J = 7.5 Hz, 2H), 1.32 (m, 4H), 0.89 (t, J = 7.5 Hz, 3H) ppm; 13C 
NMR (CDCl3, 125 MHz): δ 151.7 (Cq), 149.6 (CH), 123.9 (CH), 35.2 (CH2), 31.3 (CH2), 30.0 (CH2), 22.4 
(CH2), 14.0 (CH3) ppm; IR (neat): νmax (cm
-1) = 2965, 2927, 2858, 1600, 1413, 991, 798, 630, 536, 
503, 496; HRMS (ESI): m/z calculated for C10H16N [M+H]
+ 150,1277, found 150.1278. 
Synthesis of 4-Isobutylpyridine (16f) 
Prepared according to general procedure I using 2-bromopropane (2.16 mL, 23 mmol, 1 equiv). 
Flash chromatography (cyclohexane/EtOAc = 5:1) provided the product as a colorless oily liquid (2.67 
g, 19.7 mmol, 86%). RF = 0.40 (cyclohexane/EtOAc = 2:1); 
1H NMR (CDCl3, 500 MHz): δ 8.37 (d, J = 5.8 
Hz, 2H), 6.94 (d, J = 5.8 Hz, 2H), 2.33 (d, J = 7.3 Hz, 2H), 1.77 (tqq, J = 7.3, 7.3, 7.3 Hz, 1H), 0.78 (d, J = 
7.3 Hz, 6H)  ppm; 13C NMR (CDCl3, 125 MHz): δ 150.1 (Cq), 149.2 (CH), 124.2 (CH), 44.3 (CH2), 29.2 
(CH), 22.0 (CH3) ppm; IR (neat): νmax (cm
-1) = 2965, 2925, 2898, 1602, 1415, 784, 630, 595, 536, 490; HRMS (ESI): 
m/z calculated for C9H14N [M+H]
+ 136.1121, found 136.1122. 
General procedure II: Synthesis of 4-cycloalkylpyridines  
A flame dried three-neck round bottom flask under N2 atmosphere was charged with a solution of 
diisopropylamine (10.0 mL, 71.3 mmol, 3.1 equiv) in anhydrous THF (100 mL). The reaction mixture was cooled to 
−78 °C and a solution of n-butyllithium (2.5 M in THF, 27.6 mL, 69.0 mmol, 3.0 equiv) was added dropwis. After 
10 min, the solution was warmed to 0 °C and stirred for another 20 min. The solution was cooled to −78 °C and 4-
picoline (2.24 mL, 23 mmol, 1.0 equiv) in anhydrous THF (15 mL) was added dropwise. The resulting mixture 
stirred for 1 h resulting in a dark red solution. Then the dibromoalkane (23 mmol, 1 equiv) in anhydrous THF (10 
mL) was added drop wise at −78 °C. After stirring for 1 h, the temperature was allowed to warm to room 
temperature and the resulting mixture stirred overnight. The reaction mixture was quenched with saturated 
NH4Cl(aq) (50 mL). The layers were separated and the water layer was extracted with EtOAc (3×). The organic 
layers were combined, washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. The crude product was purified by flash column chromatography providing the cycloalkylpyridines. 
Synthesis of 4-cyclopentylpyridine (16h) 
Prepared according to general procedure II using 1,4-dibromobutane (2.75 mL, 23 mmol, 1 equiv). 
Flash chromatography (cyclohexane/EtOAc = 3:1) provided the title product as a yellow liquid (0.82 g, 
5.57 mmol, 24%). RF = 0.33 (cyclohexane/EtOAc = 2:1) 
1H NMR (CDCl3, 500 MHz): δ 8.47 (d, J = 4.8 Hz, 
2H), 7.14 (d, J = 4.8 Hz, 2H), 2.97 (tt, J = 8.3, 8.3 Hz, 1H), 2.07 (m, 2H), 1.81 (m, 2H), 1.69 (m, 2H), 1.58 
(m, 2H) ppm; 13C NMR (CDCl3, 125 MHz): δ 155.5 (Cq), 149.6 (CH), 122.6 (CH), 45.1 (CH), 33.9 (CH2), 25.5 
(CH2) ppm; IR (neat): νmax (cm
-1) = 2948, 2867, 1596, 1409, 993, 813, 630 ,545, 493; HRMS (ESI): m/z 
calculated for C10H14N [M+H]
+ 148.1121, found 148.1120. 
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Sythesis of 4-cyclohexylpyridine (16i) 
Prepared according to general procedure II using 1,4-dibromopentane (3.13 mL, 23 mmol, 1 equiv). 
Column chromatography (cyclohexane/EtOAc = 3:1) provided the title product as a yellow liquid (0.91 
g, 5.66 mmol, 25%). RF = 0.34 (cyclohexane/EtOAc = 3:1); 
1H NMR (CDCl3, 500 MHz): δ 8.47 (d, J = 4.8 
Hz, 2H), 7.11 (d, J = 4.8 Hz, 2H), 2.48 (m, 1H), 1.85 (m, 4H), 1.75 (d, J = 12.5 Hz, 1H), 1.40 (m,  4H), 1.25 
(m, 1H) ppm; 13C NMR (CDCl3, 125 MHz): δ 156.5 (Cq), 149.7 (CH), 122.4 (CH), 43.8 (CH), 33.5 (CH2), 
36.50 (CH2), 25.9 (CH2) ppm; IR (neat): νmax (cm
-1) = 2923, 2850, 1597, 1448, 1409, 991, 811, 622, 555, 
493, 420; HRMS (ESI): m/z calculated for C11H16N [M+H]
+ 162.1277, found 162.1278. 
General procedure III:  Synthesis of 4-alkylpiperidinium salts (10) 
To a three-neck round bottom flask charged with 4-alkylpyridine 16 (12.5 mmol, 1.0 equiv) were added HCl in 
methanol (1.25 M, 25.0 mL, 31.3 mmol, 2.5 equiv) and PtO2 (0.14 g, 0.63 mmol, 0.05 equiv). The flask was 
evacuated and flushed with H2 (3×) using a balloon. The mixture was stirred overnight at room temperature 
under hydrogen atmosphere. Upon completion, the reaction mixture was filtered over Celite and the residue was 
washed with additional methanol. The filtrate was concentrated under reduced pressure to afford the title 
product generally as a white solid. 
Synthesis of 4-ethylpiperidine hydrochloride (10b) 
Prepared according to general procedure III from 4-ethylpyridine (1.34 g, 12.5 mmol, 1 equiv). The 
title compound was isolated as a white solid (1.87 g, 12.5 mmol, 100%). m.p.: 176 °C; 1H NMR (CDCl3, 
500 MHz): δ 9.53 (bs, 1H), 9.21 (bs, 1H), 3.45 (m, 2H), 2.83 (m, 2H), 1.88 (d, J = 13.0 Hz, 2H), 1.59 (m, 
2H), 1.46-1.25 (m, 3H), 0.88 (t, J = 7.0 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 44.1 (CH2), 35.8 
(CH), 28.4 (CH2), 28.4 (CH2), 10.9 (CH3) ppm; IR (neat): νmax (cm
-1) = 2973, 2794, 2727, 2497, 1593, 
1456, 1396, 1076, 993, 574, 441; HRMS (ESI): m/z calculated for C7H16N [M+H]
+ 114.1277, found 114.1281. 
Synthesis of 4-propylpiperidine hydrochloride (10c) 
Prepared according to general procedure III from 4-propylpyridine (1.51 g, 12.5 mmol, 1 equiv). The 
title compound was isolated as an off-white solid (2.04 g, 12.5 mmol, 100%). m.p.: 203 °C; 1H NMR 
(CDCl3, 500 MHz): δ 9.53 (bs, 1H), 9.22 (bs, 1H), 3.44 (m, 2H), 2.82 (m, 2H), 1.93 (d, J = 12.5 Hz, 2H), 
1.64-1.44 (m, 3H), 1.27 (m, 4H), 0.87 (t, J = 6.5 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 44.1 (CH2), 
37.8 (CH2), 33.8 (CH), 28.7 (CH2), 19.4 (CH2) 14.0 (CH3) ppm; IR (neat): νmax (cm
-1) = 2941, 2923, 
2796, 2718, 1591, 1456, 1392, 1074, 956, 574; HRMS (ESI): m/z calculated for C8H18N [M+H]
+ 
128.1434, found 128.1434. 
Synthesis of 4-butylpiperidine hydrochloride (10d) 
Prepared according to general procedure III from 4-butylpyridine (1.69 g, 12.5 mmol, 1 equiv). The 
title compound was isolated as an off-white solid (2.22 g, 12.5 mmol, 100%). m.p.: 204 °C; 1H NMR 
(CDCl3, 500 MHz): δ 9.50 (bs, 1H), 9.21 (bs, 1H), 3.43 (m, 2H), 2.81 (m, 2H), 1.84 (d, J = 12.5 Hz, 2H), 
1.59 (m, 2H), 1.45 (m, 1H), 1.24 (m, 6H), 0.84 (t, J = 6.3 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 
44.1 (CH2), 35.3 (CH2), 34.0 (CH), 28.7 (CH2), 28.5 (CH2), 22.6 (CH2), 13.9 (CH3) ppm; IR (neat): νmax 
(cm-1) = 2947, 2920, 2844, 2792, 2769, 2719, 1591, 1448, 1074, 943, 576, 439; HRMS (ESI): m/z 
calculated for C9H20N [M+H]
+ 142.1590, found 142.1587. 
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Synthesis of 4-pentylpiperidine hydrochloride (10e) 
Prepared according to general procedure III from 4-pentylpyridine (1.87 g, 12.5 mmol, 1 equiv). The 
title compound was isolated as an off-white solid (2.39 g, 12.5 mmol, 100%). m.p.: 201 °C; 1H NMR 
(CDCl3, 500 MHz): δ 9.55 (bs, 1H), 9.23 (bs, 1H), 3.45 (m, 2H), 2.81 (m, 2H), 1.87 (d, J = 12.5 Hz, 2H), 
1.60 (m, 2H), 1.47 (m, 1H), 1.26 (m, 8H), 0.86 (t, J = 6.5 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 
44.1 (CH2), 35.6 (CH2), 34.1 (CH), 31.8 (CH2), 28.8 (CH2), 26.0 (CH2), 22.5 (CH2), 14.0 (CH3) ppm; IR 
(neat): νmax (cm-1) = 2945, 2910, 2846, 2792, 2767, 2734, 1589, 1448, 1396, 1074, 576, 437; HRMS 
(ESI): m/z calculated for C10H22N [M+H]
+ 156.1747, found 156.1746. 
Synthesis of 4-(isobutyl)piperidine hydrochloride (10f) 
Prepared according to general procedure III from 4-isubutylpyridine (1.69 g, 12.5 mmol, 1 equiv). 
The title compound was isolated as a white solid (2.21 g, 12.5 mmol, 100%). m.p.: 259 °C; 1H NMR 
(CDCl3, 500 MHz): δ 9.57 (bs, 1H), 9.25 (bs, 1H), 3.46 (m, 2H), 2.84 (m, 2H), 1.85 (m, 2H), 1.61 (m, 
4H), 1.17 (m, 2H), 0.86 (d, J = 6.2 Hz, 6H) ppm; 13C NMR (CDCl3, 125 MHz): δ 44.9 (CH2), 44.1 (CH2), 
31.7 (CH), 28.9 (CH2), 24.4 (CH), 22.6 (CH3) ppm; IR (neat): νmax (cm
-1) = 2890, 2796, 2769, 2736, 
1589, 1448, 595, 499; HRMS (ESI): m/z calculated for C9H20N [M+H]
+ 142.1590, found 142.1587. 
Synthesis of 4-(tert-butyl)piperidine hydrochloride (10g) 
Prepared according to general procedure III from 4-tert-butylpyridine (1.69 g, 12.5 mmol, 1 equiv) 
with additional PtO2 (0.10 equiv instead of 0.05 equiv) and a prolonged reaction time (36 h instead of 
overnight). The title compound was isolated as a white solid (2.07 g, 12.5 mmol, 93%). m.p.: 303 °C; 
1H NMR (CDCl3, 500 MHz): δ 9.54 (bs, 1H), 9.23 (bs, 1H), 3.53 (d, J = 12.0 Hz, 2H), 2.79 (q, J = 12.0 Hz, 
2H), 1.85 (d, J = 12.0 Hz, 2H), 1.70 (q, J = 12.0 Hz, 2H), 1.21 (t, J = 12.0 Hz, 1H), 0.87 (s, 9H) ppm; 13C 
NMR (CDCl3, 125 MHz): δ 44.8 (CH), 44.7 (CH2), 32.3 (Cq), 27.0 (CH3), 23.9 (CH2) ppm; IR (neat): νmax 
(cm-1) = 2960, 2837, 2798, 2777, 2761, 2744, 2719, 1591, 1448, 1396, 1361, 1078, 568, 509; HRMS (ESI): m/z 
calculated for C9H20N [M+H]
+ 142.1590, found 142.1588. 
Synthesis of 4-cyclopentylpiperidine hydrochloride (10h) 
Prepared according to general procedure III from 4-cyclopentylpyridine (0.72 g, 4.89 mmol, 1 equiv) 
on a smaller scale. The title compound was isolated as an off-white solid (0.92 g, 4.85 mmol, 99%). 
m.p.: 238 °C; 1H NMR (CDCl3, 500 MHz): δ 9.45 (bs, 1H), 9.16 (bs, 1H), 3.45 (m, 2H), 2.81 (m, 2H), 
1.98-1.43 (m, 9H), ), 1.24 (m, 1H) 1.05 (m, 2H) ppm; 13C NMR (CDCl3, 125 MHz): δ 45.1 (CH), 44.3 
(CH2), 39.9 (CH), 30.2 (CH2), 27.9 (CH2), 25.0 (CH2) ppm; IR (neat): νmax (cm
-1) = 2966, 2850, 2792, 
2765, 2738, 2704, 2495, 1589, 1444, 1396, 1076, 522; HRMS (ESI): m/z calculated for C10H20N [M+H]
+ 
154.1590, found 154.1588. 
Synthesis of 4-cyclohexylpiperidine hydrochloride (10i) 
Prepared according to general procedure III from 4-cyclohexylpyridine (0.68 g, 4.22 mmol, 1 equiv) 
on a smaller scale. The title compound was isolated as an off-white solid (0.79 g, 3.88 mmol, 92%). 
m.p.: 310 °C; 1H NMR (CDCl3, 500 MHz): δ 9.51 (bs, 1H), 9.19 (bs, 1H), 3.48 (d, J = 12.0 Hz, 2H), 2.79 
(m, 2H), 1.91-1.60 (m, 9H), 1.32-1.02 (m, 5H), 0.91 (q, J = 12.0 Hz, 2H) ppm; 13C NMR (CDCl3, 125 
MHz): δ  44.4 (CH2), 41.8 (CH), 39.8 (CH), 29.9 (CH2), 26.4 (CH2), 26.3 (CH2) 26.1 (CH2) ppm; IR (neat): 
νmax (cm-1) = 2964, 2848, 2794, 2777, 2727, 1450, 541; HRMS (ESI): m/z calculated for C11H22N 
[M+H]+ 168.1747, found 168.1745. 
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Synthesis of the pipecolic amides (12) 
General Procedure IV: 3-Step synthesis of the U-3CR products 
a) Racemic imine Synthesis (11): 
The 4-alkyl piperidinium salt 10 (6.0 mmol, 1 equiv) was dissolved in water and the pH was increased to >11 by 
addition of aqueous NH4OH (25% w/w). The resulting solution was extracted CH2Cl2 (2×). The organic layers 
where combined, washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. 
The remaining oil was redissolved in CH2Cl2 (25 mL) and the solution was cooled to 0 °C. Then, N-
chlorosuccinimide (0.82 g, 6.12 mmol, 1.02 equiv) was added portion-wise (over 5 min) to the solution. The ice 
bath was removed and the resulting mixture was stirred for 3 h until TLC indicated a clear sign of the chlorinated 
species (clearly visible under UV at relatively high RF values). Upon completion, the reaction mixture was washed 
with water (2×) and with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The 
remaining oil was redissolved in CH2Cl2 (15 mL) and slowly added to a solution of KOH (0.71 g, 12.6 mmol, 2.1 
equiv) in EtOH (15 mL) and the resulting mixture was stirred overnight. Upon completion, the mixture was 
filtered and  the filtrate was concentrated under reduced pressure. The remaining mixture was dissolved in 
CH2Cl2, washed with water (2×) and with brine, dried over anhydrous Na2SO4 and the solvent was removed under 
reduced pressure to afford the corresponding imine. Batches of 1.0 mmol of crude imine were used in the U-3CR 
reaction without further purification. 
b) U-3CR reaction: 
In a roundbottom flask, the imine (1 mmol, 1 equiv) was dissolved in CH2Cl2 (2 mL). Then, the carboxylic acid (1.2 
mmol, 1.2 equiv) and the isocyanide (1.2 mmol, 1.2 equiv) were added sequentially and the resulting mixture 
was stirred for 48 h. More CH2Cl2 (5 mL) was added and the resulting solution was washed with saturated 
aqueous Na2CO3 and with brine, dried over anhydrous Na2SO4 and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash column chromatography to obtain the product generally as a 
white solid. 
Synthesis of N-cyclohexyl-4-ethyl-1-pivaloylpiperidine-2-carboxamide (12a) 
Imine preparation according to general procedure IVa from 4-ethylpiperidine hydrochloride 
(0.90 g, 6.0 mmol, 1 equiv)  to yield 3,4,5,6-tetrahydro-4-ethylpyridine (0.54 g, 4.86 mmol, 
81%.). 
U-3CR product formation according to general procedure IVb with the imine (111 mg, 1.0 
mmol, 1 equiv), pivalic acid (123 mg, 1.2 mmol, 1.2 equiv) and cyclohexylisocyanide (149 µL, 
1.2 mmol, 1.2 equiv). Flash chromatography (cyclohexane/EtOAc = 6:1) provided the title 
product as a white solid (254 mg, 0.79 mmol, 79%). RF = 0.66 (cyclohexane/EtOAc = 2:1); m.p.: 107-108 ˚C;
 1H 
NMR (CDCl3, 500 MHz): δ 6.08 (bs, 1H), 5.09 (m, 1H), 4.16 (m, 1H), 3.72 (q, J = 4.3 Hz, 1H), 2.88 (m, 1H), 2.28 (d, J 
= 12.8 Hz, 1H), 1.87-1.51 (m, 7H), 1.34-0.95 (m, 19H), 0.87 (t, J = 7.0 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 
178.2 (Cq), 170.0 (Cq), 47.6 (CH), 44.0 (Cq), 38.8 (CH2), 33.4 (CH), 33.1 (CH2), 32.7 (CH2), 31.7 (CH2), 31.4 (CH2), 29.4 
(CH2), 28.2 (CH3), 25.4 (CH2), 24.5 (CH2), 10.9 (CH3) ppm; IR (neat): νmax (cm
-1) = 3325, 2928, 2854, 1670, 1610, 
1522, 1412, 1188,  919, 729, 646; HRMS (ESI): m/z calculated for C19H34N2NaO2 [M+Na]
+ 345.2512, found 
345.2512. 
  
Efficient Synthesis of Pipecolic Amides with a Highly Diastereoselecive U-3CR 
 
 
119 
Synthesis of N-(tert-butyl)-4-ethyl-1-(2-(4-methoxyphenyl)acetyl)piperidine-2-carboxamide (12b) 
Imine preparation according to general procedure IVa from 4-ethylpiperidine 
hydrochloride (0.90 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-
ethylpyridine (0.54 g, 4.86 mmol, 81%.). 
U-3CR product formation according to general procedure IVb with the imine 
(111 mg, 1.0 mmol, 1 equiv), 4-methoxyphenylacetic acid (199 mg, 1.2 mmol, 
1.2 equiv) and tert-butylisocyanide (135 µL, 1.2 mmol, 1.2 equiv). Flash chromatography (cyclohexane/EtOAc = 
4:1) provided the title product as an off-white solid (292 mg, 0.81 mmol, 81%). Two rotamers were present on 
NMR-timescale in a 1 : 0.28 ratio. RF = 0.41 (cyclohexane/EtOAc = 2:1); m.p.: 90 ˚C; 
1H NMR (CDCl3, 500 MHz): δ 
7.16 (m, 2.56H), 6.83 (d, J = 8.6 Hz, 2.56H), 5.9 (bs, 1H), 5.25 (bs, 0.28H), 5.15 (d, J = 5.5 Hz, 1H), 4.62 (d, J = 11.6 
Hz, 0.28H), 4.44 (d, J = 5.0 Hz, 0.28H),  3.89-3.61 (m, 7.40H), 2.90 (t, J =  11.4 Hz, 1H), 2.43 (m, 0.56H), 2.21 (d, J = 
12.0 Hz, 1H), 1.78-1.60 (m, 2.28H), 1.30-1.08 (m, 14.36H), 1.05-0.79 (m, 6.40H) ppm; 13C NMR (CDCl3, 125 MHz): 
δ 171.3 (Cq), 171.1 (Cq), 169.9 (Cq), 168.1 (Cq), 158.6 (Cq), 158.5 (Cq), 129.4 (CH), 129.3 (CH), 126.6 (Cq), 126.4 (Cq), 
114.5 (CH), 114.2 (CH), 58.3 (CH), 55.2 (CH), 55.2 (CH3), 52.4 (CH3), 51.0 (Cq), 50.8 (Cq), 44.1 (CH2), 40.7 (CH2), 40.1 
(CH2), 39.9 (CH2), 33.7 (CH), 33.0 (CH), 32.4 (CH2), 31.4 (CH2), 31.2 (CH2), 30.7 (CH2), 29.3 (CH2), 29.1 (CH2), 28.6 
(CH3), 28.3 (CH3), 10.8 (CH3), 10.7 (CH3); IR (neat): νmax (cm
-1) = 3325, 2959, 1624, 1510, 1452, 1246, 1036, 920, 
731, 644, 523; HRMS (ESI): m/z calculated for C21H33N2O3 [M+H]
+ 361.2486, found 361.2465. 
 
Synthesis of N-pentyl-1-pivaloyl-4-propylpiperidine-2-carboxamide (12c) 
Imine preparation according to general procedure IVa from 4-propylpiperidine 
hydrochloride (0.98 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-propylpyridine (0.64 
g, 5.1 mmol, 85%). 
U-3CR product formation according to general procedure IVb with the imine (125 mg, 1.0 
mmol, 1 equiv), pivalic acid (123 mg, 1.2 mmol, 1.2 equiv) and pentylisocyanide (151 µL, 1.2 
mmol, 1.2 equiv). Flash chromatography (cyclohexane/EtOAc = 5:1) provided the title 
product as a slowly crystalizing oil (254 mg, 0.78 mmol, 78%.). RF = 0.58 (cyclohexane/EtOAc 
= 2:1); 1H NMR (CDCl3, 500 MHz): δ 6.21 (bs, 1H), 5.10 (bs, 1H), 4.15 (m, 1H), 3.26 (m, 1H), 3.11 (m, 1H), 2.92 (m, 
1H), 2.27 (d, J = 12.9 Hz, 1H), 1.85 (m, 1H), 1.67 (d, J = 12.9 Hz, 1H), 1.42 (m, 2H), 1.33-1.10 (m, 17H), 1.10-0.99 
(m, 2H), 0.86 (m, 6H) ppm; 13C NMR (CDCl3, 125 MHz): δ 178.3 (Cq), 171.0 (Cq), 45.3 (CH), 44.2 (Cq), 39.1 (CH2), 
38.9 (CH2), 38.9 (CH2), 32.0 (CH2), 31.8 (CH2), 31.4 (CH), 29.3 (CH2), 29.0 (CH2), 28.2 (CH3), 22.2 (CH2), 19.5 (CH2), 
14.2 (CH3), 13.9 (CH3) ppm; IR (neat): νmax (cm
-1) = 3337, 2955, 2928, 1670, 1612, 1521, 1412, 1186, 630, 532; 
HRMS (ESI): m/z calculated for C19H36N2NaO2 [M+Na]
+ 347.2669, found 347.2670. 
Synthesis of 1-benzoyl-N-(tert-butyl)-4-propylpiperidine-2-carboxamide (12d) 
Imine preparation according to general procedure IVa from 4-propylpiperidine 
hydrochloride (0.98 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-propylpyridine 
(0.64 g, 5.1 mmol, 85%). 
U-3CR product formation according to general procedure IVb with the imine (125 mg, 
1.0 mmol, 1 equiv), benzoic acid (147 mg, 1.2 mmol, 1.2 equiv) and tert-
butylisocyanide (135 µL, 1.2 mmol, 1.2 equiv). Flash chromatography 
(cyclohexane/EtOAc = 4:1) provided the title product as a slowly crystallizing white 
solid (271 mg, 0.82 mmol, 82%). Two rotamers were present on NMR-timescale in a 1 : 0.21 ratio. RF = 0.57 
(cyclohexane/EtOAc = 2:1); m.p.: 92 ˚C; 1H NMR (CDCl3, 500 MHz): δ 7.44-7.26 (m, 6.05H), 6.41 (s, 1H), 5.81 (s, 
0.21H),  5.17 (d, J = 5.4Hz, 1H), 4.72 (d, J = 12.8 Hz, 0.21H), 4.29 (bs, 0.21H), 3.76 (d, J = 13.6 Hz, 1H), 3.01 (t, J = 
11.6 Hz, 1H), 2.79 (t, J = 12.6 Hz, 0.21H), 2.78 (d, J = 13.2 Hz, 1.21H), 1.96 (m, 1H), 1.75 (d, J = 12.7 Hz, 0.21H), 
1.62 (d, J = 12.8 Hz, 1H), 1.50 (m, 0.42H), 1.40-1.02 (m, 18.15H), 0.87 (m, 3.63H) ppm; 13C NMR (CDCl3, 125 MHz): 
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δ 172.0 (Cq), 171.8 (Cq), 170.0 (Cq), 168.8 (Cq), 135.5 (Cq), 135.3 (Cq), 130.1 (CH), 129.9 (CH), 128.7 (CH), 128.5 
(CH), 126.9 (CH), 126.1 (CH), 59.7 (CH), 53.2 (CH), 51.5 (Cq), 50.9 (Cq), 45.8 (CH2), 40.2 (CH2), 39.0 (CH2), 38.6 
(CH2), 33.4 (CH2), 33.1 (CH2), 32.1 (CH2), 31.8 (CH), 31.4 (CH), 31.3 (CH2), 28.8 (CH3), 28.7 (CH3), 19.5 (CH2), 19.4 
(CH2), 14.3 (CH3), 14.1 (CH3) ppm; IR (neat): νmax (cm
-1) = 3337, 2959, 2926, 1683, 1616, 1522, 1423, 1363, 1253, 
1224, 1203, 921, 730, 700, 646; HRMS (ESI): m/z calculated for C20H31N2O2 [M+H]
+ 331.2380, found 331.2367. 
Synthesis of methyl (1-acetyl-4-butylpiperidine-2-carbonyl)glycinate (12e) 
Imine preparation according to general procedure IVa from 4-butylpiperidine 
hydrochloride (1.07 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-butylpyridine 
(0.78 g, 5.6 mmol, 93%). 
U-3CR product formation according to general procedure IVb with the imine (139 mg, 
1.0 mmol, 1 equiv), acetic acid (69 µL, 1.2 mmol, 1.2 equiv) and methyl isocyanoacetate 
(109 µL, 1.2 mmol, 1.2 equiv). Flash chromatography (EtOAc) provided the title product as a slowly crystalizing oil 
(205 mg, 0.69 mmol, 69%). Two rotamers were present on NMR-timescale in a 1 : 0.27 ratio. RF = 0.25 (EtOAc); 
1H 
NMR (CDCl3, 500 MHz): δ 7.27 (bs, 0.27H), 6.69 (bs, 1H), 5.28 (d, J = 5.5 Hz, 1H), 4.59 (d, J = 13.5 Hz, 0.27H), 4.46 
(d, J = 5.2 Hz, 0.27H), 4.14 (m, 1.27H), (dd, J = 17.8, 5.5 Hz, 0.27H), 3.80-3.70 (m, 5.81H), 3.21 (dt, J = 13.8, 2.2 Hz, 
1H), 2.71 (dt, J = 13.3, 2.5 Hz, 0.27H), 2.52 (d, J = 12.4 Hz, 0.27H), 2.26 (d, J = 12.2 Hz, 1H), 2.16 (s, 3H), 2.11 (s, 
0.81H), 1.93 (bs, 0.27H), 1.80-1.63 (m, 2.27H), 1.43 (bs, 0.27H), 1.80-1.63 (m, 9.89H), 0.86 (t, J = 6.8 Hz, 3.81H) 
ppm; 13C NMR (CDCl3, 125 MHz): δ 171.4 (Cq), 170.9 (Cq), 170.4 (Cq), 170.4 (Cq), 170.3 (Cq), 170.2 (Cq), 58.2 (CH), 
52.3 (CH), 52.2 (CH3), 51.8 (CH3), 44.4 (CH2), 41.0 (CH2), 40.8 (CH2), 39.5 (CH2), 36.3 (CH2), 36.1 (CH2), 33.0 (CH2), 
32.1 (CH), 31.9 (CH2), 31.7 (CH2), 31.5 (CH), 31.2 (CH2), 29.7 (CH2), 28.5 (CH2), 28.5 (CH2), 22.7 (CH2), 21.7 (CH3), 
21.7 (CH3), 14.0 (CH3), 14.0 (CH3) ppm; IR (neat): νmax (cm
-1) = 3330, 2925, 1751, 1629, 1521, 1423, 1363, 1201, 
644, 572, 463; HRMS (ESI): m/z calculated for C15H27N2O4 [M+H]
+ 299.1965, found 299.1949. 
Synthesis of N-(tert-butyl)-4-butyl-1-(pent-4-enoyl)piperidine-2-carboxamide (12f) 
Imine preparation according to general procedure IVa from 4-butylpiperidine 
hydrochloride (1.07 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-butylpyridine 
(0.78 g, 5.6 mmol, 93%). 
U-3CR product formation according to general procedure IVb with the imine (139 mg, 
1.0 mmol, 1 equiv), 4-pentenoic acid (123 µL, 1.2 mmol, 1.2 equiv) and tert-
butylisocyanide (135 µL, 1.2 mmol, 1.2 equiv). Flash chromatography (cyclohexane/EtOAc = 4:1) provided the 
title product as a white solid (270 mg, 0.84 mmol, 84%). Two rotamers were present on NMR-timescale in a 1 : 
0.25 ratio. RF = 0.58 (cyclohexane/EtOAc = 2:1) m.p.: 89 ˚C; 
1H NMR (CDCl3, 500 MHz): δ 5.97 (s, 1H), 5.84 (m, 
1.25H), 5.70 (s, 0.25H), 5.11 (d, J = 6.5Hz, 1H), 5.05 (d, J = 17.2 Hz, 1.25H), 4.99 (d, J = 10.2 Hz, 1.25H), 4.63 (d, J = 
11.7 Hz, 0.25H), 4.38 (d, J = 5.4 Hz, 0.25H), 3.76 (d, J = 13.6 Hz, 1H), 3.05 (dt, J = 13.3, 2.5 Hz, 1H), 2.55-2.31 (m, 
5.5H), 2.18 (d, J = 13.5 Hz, 1H), 1.83 (m, 1H), 1.70 (m, 1.25H), 1.31-1.12 (m, 19.0H) 1.08-0.95 (m, 2.5H), 0.85 (t, J = 
7.0 Hz, 3.75H) ppm; 13C NMR (CDCl3, 125 MHz): δ 172.4 (Cq), 172.0 (Cq), 170.2 (Cq), 168.7 (Cq), 137.1 (CH2), 137.0 
(CH2), 115.6 (CH), 115.4 (CH), 57.7 (CH), 52.5 (CH), 51.5 (Cq), 50.8 (Cq), 43.5 (CH2), 39.7 (CH2), 36.4 (CH2), 36.1 
(CH2), 33.0 (CH2), 32.7 (CH2), 32.6 (CH2), 32.3 (CH), 32.1 (CH2), 31.8 (CH2), 31.6 (CH), 31.2 (CH2), 29.2 (CH2), 29.2 
(CH2), 28.7 (CH3), 28.7 (CH3), 28.6 (CH2), 28.5 (CH2), 22.8 (CH2), 22.8 (CH2), 14.0 (CH2), 14.0 (CH2) ppm; IR (neat): 
νmax (cm-1) = 3329, 2924 1676, 1628, 1541, 1452, 1425, 1363, 910, 731, 646; HRMS (ESI): m/z calculated for 
C19H34N2NaO2 [M+Na]
+ 345.2512, found 345.2528.  
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Synthesis of N-cyclohexyl-4-pentyl-1-pivaloylpiperidine-2-carboxamide (12g) 
Imine preparation according to general procedure IVa from 4-pentylpiperidine 
hydrochloride (1.15 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-pentylpyridine 
(0.85 g, 5.5 mmol, 92%). 
U-3CR product formation according to general procedure IVb with the imine (153 mg, 
1.0 mmol, 1 equiv), pivalic acid (123 mg, 1.2 mmol, 1.2 equiv) and 
cyclohexylisocyanide (149 µL, 1.2 mmol, 1.2 equiv). Flash chromatography 
(cyclohexane/EtOAc = 6:1) provided the title product as a white solid (339 mg, 0.93 mmol, 93%). RF = 0.44. 
(cyclohexane/EtOAc = 4:1); m.p.: 78 ˚C; 1H NMR (CDCl3, 500 MHz): δ 6.09 (d, J = 7.4 Hz, 1H), 5.06 (bs, 1H), 4.16 
(m, 1H), 3.73 (m, 1H), 2.89 (m, 1H), 2.28 (d, J = 12.7 Hz, 1H), 1.90-1.72 (m, 3H), 1.71-1.51 (m, 4H), 1.40-0.95 (m, 
24H), 0.85 (t, J = 6.7 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 178.2 (Cq), 170.0 (Cq), 47.6 (CH), 44.1 (CH), 38.8 
(Cq), 36.7 (CH2), 33.1 (CH2), 32.7 (CH2), 32.0 (CH2), 31.9 (CH2), 31.7 (CH), 28.2 (CH3), 26.0 (CH2), 25.4 (CH2), 24.6 
(CH2), 24.5 (CH2), 22.6 (CH2), 14.0 (CH3) ppm; IR (neat): νmax (cm
-1) = 3327, 2926, 2854, 1681, 1614, 1521, 1412, 
1365; HRMS (ESI): m/z calculated for C22H41N2O2 [M+H]
+ 365.3163, found 365.3150. 
Synthesis of N-(tert-butyl)-1-(2-(4-methoxyphenyl)acetyl)-4-pentylpiperidine-2-carboxamide (12h) 
Imine preparation according to general procedure IVa from 4-
pentylpiperidine hydrochloride (1.15 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-
tetrahydro-4-pentylpyridine (0.85 g, 5.5 mmol, 92%). 
U-3CR product formation according to general procedure IVb with the 
imine (153 mg, 1.0 mmol, 1 equiv), 4-methoxyphenylacetic acid (199 mg, 1.2 
mmol, 1.2 equiv) and tert-butylisocyanide (135 µL, 1.2 mmol, 1.2 equiv). Flash chromatography 
(cyclohexane/EtOAc = 3:1) provided the title product as a white solid (345 mg, 0.85 mmol, 85%). Two rotamers 
were present on NMR-timescale in a 1 : 0.27 ratio. RF = 0.36 (cyclohexane/EtOAc = 2:1); m.p.: 65-66 ˚C; 
1H NMR 
(CDCl3, 500 MHz): δ 7.17 (d, J = 8.5 Hz, 2.54H), 6.85 (d, J = 8.5 Hz, 2.54H), 5.90 (bs, 1H), 5.26 (bs, 0.27H), 5.16 (d, J 
= 5.4 Hz, 1H), 4.63 (d, J = 13.2 Hz, 0.27H), 4.44 (d, J = 4.7 Hz, 0.27H), 3.74-3.67 (m, 7.35H), 4.63 (t, J = 13.2 Hz, 
0.27H), 2.43 (m, 0.54H), 2.22 (d, J = 12.5 Hz, 1H), 1.78 (m, 1H), 1.64 (m, 2.27H), 1.42 (bs, 0.27H), 1.33-1.11 (m, 
20.59H), 1.04 (m, 1.27H), 0.86 (m, 5.08H) ppm; 13C NMR (CDCl3, 125 MHz): δ 171.4 (Cq), 171.2 (Cq), 169.9 (Cq), 
168.2 (Cq), 158.7 (Cq), 158.5 (Cq), 129.4 (CH), 129.4 (CH), 126.7 (Cq), 126.5 (Cq), 114.6 (CH), 114.3 (CH), 58.4 (CH), 
55.3 (CH), 55.3 (CH3), 52.5 (CH3), 51.1 (Cq), 50.9 (Cq), 44.2 (CH2), 40.7 (CH2), 40.2 (CH2), 40.0 (CH2), 36.8 (CH2), 36.5 
(CH2), 32.8 (CH2), 32.3 (CH), 32.1 (CH2), 32.0 (CH2), 31.9 (CH2), 31.7 (CH2), 31.6 (CH), 31.3 (CH2), 28.7 (CH3), 28.3 
(CH3), 26.1 (CH2), 26.0 (CH2), 22.6 (CH2), 22.6 (CH2), 14.0 (CH3), 14.0 (CH3) ppm; IR (neat): νmax (cm
-1) = 3335, 
2924, 1680, 1626, 1510, 1450, 1245, 1176, 1034, 640, 576, 530; HRMS (ESI): m/z calculated for C24H39N2O3 
[M+H]+ 403.2955, found 403.2968. 
Synthesis of N-cyclohexyl-4-isobutyl-1-pivaloylpiperidine-2-carboxamide (12i) 
Imine preparation according to general procedure IVa from 4-isobutylpiperidine 
hydrochloride (1.07 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-
isobutylpyridine (0.75 g, 5.4 mmol, 90%). 
U-3CR product formation according to general procedure IVb with the imine (139 mg, 
1.0 mmol, 1 equiv), pivalic acid (123 mg, 1.2 mmol, 1.2 equiv) and 
cyclohexylisocyanide (149 µL, 1.2 mmol, 1.2 equiv). Flash chromatography 
(cyclohexane/EtOAc = 6:1) provided the title product as a white crystalline solid (286 
mg, 0.81 mmol, 81%). RF = 0.64 (cyclohexane/EtOAc = 2:1); m.p.: 96 ˚C; 
1H NMR (CDCl3, 500 MHz): δ 6.13 (bs, 
1H), 5.10 (bs, 1H), 4.16 (bs, 1H), 3.74 (m, 1H), 2.91 (m, 1H), 2.27 (d, J = 11.8 Hz, 1H), 1.95 (bs, 1H), 1.84 (d, J = 9.2 
Hz, 1H), 1.76 (d, J = 9.1 Hz, 1H), 1.72-1.59 (m, 4H), 2.27 (d, J = 9.1 Hz, 1H), 1.40-1.24 (m, 1H), 1.20-0.96 (m, 7H), 
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0.89 (d, J = 6.6 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 178.3 (Cq), 170.1 (Cq), 47.6 (CH), 
46.1 (CH2), 44.2 (CH), 38.8 (Cq), 33.2 (CH2), 32.8 (CH2), 32.3 (CH2), 31.9 (CH2), 29.4 (CH), 28.2 (CH3), 25.4 (CH2), 24.6 
(CH2), 24.5 (CH), 22.9 (CH3), 22.5 (CH3) ppm; IR (neat): νmax (cm
-1) = 3339, 2930, 2853, 1678, 1610, 1518, 1412, 
1366, 1186, 976, 920, 731, 646, 467; HRMS (ESI): m/z calculated for C21H38N2NaO2 [M+Na]
+ 373.2825, found 
373.2833. 
Synthesis of 1-benzoyl-N-(tert-butyl)-4-isobutylpiperidine-2-carboxamide (12j) 
Imine preparation according to general procedure IVa from 4-isobutylpiperidine 
hydrochloride (1.07 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-isobutylpyridine 
(0.75 g, 5.4 mmol, 90%). 
U-3CR product formation according to general procedure IVb with the imine (139 mg, 
1.0 mmol, 1 equiv), benzoic  acid (147 mg, 1.2 mmol, 1.2 equiv) and tert-butylisocyanide 
(135 µL, 1.2 mmol, 1.2 equiv). Flash chromatography (cyclohexane/EtOAc = 7:2) provided 
the title product as a white solid (294 mg, 0.91 mmol, 91%). Two rotamers were present 
on NMR-timescale in a 1 : 0.23 ratio. RF = 0.57 (cyclohexane/EtOAc = 2:1); m.p.: 115 ˚C; 
1H NMR (CDCl3, 500 
MHz): δ 7.45-7.35 (m, 6.15H), 6.39 (bs, 1H), 5.78 (bs, 0.23H), 5.18 (d, J = 5.4 Hz, 1H), 4.73 (d, J = 12.6 Hz, 0.23H), 
4.30 (bs, 0.23H), 3.67 (d, J = 13.7 Hz, 1H), 3.01 (t, J = 12.1 Hz, 1H), 2.82 (t, J = 12.1 Hz, 0.23H), 2.28 (d, J = 13.3 Hz, 
1.23H), 2.03 (m, 1H), 1.76-1.64 (m, 1.69H), 1.61 (d, J = 12.8 Hz, 1.23H), 1.35 (s, 11.07H), 1.19-1.01 (m, 4.92H), 
0.91 (d, J = 6.6 Hz, 3.69H), 0.88 (d, J = 6.6 Hz, 3.69H) ppm; 13C NMR (CDCl3, 125 MHz): δ 172.0 (Cq), 171.9 (Cq), 
170.0 (Cq), 168.8 (Cq), 135.5 (Cq), 135.3 (Cq), 130.1 (CH), 130.0 (CH), 128.8 (CH), 128.6 (CH), 127.0 (CH), 126.1 (CH), 
59.7 (CH), 53.3 (CH), 51.6 (Cq), 50.9 (Cq), 46.3 (CH2), 45.8 (CH2), 45.8 (CH2), 40.3 (CH2), 33.2 (CH2), 32.5 (CH2), 31.9 
(CH2), 31.7 (CH2), 30.0 (CH), 29.4 (CH), 28.8 (CH3), 28.7 (CH3), 24.6 (CH), 24.5 (CH), 22.9 (CH3), 22.8 (CH3), 22.7 
(CH3), 22.6 (CH3) ppm; IR (neat): νmax (cm
-1) = 3327, 2957, 1682, 1620, 1533, 1425, 1366, 1254, 700; HRMS (ESI): 
m/z calculated for C21H33N2O2 [M+H]
+ 345.2537, found 345.2529. 
Synthesis of 1-acetyl-4-(tert-butyl)-N-pentylpiperidine-2-carboxamide (12k) 
Imine preparation according to general procedure IVa from 4-(tert-butyl)piperidine 
hydrochloride (1.07 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-tert-butylpyridine (0.71 
g, 5.1 mmol, 85%). 
U-3CR product formation according to general procedure IVb with the imine (139 mg, 1.0 
mmol, 1 equiv), acetic acid (69 µL, 1.2 mmol, 1.2 equiv) and pentylisocyanide (151 µL, 1.2 
mmol, 1.2 equiv). Flash chromatography (cyclohexane/EtOAc = 6:1) provided the title product 
as a white solid (284 mg, 0.96 mmol, 96%). Two rotamers were present on NMR-timescale in a 
1 : 0.30 ratio. RF = 0.31 (cyclohexane/EtOAc = 6:1); m.p.: 100 ˚C; 
1H NMR (CDCl3, 500 MHz): δ 6.48 (bs, 0.30H), 
6.21 (bs, 1H), 5.21 (d, J = 4.6 Hz, 1H), 4.62 (d, J = 13.6 Hz, 0.30H), 4.44 (bs, 0.30H), 3.74 (d, J = 12.9 Hz, 1H), 3.26-
3.08 (m, 3.60H), 2.52 (m, 0.60H), 2.22 (d, J = 13.1Hz, 1H), 2.13 (s, 3H), 2.07 (s, 0.90H), 1.72-1.51 (m, 2.30H), 1.49-
1.39 (m, 2.60H), 1.33-1.05 (m, 8.10H), 0.83 (m, 15.60H) ppm; 13C NMR (CDCl3, 125 MHz): δ 170.8 (Cq), 170.5 (Cq), 
170.2 (Cq), 169.3 (Cq), 58.5 (CH), 52.1 (CH), 44.7 (CH2), 42.3 (CH), 41.4 (CH), 39.9 (CH2), 32.0 (Cq), 32.0 (Cq), 29.2 
(CH2), 29.0 (CH2), 29.0 (CH2), 27.8 (CH2), 26.9 (CH3), 26.9 (CH3), 26.6 (CH2), 26.6 (CH2), 25.9 (CH2), 22.2 (CH2), 22.2 
(CH2), 21.7 (CH3), 21.6 (CH3), 13.9 (CH3), 13.9 (CH3) ppm; IR (neat): νmax (cm
-1) = 3319, 2955, 2868, 1631, 1529, 
1423, 1365, 1259, 1186, 993, 730, 629, 528; HRMS (ESI): m/z calculated for C17H32N2NaO2 [M+Na]
+ 319.2356, 
found 319.2369. 
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Synthesis of N,4-di-tert-butyl-1-(pent-4-enoyl)piperidine-2-carboxamide (12l) 
Imine preparation according to general procedure IVa from 4-(tert-butyl)piperidine 
hydrochloride (1.07 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-tert-butylpyridine 
(0.71 g, 5.1 mmol, 85%). 
U-3CR product formation according to general procedure IVb with the imine (139 mg, 
1.0 mmol, 1 equiv), 4-pentenoic acid (123 µL, 1.2 mmol, 1.2 equiv) and tert-
butylisocyanide (135 µL, 1.2 mmol, 1.2 equiv). Flash chromatography 
(cyclohexane/EtOAc = 4:1) provided the title product as a white solid (312 mg, 0.97 mmol, 97%). Two rotamers 
were present on NMR-timescale in a 1 : 0.20 ratio. RF = 0.54. (cyclohexane/EtOAc = 2:1); m.p.: 126 ˚C; 
1H NMR 
(CDCl3, 500 MHz): δ 5.96 (bs, 1H), 5.85 (m, 1.20H),  5.69 (bs, 0.20H), 5.16 (d, J = 5.7 Hz, 1H), 5.06 (d, J = 17.2 Hz, 
1.20H), 5.00 (d, J = 10.2 Hz, 1.20H), 4.67 (d, J = 13.5 Hz, 0.20H), 4.43 (bs, 0.20H), 3.81 (d, J = 13.5 Hz, 1H), 3.05 (dt, 
J = 13.2, 2.5 Hz, 1H), 2.53-2.33 (m, 5.20H), 2.19 (d, J = 13.3 Hz, 1H), 1.70 (d, J = 12.9 Hz, 1H), 1.63 (m, 1.20H), 1.33 
(s, 1.80H), 1.28 (s, 9H), 1.17 (m, 2.60H), 0.85 (s, 9H), 0.84 (s, 1.80H) ppm; 13C NMR (CDCl3, 125 MHz): δ 172.3 (Cq), 
171.9 (Cq), 170.3 (Cq), 168.7 (Cq), 137.1 (CH), 137.0 (CH), 115.6 (CH2), 115.4 (CH2), 57.9 (CH), 52.6 (CH), 51.1 (Cq), 
50.8 (Cq), 43.9 (CH2), 42.4 (CH), 41.3 (CH), 40.2 (CH2), 32.6 (CH2), 32.5 (CH2), 32.0 (Cq), 32.0 (Cq), 29.2 (CH2), 29.2 
(CH2), 28.7 (CH3), 28.7 (CH3), 27.8 (CH2), 27.0 (CH3), 26.9 (CH3), 26.8 (CH2), 26.4 (CH2), 26.0 (CH2) ppm; IR (neat): 
νmax (cm-1) = 3323, 2959, 1682, 1626, 1541, 1450, 1363, 1263, 1224, 910, 632, 530; HRMS (ESI): m/z calculated 
for C19H35N2O2 [M+H]
+ 323.2693, found 323.2676. 
Synthesis of methyl (4-cyclopentyl-1-pivaloylpiperidine-2-carbonyl)glycinate (12m) 
Imine preparation according to general procedure IVa on a 3 mmol scale from 4-
cyclopentylpiperidine hydrochloride (0.57 g, 3.0 mmol, 1 equiv) to yield 3,4,5,6-
tetrahydro-4-cyclopentylpyridine (0.39 g, 2.55 mmol, 85%). 
U-3CR product formation according to general procedure IVb on a 0.5 mmol scale 
with the imine (76 mg, 0.5 mmol, 1 equiv), pivalic acid (61 mg, 0.6 mmol, 1.2 equiv) 
and methyl isocyanoacetate (55 µL, 0.6 mmol, 1.2 equiv). Flash chromatography 
(cyclohexane/EtOAc = 5:2) provided the title product as a slowly crystalizing oil (109 
mg, 0.31 mmol, 62%). RF = 0.12 (cyclohexane/EtOAc = 4:1); 
1H NMR (CDCl3, 500 MHz): δ 6.68 (bs, 1H), 5.24 (bs, 
1H), 4.21 (m, 2H), 3.80 (dd, J = 18.2, 4.2 Hz, 1H), 3.72 (s, 3H), 3.04 (t, J = 13.2 Hz, 1H), 2.37 (d, J = 13.2 Hz, 1H), 
1.72-1.68 (m, 3H), 1.59 (m, 3H), 1.53-1.37 (m, 3H), 1.33 (s, 9H), 1.28-1.05 (m, 4H) ppm; 13C NMR (CDCl3, 125 
MHz): δ 178.6 (Cq), 171.7 (Cq), 170.3 (Cq), 52.3 (CH), 46.2 (CH3), 44.5 (CH2), 40.8 (CH2), 38.9 (Cq), 37.6 (CH), 37.6 
(CH), 31.0 (CH2), 30.9 (CH2), 30.2 (CH2), 30.1 (CH2), 28.3 (CH3), 25.3 (CH2), 25.2 (CH2) ppm; IR (neat): νmax (cm
-1) = 
3356, 2949, 2868, 1753, 1680, 1618, 1516, 1412, 1366, 1201, 983, 536; HRMS (ESI): m/z calculated for 
C19H33N2O4 [M+H]
+ 353.2435, found 353.2445. 
Synthesis of N-(tert-butyl)-4-cyclopentyl-1-(2-(4-methoxyphenyl)acetyl)piperidine-2-carboxamide (12n) 
Imine preparation according to general procedure IVa on a 3 mmol scale from 
4-cyclopentylpiperidine hydrochloride (0.57 g, 3.0 mmol, 1 equiv) to yield 
3,4,5,6-tetrahydro-4-cyclopentyl-pyridine (0.39 g, 2.55 mmol, 85%). 
U-3CR product formation according to general procedure IVb on a 0.5 mmol 
scale with the imine (76 mg, 0.5 mmol, 1 equiv), 4-methoxyphenylacetic acid 
(100 mg, 0.6 mmol, 1.2 equiv) and tert-butylisocyanide (62 µL, 0.6 mmol, 1.2 
equiv). Column chromatography (cyclohexane/EtOAc = 3:1) provided the title product as a white solid (173 mg, 
0.43 mmol, 86%). Two rotamers were present on NMR-timescale in a 1 : 0.27 ratio. RF = 0.42 (cyclohexane/EtOAc 
= 2:1); m.p.: 104 ˚C; 1H NMR (CDCl3, 500 MHz): δ 7.16 (d, J = 8.5 Hz, 2.54H), 7.84 (d, J = 8.5 Hz, 2.54H), 5.92 (bs, 
1H), 5.23 (bs, 0.27H), 5.15 (d, J = 4.8 Hz, 1H), 4.61 (d, J = 13.4 Hz, 0.27H), 4.44 (bs, 0.27H), 3.85-3.66 (m, 7.35H), 
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2.91 (t, J = 13.2 Hz, 1H), 2.43 (m, 0.54H), 2.26 (d, J = 12.9 Hz, 1H), 1.78-1.31 (m, 12.7H), 1.22 (s, 9.27H), 1.13 (s, 
2.43H), 1.11-1.02 (m, 2.27H), 1.00-0.90 (m, 1.27H) ppm; 13C NMR (CDCl3, 125 MHz): δ 171.4 (Cq), 171.1 (Cq), 170.0 
(Cq), 168.1 (Cq), 158.6 (Cq), 158.5 (Cq), 129.4 (CH), 129.4 (CH), 126.7 (Cq), 126.5 (Cq), 114.5 (CH), 114.2 (CH), 58.3 
(CH), 55.2 (CH), 55.2 (CH3), 52.4 (CH3), 51.1 (Cq), 50.8 (Cq), 46.1 (CH), 45.9 (CH), 44.2 (CH2), 40.7 (CH2), 40.2 (CH2), 
39.9 (CH2), 37.9 (CH), 37.3 (CH), 31.8 (CH2), 31.0 (CH2), 30.7 (CH2), 30.3 (CH2), 30.1 (CH2), 30.1 (CH2), 30.0 (CH2), 
29.6 (CH2), 28.6 (CH3), 28.3 (CH3), 25.2 (CH2), 25.2 (CH2), 25.2 (CH2), 25.1 (CH2) ppm; IR (neat): νmax (cm
-1) = 3337, 
2951, 2866, 1678, 1624, 1510, 1450, 1246, 1178, 1036, 910, 729, 646, 526; HRMS (ESI): m/z calculated for 
C24H37N2O3 [M+H]
+ 401.2799, found 401.2813. 
Synthesis of 4-cyclohexyl-N-pentyl-1-pivaloylpiperidine-2-carboxamide (12o) 
Imine preparation according to general procedure IVa on a 3 mmol scale from 4-
cyclohexylpiperidine hydrochloride (0.61 g, 3.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-
cyclohexylpyridine (0.46 g, 2.76 mmol, 92%). 
U-3CR product formation according to general procedure IVb on a 0.5 mmol scale with the 
imine (83 mg, 0.5 mmol, 1 equiv), pivalic acid (61 mg, 0.6 mmol, 1.2 equiv) and 
pentylisocyanide (78 µL, 0.6 mmol, 1.2 equiv). Flash chromatography (cyclohexane/EtOAc = 
4:1) provided the title product as a white solid (138 mg, 0.38 mmol, 76%). RF = 0.31 
(cyclohexane/EtOAc = 4:1); m.p.: 108 ˚C; 1H NMR (CDCl3, 500 MHz): δ 6.19 (bs, 1H), 5.11 (bs, 
1H), 4.18 (bs, 1H), 3.25 (m, 1H), 3.11 (m, 1H), 2.89 (m, 1H), 2.29 (d, J = 12.0 Hz, 1H), 1.76-1.59 (m, 1H), 1.42 (m, 
2H), 1.27 (s, 9H), 1.26-0.90 (m, 12H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (CDCl3, 125 MHz): δ 178.2 (Cq), 171.1 (Cq), 
44.4 (CH), 42.5 (CH), 39.1 (CH2), 38.8 (Cq), 37.0 (CH), 29.9 (CH2), 29.6 (CH2), 29.3 (CH2), 29.0 (CH2), 28.8 (CH2), 28.2 
(CH3), 26.6 (CH2), 26.4 (CH2), 22.2 (CH2), 13.9 (CH3) ppm; IR (neat): νmax (cm
-1) = 3329, 2922, 2851, 1664, 1612, 
1522, 1412, 1165, 997, 922, 731, 629, 532; HRMS (ESI): m/z calculated for C22H41N2O2 [M+H]
+ 365.3163, found 
365.3173. 
Synthesis of N-(tert-butyl)-4-cyclohexyl-1-(pent-4-enoyl)piperidine-2-carboxamide (12p) 
Imine preparation according to general procedure IVa on a 3 mmol scale from 4-
cyclohexylpiperidine hydrochloride (0.61 g, 3.0 mmol, 1 equiv) to yield 3,4,5,6-
tetrahydro-4-cyclohexylpyridine (0.46 g, 2.76 mmol, 92%). 
U-3CR product formation according to general procedure IVb on a 0.5 mmol scale with 
the imine (83 mg, 0.5 mmol, 1 equiv), 4-pentenoic acid (62 µL, 0.6 mmol, 1.2 equiv) and 
tert-butylisocyanide (62 µL, 0.6 mmol, 1.2 equiv). Flash chromatography 
(cyclohexane/EtOAc = 4:1) provided the title product as a white solid (155 mg, 0.44 
mmol, 89%). Two rotamers were present on NMR-timescale in a 1 : 0.21 ratio. RF = 0.30 (cyclohexane/EtOAc = 
4:1); m.p.: 140 ˚C; 1H NMR (CDCl3, 500 MHz): δ 5.96 (bs, 1H), 5.84 (m, 1.21H), 5.70 (bs, 0.21H), 5.14 (d, J = 4.5 Hz, 
1H), 5.05 (d, J = 17.1 Hz, 1.21H), 4.99 (d, J = 10.1 Hz, 1.21H), 4.65 (d, J = 12.9 Hz, 0.21H), 4.40 (bs, 0.21H), 3.79 (d, 
J = 13.3 Hz, 1H), 3.04 (dt, J = 13.2, 1.5 Hz, 1H), 2.54-2.31 (m, 5.26H), 2.19 (d, J = 14.1 Hz, 1H), 1.77-1.56 (m, 
8.47H), 1.32 (s, 1.89H), 1.28 (s, 9H), 1.1.24-0.81 (m, 9.68H) ppm; 13C NMR (CDCl3, 125 MHz): δ 172.3 (Cq), 171.9 
(Cq), 170.3 (Cq), 168.7 (Cq), 137.1 (CH), 137.0 (CH), 115.6 (CH2), 115.4 (CH2), 57.8 (CH), 52.6 (CH), 51.5 (Cq), 50.9 
(Cq), 43.7 (CH2), 42.5 (CH), 42.2 (CH), 40.0 (CH2), 37.7 (CH), 36.8 (CH), 32.6 (CH2), 32.5 (CH2), 30.2 (CH2), 29.9 (CH2), 
29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.2 (CH2), 29.2 (CH2), 29.1 (CH2), 29.0 (CH2), 28.7 (CH3), 28.7 (CH3), 28.2 (CH2), 
26.6 (CH2), 26.6 (CH2), 26.5 (CH2), 26.4 (CH2) ppm; IR (neat): νmax (cm
-1) = 3335, 2922, 2851, 1682, 1627, 1535, 
1448, 1425, 1364, 1259, 1224, 999, 910, 730, 644, 403; HRMS (ESI): m/z calculated for C21H37N2O2 [M+H]
+ 
349.2850, found 349.2857. 
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Synthesis of 1-acetyl-N-(tert-butyl)-4-phenylpiperidine-2-carboxamide (12q) 
 Imine preparation according to general procedure IVa on a 6.0 mmol scale from 4-
phenylpiperidine (0.97 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-phenylpyridine 
(0.91 g, 5.72 mmol, 95%). 
U-3CR product formation according to general procedure IVb on a 0.35 mmol scale with the 
imine (56 mg, 0.35 mmol, 1 equiv), acetic acid (24 µL, 0.42 mmol, 1.2 equiv) and tert-
butylisocyanide (48 µL, 0.42 mmol, 1.2 equiv). Flash chromatography (EtOAc) provided the 
title product as a white solid (101 mg, 0.33 mmol, 95%). Two rotamers were present on 
NMR-timescale in a 1 : 0.18 ratio. RF = 0.30 (EtOAc); 
1H NMR (CDCl3, 500 MHz): δ 7.34-7.20 (m, 5.90H), 6.07 (bs, 
1H), 5.82 (bs, 0.18H), 5.25 (d, J = 5.5 Hz, 1H), 4.81 (d, J = 13.5 Hz, 0.18H), 4.47 (d, J = 5.0 Hz, 0.18H), 3.87 (d, J = 
13.5 Hz, 1H), 3.35 (dt, J = 13.0, 2.5 Hz, 1H), 3.25 (tt, J = 12.5, 3.5 Hz, 1H), 2.75 (m, 0.56), 2.37 (m, 1H), 2.22 (s, 3H), 
2.18 (s, 0.56H), 1.92 (m, 1.18H), 1.72-1.60 (m, 2.36H), 1.41 (s, 1.62H), 1.36 (s, 9H) ppm. 13C NMR (CDCl3, 125 
MHz): δ 170.7 (Cq), 170.3 (Cq), 170.0 (Cq), 168.3 (Cq), 145.2 (Cq), 144.6 (Cq), 128.5 (CH), 128.5 (CH), 126.8 (CH), 
126.7 (CH), 126.5 (CH), 126.4 (CH), 58.7 (CH), 52.4 (CH), 51.7 (Cq), 51.0 (Cq), 44.4 (CH2), 39.7 (CH2), 38.4 (CH), 37.6 
(CH3), 34.0 (CH2), 33.0 (CH2), 32.6 (CH2), 31.6 (CH2), 28.9 (CH3), 28.8 (CH3), 21.7 (CH3), 21.7 (CH3) ppm. IR (neat): 
νmax (cm-1) = 3317, 2966, 1678, 1627, 1533, 1421, 1364, 1256, 1225, 729, 698; HRMS (ESI): m/z calculated for 
C18H26N2NaO2 [M+Na]
+ 325.1886, found 325.1901. 
Synthesis of 1-acetyl-N-cyclohexyl-4-phenylpiperidine-2-carboxamide (12r) 
Imine preparation according to general procedure IVa on a 6.0 mmol scale from 4-
phenylpiperidine (0.968 g, 6.0 mmol, 1 equiv) to yield 3,4,5,6-tetrahydro-4-
phenylpyridine (0.910 g, 5.72 mmol, 95%). 
U-3CR product formation according to general procedure IVb on a 0.35 mmol scale with 
the imine (56 mg, 0.35 mmol, 1 equiv), acetic acid (24 µL, 0.42 mmol, 1.2 equiv) and 
cyclohexyl isocyanide (52 µL, 0.42 mmol, 1.2 equiv). Flash chromatography (EtOAc) 
provided the title product as a white solid (103 mg, 0.31 mmol, 90%); Two rotamers 
were present on NMR-timescale in a 1 : 0.24 ratio. RF = 0.40 (EtOAc);  
1H NMR (CDCl3, 500 MHz): δ 7.34-7.18 (m, 
6.20H), 6.11 (d, J = 7.5 Hz, 1H), 6.05 (d, J = 8.5 Hz, 0.24H), 5.29 (d, J = 5.5 Hz, 1H), 4.78 (d, J = 13.5 Hz, 0.24H), 4.51 
(d, J = 5.5 Hz, 0.24H), 3.85 (d, J = 13.5 Hz, 1H), 3.76 (m, 1.24H), 3.33 (dt, J = 13.0, 2.5 Hz, 1H), 3.20 (tt, J = 12.5, 3.5 
Hz, 1H), 2.72 (m, 0.72), 2.38 (m, 1H), 2.20 (s, 3H), 2.16 (s, 0.72H), 1.97-1.80 (m, 3.72H), 1.77-1.56 (m, 6.2H), 1.42-
1.30 (m, 2.48H), 1.23-1.10 (m, 3.72H) ppm. 13C NMR (CDCl3, 125 MHz): δ 170.7 (Cq), 170.3 (Cq), 169.7 (Cq), 167.9 
(Cq), 145.1 (Cq), 144.5 (Cq), 128.5 (CH), 128.5 (CH), 126.7 (CH), 126.7 (CH), 126.5 (CH), 126.4 (CH), 58.3 (CH), 51.9 
(CH), 48.7 (CH), 48.0 (CH), 44.4 (CH2), 39.6 (CH2), 38.4 (CH), 37.7 (CH), 33.1 (CH2), 33.0 (CH2), 32.8 (CH2), 32.5 
(CH2), 25.4 (CH2), 25.3 (CH2), 24.9 (CH2), 24.7 (CH2), 21.8 (CH3), 21.7 (CH3) ppm. IR (neat): νmax (cm
-1) = 3300, 
2930, 2854, 1631, 1527, 1421, 730, 633, 534, 496; HRMS (ESI): m/z calculated for C20H28N2NaO2 [M+Na]
+ 
351.2043, found 351.2058. 
 
Synthesis of Argatroban (27) 
 
1-(4-Methoxyphenyl)-4-methyl-5,6-dihydropyridin-2(1H)-one (40) 
Methyl vinyl ketone (2.0 mL, 28.5 mmol, 1.5 equiv) was added to a flask containing 
anisidine (2.34 g, 19.0 mmol, 1.0 equiv). The mixture was stirred for 3 hours at room 
temperature and then concentrated under reduced pressure. The residue was co-
evaporated three times to remove the excess methyl vinyl ketone, furnishing a dark 
brown oil (3.68 g, 19.0 mmol, 100%). The product was used in the next reaction step 
without further purification. 
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1-(4-Methoxyphenyl)-4-methyl-5,6-dihydropyridin-2(1H)-one (42) 
Preparation of monoethyl malonyl chloride (41): Oxalyl chloride (13.6 mL, 161 mmol, 2.14 equiv) 
was added dropwise to a solution of monoethyl malonate (12.6 mL, 107 mmol, 1.43 equiv) in 
anhydrous CH2Cl2 (100 mL) at 0 °C. A catalytic amount of DMF (0.5 mL) was added resulting in the 
gas evolution. After stirring for 1 h the ice bath was removed and the reaction was stirred for 
another hour. The yellow solution was then concentrated under reduced pressure and co-
evaporated with CH2Cl2 (2×) to obtain the product as a dark yellow oil, which was used without 
further purification. 
A solution of freshly prepared monoethyl malonylchloride 41 (13.7 mL , 75.0 mmol, 1.0 equiv) in CH2Cl2 (30 mL) 
was added dropwise at 0 °C to a solution of aza-Michael product 40 (14.5 g, 75.0 mmol, 1.0 equiv) in CH2Cl2 (40 
mL). After complete addition, saturated aqueous Na2CO3 (80 mL) was added portion wise and the mixture was 
stirred vigorously. After 15 min the ice bath was removed and the mixture was stirred for another 45 min at 
room temperature. Then, water (50 mL) was added and the mixture was extracted with CH2Cl2 (3 × 50 mL). The 
combined fractions were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure. The residue was redissolved into ethanol (250 mL) and NaOEt (10.2 g, 150 mmol, 2.0 equiv) 
was added while stirring vigorously. After 15 min KOH (8.42 g, 150 mmol, 2.0 equiv) was added and the mixture 
was heated to reflux temperature for 16 h. The mixture was allowed to cool down to rt and a 1:1 mixture of 
brine and 10% HCl solution were added (200 mL). The resulting dark mixture was then extracted with ethyl 
acetate (5 × 100 mL). Finally, the combined organic layers were concentrated under reduced pressure and the 
residue was purified by flash chromatography (cyclohexane/EtOAc = 1:2) to yield the title product as an off-white 
solid (13.1 g, 60.1 mmol, 80%). RF = 0.25 (cyclohexane/EtOAc = 1:2); m.p.: 104 ˚C; 
1H NMR (CDCl3, 500 MHz): δ 
7.19 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 5.83 (s, 1H), 3.77 (s, 3H), 3.75 (t, J = 6.8 Hz, 2H), 2.41 (t, J = 6.8 Hz, 
2H), 1.95 (s, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 164.8 (Cq), 157.3 (Cq), 151.4 (Cq), 135.6 (Cq), 126.3 (CH), 121.1 
(CH), 114.0 (CH), 55.3 (CH3), 48.6 (CH2), 29.7 (CH2), 22.7 (CH3) ppm; IR (neat): νmax (cm
-1) = 1633, 1508, 1433, 
1326, 1236, 1022, 864, 833, 561, 530; HRMS (ESI): m/z calculated for C13H16NO2 [M+H]
+ 218.1176, found 
218.1168. 
(R)-1-(4-Methoxyphenyl)-4-methylpiperidin-2-one (43) 
A schlenk vial was charged with CuCl2 (3.4 mg, 0.025 mmol, 0.05 equiv), (R)-p-tolBINAP (17 mg, 
0.025 mmol, 0.05 equiv), NaOtBu (9.6 mg, 0.1 mmol, 0.2 equiv) and PMHS (0.12 mL, 2.0 mmol, 4 
equiv), which were suspended in cyclohexane (0.75 ml) and cooled with an ice/salt bath. A solution 
of lactam ## (109 mg, 0.5 mmol, 1.0 equiv) in i-PrOH (0.15 mL, 2.0 mmol, 4.0 equiv) and anhydrous 
THF were added dropwise to the reaction mixture resulting in the evolution of gas. After 2 h the 
dark mixture was quenched with a 10% HCl solution (5 mL) and extracted with EtOAc (3× 5 mL). The 
organic layers were combined, washed with brine (10 mL) dried over Na2SO4, filtered and 
concentrated. The residue was purified by flash chromatography (cyclohexane/EtOAc = 1:2) to 
furnish the title product as a white crystalline solid (95 mg, 0.43 mmol, 87%). 90% ee [Dr. Maisch Chiral AM, 
heptane/isopropanol = 85:15, v = 0.7 mL/min, λ = 254 nm, t (minor) = 13.353 min, t (major) = 24.337 min]; RF = 
0.25 (cyclohexane/EtOAc = 1:2); m.p.: 86 ˚C; [α]D
20+40° (c = 1.00, CHCl3); 
1H NMR (CDCl3, 500 MHz): δ 7.14 (d, J = 
9.0 Hz, 2H), 6.90 (d, J = 9.0 Hz, 2H), 3.78 (s, 3H), 3.63 (ddd, J = 12.0, 12.0, 4.5 Hz, 1H), 3.55 (ddd, J = 9.0, 5.5, 3.5 
Hz, 1H), 2.18-2.04 (m, 2H), 1.94 (m, 1H), 1.61 (m, 1H), 1.07 (d, J = 6.5 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 
169.9 (Cq), 158.0 (Cq), 135.9 (Cq), 127.3 (CH), 114.4 (CH), 55.3 (CH3), 51.0 (CH2), 40.9 (CH2), 31.2 (CH2), 28.1 (CH), 
21.0 (CH3) ppm; IR (neat): νmax (cm
-1) = 1634, 1508, 1431, 1238, 1167, 1151, 1022, 825, 559, 526; HRMS (ESI): 
m/z calculated for C13H18NO2 [M+H]
+ 220.1332, found 220.1339. 
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rac-1-(4-Methoxyphenyl)-4-methylpiperidin-2-one ((±)-43) 
Methanol (25 mL) was added to a nitrogen flushed flask charged with lactam 39 (1.09 g, 5.0 mmol, 
1.0 equiv) and Pd/C (10 w/w %, 0.265 g, 0.05 equiv). The flask was then exposed to an atmospheric 
pressure of H2 for 16 h at room temperature. The suspension was filtered over Celite and the 
filtrate was concentrated in vacuo to yield a white crystalline solid (1.07 g, 4.89 mmol, 98%). 
(R)-4-methylpiperidin-2-one (S1) 
To a solution of lactam 43 (280 mg, 1.28 mmol, 1.0 equiv) in acetonitrile (10 mL) at room 
temperature was added dropwise a solution of CAN (2.10 g, 3.83 mmol, 3 equiv) in water (10 mL). 
The resulting mixture was stirred for 1 hour, after which CH2Cl2 (10 mL) was added and the organic 
layer was separated. The water layer was extracted with CH2Cl2 (5 x 10 mL) and the combined 
fractions were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography (EtOAc : MeOH = 96:4) to yield the title 
product as a pale yellow solid (94 mg, 0.83 mmol, 65%). RF = 0.4 (EtOAc/MeOH = 9:1); m.p.: 85 ˚C; 
1H NMR 
(CDCl3, 500 MHz): δ 7.26 (bs, 1H), 3.33-3.16 (m, 2H), 2.36 (q, J = 10 Hz, 1H), 1.87 (m, 2H), 1.74 (d, J = 15 Hz, 1H), 
1.34 (m, 1H), 1.07 (d, J = 6.0 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 172.8 (Cq), 40.9 (CH2), 39.4 (CH2), 29.9 
(CH2), 27.3 (CH), 21.0 (CH3) ppm; IR (neat): νmax (cm
-1) = 3282, 2952, 1649, 1497, 1458, 1412, 1339, 1111. HRMS 
(ESI): m/z calculated for C6H11NNaO [M+Na]
+ 136.0733, found 136.0732. 
tert-butyl (R)-4-methyl-2-oxopiperidine-1-carboxylate (S2) 
Lactam S1 (87 mg, 0.77 mmol, 1.0 equiv) was dissolved into anhydrous CH2Cl2 (8 mL) and Et3N 
(0.214 mL, 1.54 mmol, 2.0 equiv), DMAP (94 mg, 0.77 mmol, 1.0 equiv) and Boc2O (0.318 mL, 1.38 
mmol, 1.8 equiv) were added respectively at rt. After stirring for 16 hours the mixture was 
concentrated under reduced pressure. The crude residue was purified by flash chromatography 
(cyclohexane/ EtOAc = 85:15) to yield a yellow oil (101 mg, 0.47 mmol, 62%). RF = 0.30 
(cyclohexane/EtOAc = 4:1); [α]D
20+42° (c = 1.00, CHCl3); 
1H NMR (CDCl3, 500 MHz): δ 3.78 (m, 1H), 3.47 (m, 1H), 
2.58 (m, 1H), 2.10 (m, 1H), 2.11-1.64 (m, 2H), 1.51 (s, 9H), 1.45 (m, 1H), 1.01 (d, J = 10.5 Hz, 3H) ppm; 13C NMR 
(CDCl3, 125 MHz): δ 171.1 (Cq), 82.9 (Cq), 45.6 (CH2), 43.1 (CH2), 30.9 (CH2), 28.0 (CH), 27.7 (CH3), 21.2 (CH3) ppm; 
IR (neat): νmax (cm-1) = 2976, 2363, 1717, 1699, 1521, 1251, 1173; HRMS (ESI): m/z calculated for C11H19NNaO3 
[M+Na]+ 236.1257, found 236.1262. 
tert-butyl (R)-4-methyl-3,4-dihydropyridine-1(2H)-carboxylate (S3) 
A solution of DIBAL (1 M, 1.34 mL, 1.34 mmol, 3 equiv) in anhydrous THF was added dropwise to a 
solution of lactam S2 (95 mg, 0.45 mmol, 1 equiv) in anhydrous THF (5 mL) at −78 °C. After 1 h the 
solution was quenched with saturated NH4Cl(aq) (5 mL) and allowed to warm to rt. Then saturated 
Na2CO3(aq) (5 mL) was added and the water layer was carefully extracted with CH2Cl2 (3× 10 mL). The 
combined organic layers were subsequently washed with brine (1 × 10 mL), dried over Na2SO4, filtered 
and concentrated under reduced pressure to leave a yellow oil,  which was used in the next step without further 
purification. 1H NMR (CDCl3, 500 MHz): δ 3.78 (m, 1H), 3.47, (m, 1H), 2.58 (m, 1H), 2.10 (m, 1H), 2.11-1.64 (m, 
2H), 1.51 (s, 9H), 1.45 (m, 1H), 1.01 (d, J = 10.5 Hz, 3H) ppm. 
(R)-4-methyl-2,3,4,5-tetrahydropyridine ((R)-11a) 
TFA (0.31 mL, 4.1 mmol, 10 equiv) was added dropwise to a solution of enamine S3 (81 mg, 0.41 mmol, 
1 equiv) in dry CH2Cl2 (4 mL). After 1h the mixture was concentrated to dryness to remove the excess 
TFA. The residue was dissolved into CH2Cl2 (5 mL) and washed with sat. Na2CO3 (5 mL). The water layer 
was extracted again with CH2Cl2 (2× 5 mL) and the combined organic layers were concentrated to a 
volume of 4 mL. This solution was used as such in the next reaction. 
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Nω,Nω'-bis((benzyloxy)carbonyl)-N2-((3-methylquinolin-8-yl)sulfonyl)-L-arginine (46) 
TFA (65 mL) was added to a solution of Boc-Arg(Cbz)2-OH (2.5 g, 4.61 mmol, 1 
equiv) in CH2Cl2 (65 mL) at 0 °C. The reaction mixture was stirred for 1 h at this 
temperature and then concentrated under reduced pressure. The resulting 
residue was co-evaporated two times with toluene to furnish an off-white foamy 
solid. The residue was redissolved into a 2:1 mixture of THF and H2O (120 mL) 
and DIPEA (4.00 mL, 23.0 mmol, 5 equiv) was added. Then, the resulting solution 
was cooled to 0 °C and 3-methylquinoline-8-sulfonyl chloride (1.34 g, 5.53 mmol, 
1.2 equiv) was added portionwise. After complete addition, the reaction mixture 
was allowed to warm to room temperature and stirred for 16 h. Next, EtOAc was added (50 mL) and the layers 
were separated. The water layer was extracted with ethyl acetate (2× 50 mL) and the combined layers were 
washed with saturated NH4Cl(aq) and Brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
The residue was purified by flash chromatography (cyclohexane/EtOAc = 1:4) to obtain the title product as a 
white foamy solid (2.94 g, 4.54 mmol, 98%). RF = 0.20 (cyclohexane/EtOAc = 1:4); m.p.: 160 °C [α]D
20+80° (c = 1.00, 
CHCl3); 
1H NMR (CDCl3, 500 MHz): δ 9.36 (bs, 1H), 9.27 (bs, 1H), 8.78 (s, 1H), 8.26 (d, J = 7.0 Hz, 1H), 7.92 (s, 1H), 
7.88 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.42-7.35 (m, 5H), 7.26-7.14 (m, 5H), 5.23 (s, 2H), 4.94 (d, J = 12.5 
Hz, 1H), 4.81 (d, J = 12.5 Hz, 1H), 4.24 (bs, 1H), 3.91 (m, 2H), 2.46 (s, 3H), 1.89-1.61 (m, 4H) ppm; 13C NMR (CDCl3, 
125 MHz): δ 174.1 (Cq), 163.3 (Cq), 160.5 (Cq), 155.7 (Cq), 153.0 (CH), 141.1 (Cq), 136.5 (Cq), 136.0 (Cq), 125.6 (CH), 
134.5 (Cq), 132.9 (CH), 132.1 (Cq), 129.9 (CH), 128.8 (CH), 128.6 (Cq), 128.4 (CH), 128.3 (CH), 127.7 (CH), 127.5 
(CH), 125.3 (CH), 69.0 (CH2), 66.7 (CH2), 55.9 (CH), 29.2 (CH2), 24.3 (CH2), 18.6 (CH3) ppm; IR (neat): νmax (cm
-1) = 
2986, 2363, 1717, 1607, 1508, 1240, 1161, 1095, 696, 584; HRMS (ESI): m/z calculated for C23H34N5O8S [M+H]
+ 
648.2123, found 648.2121. 
1-(Nω,Nω'-bis(1-(benzyloxy)carbonyl)-N2-((3-methylquinolin-8-yl)sulfonyl)-L-arginyl)-N-(6-bromopyridin-2-yl)-4- 
methylpiperidine-2-carboxamide (47) 
 Tetrahydro-4-methylpyridine (146 mg, 1.50 mmol, 1.0 equiv) 
was dissolved in TFE (10 mL). Then, amino acid 46 (1.46 g, 2.25 
mmol, 1.5 equiv) and 2-bromo-6-isocyanopyridine (34, 329 mg, 
1.80 mmol, 1.20 equiv) were added sequentially. After 48 h the 
mixture was concentrated in vacuo and purified using flash 
chromatography (cyclohexane/EtOAc = 4:1) to yield an off-white 
foam (902 mg, 0.97 mmol, 65%). The product is a 1:1 mixture of 
diastereoisomers. NMR-analysis also shows rotamers of which 
the major signals are reported 1H NMR (CDCl3, 500 MHz): δ 9.45 
(bs, 2H), 9.28 (bs, 2H), 8.92 (s, 1H), 8.82 (s, 2H), 8.33 (d, J = 7.0 Hz, 1H), 8.24 (d, J = 7.5 Hz, 1H), 8.03-7.90 (m, 4H), 
7.78 (s, 1H), 7.74 (s, 1H), 7.70 (d, J = 7.0 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.49-7.25 (m, 21H), 
7.14 (m, 2H), 5.30-5.04 (m, 8H), 4.79 (d, J = 5.5 Hz, 1H), 4.72 (m, 1H), 4.50 (m, 1H), 4.46 (d, J = 5.5 Hz, 1H), 4.08-
3.93 (m, 4H), 3.70 (d, J = 13.5 Hz, 1H), 3.65 (d, J = 13.5 Hz, 1H), 3.04 (dt, J = 13.0, 2.0 Hz, 1H), 2.95 (dt, J = 13.0, 2.0 
Hz, 1H), 2.95 (s, 3H), 2.40 (s, 3H), 1.95 (d, J = 14.0 Hz, 1H), 1.89-1.50 (m, 12H), 1.40 (d, J = 12.5 Hz, 1H), 0.92 (m, 
2H), 0.82 (d, J = 6.5 Hz, 3H), 0.80 (d, J = 6.5 Hz, 3H), 0.63 (dq, J = 12.5, 4.0 Hz, 1H), 0.37 (dt, J = 13.0, 6.0 Hz, 1H) 
ppm; 13C NMR (CDCl3, 125 MHz): δ 171.4 (Cq), 171.1 (Cq), 168.8 (Cq), 168.7 (Cq), 163.8 (Cq), 163.7 (Cq), 160.5 (Cq), 
160.5 (Cq), 155.8 (Cq), 155.8 (Cq), 153.3 (CH), 152.7 (CH), 150.8 (Cq), 150.7 (Cq), 141.5 (Cq), 141.4 (Cq), 140.3 (CH), 
140.1 (CH), 139.3 (Cq), 139.2 (Cq), 136.8 (Cq), 136.8 (Cq), 136.8 (Cq), 135.2 (CH), 135.0 (CH), 134.7 (Cq), 134.6 (Cq), 
132.7 (CH), 132.6 (CH), 132.2 (CH), 131.7 (CH), 128.8 (CH), 128.8 (CH), 128.8 (CH), 128.8 (CH), 128.7 (CH), 128.7 
(CH), 128.5 (CH), 128.5 (Cq), 128.4 (CH), 128.4 (Cq), 128.4 (CH), 128.3 (CH), 128.1 (CH), 127.9 (CH), 127.8 (CH), 
127.7 (CH), 125.3 (CH), 125.1 (CH), 123.7 (CH), 123.6 (CH), 112.4 (CH), 112.0 (CH), 69.0 (CH2), 68.9 (CH2), 66.9 
(CH2), 66.9 (CH2), 54.1 (CH), 53.3 (CH), 53.0 (CH), 52.8 (CH), 44.0 (CH2), 43.9 (CH2), 43.6 (CH2), 43.3 (CH2), 33.6 
(CH2), 33.5 (CH2), 33.1 (CH2), 33.0 (CH2), 30.8 (CH2), 30.4 (CH2), 26.5 (CH), 26.3 (CH), 24.7 (CH2), 24.5 (CH2), 21.7 
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(CH3), 21.6 (CH3), 18.8 (CH3), 18.7 (CH3) ppm; IR (neat): νmax (cm
-1) = 1717, 1604, 1564, 1508, 1431, 1384, 1223, 
1155, 1090, 696, 581; HRMS (ESI): m/z calculated for C44H48BrN8O8S [M+H]
+ 927.2494, found 927.2510. 
(2R,4R)-1-(Nω'-((benzyloxy)carbonyl)-N2-((3-methylquinolin-8-yl)sulfonyl)-L-arginyl)-4-methylpiperidine-2-
carboxylic acid (S4) 
 U-3CR product 47 (186 mg, 0.20 mmol, 1.0 equiv) was dissolved into 
ethanol (2 mL) and aqueous NaOH (2 N, 1.0 mL, 2.0 mmol, 10 equiv) was 
added dropwise to the solution. The resulting mixture was heated to reflux 
and stirred for 1 hour. The mixture was cooled to room temperature and 
CH2Cl2 (3 mL) was added. The water layer was acidified to pH 2 with an 
aqueous HCl solution (2 M) and extracted with CH2Cl2 (3×). The collected 
organic fractions were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude product was further purified using flash 
chromatography (EtOAc/iPrOH/H2O = 5:2:0.25) to yield an off-white 
powder (120 mg, 0.188 mmol, 94%). The resulting product is a mixture of two diastereoisomers of the 
hydrolyzed product and in addition the second Cbz-group is partially cleaved. A small amount of the 
diastereomers was separated by semi-preparative reversed phase HPLC [Dr. Maisch ReproSil-Pur 120 C18-AQ, 
5μm, 250 × 8 mm, H20/MeCN with 0.1% TFA = 60/40, v = 3.0 mL/min, λ = 210 nm, t (desired) = 13.668 min, t 
(undesired) = 15.679 min] to yield about 4.0 mg of the desired diastereoisomer. RF = 0.75 (EtOac/iPrOH/H2O = 
4:2:1); [α]D
20+130° (c = 0.20, MeOH); 1H NMR (CDCl3, 500 MHz): δ 8.93 (s, 1H), 8.31 (d, J = 6.5 Hz, 1H), 8.15 (s, 1H), 
8.01 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 7.5 Hz, 1H), 7.45-7.36 (m, 5H), 5.22 (s, 1H), 4.44-4.36 (m, 2H), 3.85 (d, J = 12.5 
Hz, 1H), 3.38-3.12 (m, 3H), 2.58 (s, 1H), 2.10 (m, 1H), 1.78-1.45 (m, 6H), 0.88 (m, 1H), 0.79 (d, J = 6.0 Hz, 3H), 0.67 
(m, 1H) ppm. HRMS (ESI): m/z calculated for C31H44N6O7S [M+H]
+ 639.2595, found 639.2581. 
Argatroban  (27) 
Carboxylic acid S4 (2 mg, 0.003 mmol, 1.0 equiv) was dissolved in a 1:1 
mixture of ethanol and acetic acid (2 mL) and Pd/C (10 w/w %, 1 mg, about 
0.1-0.2 equiv) was added. The reaction flask was exposed to an 
atmospheric pressure of H2 and stirred for 16 h at rt. Then, the suspension 
was filtrated over Celite and concentrated in vacuo to yield argatroban as a 
white solid (2 mg). The product was not further purified due to the small 
amount. The spectrum contains some minor impurities. 1H NMR (MeOD, 
500 MHz): δ 7.44 (d, J = 7.5 Hz, 1H), 7.10 (d, J = 7.0 Hz, 1H), 6.57 (t, J = 6.5 
Hz, 1H), 4.13 (m, 2H), 4.00 (m, 1H), 3.43 (m, 1H), 3.22-2.68 (m, 5H), 2.43 
(m, 1H), 2.15 (m, 1H), 1.99 (m, 1H), 1.69 (m, 3H), 1.50 (m, 3H), 1.07 (d, J = 
6.5 Hz, 3H), 0.70 (m, 1H), 0.88 (d, J = 5.5 Hz, 3H), 0.65 (m, 1H) ppm. HRMS (ESI): m/z calculated for C23H37N6O5S 
[M+H]+ 509.2541, found 509.2525. 
4-Methyl-1-(((3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonyl)-L-arginyl)piperidine-2-carboxylic acid (27) 
Carboxylic acid S4 (32 mg, 0.05 mmol, 1.0 equiv) was dissolved in a 1:1 
mixture of ethanol and acetic acid (5 mL) and Pd/C (10 w/w %, 6 mg, 0.005 
mmol, 0.1 equiv) was added. The reaction flask was exposed to an 
atmospheric pressure of H2 and stirred for 16 h at rt. Then, the suspension 
was filtrated over Celite, concentrated in vacuo and purified by flash 
chromatography (CH2Cl2/MeOH = 80:20) to yield the title compound as a 
white solid (22 mg, 0.044 mmol, 88%). 
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An IMCR Approach Towards ACE Inhibitor Analogues 
 
 
 
Abstract: ACE Inhibitors are an important class of cardiovascular drugs. The synthesis of 
structural analogues is crucial for the discovery of more potent derivatives. In this Chapter, 
we describe the development of a simple two-step procedure to make a new set of 
optically pure analogues. This procedure consists of a diastereoselective U-3CR with our 
recently developed reagent 2-bromo-6-isocyanopyridine followed by a chemoselective 
hydrolytic cleavage of the resulting Ugi product. To demonstrate the utility of this 
methodology, we composed a small library with the use of chemically diverse carboxylic 
acids. 
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Introduction 
The pharmaceutical industry is continuously searching for new drugs with higher 
activity and less (hazardous) adverse effects. Lately, focus shifts to compounds that 
show a higher degree in three dimensionality of their molecular structure. This, 
because of disappointing number of positive hits from the currently produced 
aromatic and achiral ‘flatland’ compound libraries.
1,2
 An important family of drugs 
regarding hypertension and hearth failures are the Angiotensin-converting enzyme 
(ACE) inhibitors (Figure 1).
3,4
 ACE is an important unit of the renin-angiotensin 
system (RAS), which is a hormone system that regulates blood pressure. RAS is 
activated by lowered blood pressure and the release of the enzyme renin (Figure 2). 
Renin cleaves a decapeptide called angiotensin I from the protein angiotensinogen, 
which is produced by the liver and circulates in the blood. Subsequently, ACE 
removes two more amino acid residues from angiotensin I to convert it into the 
octapeptide angiotensin II, which is the active component in RAS. Angiotensin II is – 
amongst others – responsible for constriction of blood vessels to regulate blood 
pressure. 
 
 
Figure 1. Selected examples of ACE inhibitors. 
The ACE inhibitors actively block the conversion of angiotensin I to angiotensin II. 
Although many ACE inhibitors have been on the market for several decades, they 
suffer from many common side effects.
5
 Since the discovery of captopril (1),
6
 many 
structurally related ACE inhibitors have appeared in the literature, including those 
with variations in the proline ring e.g. Ramipril (3) and Perindopril (4). The core 
structure of the traditional ACE inhibitors offers a good starting point for the design 
of a new generation of cardiovascular drugs. The molecular skeleton of many of 
these ACE inhibitors typically consists of a dipeptide with a (substituted) L-proline at 
the carboxyl terminus. Currently, a more detailed picture of the binding motif of the 
first-generation drugs to the target enzyme exists. This promotes the design of new 
inhibitors with a more selective binding affinity.
7
 Consequently, a straightforward 
method is required to synthesize such analogues. 
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Figure 2. Effect of ACE inhibitors on RAS. 
In this context, isocyanide-based multicomponent reactions (IMCRs) are very valuable 
tools, since they can rapidly generate large compound libraries with the use of simple, 
commercial starting materials.
8-14
 The typical proline core of the ACE inhibitors can be 
obtained by an Ugi three-component reaction (U-3CR) between an isocyanide (7), a 
carboxylic acid (6) and 1-pyrroline 5 (Scheme 1). This strategy has been successfully 
applied in the synthesis of aza-C-glycosides,
15-18
 mono-substituted prolyl peptides,
19-23
 
functionalized spiroindolines
24-26
 and in the total synthesis of several natural products.
27
 
Importantly, the diastereoselectivity in the U-3CR is generally not trivial. The groups of 
Overkleeft and Ichikawa provided many new insights in the stereocontrol of these 
reactions with experimental and computational studies on the mechanism of the U-3CR of 
1-pyrroline derivatives.
15,17,23 
 
Scheme 1. Synthesis of prolyl peptides with an U-3CR. 
Our group discovered that the use of conformationally restricted bicyclic 1-pyrrolines (like 
9), which can elegantly be obtained with excellent optical purity by an enzymatic 
desymmetrization reaction with MAO-N,
28
 are valuable substrates for the U-3CR (Scheme 
2).
29-31
 The Ugi-products are obtained with high diastereoselectivity due the steric bulk of 
the cyclopentyl ring. Furthermore, this method was successfully applied to the efficient 
synthesis of the hepatitis C drug, telaprevir.
32
  
We envisaged the use of the above-mentioned strategy for the diastereoselective 
synthesis of a new set of optically pure ACE inhibitor analogues with a bicyclic proline 
backbone (Scheme 2). The use of a general isocyanide would provide us with the 
corresponding prolyl peptides (10) instead of the carboxylic acids. In order to obtain the 
required carboxylic acid moiety on the proline ring, a method is required to selectively 
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hydrolyze the resulting secondary amide of the Ugi product. Recently, we have developed 
2-bromo-6-isocyanopyridine (11)
33,34
 as a new convertible isocyanide.
35-40
 The isocyanide 
allows modification of the resulting secondary amide of the Ugi product to the desired 
carboxylic acid under aqueous basic conditions. We were anxious to see if we could 
combine the diastereoselective U-3CR with convertible isocyanide 11 to get quick access 
to a new set of optically pure ACE inhibitor analogues (13). 
 
Scheme 2. Envisioned strategy to obtain ACE inhibitor analogues 13. 
Results and Discussion 
We started our investigation with propionic acid in combination with the bicyclic 
imine 9 and 2-bromo-6-isocyanopyridine (11) as our benchmark reaction (12a, 
Scheme 3). Given our positive experience with 2,2,2-trifluoroethanol (TFE) as 
solvent for the U-4CR with isocyanide 11,
33
 we decided to use this solvent in the U-
3CR. Gratifyingly, the IMCR-product was obtained with full consumption of the 
imine input (9). The diastereoselectivity was determined by 
1
H NMR analysis of the 
crude product and was in line with previously reported d.r.’s of reactions with imine 
9.
29
 The distinctive α-proton signal of the proline moiety appears as a broad singlet 
(or doublet with a very small (J = ~2.5 Hz) coupling constant) for the major trans-
diastereoisomer in 
1
H NMR. The 
1
H-signal of the same proton of the cis-
diastereomer clearly shows coupling with the adjacent bridge-head proton and 
therefore appears as a doublet (J = ~9.0 Hz, Figure 3). Both stereoisomers were 
readily separable by flash chromatography to afford the desired trans-
diastereoisomer of 12a in 87% yield. 
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Figure 3.  Characteristic 1H NMR signal of the α-proton of the proline ring of both 
diastereoisomers in the crude reaction mixture. 
 
Our next goal was to explore the scope of this reaction by varying the carboxylic 
acid input (Scheme 3). As expected, other aliphatic and benzylic carboxylic acid 
inputs are accepted to give the corresponding U-3CR products 12b,c in high yields 
and with similar diastereoselectivity. To examine the feasibility of the reaction with 
structurally related derivatives of the ACE inhibitors, we used (S)-3-(acetylthio)-2-
methylpropanoic acid as input for captopril analogue 12d as well as different N-
protected amino acids like N-Boc-glycine (6e), N-Boc-alanine (6f) and N-Boc lysine 
(6g), which would result in various ACE inhibitors that are closely related to the 
second generation drugs such as Lisinopril (2) and Ramipril (3). Pleasingly, all 
examples could be obtained in nearly identical yield as the benchmark reaction. 
Moreover, the additional stereocenter on the carboxylic acid input had no influence 
on the diastereoselectivity of the reaction.
29
 Finally, (hetero)aromatic carboxylic 
acids are excellent substrates for this U-3CR providing 12h, 12i and 12j in high 
yields and good d.r.’s. 
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Scheme 3. Scope of the diastereoselective U-3CR. The d.r. was determined by 1H NMR analysis of the 
crude reaction mixture. The yields correspond to the isolated yield of the major diastereoisomer. 
With a chemically diverse set of prolyl peptides (12) in hand, we continued our 
investigation by screening the conditions for the selective hydrolysis of the secondary 
pyridinyl amide. Initially, we performed the hydrolysis on our benchmark substrate (12a) 
with 5 equivalents of aqueous NaOH (10 M) in MeOH at room temperature. After 16 
hours, the conversion to the carboxylic acid (13a) was incomplete. To drive this reaction to 
completion, the amount of base was increased to 10 equivalents and the temperature 
raised to 50 °C. After these modifications, the hydrolysis proceeded with full conversion 
and carboxylic acid 13a was obtained in a moderate yield (66%) after a simple acid-base 
extraction (Scheme 4). 
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Scheme 4. Hydrolysis of the pyridinyl amide. The yield in brackets corresponds to the amount 
of undesired 6. aConditions: 5 equiv NaOH at 50 °C, bConditions: 5 equiv LiOH at 35 °C. c13j and 
6j were separated by flash chromatography. 
The tert-butyl and 4-methoxybenzyl prolyl peptides (13b and 13c respectively) were 
subjected to the same hydrolysis conditions and the carboxylic acids were obtained in 
good to excellent yields. For N-Boc glycine prolyl peptide 12e the starting material was 
fully consumed, however we discovered that the product was contaminated with 
significant amounts (up to 30%) of N-Boc glycine (6e). Cleavage of the tertiary amide 
results in the formation of amino acid 15 in combination with the corresponding 
carboxylic acid (Scheme 5). Amino acid 15 is removed during the aqueous workup, 
however the carboxylic acid (6) is obtained as a side product. Apparently, the prolyl 
tertiary amide is relatively sensitive to hydrolytic cleavage due to ring strain in the 
azabicyclo[3.3.0]octane ring system. If the tertiary amide is electrophilic enough, 
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depending on the electronic properties of the R
2
-substituent, it becomes susceptible to 
hydrolysis. Consequently, we sought for milder reaction conditions in order to gain more 
chemoselectivity in this reaction step. 
 
Scheme 5. ‘Undesired’ hydrolysis of the tertiary amide. 
The high amount of NaOH (10 equiv) was replaced by 5 equivalents of aqueous LiOH (4 M) 
and the temperature lowered to 35 °C. With these conditions, N-Boc glycine prolyl peptide 
12e was hydrolyzed to the corresponding carboxylic acid (13e) in high yield (88%) along 
with only 12% of N-Boc glycine 6e. Interestingly, N-Boc alanine prolyl peptide 12f did not 
show any tertiary amide cleavage. Apparently, the electron-donating effect of the methyl 
group in combination with the increased steric hindrance fully prevents the undesired side 
reaction. The lysine derivative 13g showed similar results in terms of conversion, however, 
the isolated yield was much lower, possibly due to the workup strategy. The product is 
significantly more lipophilic resulting in a less efficient acid-base extraction. 
As expected, basic hydrolysis of captopril analog 12d cleaved both the secondary amide 
and the thioacetate group. Analysis of the product showed that the resulting thiol was 
quantitatively oxidized to the disulfide (13d). The aqueous basic conditions make the 
oxidation very favorable and nearly impossible to prevent. However, the disulfide is a 
common intermediate in the synthesis of captopril and analogues thereof.
41,42
 The 
aromatic tertiary amides (of 12h, 12i and 12j) are more electrophilic and were therefore 
expected to form more undesired byproduct 6. Phenyl derivative 12h was obtained in 80% 
yield accompanied by 7% of benzoic acid. The more electron-rich 12i showed similar yields 
of the desired product along with a smaller amount of 6i due to the donating character of 
the substituents on the aromatic ring. Finally, the thiophene derivative 12j showed a 
slightly higher degree of hydrolysis. Fortunately, the undesired mixtures of acids are 
readily separated by an alternative workup with flash chromatography. 
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Conclusions 
In conclusion, we have generated a small library of new optically pure ACE inhibitor 
analogues by an efficient convergent two-step synthesis route. The method comprises of a 
diastereoselective U-3CR between a 3,4-disubstituted pyrroline, 2-bromo-6-isocyano-
pyridine and several carboxylic acids with diverse electronic properties. Afterwards, the 
secondary amide was selectively hydrolyzed under mildly basic conditions to obtain the 
desired analogues. 
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Experimental Section 
General Remarks 
Unless stated otherwise, all solvents and commercially available reagents were used as purchased. All reaction 
were performed under air, unless stated otherwise. Infrared (IR) spectra were recorded neat using a Shimadzu 
FTIR-8400s spectrophotometer and wavelengths are reported in cm-1. Nuclear magnetic resonance (NMR) 
spectra were recorded on a Bruker Avance 500 (125.78 MHz for 13C) using the residual solvent as internal (1H: δ 
7.26 ppm, 13C{1H}: δ 77.0 ppm for CDCl3. Chemical shifts (δ) are given in ppm and coupling constants (J) are 
quoted in hertz (Hz). Resonances are described as s (singlet), d (doublet), t (triplet), q (quartet), bs (broad singlet) 
and m (multiplet) or combinations thereof. Melting points were recorded on a Büchi M-565 melting point 
apparatus and are uncorrected. Electrospray Ionization (ESI) high-resolution mass spectrometry was carried out 
using a Bruker micrOTOF-Q instrument in positive ion mode (capillary potential of 4500 V). Flash 
chromatography was performed on Silicycle Silia-P Flash Silica Gel (particle size 40-63 μm, pore diameter 60 Å) 
using the indicated eluent. Thin Layer Chromatography (TLC) was performed using TLC plates from Merck (SiO2, 
Kieselgel 60 F254 neutral, on aluminum with fluorescence indicator) and compounds were visualized by UV 
detection (254 nm) and KMnO4 stain. 
 
Synthesis of the prolyl peptides (12) 
General procedure I: Synthesis of  the pipecolic amides 12 
Imine 9 (218 mg, 2.00 mmol, 1.00 equiv) and carboxylic acid 6 (3.00 mmol, 1.50 equiv) were dissolved in TFE (8 
mL). 2-Bromo-6-isocyanopyridine (10) (458 mg, 2.50 mmol, 1.25 equiv) was added and the resulting mixture was 
typically stirred for 48 hours at room temperature. Then, the reaction mixture was diluted with EtOAc (10 mL) 
and washed with aqueous Na2CO3 (3×). The organic layer was dried with MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography (cyclohexane : EtOAc) to yield Ugi product 
11 generally as a foamy solid. 
 
(1S,3aR,6aS)-N-(6-bromopyridin-2-yl)-2-propionyloctahydrocyclopenta[c]pyrrole-1-carboxamide (12a) 
Following general procedure I on a 0.5 mmol scale in TFE (2 mL) with propionic acid 
(56 mg, 0.750 mmol, 1.5 equiv). Purified by flash chromatography using 
cyclohexane/EtOAc (2:1) to obtain the title product as a foamy solid (160 mg, 0.44 
mmol, 87%). RF = 0.20 Flash (cyclohexane/EtOAc = 2:1); m.p. = 53 °C; [α]D
20 –13 ° (c = 
1.00, CHCl3);. Two rotamers were present on NMR timescale (R
1 : R2 = 6 : 1) of which 
the signals of the major rotamer are reported. 1H NMR (500 MHz, CDCl3): δ 9.29 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 
7.42 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 7.5 Hz, 1H), 4.57 (s, 1H), 3.75 (dd, J = 10.0, 8.0 Hz, 1H), 3.26 (dd, J = 10.5, 3.6 
Hz, 1H), 2.81 (m, 2H), 2.32 (m, 2H), 1.90 (m, 1H), 1.83 (m, 1H), 1.68 (m, 1H), 1.58 – 1.40 (m, 2H), 1.09 (t, J = 7.5 
Hz, 3H) ppm; 13C NMR (125 MHz, CDCl3): δ 173.6 (Cq), 170.8 (Cq), 151.3 (Cq), 140.0 (CH), 139.0 (Cq), 123.1 (CH), 
112.3 (CH), 66.9 (CH), 53.3 (CH2), 46.3 (CH), 42.8 (CH), 31.9 (CH2), 31.8 (CH2), 27.7 (CH2), 25.2 (CH2), 8.6 (CH3) 
ppm; IR (neat): vmax (cm-1) = 3238 (w), 2924 (m), 1701 (m), 1622 (m), 1566 (s), 1431 (s), 1300 (m), 1155 (s), 789 
(m); HRMS (ESI): m/z calculated for C16H20BrN3NaO2 [M + Na]
+ 388.0637, found = 388.0630. 
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(1S,3aR,6aS)-N-(6-bromopyridin-2-yl)-2-pivaloyloctahydrocyclopenta[c]pyrrole-1-carboxamide (12b) 
Following general procedure I with pivalic acid (306 mg, 3.00 mmol, 1.5 equiv). 
Purified by flash chromatography using cyclohexane/EtOAc (8:1) to obtain the title 
product as a foamy solid (655 mg, 1.66 mmol, 83%). RF = 0.23 (Cyclohexane/EtOAc = 
8:1); m.p. 66 °C; [α]D
20–° (c = 1.00, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 9.09 (bs, 1H), 
8.08 (d, J = 8.0 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 7.11 (d, J = 7.5 Hz, 1H), 4.54 (bs, 1H), 
3.86 (t, J = 8.8 Hz, 1H), 3.68 (d, J = 10.1 Hz, 1H), 2.80 (bs, 1H), 2.71 (bs, 1H), 1.90 – 
1.84 (m, 2H), 1.68 (m, 1H), 1.55 (m, 2H), 1.42 (m, 1H), 1.25 (s, 9H) ppm; 13C NMR 
(125 MHz, CDCl3): δ 177.5 (Cq), 171.4 (Cq), 151.5 (Cq), 140.2 (CH), 139.0 (Cq), 123.2 (CH), 112.4 (CH), 69.2 (CH), 
54.2 (CH2), 44.7 (CH), 44.0 (CH), 38.7 (CH2), 32.7 (CH2), 32.1 (CH2), 27.3 (CH3), 25.6 (CH2) ppm; IR (neat): vmax (cm
-
1) = 3240 (w), 2957 (m), 1701 (m), 1566 (s), 1526 (m), 1431 (s), 1300 (m), 1153 (s), 787 (m); HRMS (ESI): m/z 
calculated for C18H24BrN3NaO2 [M + Na]
+ 416.0944, found = 416.0961. 
 
(1S,3aR,6aS)-N-(6-bromopyridin-2-yl)-2-(2-(4-methoxyphenyl)acetyl)octahydrocyclopenta[c]pyrrole-1-carbox-
amide (12c) 
Following general procedure I with p-methoxyphenylacetic acid (499 
mg, 3.00 mmol, 1.50 equiv). Purified by flash chromatography using 
cyclohexane/EtOAc (4:1) to obtain the title product as a foamy solid 
(711 mg, 1.55 mmol, 78%). RF = 0.19 (Cyclohexane/EtOAc = 4:1); m.p. = 
67 °C; [α]D
20 –5 ° (c = 1.00, CHCl3); Two rotamers were present on NMR timescale (R
1 : R2 = 7 : 1) of which the 
signals of the major rotamer are reported. 1H NMR (500 MHz, CDCl3): δ 8.94 (s, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.50 
(t, J = 8.0 Hz, 1H), 7.18 (m, 3H), 6.87 (d, J = 8.6 Hz, 2H), 4.53 (d, J = 2.5 Hz, 1H), 3.78 (s, 3H), 3.66 (m, 3H), 3.35 (dd, 
J = 10.7, 4.6 Hz, 1H), 2.92 (m, 1H), 2.78 (m, 1H), 1.95 (m, 1H), 1.80 (m, 1H), 1.66 (m, 1H), 1.58 (m, 1H), 1.48 (m, 
1H), 1.31 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ 171.5 (Cq), 170.2 (Cq), 158.5 (Cq), 151.2 (Cq), 140.3 (CH), 
139.2 (Cq), 129.8 (CH), 125.9 (Cq), 123.5 (CH), 114.2 (CH), 112.4 (CH), 67.2 (CH3), 55.2 (CH), 52.9 (CH2), 45.7 (CH), 
43.0 (CH), 41.2 (CH2), 32.2 (CH2), 32.0 (CH2), 25.4 (CH2) ppm; IR (neat): vmax (cm
-1) = 3265 (w), 2951 (m), 2361 
(m), 1701 (m), 1624 (m), 1510 (s), 1429 (s), 1244 (s), 1153 (s), 1034 (s), 906 (s), 725 (s); HRMS (ESI): m/z 
calculated for C22H24BrN3NaO3 [M + Na]
+ 480.0880, found = 480.0887. 
S-((S)-3-((1S,3aR,6aS)-1-((6-bromopyridin-2-yl)carbamoyl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-2-methyl-3-
oxopropyl) ethanethioate (12d) 
Following general procedure I with (S)-3-(acetylthio)-2-methylpropanoic acid 
(487 mg, 3.00 mmol, 1.5 equiv).  Purified by flash chromatography using 
cyclohexane/EtOAc (6:1) to obtain the title product as an oil (802 mg, 1.77 
mmol, 88%). RF = 0.5 (Cyclohexane/EtOAc = 2:1); [α]D
20 –62 ° (c = 1.00, CHCl3); 
Two rotamers were present on NMR timescale (R1 : R2 = 8 : 1) of which the 
signals of the major rotamer are reported. 1H NMR (500 MHz, CDCl3): δ 9.29 (s, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.39 
(t, J = 8.0 Hz, 1H), 7.08 (d, J = 7.5 Hz, 1H), 4.63 (d, J = 1.5 Hz, 1H), 3.80 (dd, J = 10.0, 8.0 Hz, 1H), 3.46 (dd, J = 10.5, 
4.0 Hz, 1H), 3.09 (dd, J = 13.5, 8.0 Hz, 1H), 2.95 (m, 1H), 2.81 (m, 3H), 2.29 (s, 3H), 1.98 – 1.81 (m, 2H), 1.72 (m, 
1H), 1.57 (m, 2H), 1.47 (m, 1H), 1.21 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (125 MHz, CDCl3): δ 196.1 (Cq), 174.2 (Cq), 
170.7 (Cq), 151.3 (Cq), 140.0 (CH), 139.1 (Cq), 123.1 (CH), 112.2 (CH), 66.9 (CH), 53.4 (CH2), 46.3 (CH), 42.9 (CH), 
38.2 (CH), 32.3 (CH2), 32.3 (CH2), 32.1 (CH2), 30.5 (CH3), 25.4 (CH2), 16.8 (CH3) ppm; IR (neat): vmax (cm
-1) = 2951 
(m), 1690 (s), 1625 (m), 1566 (s), 1461 (s), 1155 (s), 1128 (s); HRMS (ESI): m/z calculated for C19H25BrN3O3S [M + 
H]+ 454.0795, found = 454.0773. 
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tert-Butyl (2-((1S,3aR,6aS)-1-((6-bromopyridin-2-yl)carbamoyl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-2-
oxoethyl)carbamate (12e) 
Following general procedure I with boc-glycine (526 mg, 3.00 mmol, 1.5 
equiv). Purified by flash chromatography using cyclohexane/EtOAc (4:1) to 
obtain the title product as foamy solid (825 mg, 1.77 mmol, 88%). RF = 0.20 
(Cyclohexane /EtOAc = 4:1); m.p. = 192 - 193 °C; [α]D
20 –30 ° (c = 1.00, CHCl3); 
Two rotamers were present on NMR timescale (R1 : R2 = 9 : 1) of which the signals of the major rotamer are 
reported. 1H NMR (500 MHz, CDCl3): δ 9.04 (s, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.18 (d, J = 7.5 
Hz, 1H), 5.55 (bs, 1H), 4.55 (s, 1H), 4.04 (dd, J = 17.5, 4.5 Hz, 1H), 3.92 (dd, J = 17.5, 4.5 Hz, 1H), 3.80 (dd, J = 10.0, 
8.0 Hz, 1H), 3.27 (dd, J = 10.0, 4.0 Hz, 1H), 2.91 (m, 2H), 2.05 – 1.88 (m, 2H), 1.75 (m, 1H), 1.53 (m, 1H), 1.58 – 
1.48 (m, 2H), 1.41 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3): δ 169.9 (Cq), 168.7 (Cq), 155.7 (Cq), 151.2 (Cq), 140.4 
(CH), 139.3 (Cq), 123.6 (CH), 112.4 (CH), 79.7 (Cq), 67.5 (CH), 52.4 (CH2), 46.1 (CH), 43.2 (CH2), 43.0 (CH), 32.1 
(CH2), 32.0 (CH2), 28.3 (CH), 25.4 (CH2) ppm; IR (neat): vmax (cm
-1) = 3246 (w), 2966 (w), 1701 (m), 1643 (m), 
1566 (s), 1528 (m), 1431 (s), 1155 (s), 1057 (m), 910 (m), 866 (m), 789 (m), 731 (m); HRMS (ESI): m/z calculated 
for C20H27BrN4NaO4 [M + Na]
+ 489.1108, found = 489.1108. 
 
tert-Butyl ((S)-1-((1S,3aR,6aS)-1-((6-bromopyridin-2-yl)carbamoyl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-1-
oxopropan-2-yl)carbamate (12f) 
Following general procedure I with Boc-alanine (568 mg, 3.00 mmol, 1.50 
equiv). Purified by flash chromatography using cyclohexane/EtOAc (5:1) to 
obtain the title product as foamy solid (843 mg, 1.75 mmol, 88%). RF = 0.20 
(Cyclohexane/EtOAc = 5:1); m.p. = 185 °C; [α]D
20 –43 ° (c = 1.00, CHCl3); Two 
rotamers were present on NMR timescale (R1 : R2 = 10 : 1) of which the signals 
of the major rotamer are reported. 1H NMR (500 MHz, CDCl3): δ 9.06 (s, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 
8.0 Hz, 1H), 7.16 (d, J = 7.5 Hz, 1H), 5.60 (d, J = 8.0 Hz, 1H), 4.59 (s, 1H), 4.52 (t, J = 7.0 Hz, 1H), 3.82 (t, J = 8.5 Hz, 
1H), 3.59 (d, J = 10.5 Hz, 1H), 2.89 (m, 2H), 2.04 – 1.85 (m, 2H), 1.75 (m, 1H), 1.67 – 1.50 (m, 3H), 1.41 (s, 9H), 
1.35 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (125 MHz, CDCl3): δ 172.7 (Cq), 170.2 (Cq), 155.2 (Cq), 151.3 (Cq), 140.3 (CH), 
139.3 (Cq), 123.5 (CH), 112.4 (CH), 79.5 (Cq), 67.2 (CH), 53.2 (CH2) 47.7 (CH), 46.0 (CH), 43.2 (CH), 32.4 (CH2), 32.0 
(CH2), 28.3 (CH3), 25.6 (CH2), 18.4 (CH3) ppm; IR (neat): vmax (cm
-1) = 3240 (w), 2962 (m), 2361 (m), 1697 (m), 
1636 (m), 1566 (s), 1429 (s), 1153 (s), 910 (m), 787 (s), 729 (s); HRMS (ESI): m/z calculated for C21H29BrN4NaO4 [M 
+ Na]+ 503.1264, found = 503.1251. 
 
Benzyl t-butyl ((S)-6-((1S,3aR,6aS)-1-((6-bromopyridin-2-yl)carbamoyl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-
6-oxohexane-1,5-diyl)dicarbamate (12g) 
Following general procedure I on a 1.00 mmol scale in TFE (5 mL) with Boc-
Lys(Cbz)-OH (571 mg, 1.50 mmol, 1.50 equiv). Purified by flash 
chromatography using cyclohexane/EtOAc (2:1) to obtain the title product 
as an oil (580 mg, 0.86 mmol, 86%). RF = 0.20 (Cyclohexane/EtOAc = 2:1); 
[α]D
20 –16 ° (c = 1.00, CHCl3); Two rotamers were present on NMR timescale 
(R1 : R2 = 7 : 1) of which the signals of the major rotamer are reported. 1H 
NMR (500 MHz, CDCl3): δ 8.68 (s, 1H), 8.03 (d, J = 7.5 Hz, 1H), 7.37 – 7.20 
(m, 6H), 7.04 (d, J = 7.5 Hz, 1H), 5.91 (bs, 1H), 5.39 (bs, 1H), 5.05 (s, 2H), 4.67 
(s, 1H), 4.50 (m, 1H), 3.86 (t, J = 9.0 Hz, 1H), 3.62 (d, J = 9.5 Hz, 1H), 3.23 – 
3.11 (m, 2H), 2.82 (m, 1H), 2.73 (m, 1H), 1.86 (m, 2H), 1.80 – 1.62 (m, 3H), 1.61 – 1.41 (m, 7H), 1.35 (s, 9H) ppm; 
13C NMR (125 MHz, CDCl3): δ 171.6 (Cq), 171.1 (Cq), 156.3 (Cq), 155.5 (Cq), 151.4 (Cq), 140.1 (CH), 138.8 (Cq), 136.6 
(Cq), 128.2 (CH), 127.8 (CH), 127.7 (CH), 123.0 (CH), 112.2 (CH), 79.0 (Cq), 66.8 (CH), 66.1 (CH2), 53.4 (CH2), 51.3 
(CH), 46.9 (CH), 43.0 (CH), 40.4 (CH2), 32.3 (CH2), 31.8 (CH2), 31.8 (CH2), 28.8 (CH2), 28.0 (CH3), 25.3 (CH2), 21.6 
(CH2) ppm; IR (neat): vmax (cm
-1) = 3323 (w), 2957 (m), 1695 (s), 1629 (m), 1566 (s), 1521 (m), 1429 (s), 1244 (s), 
1155 (s), 1128 (s), 750 (s); HRMS (ESI): m/z calculated for C32H43BrN5O6 [M + H]
+ 672.2391, found = 672.2342. 
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(1S,3aR,6aS)-2-benzoyl-N-(6-bromopyridin-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide (12h) 
Following general procedure I with benzoic acid (366 mg, 3.00 mmol, 1.5 equiv). 
Purified by flash chromatography using cyclohexane/EtOAc (8:1) to obtain the 
title product as a foamy solid (635 mg, 1.53 mmol, 77%). RF = 0.15 
(Cyclohexane/EtOAc = 8:1); m.p. = 67 °C; [α]D
20 –28 ° (c = 1.00, CHCl3); 
1H NMR 
(500 MHz, CDCl3): δ 9.00 (s, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.55 (m, 3H), 7.48 – 7.38 
(m, 3H), 7.19 (d, J = 8.0 Hz, 1H), 4.75 (s, 1H), 3.85 (dd, J = 11.0, 7.5 Hz, 1H), 3.42 
(d, J = 11.1 Hz, 1H), 3.11 (m, 1H), 2.77 (m, 1H), 2.00 (m, 1H), 1.85 (m, 1H), 1.80 – 
1.57 (m, 3H), 1.32 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ 170.8 (Cq), 170.0 (Cq), 151.2 (Cq), 140.3 (CH), 139.3 
(Cq), 135.5 (Cq), 130.4 (CH), 128.3 (CH), 127.4 (CH) 123.6 (CH), 112.4 (CH), 67.4 (CH), 56.0 (CH2), 45.6 (CH), 43.5 
(CH), 32.7 (CH2), 32.1 (CH2), 25.8 (CH2) ppm; IR (neat): vmax (cm
-1) = 3244 (w), 2957 (m), 2361 (m), 1705 (m), 
1566 (s), 1431 (s), 1155 (s), 789 (m), 729 (m); HRMS (ESI): m/z calculated for C20H20BrN3NaO2 [M + Na]
+ 436.0631, 
found = 436.0629. 
 
(1S,3aR,6aS)-N-(6-bromopyridin-2-yl)-2-(4-methoxy-2-methylbenzoyl)octahydrocyclopenta[c]pyrrole-1-
carboxamide (12i) 
Following general procedure I with 2-methoxy-4-methylbenzoic acid (499 mg, 
3.00 mmol, 1.50 equiv). Purified by flash chromatography using 
cyclohexane/EtOAc (6:1) to obtain the title product as a foamy solid (737 mg, 
1.61 mmol, 80%). RF = 0.20 (Cyclohexane : EtOAc = 6:1); m.p. = 88 °C; [α]D
20 –56 
° (c = 1.00, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 9.11 (s, 1H), 8.25 (d, J = 8.0 Hz, 
1H), 7.55 (t, 8.0 Hz, 1H), 7.20 (m, 2H), 7.14 (s, 1H), 6.90 (d, J = 8.5 Hz, 1H), 4.83 (s, 1H), 4.12 (bs, 3H), 3.73 (m, 1H), 
3.17 (dd, J = 11.5, 3.0 Hz, 1H), 3.00 (m, 1H), 2.64 (m, 1H), 2.31 (s, 3H), 2.08 (m, 1H), 1.88 –1.69 (m, 3H), 1.59 (m, 
1H), 1.34 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 170.7 (Cq), 168.7 (Cq), 151.2 (Cq), 140.4 (CH), 139.2 (Cq), 131.6 
(CH), 130.5 (Cq), 127.9 (CH), 125.4 (Cq), 123.6 (CH), 112.5 (CH), 110.9 (CH), 66.2 (CH), 56.1 (CH3), 54.1 (CH2), 48.0 
(CH), 42.4 (CH), 33.4 (CH2), 32.2 (CH2), 25.7 (CH2), 20.3 (CH3) ppm; IR (neat): vmax (cm
-1) = 2951 (m), 1697 (m), 
1622 (m), 1566 (s), 1431 (s), 1250 (m), 1155 (s), 1028 (m), 789 (m); HRMS (ESI): m/z calculated for C22H25BrN3O3 
[M + H]+ 458.1074, found = 458.1073. 
(1S,3aR,6aS)-N-(6-bromopyridin-2-yl)-2-(thiophene-2-carbonyl)octahydrocyclopenta[c]pyrrole-1-carboxamide 
(12j) 
Following general procedure I with 2-thiophenecarboxylic acid (384 mg, 3.00 
mmol, 1.50 equiv). Purified by flash chromatography using cyclohexane/EtOAc 
(8:1) to obtain the title product as a foamy solid (738 mg, 1.76 mmol, 88%). RF = 
0.15 (Cyclohexane/EtOAc = 8:1); m.p. = 75 °C; [α]D
20 –12 ° (c = 1.00, CHCl3); 
1H 
NMR (500 MHz, CDCl3): δ 9.03 (s, 1H), 8.14 (d, J = 7.5 Hz, 1H), 7.59 (bs, 1H), 7.51 
(m, 2H), 7.16 (d, J = 7.5 Hz, 1H), 7.08 (bs, 1H), 4.77 (s, 1H), 4.16 (t, J = 7.5 Hz, 1H), 
3.76 (d, J = 9.0 Hz, 1H), 2.98 (m, 2H), 1.98 (m, 1H), 1.89 (m, 1H), 1.78 (m, 1H), 1.64 (m, 2H), 1.49 (m, 1H) ppm; 13C 
NMR (125 MHz, CDCl3): δ 170.3 (Cq), 162.8 (Cq), 151.2 (Cq), 140.3 (CH), 139.2 (Cq), 137.9 (Cq), 130.9 (CH), 130.7 
(CH), 127.3 (CH), 123.5 (CH), 112.5 (CH), 68.5 (CH), 55.4 (CH2), 45.8 (CH), 43.9 (CH), 31.8 (CH2), 29.6 (CH2), 25.2 
(CH2) ppm; IR (neat): vmax (cm
-1) = 3256 (w), 2957 (m), 2359 (m), 1697 (m), 1566 (s), 1429 (s), 1298 (s), 1155 (s), 
910 (m), 789 (m), 731 (m); HRMS (ESI): m/z calculated for C18H18BrN3NaO2S [M + Na]
+ 442.0195, found = 
442.0195. 
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Hydrolysis of the prolyl peptides 
General procedure II: Synthesis of the ACE inhibitor analogues (13)   
Ugi product 12 (0.5 mmol, 1 equiv) was dissolved in MeOH (2.5 mL) and 4N LiOH (0.625 mL, 5.0 equiv) or  10N 
NaOH (0.25 mL, 5.0 equiv) was added. The reaction mixture was stirred overnight typically at 50 °C. Then, the 
mixture was cooled to room temperature and diluted with H2O and CH2Cl2. The layers were separated and the 
aqueous layer was washed with CH2Cl2 and EtOAc. Then, the water layer was acidified to pH = 1 with 12 N HCl 
and extracted with EtOAc (3×). The organic layers were combined, dried with MgSO4, filtered and concentrated 
under reduced pressure to yield the desired carboxylic acid.  
(1S,3aR,6aS)-2-propionyloctahydrocyclopenta[c]pyrrole-1-carboxylic acid (13a) 
Following general procedure II in MeOH (2.0 mL) with 12a (147 mg, 0.40 mmol) and 10 N 
NaOH (0.20 mL, 5.0 equiv). The title compound was obtained as an off-white solid (56 mg, 
0.27 mmol, 66%). [α]D
20 –52 ° (c = 0.50, CHCl3); Two rotamers were present on NMR timescale 
(R1 : R2 = 6 : 1) of which the signals of the major rotamer are reported. 1H NMR (500 MHz, 
CDCl3): δ 6.76 (bs, 1H), 4.38 (d, J = 2.5 Hz, 1H), 3.75 (dd, J = 10.5, 8.0 Hz, 1H), 3.29 (dd, J = 
10.5, 4.5 Hz, 1H), 2.89 (m, 1H), 2.82 (m, 1H), 2.34 (m, 2H), 1.99 (m, 1H), 1.89 (m, 1H), 1.75 (m, 
1H), 1.64 (m, 1H), 1.55 (m, 1H), 1.46 (m, 1H), 1.15 (t, J = 7.5 Hz, 3H) ppm; 13C NMR (125 MHz, CDCl3): δ 174.9 (Cq), 
174.3 (Cq), 65.6 (CH), 53.4 (CH2), 46.3 (CH), 42.7 (CH), 32.1 (CH2), 31.8 (CH2), 27.8 (CH2), 25.3 (CH2), 8.7 (CH3) ppm; 
IR (neat): vmax (cm-1) = 2951 (w), 2361 (m), 1732 (m), 1595 (w), 1448 (w), 1182 (w), 908 (s), 727 (s); HRMS (ESI): 
m/z calculated for C11H17NNaO3 [M + Na]
+ 234.1101, found = 234.1104. 
 
(1S,3aR,6aS)-2-pivaloyloctahydrocyclopenta[c]pyrrole-1-carboxylic acid (13b) 
Following general procedure II in MeOH (2.5 mL) with 12b (197 mg, 0.50 mmol) and 10 N 
NaOH (0.25 mL, 5.0 equiv). The title compound was obtained as an off-white solid (91 mg, 
0.38 mmol, 76%). [α]D
20 –77 ° (c = 1.00, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 8.48 (bs, 1H), 4.33 
(d, J = 2.5 Hz, 1H), 3.80 (dd, J = 10.0, 7.5 Hz, 1H), 3.65 (dd, J = 10.5, 2.5 Hz, 1H), 2.75 (m, 1H), 
2.68 (m, 1H), 1.93 (m, 1H), 1.85 (m, 1H), 1.69 (m, 1H), 1.64 – 1.52 (m, 2H), 1.39 (m, 1H), 1.22 
(s, 9H) ppm; 13C NMR (125 MHz, CDCl3): δ 178.0 (Cq), 176.6 (Cq), 67.5 (CH), 53.9 (CH2), 45.0 
(CH), 43.9 (CH), 38.6 (Cq), 32.8 (CH2), 31.8 (CH2), 27.1 (CH3), 25.4 (CH2) ppm; IR (neat): vmax 
(cm-1) = 2957 (m), 1717 (m), 1591 (w), 1408 (m), 1178 (m), 912 (m), 729 (s), 625 (m); HRMS (ESI): m/z calculated 
for C13H22NO3  [M + H]
+ 240.1594, found = 240.1590. 
 
(1S,3aR,6aS)-2-(2-(4-methoxyphenyl)acetyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid (13c) 
Following general procedure II in MeOH (2.5 mL) with 12c (229 mg, 0.50 mmol) 
and 10 N NaOH (0.25 mL, 5.0 equiv). The title compound was obtained as a white 
solid (138 mg, 0.45 mmol, 91%). [α]D
20 –61 ° (c = 1.00, CHCl3); Two rotamers were 
present on NMR timescale (R1 : R2 = 5 : 1) of which the signals of the major 
rotamer are reported. 1H NMR (500 MHz, CDCl3): δ 7.16 (d, J = 8.5 Hz, 2H), 7.07 
(bs, 1H), 6.85 (d, J = 8.5 Hz, 2H), 4.38 (d, J = 3.5 Hz, 1H), 3.78 (s, 3H), 3.72 (dd, J = 
10.5, 8.0 Hz, 1H), 3.65 (s, 2H), 3.33 (dd, J = 10.5, 4.5 Hz, 1H), 2.85 (m, 1H), 2.75 (m, 1H), 1.96 (m, 1H), 1.81 (m, 
1H), 1.72 – 1.55 (m, 3H), 1.37 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ 174.7 (Cq), 171.0 (Cq), 158.5 (Cq), 129.9 
(CH), 125.8 (Cq), 114.1 (CH), 65.6 (CH), 55.2 (CH3), 53.6 (CH2), 46.5 (CH), 42.7 (CH), 40.9 (CH2), 32.3 (CH2), 31.7 
(CH2), 25.2 (CH2) ppm; IR (neat): vmax (cm
-1) = 2957 (m), 1728 (m), 1597 (m), 1512 (s), 1452 (m), 1244 (s), 1032 
(s), 750 (s); HRMS (ESI): m/z calculated for C17H21NNaO4 [M + Na]
+ 326.1363, found = 326.1350. 
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 (1S,1'S,3aR,3a'R,6aS,6a'S)-2,2'-((2S,2'S)-3,3'-disulfanediylbis(2-methylpropanoyl))bis(octahydrocyclo-
penta[c]pyrrole-1-carboxylic acid) (13d) 
Following general procedure II in MeOH (5.0 mL) with 12d (454 mg, 1.0 mmol) and 4 
N LiOH (1.25 mL, 5.0 equiv) at 35 °C. The title compound was obtained as an oil (256 
mg, 0.50 mmol, 100%). [α]D
20 –100 ° (c = 1.00, CHCl3); The signals of the major rotamer 
are reported. 1H NMR (500 MHz, CDCl3): δ 10.13 (bs, 2H), 4.38 (s, 2H), 3.79 (m, 2H), 
3.52 (d, J = 10.0 Hz, 2H), 3.10 (m, 2H), 2.96 (m, 2H), 2.79 (m, 4H), 2.63 (m, 2H), 1.96 
(m, 2H), 1.85 (m, 2H), 1.73 (m, 2H), 1.59 (m, 4H), 1.49 (m, 2H), 1.20 (d, J = 6.0 Hz, 6H) 
ppm; 13C NMR (125 MHz, CDCl3): δ 175.4 (Cq), 174.9 (Cq), 65.2 (CH), 53.3 (CH2), 46.7 (CH), 42.7 (CH), 40.6 (CH2), 
37.3 (CH), 32.4 (CH2), 31.9 (CH2), 25.2 (CH2), 16.8 (CH3) ppm; IR (neat): vmax (cm
-1) = 2959 (m), 1712 (m), 1603 
(w), 1438 (m), 1218 (m), 1184 (m), 906 (s); HRMS (ESI): m/z calculated for C24H37N2O6S2 [M + H]
+ 513.2088, found 
= 513.2067. 
 
(1S,3aR,6aS)-2-((tert-butoxycarbonyl)glycyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid (13e) 
Following general procedure II in MeOH (2.5 mL) with 12e (232 mg, 0.50 mmol) and 4 N 
LiOH (0.625 mL, 5.0 equiv) at 35 °C. The title compound was obtained as a yellow solid 
(138 mg, 0.44 mmol, 88%). The product was contaminated with 12 mol% N-Boc-glycine 
(6e). [α]D
20 –38 ° (c = 1.00, CHCl3); Two rotamers were present on NMR timescale (R
1 : R2 
= 3 : 1) of which the signals of the major rotamer are reported. 1H NMR (500 MHz, 
CDCl3): δ 6.80 (bs, 1H), 5.55 (s, 1H), 4.36 (d, J = 2.5 Hz, 1H), 4.05 (dd, J = 17.5, 5.5 Hz, 
1H), 3.84 (dd, J = 17.0, 3.5 Hz, 1H), 3.74 (dd, J = 10.0, 8.5 Hz, 1H), 3.29 (dd, J = 10.5, 3.5 Hz, 1H), 2.90 – 2.80 (m, 
2H), 2.00 (m, 1H), 1.88 (m, 1H), 1.74 (m, 1H), 1.69 – 1.58 (m, 2H), 1.50 (m, 1H), 1.43 (s, 9H) ppm; 13C NMR (125 
MHz, CDCl3): δ 176.3 (Cq), 168.7 (Cq), 155.9 (Cq), 79.8 (Cq), 65.5 (CH), 52.2 (CH2), 47.0 (CH), 43.0 (CH2), 42.8 (CH), 
32.5 (CH2), 32.0 (CH2), 28.3 (CH3), 25.3 (CH2) ppm; IR (neat): vmax (cm
-1) = 3240 (w), 2970 (m), 1711 (w), 1647 
(w), 1456 (m), 1163 (s), 1055 (m), 860 (m); HRMS (ESI): m/z calculated for C15H24N2NaO5 [M + Na]
+ 335.1577, 
found = 335.1569. 
(1S,3aR,6aS)-2-((tert-butoxycarbonyl)-L-alanyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid (13f) 
Following general procedure II in MeOH (1.5 mL) with 12f (120 mg, 0.25 mmol) and 4 N 
LiOH (0.313 mL, 5.0 equiv) at 35 °C. The title compound was obtained as a white solid 
(74 mg, 0.23 mmol, 91%). [α]D
20 –45 ° (c = 1.00, CHCl3); Two rotamers were present on 
NMR timescale (R1 : R2 = 5 : 1) of which the signals of the major rotamer are reported. 1H 
NMR (500 MHz, CDCl3): δ 6.07 (bs, 1H), 5.56 (d, J = 8.5 Hz, 1H), 4.48 (dq, J = 7.5, 7.5 Hz, 
1H), 4.38 (d, J = 2.5 Hz, 1H), 3.75 (dd, J = 10.0, 7.5 Hz, 1H), 3.58 (dd, J = 10.5, 2.5 Hz, 1H), 
2.78 (m, 2H), 1.98 (m, 1H), 1.88 (m, 1H), 1.76 (m, 1H), 1.61 (m, 2H), 1.48 (m, 1H), 1.41 (s, 
9H), 1.30 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (125 MHz, CDCl3): δ 175.0 (Cq), 172.7 (Cq), 155.2 (Cq), 79.7 (Cq), 65.2 
(CH), 52.9 (CH2), 47.6 (CH), 46.9 (CH), 42.9 (CH), 32.6 (CH2), 31.8 (CH2), 28.3 (CH3), 25.3 (CH2), 17.9 (CH3) ppm; IR 
(neat): vmax (cm-1) = 3255 (w), 2928 (m), 1709 (m), 1645 (m), 1456 (s), 1167 (s), 1057 (m); HRMS (ESI): m/z 
calculated for C16H26N2NaO5 [M + Na]
+ 349.1734, found = 349.1732. 
 
 (1S,3aR,6aS)-2-(N6-((benzyloxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysyl)octahydrocyclopenta[c]-pyrrole-1-
carboxylic acid (13g) 
Following general procedure II in MeOH (2.0 mL) with 12g (135 mg, 0.20 mmol) and 4 N 
LiOH (0.313 mL, 5.0 equiv) at 35 °C. The title compound was obtained as an oil (40 mg, 
0.08 mmol, 39%). [α]D
20 = –36 ° (c = 1.00, CHCl3); Two rotamers were present on NMR 
timescale (R1 : R2 = 2.5 : 1). 1H NMR (500 MHz, CDCl3): δ 8.30 (bs, 1H), 7.41 – 7.28 (m, 
5H), 5.65 (d, J = 8.5 Hz, 1H), 5.38 (bs, 1H), 5.06 (s, 2H), 4.45 (m, 1H), 4.37 (d, J = 11.5 Hz, 
1H), 3.74 (m, 1H), 3.61 (d, J = 11.5 Hz, 1H), 3.13 (m, 2H), 2.73 (m, 2H), 1.94 (m, 1H), 1.85 
(m, 1H), 1.72 (m, 2H), 1.65 – 1.34 (m, 8H), 1.40 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3): 
δ 174.5 (Cq), 171.9 (Cq), 156.6 (Cq), 155.6 (Cq), 136.6 (Cq), 128.4 (CH), 128.1 (CH), 127.8 
(CH), 79.6 (Cq), 66.5 (CH2), 65.1 (CH), 52.9 (CH2), 51.4 (CH), 47.0 (CH), 42.9 (CH), 40.7 
(CH2), 32.5 (CH2), 31.7 (CH2), 29.6 (CH2), 29.1 (CH2), 28.3 (CH3), 25.3 (CH2), 21.8 (CH2) ppm; IR (neat): vmax (cm
-1) = 
2964 (m), 1704 (m), 1641 (m), 1506 (m), 1454 (m), 1244 (m), 1169 (s), 902 (s), 723 (s); HRMS (ESI): m/z calculated 
for C27H40N3O7 [M + H]
+ 518.2861, found = 518.2860. 
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(1S,3aR,6aS)-2-benzoyloctahydrocyclopenta[c]pyrrole-1-carboxylic acid (13h) 
Following general procedure II in MeOH (2.5 mL) with 12h (201 mg, 0.48 mmol) and 10 N 
NaOH (0.25 mL, 5.0 equiv). The title compound was obtained as a white solid (101 mg, 
0.39 mmol, 80%). The product was contaminated with 7 mol% benzoic acid (6h). [α]D
20 = –
25 ° (c = 1.00, CHCl3); Two rotamers were present on NMR timescale (R
1 : R2 = 4 : 1) of 
which the signals of the major rotamer are reported. 1H NMR (500 MHz, CDCl3): δ 9.21 (bs, 
1H), 7.53 (d, J = 7.0 Hz, 2H), 7.48 – 7.36 (m, 3H), 4.61 (d, J = 3.5 Hz, 1H), 3.80 (dd, J = 11.0, 
7.5 Hz, 1H), 3.36 (dd, J = 11.0, 3.0 Hz, 1H), 2.92 (m, 1H), 2.69 (m, 1H), 2.03 (m, 1H), 1.94 – 
1.72 (m, 3H), 1.63 (m, 1H), 1.38 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ 175.8 (Cq), 170.8 (Cq), 135.6 (Cq), 130.3 
(CH), 128.3 (CH), 127.1 (CH), 65.4 (CH), 55.7 (CH2), 47.0 (CH), 43.2 (CH), 32.7 (CH2), 31.8 (CH2), 25.5 (CH2) ppm; IR 
(neat): vmax (cm-1) = 2928 (m), 2363 (s), 1734 (s), 1595 (s), 1448 (m), 1184 (w), 702 (s); HRMS (ESI): m/z 
calculated for C15H17NNaO3 [M + Na]
+ 282.1101, found = 282.1098. 
 
 (1S,3aR,6aS)-2-(2-methoxy-4-methylbenzoyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid (13i) 
Following general procedure II in MeOH (2.5 mL) with 12i (229 mg, 0.50 mmol) and 10 N 
NaOH (0.25 mL, 5.0 equiv) at 35 °C. The title compound was obtained as a yellow solid 
(120 mg, 0.39 mmol, 79%). The product was contaminated with 4 mol% 2-methoxy-4-
methylbenzoic acid (6i). [α]D
20 –77 ° (c = 1.00, CHCl3); Two rotamers were present on 
NMR timescale (R1 : R2 = 3 : 1) of which the signals of the major rotamer are reported. 1H 
NMR (500 MHz, CDCl3): δ 7.45 (bs, 1H), 7.16 (d, J = 8.0 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 
6.81 (dd, J = 8.5, 2.0 Hz, 1H), 4.57 (s, 1H), 3.80 (s, 3H), 3.56 (m, 1H), 3.18 (d, J = 11.0 Hz, 
1H), 3.05 (m, 1H), 2.68 (m, 1H), 2.29 (s, 3H), 2.01 (m, 1H), 1.80 (m, 2H), 1.65 (m, 2H), 
1.42 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ 174.1 (Cq), 170.1 (Cq), 152.8 (Cq), 131.5 (CH), 130.4 (Cq), 128.3 
(CH), 125.1 (Cq), 111.1 (CH), 65.7 (CH3), 55.6 (CH3), 54.3 (CH2), 46.4 (CH), 42.4 (CH), 32.5 (CH2), 31.7 (CH2), 25.4 
(CH2), 20.3 (CH3) ppm; IR (neat): vmax (cm
-1) = 2953 (m), 1730 (m), 1578 (w), 1439 (m), 1252 (m), 1030 (s), 908 
(s), 727 (s), 646 (m); HRMS (ESI): m/z calculated for C17H21NNaO4  [M + Na]
+ 326.1363, found = 326.1353. 
 
(1S,3aR,6aS)-2-(thiophene-2-carbonyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid (13j) 
Following general procedure II in MeOH (2.5 mL) with 12j (204 mg, 0.49 mmol) and 10 N 
NaOH (0.25 mL, 5.0 equiv). Purified by flash chromatography using CH2Cl2/MeOH/AcOH 
(98:2:1) to obtain the title product as a white solid (100 mg, 0.37 mmol, 78%). RF = 0.30 
(CH2Cl2/MeOH/AcOH = 97:3:1);. [α]D
20 –47 ° (c = 1.00, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 
8.53 (bs, 1H), 7.60 (d, J = 3.0 Hz, 1H), 7.53 (d, J = 4.5 Hz, 1H), 7.09 (t, J = 4.5 Hz, 1H), 4.60 (s, 
1H), 4.11 (m, 1H), 3.73 (dd, J = 10.0, 3.0 Hz, 1H), 2.88 (m, 2H), 2.03 (m, 1H), 1.90 (m, 1H), 
1.82 (m, 1H), 1.67 (m, 2H), 1.50 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ 177.1 (Cq), 162.9 
(Cq), 137.7 (Cq), 131.1 (CH), 130.8 (CH), 127.3 (CH), 66.6 (CH), 55.1 (CH2), 46.4 (CH), 43.7 (CH), 31.9 (CH2), 31.6 
(CH2), 25.1 (CH2) ppm; IR (neat): vmax (cm
-1) = 2957 (m), 3261 (s), 1717 (m), 1576 (m), 1431 (s), 1215 (w), 741 
(m); HRMS (ESI): m/z calculated for C13H15NNaO3S [M + Na]
+ 288.0665, found = 288.0652.   
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6.1 Introduction 
In this thesis, the importance of isocyanide chemistry for the synthesis of pharmaceuticals 
and the generation of compound libraries has been demonstrated. Furthermore, we have 
shown solutions for the general limitations of IMCRs, such as their limited scaffold 
diversity and the difficult stereocontrol. 2-Isocyano-6-bromopyridine was developed as 
novel convertible isocyanide for Ugi chemistry, which provides a convenient handle to 
selectively introduce post-transformations at the normally inert secondary amide (Chapter 
2). In addition, the reagent was used as a tool in the one-pot synthesis of valuable α-
hydroxy acids from primary alcohols (Chapter 3).  
To gain control in the stereoselectivity, we have developed a highly diastereoselective U-
3CR with 4-substituted Δ
1
-piperideines, which are ideally obtained through an enzymatic 
desymmetrization from the corresponding piperidines (Chapter 4). Aliphatic or aromatic 
substituents on the piperidine ring fully control the attack of the isocyanide, leading to the 
selective formation of the trans pipecolic amides. This methodology was combined with 
the convertible isocyanide with the use of 3,4-substituted pyrrolines to obtain novel 
optically pure ACE inhibitors in two steps (Chapter 5). Finally, these novel methodologies 
have led to the short and efficient synthesis of some relevant pharmaceuticals like 
carfentanil and argatroban.
 
 
6.2 Future Directions 
This chapter will describe potential future directions of the chemistry with 2-
bromo-6-isocyanopyridine (1, Scheme 1). There are many compound classes with 
(poly)peptidic backbones, which are all possible targets for the convertible 
isocyanide. Herein we will highlight the applications of 1 in the synthesis of the 
cardiovascular drug Valsartan (2) and novel derivatives of penicillin (3). Moreover, 
the potential of the convertible isocyanide could be extended to solid phase 
chemistry. Especially when the isocyanide is attached to a solid support (4) 
purification of the IMCR products is very straightforward. Finally, the novel 
pipecolic amides (5) from Chapter 4 have great synthetic potential for follow-up 
chemistry to make poly-substituted piperidines with directed C-H activation (6) or 
metallaphotoredox cross-coupling chemistry (7). 
 
 
Conclusions & Outlook 
 
 
153 
 
Scheme 1. Novel applications for isocyanide 1. 
6.2.1 Applications of 2-bromo-6-isocyanopyridine 
An interesting target for convertible isocyanide 1 is the anti-hypertensive drug Valsartan. 
Valsartan is an angiotensin II receptor antagonist and mainly used for the treatment of 
high blood pressure similarly to ACE inhibitors (Chapter 5).
1
 Whereas the mode of action 
of the ACE inhibitors relies on the inhibition of the conversion of angiotensin I to 
angiotensin II, Valsartan selectively blocks the activity of angiotensin II itself. Angiotensin II 
is – amongst other things – responsible for constriction of blood vessels causing high 
blood pressure (Figure 2, Chapter 5).
2
  
The basic skeleton of Valsartan comprises a tertiary amide and a carboxylic acid. An U-4CR 
with the convertible isocyanide results in the desired scaffold after selective hydrolysis of 
the resulting secondary amide. Valsartan contains an interesting tetrazole moiety, which 
should be present on the amine input of the Ugi reaction. Introduction of this tetrazole 
can be achieved via two different routes (Scheme 2). The first route involves the synthesis 
of carboxylic acid 8 with suitable U-4CR inputs: 2-bromo-6-isocyanopyridine (1), 
isobutyraldehyde (11), pentanoic acid (10) and 4-bromobenzyl amine (9, Route A). The 
carboxylic acid (8) which is formed after basic hydrolysis of the U-4CR product is a 
common intermediate in the synthesis of Valsartan. The aryl tetrazole moiety can be 
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introduced by a Suzuki cross-coupling reaction with the corresponding boronic acid
3,4
 or 
by selective C—H arylation with N-protected phenyl tetrazoles.
5,6
 
 
Scheme 2. Retrosynthetic analysis of the IMCR approach towards Valsartan. 
 
The second strategy involves the synthesis of azido tetrazole 12 (Route B). Staudinger 
reduction of azide 12 followed by an aza-Wittig reaction with aldehyde 11 leads to the 
formation of the corresponding imine (not shown). This imine can be used in a U-3CR, in 
combination with carboxylic acid 10 and convertible isocyanide 1. Valsartan is obtained 
after hydrolytic cleavage of the secondary amide of the Ugi product. This route is 
especially interesting if the desired azido tetrazole (12) can be obtained by a combination 
of two different ‘azide reactions’ on substrate 13. These transformations involve an SN2 
substitution on the benzylic bromide to generate the benzylic azide and an addition on the 
aromatic nitrile to form the tetrazole. Ideally, both reaction are performed in one pot. 
For route A, the synthesis of carboxylic acid 8 is very straightforward and was 
accomplished by the envisioned U-4CR in TFE in high yield (Scheme 3). The subsequent 
hydrolysis, however, proved to be more challenging than expected. At room temperature 
only limited conversion of the secondary amide to the carboxylic acid was observed. In 
order to reach full conversion of 14, the temperature was raised to reflux of the H2O/EtOH 
mixture. 
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Scheme 3. Synthesis of intermediate 8 by an U-4CR. 
The feasibility of route B relies on the synthesis of azido tetrazole 12 by a one-pot double 
azide reaction (Scheme 4). The benzylic bromide is an ideal electrophile for an SN2 
substitution and should proceed without any difficulties. The synthesis of tetrazoles from 
nitriles by the addition of azides is well described and typically requires high reaction 
temperatures in combination with a Lewis acid such as ZnX2
7,8
 or trialkyltin chloride.
9,10
 As 
expected, the initial screening results show full conversion of the benzyl bromide to the 
benzylic azide. However, addition of a Lewis acid and elevation of the reaction 
temperature provided only trace amounts of the desired tetrazole. In addition, the 
benzylic azide rapidly decomposed under these conditions to the aromatic aldehyde. 
 
Scheme 4. Attempts to directly introduce two azide moieties. 
The elevated temperature and possibly the involvement of a Lewis acid enhance the 
elimination of molecular nitrogen from the benzylic azide to form a reactive nitrene 
species (16, Scheme 5). The nitrene rapidly undergoes a 1,2-H shift to form imine 17. 
During the workup the imine is hydrolyzed to the aromatic aldehyde (15) with the 
expulsion of ammonia. The fragmentation is faster than the tetrazole formation, which 
makes it impossible to do the double azide reaction simultaneously at an early stage of the 
envisioned strategy. Route B is in principle still possible with an SN2 substitution, but 
without direct introduction of the tetrazole. The tetrazole can be introduced at the end of 
the synthesis route, since the Ugi product is less sensitive to the harsh condition for the 
tetrazole formation. Moreover, late stage introduction of the tetrazole moiety from the 
aromatic nitrile in the depeptidic structure is well described in literature.
11,12
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Scheme 5. Fragmentation of benzyl azide 13 to aldehyde 15.  
The convertible isocyanide 1 can be an efficient tool in the convergent synthesis of 
pharmaceuticals. In addition, the reagent is also applicable to the synthesis of 
pharmaceutically relevant compound libraries. An interesting example would be the 
synthesis of penicillin derivatives in just two reaction steps. The synthesis of new 
antibiotics is highly desirable due to the increasing resistance of the bacteria. In order to 
find new active compounds, a divergent synthetic approach is desired for the high 
throughput screening of novel candidates. Already in 1962, Ugi and Wischhöfer described 
an efficient IMCR approach for the synthesis of the substituted bicyclic ring system of 
penicillin by the combination of an Asinger condensation and an Ugi reaction.
13
 
We envisioned a different approach, which also comprises an U-4CR. This U-4CR combines 
convertible isocyanide 1 with N-Boc prolinal (18) and various aldehydes and amines to 
make the corresponding Ugi product (21, Scheme 6). The dipeptide can be converted 
under acidic conditions to β-lactam 3 by an intramolecular cyclization. The β-lactam has 
many structural similarities to penicillin and the method allows for many variations at the 
carboxylic acid (R
1
) and amine (R
2
) inputs. For structural variations in the bicyclic lactam a 
more structurally advanced aldehyde input is required.  
Scheme 6. Synthesis of penicillin derivatives (3) with an U-4CR. 
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Unfortunately, an U-4CR with 4-methoxyphenylacetic acid (22) and 4-chlorobenzylamine 
(23) did not lead to the desired Ugi product (Scheme 7). 
1
H NMR analyses of the crude 
reaction mixture showed formation of a new product in combination with a significant 
amount of unreacted carboxylic acid 22. Purification of the crude mixture revealed that 
urea 24 was formed as the major product. The urea is formed when the nitrilium 
intermediate (25) of the Ugi reaction is not trapped by the carboxylate, but by the tert-
butyl carbamate group. The Thorpe-Ingold effect of the pyrroline group brings the 
carbamate in close proximity of the nitrilium, which causes a fast intramolecular 
cyclization. The urea is formed after de-tert-butylation to neutralize the generated 
positive charge followed by a Mumm-type rearrangement. Although urea 24 was not the 
desired product, it still possesses interesting features and can easily be diversified at the 
activated secondary amide.  
 
Scheme 7. Formation of undesired urea 24. 
As discussed in Chapter 1, attachment of a convertible isocyanide to a resin has many 
advantages. Above all, the purification of the IMCR products is significantly simplified. In 
addition, the cleavage of the resulting secondary amide directly removes the desired 
product from the resin. With this method it is possible to quickly generate very large 
compound libraries with parallel synthesis, which is highly desirable for lead discovery 
programs of the pharmaceutical industry. 
In this context, 2-bromo-6-isocyanopyridine has some additional advantages when it is 
attached to a solid support (Scheme 8). After cleavage of the IMCR product, the resulting 
amine can be reactivated to the isocyanide making the resin recyclable. Isocyanide 1 can 
be introduced to a solid support by a Suzuki reaction between resin-bound boronic ester 
(28) and N-(5,6-dibromopyridin-2-yl)formamide (29).
14
 The resulting formamide (30) can 
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be dehydrated with phosphoryl chloride in the presence of Et3N to furnish desired 
isocyanide 4.
15
 The isocyanide can be used for the generation of different IMCR products, 
which are simultaneously cleaved from the resin during the post-condensation at the 
secondary amide. The resin will still be functionalized with the aminopyridine (32), which 
can be regenerated to the isocyanide in two reaction steps (via 30). The initial 
modification of the resin requires some synthetic effort, however the reactivation to the 
desired 4 is relatively straightforward.  
 
Scheme 8. Application and recyclability of isocyanide 4 on a solid support. 
Moreover, isocyanide 1 can have a second application in solid-phase chemistry. 
Functionalization of the resin with carboxylic acid residues (34) give the opportunity to 
generate unnatural polypeptides (Scheme 9). Hydrolytic cleavage of the U-4CR product 
with isocyanide 1 produces a new carboxylic acid (36), which can be used in a second U-
4CR. Iteration of this cycle followed by the cleavage of the linker leads to the formation of 
unnatural N-substituted polypeptides (38). The disadvantages of this method are the 
necessity of a cleavable linker on the resin together with the lack of stereocontrol in the 
sequential Ugi reactions. In every U-4CR a new stereocenter is generated (except when 
the carbonyl input is formaldehyde or a symmetrical ketone), which results in isomeric 
mixtures of the N-substituted polypeptide (38).  
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Scheme 9. Synthesis of unnatural N-substituted polypeptides (38) with the use of solid-phase chemistry. 
 
6.2.2 Scaffold diversification of the pipecolic amides 
In Chapter 4, the synthesis of 4-substituted pipecolic amides by a highly diastereoselective 
U-3CR with different 4-substituted Δ
1
-piperideines is described. In combination with the 
biocatalytic desymmetrization of 4-substituted piperidines with MAO-N, this method gives 
access to optically pure unnatural (poly)peptides. The pipecolic amides can be even more 
valuable when submitted to follow-up chemistry to further decorate the basic scaffold, 
since (poly)substituted piperidines appear frequently in pharmaceutically active 
compounds.
16
 Most traditional functionalization reactions of IMCRs rely on the 
introduction of a “smart” functional group in the IMCR inputs. These groups are activated 
after the IMCR to generate new scaffold such as a rich variety of heterocycles.
17-19
  
An alternative method to introduce more functionality to the piperidine ring is with the 
use of directed C(sp
3
)—H functionalization (Scheme 10). In recent years, there has been an 
increasing interest in the selective functionalization of C(sp
3
)—H bonds by transition metal 
catalysis.
20,21
 Direct C(sp
3
)—H bond activation avoids the pre-functionalization of 
substrates thereby improving the atom and step economy. This functionalization is 
considered rather challenging due to the thermodynamic stability of the C(sp
3
)—H bond 
(especially compared to C(sp
2
)—H and C(sp)—H bonds) and the high abundance of 
C(sp
3
)—H bonds in the target substrates. Selective C—H activation has been commonly 
achieved by the use of directing groups. The directing groups typically consist of an 
electron-poor amide such as 43 (monodentate) or an amide with an additional hetero 
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atom such as 41 and 42 (bidentate). The directing groups can selectively coordinate to a 
metal center and form a thermodynamically favorable five or six-membered metallacycle. 
Scheme 10. Directing group assisted C—H functionalization of the pipecolic amides. 
 
For the envisioned functionalization on the piperidine ring of the pipecolic amides, the 
introduction of a directing group is thus required. In principle, since the directing group is 
typically a secondary amide, it could already be introduced in the U-3CR with the 
corresponding isocyanide input (Scheme 10). However, very electron poor isocyanides, 
such as 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl isocyanide (45a), are generally not 
stable due to rapid polymerization. Furthermore, the group of Baran discovered that 8-
isocyanoquinoline (45b) also suffered from severe stability issues.
22
 The isocyanide readily 
forms the cyclized zwitterionic isomer, which is trapped by the alcoholic solvent to form 
the dearomatized benzamidazoles. Similar (and probably more severe) instability can be 
expected for 45c. Nevertheless, the directing group can be introduced with a slight detour 
using the convertible isocyanide 1 (Scheme 11). The amide of U-3CR product 46 can be 
hydrolyzed to the carboxylic acid followed by a peptide coupling reagent mediated 
amidation with the desired amine to obtain 39. In principle prolyl peptide 46 already 
contains an activated amide (similar to an activated carboxylic acid with a peptide 
coupling reagent) which makes a direct amidation also feasible.     
 
Scheme 11. Introduction of a directing group on the piperidine scaffold. DG = Directing group. 
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Recently, several group have shown the C(sp
3
)—H arylation on similar piperidine scaffolds, 
emphasizing broad interest in these products.
23-25
 Moreover, the directing group assisted 
C(sp
3
)—H functionalization chemistry can be used for the introduction of C—N, C—O and 
even C—X bonds. There are two potential mechanism involved in the C—H 
functionalization reaction (Scheme 11). The catalytic cycle that involves a Pd
II
/Pd
IV
 
pathway (Scheme 12A) is most commonly accepted. The mechanism starts with Pd(OAc)2 
(47) which undergoes the directing group assisted C—H activation to form the five-
membered palladacycle 48. Oxidative addition of the aryl halide (49), generally in 
combination with a silver oxidant, results in the highly coordinated Pd
IV
 species 50. Finally, 
reductive elimination provides the desired product (39) and regenerates the catalytic Pd
II
 
species (51). The required five-membered palladacycle (48) has to be in cis-configuration 
for steric reasons making the proposed arylation very likely to be diastereoselective. 
 
Scheme 12. Possible mechanisms of the C(sp3)—H arylation; ligands are omitted for clarity. 
Another interesting modification to the piperidine scaffold could be achieved with the 
photoredox chemistry developed by the group of Macmillan.
26
 They combined a 
photoredox induced single-electron transfer (SET) based decarboxylation with a nickel-
catalyzed cross-coupling reaction. To introduce aryl, vinyl and even alkyl groups at the 
carboxylic acid position of N-protected cyclic amino acids.
27-30
 We have developed an 
efficient method to generate N-protected pipecolic acids 55 and proline derivatives 56 
(Chapter 4 and 5 respectively), which are ideal inputs for the photoredox chemistry of 
Macmillan (Scheme 13). 
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Scheme 13. Decarboxylative photoredox mediated cross-coupling reactions. 
The decarboxylative nickel-catalyzed cross-coupling reaction involves two synergistic 
catalytic cycles (Scheme 14).
29
 The first step is the visible-light excitation of Ir
III
 complex 60 
to form the excited Ir
III
 61, which is a strong oxidant. A single electron oxidation of the 
carboxylate (55 or 56) by 61 results in a carboxyl radical along with Ir
II 
complex 62. The 
carboxyl radical is expected to rapidly expel CO2 to form alkyl radical 63. Simultaneously, 
active Ni
0
 complex 64 is generated by two SET reductions of NiCl2 precatalyst by the Ir
II
 62 
(not shown). The nickel catalytic cycle starts with Ni
0
 catalyst 64, which reacts with alkyl 
radical 63 to form Ni
I
 complex 65. Oxidative addition of the alkyl or aryl bromide 57 
generates Ni
III
 complex 66, which furnishes the desired product 58/59 after reductive 
elimination. The resulting Ni
I
 species 67 can be reduced to the active Ni
0
 complex by SET 
from the Ir
II
 photocatalyst (57) to close both catalytic cycles. 
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Scheme 14. Synergistic metallaphotoredox mediated cross-coupling;29 ligands are omitted for clarity. 
Presumably, the conformational restriction in the five and six-membered rings of the 
potential starting materials would cause the reaction to proceed with a considerable 
stereospecificity. Otherwise, there is the option to use chiral ligands on the nickel catalyst, 
which are recently reported by Macmillan.
30
  
Conclusions 
To conclude, this chapter provided a brief impression of the future applications of IMCR 
chemistry with 6-bromo-2-isocyanopyridine. We expect that the reagent will have 
unmatched potential in the field of drug discovery, due to the vast potential of feasible 
modifications of the Ugi products. Furthermore, diastereoselective transformations of 4-
substituted dehydropiperidines are relatively underexploited. Especially optically pure Δ
1
-
piperideines are versatile building blocks for numerous diastereoselective 
(multicomponent) reactions to obtain pharmaceutically relevant substituted piperidines.  
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Experimental Section 
General Remarks 
Unless stated otherwise, all solvents and commercially available reagents were used as purchased. All reaction 
were performed under air, unless stated otherwise. Infrared (IR) spectra were recorded neat using a Shimadzu 
FTIR-8400s spectrophotometer and wavelengths are reported in cm-1. Nuclear magnetic resonance (NMR) 
spectra were recorded on a Bruker Avance 500 (125.78 MHz for 13C) or Bruker Avance 400 (100.62 MHz for 13C) 
using the residual solvent as internal (1H: δ 7.26 ppm, 13C{1H}: δ 77.16 ppm for CDCl3). Chemical shifts (δ) are 
given in ppm and coupling constants (J) are quoted in hertz (Hz). Resonances are described as s (singlet), d 
(doublet), t (triplet), q (quartet), bs (broad singlet) and m (multiplet) or combinations thereof. Chiral HPLC was 
recorded using a LC10VP with a SCL-10A VP system controller, LC-10AT VP liquid chromatograph, SPD-M10A VP 
diode array detector and CTO-10AC VP column oven from Shimadzu. Melting points were recorded on a Büchi M-
565 melting point apparatus and are uncorrected. Electrospray Ionization (ESI) high-resolution mass 
spectrometry was carried out using a Bruker micrOTOF-Q instrument in positive ion mode (capillary potential of 
4500 V). Flash chromatography was performed on Silicycle Silia-P Flash Silica Gel (particle size 40-63 μm, pore 
diameter 60 Å) using the indicated eluent. Thin Layer Chromatography (TLC) was performed using TLC plates 
from Merck (SiO2, Kieselgel 60 F254 neutral, on aluminum with fluorescence indicator) and compounds were 
visualized by UV detection (254 nm) and KMnO4 stain. 
 
Synthesis of the Valsartan intermediates 
N-(4-bromobenzyl)-N-(1-((6-bromopyridin-2-yl)amino)-3-methyl-1-oxobutan-2-yl)pentanamide (14) 
In a 10 mL round-bottom flask 4-bromobenzylamine (92.9 mg, 0.50 mmol, 
1 equiv) was dissolved in TFE (1.7 mL). Isobutyraldehyde (47 µL, 0.50 
mmol, 1 equiv) and valeric acid (83 µL, 0.75 mmol, 1.5 equiv) were added 
to the solution. Finally 2-bromo-6-isocyanopyridine (114 mg, 0.625 mmol, 
1.25 equiv) was added and the resulting mixture stirred for 48 hours at 
room temperature.  Then, the solvent was removed under reduced 
pressure and the residue was purified by flash chromatography 
(cyclohexane/EtOAc = 12:1) to yield the title compound as a slowly crystallizing solid (219 mg, 0.42 mmol, 84%). 
RF = 0.38 (cyclohexane : EtOAc = 12:1); m.p. = 104.0 – 108.0 °C; 
1H-NMR (500 MHz, CDCl3): 8.82 (bs, 1H), 7.68 (d, J 
= 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 7.26 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 1H), 6.96 (d, J = 8.5 Hz, 2H), 4.75 
(d, J = 11.0 Hz, 1H), 4.62 (d, J = 17.5 Hz, 1H), 4.55 2.48 (d, J = 17.5 Hz, 1H), 2.49 (m, 1H), 2.39 (m, 1H), 2.26 (m, 
1H), 1.63 (m, 2H), 1.28 (m, 2H), 0.99 (d, J = 7.5 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H) ppm; 13C-
NMR (125 MHz, CDCl3): δ 175.6 (Cq), 168.8 (Cq), 150.9 (Cq), 140.2 (CH), 139.3 (Cq), 136.0 (Cq), 131.6 (CH), 127.7 
(CH), 123.7 (CH), 121.0 (Cq), 112.4 (CH), 64.6 (CH), 48.0 (CH2), 33.6 (CH2), 27.5 (CH2), 26.4 (CH), 22.4 (CH2), 19.7 
(CH3), 18.5 (CH3), 13.8 (CH3), ppm; IR (neat): vmax (cm
-1) = 2961 (m), 1697 (s), 1630 (m), 1566 (s), 1529 (s), 1431 
(s), 1391 (m), 1304 (m), 1155 (s), 1126 (s), 1072 (m), 789 (m); HRMS (ESI): m/z calculated for C22H28Br2N3O2 [M + 
H]+ 524.0543, found = 524.0529. 
 
N-(4-bromobenzyl)-N-pentanoylvaline (8) 
In a 10 mL round-bottom flask Ugi product 14 (105 mg, 0.20 mmol, 1 equiv) of Ugi 
product was dissolved in EtOH (2 mL). To the solution aqueous NaOH (2N, 1.0 mL, 2.0 
mmol, 10 equiv) was added and the resulting mixture was stirred for 24 h at reflux 
temperature. After cooling to room temperature H2O (10 mL) was added and the 
aqueous layer was washed EtOAc (2×). The aqueous phase was acidified with an 
aqueous solution of HCl (12 M) until pH < 3 was reached and then extracted with 
EtOAc (3×). The organic phases were combined, washed with brine, dried over Na2SO4, filtered and concentrated 
to obtain the title compound as an off-white solid (67 mg, 0.18 mmol, 90%). Two rotamers were present on NMR 
timescale (R1 : R2 = 3 : 1) of which the signals of the major rotamer are reported. 1H-NMR (500 MHz, CDCl3): δ 
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7.47 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.5 Hz, 2H), 4.70 (d, J = 17.0 Hz, 1H), 4.38 (d, J = 17.0 Hz, 1H), 3.85 (d, J = 10.0 
Hz, 1H), 2.59 (m, 1H), 2.35 (m, 2H), 1.61 (m, 2H), 1.30 (m, 2H), 0.99 (d, J = 6.5 Hz, 3H), 0.88 (m, 6H) ppm; 13C-NMR 
(125 MHz, CDCl3): δ 176.7 (Cq), 172.6 (Cq), 134.7 (Cq), 132.1 (CH), 128.3 (CH), 121.9 (Cq), 70.1 (CH), 53.2 (CH2), 33.9 
(CH2), 27.2 (CH), 27.1 (CH2), 22.3 (CH2), 19.8 (CH3), 19.3 (CH3), 13.8 (CH3) ppm; IR (neat): vmax (cm
-1) = 2961 (w), 
1734 (m), 1605 (w), 1458 (m), 1404 (m), 1196 (w), 1103 (m), 1072 (s), 1011 (s), 793 (m), 754 (s), 667 (m); HRMS 
(ESI): m/z calculated for C17H24BrNNaO3 [M + Na]
+ 392.0832, found = 392.0819. 
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The pharmaceutical industry invests a lot of time and resources in the discovery of new 
and improved drugs. A large number of the current set of drugs and probably also a large 
number of the future drugs have a very complex molecular structure. Nowadays, for a 
well-trained organic chemist it is not the question if the active target drug can be 
synthesized, but rather how efficiently it can be done. The traditional lengthy, linear 
synthetic approaches are very expensive and go hand in hand with the generation of vast 
amounts of chemical waste. Therefore, there is a demand for clean and efficient methods 
to synthesize these challenging compounds with high atom economy and other green 
metrics. Multicomponent reactions (MCRs) are excellent tools for these goals. In MCRs, 
three or more reagents are selectively combined to form a structurally complex scaffold, 
ideally with all atoms of the starting materials incorporated.  
One of the most important reaction inputs of MCRs are isocyanides. These versatile 
reagents have both a nucleophilic and electrophilic character. As a result of their unique 
reactivity they participate in many MCRs, including the Ugi and Passerini reactions. The 
utility of isocyanide chemistry in the synthesis of natural products and pharmaceuticals is 
rapidly increasing, as demonstrated by the selected examples in Chapter 1. 
Although isocyanide-based multicomponent reactions (IMCRs) offer many advantages 
compared to linear synthesis, they also suffer from some severe limitations: (i) The 
products of IMCRs generally have the same molecular skeleton, (ii) the commercial 
availability of many isocyanides is limited and (iii) the IMCR products generally contain a 
new stereocenter, which is difficult to control. The key objective of this thesis is to address 
the above mentioned limitations of IMCRs by the development of a novel convertible 
isocyanide and with the use of diastereoselective IMCRs (Scheme 1). These methods offer 
significant advantages in the synthesis of pharmaceutically relevant compounds.  
The first two limitations (i and ii) of IMCRs can be resolved by the use of a convertible 
isocyanide. In the past decades many convertible isocyanides have been developed for a 
broad range of chemically different post transformations (Chapter 1). However, the 
current set of convertible isocyanides generally suffers from some severe disadvantages, 
including the stability/handling of the isocyanide, its multistep and/or tedious synthesis or 
the difficult and/or harsh post-transformation conditions. 
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Scheme 1. Overview of various targets of chemistry with 2-bromo-6-isocyanopyridine. 
We envisioned the use of 2-isocyanopyridines as novel class of convertible isocyanides 
(Chapter 2). The electron-withdrawing properties of the pyridine ring make the resulting 
secondary amide sufficiently electrophilic for a nucleophile to attack the activated 
carbonyl under basic reaction conditions. On the other hand, the basic pyridine nitrogen 
can be protonated under acidic conditions, which also enhances the electrophilicity of the 
secondary amide to make it more susceptible to nucleophile attack. Comparison of several 
different isocyanopyridines indicated that 2-bromo-6-isocyanopyridine (1) is the best 
candidate for both the IMCR and post-transformation. The isocyanide 1 performed well in 
many Ugi four-component reactions (U-4CRs) and the resulting secondary amides of the 
Ugi products were readily converted to the corresponding carboxylic acids (Scheme 2). 
Furthermore, the secondary amides of the Ugi products (3) were transformed into other 
functional groups, such as (thio)esters and amides, under both basic and acidic conditions. 
Finally, we demonstrated the utility of the isocyanide in the efficient synthesis of the 
extremely potent narcotic carfentanil (5) in only two reaction steps. 
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Scheme 2. Applicability of 2-bromo-6-isocyanopyridine in the U-4CR and in the synthesis of carfentanil. 
The efficiency and convertibility of the isocyanide prompted us to investigate other IMCRs 
such as the Passerini reaction (Chapter 3). Oxidation of a primary alcohol (17) with 
PhI(OAc)2 and a catalytic amount of TEMPO results in the corresponding aldehyde 
together with two equivalents of acetic acid (Scheme 3). Addition of isocyanide 1 to the 
reaction mixture provides the Passerini product. Finally, hydrolysis of both the activated 
secondary amide and the ester group with aqueous NaOH furnishes the α-hydroxy acids 
(18, R
2
 = H). The one-pot oxidation/Passerini/hydrolysis sequence tolerates a broad range 
of functional groups on the primary alcohol input. Furthermore, a minor modification to 
the reaction conditions extends the range of accessible products to α-hydroxy esters (18, 
R
2
 = alkyl). 
 
Scheme 3. One-pot synthesis of α-hydroxy acids and esters. 
Our next goal was to gain control in the stereoselectivity of IMCRs. Since there is no 
asymmetric catalyst available for the U-4CR, we were interested in the use of optically 
pure reaction inputs for the U-4CR that can induce diastereoselectivity. Previously, we 
described the use of an engineered variant of monoamine oxidase (MAO-N D5) for the 
oxidation of 3,4-disubstituted meso-pyrrolidines to the corresponding imines in high 
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optical purity (Chapter 4). These 1-pyrrolidines are excellent substrates for an U-3CR to 
obtain the corresponding prolyl peptides in good to excellent diastereomeric ratios.  
We envisioned that we could extend the above mentioned methodology to the oxidation 
of prochiral 4-substituted piperidines (8) with MAO-N (Chapter 4). The 4-substituted 
piperidines were synthesized by an efficient two-step procedure involving alkylation of 4-
picoline (19) and subsequent catalytic hydrogenation of the pyridine ring involving 
catalytic PtO2 (Scheme 4). The parent MAO-N D5 variant showed limited activity for the 
piperidine substrates. Fortunately, the activity was greatly enhanced by several rounds of 
directed evolution with MAO-N D5 and D9 as parent enzymes. 
 
Scheme 4. Biocatalytic synthesis of enantiomerically enriched Δ1-piperideines. 
Alternatively, the 4-substituted piperidines (8) can be chemically oxidized to racemic Δ
1
-
piperideines 9 by N-chlorination with NCS followed by elimination with ethanolic KOH. 
These Δ
1
-piperideines proved very suitable inputs for the U-3CR in combination with 
chemically diverse isocyanides (20) and carboxylic acids (13) leading to a wide variety of 
biologically interesting pipecolic amides (10). Interestingly, the reaction proceeded with 
excellent diastereoselectivity. The substituent on the piperidine input fully controlled the 
newly formed stereocenter of the pipecolic amides.  
 
Scheme 5. Diastereoselective synthesis of pipecolic amides. 
As a demonstration of the potential of the U-3CR, we used our methodology in 
combination with our recently developed convertible isocyanide 2-bromo-6-
isocyanopyridine (1) as a key step in the synthesis of the anticoagulant argatroban (7, 
Scheme 6). The synthesis is convergent and requires only protection of the guanidine 
group of the arginine residue. 
Summary
 
 
172 
 
Scheme 6. Key step of the synthesis of argatroban. 
We then decided to investigate the use of 1-pyrrolidine 22 in combination with 2-bromo-
6-isocyanopyridine (1) to obtain N-functionalized proline derivatives 4 after hydrolysis of 
the activated amide of Ugi products 23 (Chapter 5). The resulting carboxylic acids 4 
strongly resemble the class of ACE inhibitors. The synthesis of structural analogues is 
crucial for the discovery of more potent derivatives. To demonstrate the utility of this 
methodology, we composed a small library with the use of chemically diverse carboxylic 
acids (Scheme 7).  
 
Scheme 7. Synthesis of ACE inhibitor analogues. 
In conclusion, the results described in this thesis indicate that IMCRs are very valuable 
tools for the synthesis of complex, optically pure compounds. The general shortcomings of 
IMCRs are tackled by the development of 2-bromo-6-isocyanopyridine as novel 
convertible isocyanide and with the use of highly diastereoselective IMCRs with 
enantiomerically enriched imine inputs derived from a biocatalytic oxidation with MAO-N. 
The value of this new methodology is demonstrated by the synthesis of known drugs and 
libraries of other pharmaceutically relevant compounds. 
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De farmaceutische industrie is continu op zoek naar betere en actievere medicijnen. Een 
groot deel van de huidige medicijnen en hoogstwaarschijnlijk ook van de toekomstige 
geneesmiddelen bestaat uit chemisch gezien zeer ingewikkelde verbindingen. Het is voor 
een goede organisch chemicus tegenwoordig niet meer zozeer de vraag óf we deze 
verbindingen kunnen maken, maar hoe efficiënt we dat kunnen. Traditionele lange 
lineaire syntheseroutes gaan hand in hand met de productie van grote hoeveelheden 
chemisch afval. Er is daarom een grote vraag naar nieuwe convergente synthetische 
methodes die zorgen voor een schonere en efficiëntere productie van deze uitdagende 
verbindingen. Multicomponentreacties (MCRs) zijn uitstekende hulpmiddelen om deze 
doelen te bereiken. In dit type reacties worden selectief drie of meer simpele reactanten 
gecombineerd tot structureel complexe producten in één pot, waarbij idealiter alle 
atomen van de uitgangsstoffen in het product terecht komen.  
Eén van de belangrijkste reactanten in MCRs zijn isocyanides. Deze verbindingen hebben 
zowel een nucleofiel als een elektrofiel karakter en zijn door hun unieke reactiviteit niet 
meer weg te denken uit een groot scala aan MCRs, waaronder de bekende Ugi en 
Passerini reactie. Aan de hand van de vele medicijnen en natuurstoffen die in de 
afgelopen decennia op een efficiënte manier zijn gemaakt met gebruik van isocyanides 
wordt duidelijk dat deze chemie sterk in populariteit toeneemt (Hoofdstuk 1).  
Uit Hoofdstuk 1 is het duidelijk geworden dat er erg veel voordelen zijn voor het gebruik 
van isocyanide-gebaseerde multicomponentreacties (IMCRs), echter zijn er ook een aantal 
nadelen aan verbonden: (i) de producten die gemaakt worden met IMCRs hebben vaak 
een zeer vergelijkbaar moleculair skelet, (ii) slechts een zeer beperkt aantal isocyanides is 
commercieel verkrijgbaar en (iii) bij de meeste IMCRs wordt er een nieuwe stereocentrum 
gevormd, waarvan de stereochemie zeer lastig te beïnvloeden is. Het hoofddoel van dit 
proefschrift is om deze beperkingen aan te pakken door de ontwikkeling van een nieuw 
omzetbaar isocyanide en door gebruik te maken van diastereoselectieve IMCRs (Schema 
1). Deze nieuwe methodes bieden significante voordelen voor de synthese van medicijnen 
en andere verbindingen die relevant zijn voor de farmaceutische industrie.   
De eerste twee beperkingen (i en ii) van IMCRs kunnen worden verholpen door gebruik te 
maken van een omzetbaar isocyanide. In de afgelopen decennia zijn er in de literatuur een 
groot aantal omzetbare isocyanides verschenen die omgezet kunnen worden met 
chemisch zeer verschillende methodes (Hoofdstuk 1). Deze huidige set van omzetbare 
isocyanides hebben echter een aantal typische nadelen, zoals de 
stabiliteit/hanteerbaarheid van het isocyanide, de lange en/of moeilijke synthese van de 
verbinding of de moeilijke en/of heftige condities die nodig zijn voor de vervolgreacties. 
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Schema 1. Overzicht van de verschillende moleculaire targets die gemaakt kunnen worden met 2-bromo-6-
isocyanopyridine. 
Naar onze mening zijn 2-isocyanopyridines erg goede kandidaten voor een nieuw type 
omzetbare isocyanides zonder de bovengenoemde nadelen (Hoofdstuk 2). De 
elektronenzuigende eigenschappen van de pyridinering maken het secondaire amide, dat 
gevormd wordt in de meeste IMCRs, elektrofiel genoeg om aangevallen te worden door 
een extern nucleofiel onder basische condities. Tevens kan de basische pyridine stikstof 
geprotoneerd worden onder zure condities. Hierdoor wordt de carbonyl groep van het 
secondaire amide veel elektrofieler en kan het aangevallen worden door een nucleofiel. 
Een groot aantal chemisch verschillende 2-isocyanopyridines zijn gescreend op hun 
reactiviteit in Ugi reactie en in de vervolgreacties van de resulterende producten. Uit deze 
studie bleek 2-bromo-6-isocyanopyridine (1) op beide punten de optimale kandidaat. 
Isocyanide 1 presteert goed in een groot scala aan Ugi vier-componentenreacties (U-4CRs) 
met chemisch verschillende inputs en alle producten konden vervolgens selectief worden 
omgezet naar de corresponderende carbonzuren onder mild basische condities (Schema 
2). Naast een omzetting naar het carbonzuur kan het reactieve secondaire amide worden 
omgezet naar verschillende andere functionele groepen, zoals (thio)esters en andere 
amides onder zowel basische als zure condities. Om te bewijzen dat isocyanide 1 een 
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waardevolle verbindingen is hebben we gebruik gemaakt van het reagens in de efficiënte 
tweestapssynthese van het zeer potente verdovende middel carfentanil (5). 
 
Schema 2. Gebruik van 2-bromo-6-isocyanopyridine in de U-4CR en in de synthese van carfentanil. 
De brede toepasbaarheid en de gemakkelijke omzetbaarheid van het isocyanide in de Ugi-
reactie motiveerde ons om het reagens te testen in andere IMCRs, zoals de Passerini-
reactie (Hoofdstuk 3). Oxidatie van een primair alcohol (17) met PhI(OAc)2 in 
aanwezigheid van een katalytische hoeveelheid TEMPO genereert het overeenkomstige 
aldehyde en twee equivalenten azijnzuur (Schema 3). Toevoeging van het isocyanide (1) 
aan dit reactiemengsel leidt tot de vorming van het Passerini-product. Vervolgens wordt 
er natronloog toegevoegd aan het reactiemengsel waardoor zowel het geactiveerde 
secondaire amide als de estergroep worden gehydrolyseerd, hetgeen resulteert in het 
gewenste α-hydroxycarbonzuur (18, R = H). Deze éénpots-oxidatie/Passerini/hydrolyse 
methode tolereert veel verschillende functionele groepen op de primaire alcohol input en 
de methode kan met een kleine modificatie worden uitgebreid naar de synthese van α-
hydroxyesters (18, R = alkyl). 
 
Schema 3. Eénpots-synthese van α-hydroxycarbonzuren en -esters. 
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De derde tekortkoming van IMCRs (iii) is de lastige controle over de stereochemie. 
Aangezien er geen asymmetrische katalysatoren beschikbaar zijn voor de U-4CR, zijn wij 
geïnteresseerd in het gebruik van optisch zuivere uitgangsstoffen voor de U-4CR. Dit zou 
in potentie kunnen leiden tot een zeer diastereoselectieve reactie. In eerder onderzoek 
zijn gemodificeerde varianten van monoamine oxidase (MAO-N D5) gebruikt voor de 
synthese van 3,4-digesubstitueerde meso-pyrolidines naar de overeenkomstige imines 
met hoge enantioselectiviteit (Hoofdstuk 4). Deze 1-pyrrolidines zijn zeer goede 
substraten voor een U-3CR om zogeheten prolylpeptides te maken met goede tot 
uitstekende diastereoselectiviteit. 
In onze ogen kon de bovenstaande chemie worden uitgebreid naar de enzymatische 
oxidatieve desymmetrisering van 4-gesubstitueerde piperidines (Hoofdstuk 4). De 
benodigde piperidines kunnen worden gesynthetiseerd door middel van een efficiënte 
tweestapsmethode uitgaande van 4-picoline (19) (Scheme 4). 4-Picoline kan relatief 
eenvoudig gedeprotoneerd worden met een sterke base en het resulterende anion kan 
gealkyleerd worden met verschillende alkylbromides. De resulterende 4-alkylpyridines 
kunnen worden gehydrogeneerd met waterstof in aanwezigheid van een katalytische 
hoeveelheid PtO2 tot de gewenste 4-alkylpiperidines (8). MAO-N D5 had maar een 
beperkte activiteit voor deze 4-alkylpiperidines. Echter, de activiteit van het enzym kon 
sterk worden verbeterd door middel van gerichte evolutie van de D5 en D9 varianten van 
MAO-N. 
 
Schema 4. Biokatalytische synthese van optisch verrijkte Δ1-piperideines. 
Ondertussen waren de racemische Δ
1
-piperideines (9) gesynthetiseerd op een chemische 
manier door middel van een chlorinering van de piperidine stikstof met NCS gevolgd door 
een eliminatiereactie met KOH in ethanol. De gevormde Δ
1
-piperideines bleken 
uitstekende substraten voor de U-3CR. Met deze methode konden verscheidene 
biologisch interessante pipecolamides (10) gemaakt worden (Schema 5). Tevens verliep 
deze reactie met een uitstekende diastereoselectiviteit. De reeds aanwezige substituent 
op de piperidine-ring heeft volledige invloed op het nieuwe stereocentrum, door een 
selectieve axiale aanval van het isocyanide. 
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Schema 5. Diastereoselectieve synthese van pipecolamides. 
Om te laten zien hoe nuttig de bovengenoemde diastereoselectieve U-3CR is, hebben we 
deze methodologie toegepast in combinatie met ons nieuwe isocyanide (1) in de synthese 
van het antistollingsmedicijn argatroban (7, Schema 6). De synthese is zeer convergent en 
zet eigenlijk in één reactiestap het belangrijkste gedeelte van het skelet van argatroban in 
elkaar. Hierdoor hoeft slechts de guanidine groep beschermd te worden om de synthese 
te kunnen voltooien. 
 
Schema 6. Belangrijkste stap in de synthese van argatroban. 
Vervolgens besloten we om ook naar andere diastereoselectieve IMCRs te kijken die 
gecombineerd kunnen worden met het omzetbare isocyanide 1 (Hoofdstuk 5). Een 
combinatie van 2-bromo-isocyanopyridine met optisch zuiver 1-pyrrolidine 22 en een 
aantal verschillende carbonzuren leidt tot N-gefunctionaliseerde prolines 4 na hydrolyse 
van het corresponderende Ugi-product (23, Schema 7). Deze prolines 4 hebben een sterke 
structurele gelijkenis aan een aantal bekende ACE-remmers. Deze verbindingen worden 
vaak ingezet als medicatie tegen hoge bloeddruk en hartfalen. In de zoektocht naar nog 
actievere ACE-remmers is de efficiënte synthese van nieuwe analogen uiterst belangrijk. 
Met deze methode kunnen we een groot aantal nieuwe analogen maken door chemisch 
verschillende carbonzuren te gebruiken in de U-3CR.  
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Schema 7. Synthese van optisch zuivere ACE-remmer analogen. 
De resultaten die beschreven zijn in dit proefschrift tonen aan dat IMCRs zeer waardevolle 
hulpmiddelen zijn voor de synthese van optische zuivere complexe verbindingen. De 
tekortkomingen van de IMCRs zijn verholpen door de ontwikkeling van het nieuwe 
omzetbare isocyanide 2-bromo-6-isocyanopyridine en door gebruik te maken van zeer 
diastereoselectieve IMCRs. De optisch zuivere inputs voor deze reactie kunnen worden 
verkregen door middel van een biokatalytische oxidatie met behulp van het enzym MAO-
N. Dat deze nieuwe methodes van groot belang zijn voor de farmaceutische industrie is 
aangetoond door deze methode te gebruiken in de synthese van een groot aantal 
farmaceutisch relevante verbindingen. 
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Dankwoord 
Na vijf jaar is dit toch echt het einde van een prachtige tijd op de VU. Ik kan met alle 
eerlijkheid zeggen dat ik hier een van de mooiste tijden van mijn leven heb gehad 
en dat komt allemaal door jullie. Collega’s, studenten en in de meeste gevallen 
vrienden; jullie hebben ervoor gezorgd dat ik elke dag met plezier en volle 
motivatie naar de universiteit ben gekomen, wat heeft geresulteerd tot dit mooie 
boekje. Vandaar dat ik uitgebreid de ruimte wil nemen om jullie te bedanken! 
Om te beginnen wil ik uiteraard mijn promotor Romano en copromotor Eelco 
bedanken! Ik kan me nog goed herinneren dat ik vijf jaar geleden binnenkwam (in 
mijn korte broek) voor mijn sollicitatie gesprek. Vanaf het eerste moment voelde ik 
mij daar op mijn gemak en een gewaardeerd onderdeel van de SyBOrCh groep. 
Voor mij waren jullie de ideale begeleiding in het promotie traject. Een perfecte 
combinatie van een ruime chemische vrijheid binnen de projecten, maar ook de 
juiste sturing om de chemie op weg te helpen richting een passende publicatie. 
Daarnaast heb ik het erg gewaardeerd dat jullie alle sociale activiteiten hebben 
aangemoedigd wat erg vruchtbaar is geweest voor de werksfeer en de 
samenwerking binnen de groep(en). Ik weet zeker dat ik al onze gesprekken, zowel 
chemie als niet chemie gerelateerd, erg ga missen. 
I am very grateful for all the members of my reading and/or promotion defense 
committee. I would like to thank Prof. Dr. Bert Windhorst, Prof. Dr. Till Opatz, Prof. 
Dr. Alexander Dömling, Prof. Dr. Peter Timmerman, Dr. Mario van der Stelt, and 
Dr. Jean-Paul Seerden to help me finish the final stage of my PhD.  
Since the research of my PhD was a small part of a big collaboration called CHEM21, 
I would like to thank everybody within this collaboration, whom I had the pleasure 
to meet during one of many meetings. In particular I would like to mention the 
group of Nick Turner from Manchester, who played an important role in the 
chemistry that is presented in Chapter 4 of this thesis. Nick, Anthony, Jeff, Gao-Wei 
and Susanne, you have been a great support. Voor ditzelfde hoofdstuk wil ik Leon 
van Mercachem en René van Screening Devices ook heel erg bedanken voor alle 
hulp met de lastige scheidingen in de synthese van argatroban. 
De aller belangrijkste contributie aan dit boekje is het werk dat al mijn studenten 
voor mij hebben gedaan. Het was voor mij een voorrecht om jullie te mogen 
begeleiden en ik denk dat ik minstens zoveel van jullie heb geleerd als jullie van mij! 
Het begon meteen goed met ‘de helft van de groepsleden van ABBA’: Ben en Björn 
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en vervolgens vier enthousiaste tweede-jaars: Ellymay, Marie, Dick en Jasper. Jullie 
hebben mij een hoop bijgebracht qua management van mijn eigen kleine 
onderzoeksteam. Valentinos, you were my first master student and I still envy you 
for your dedicated working spirit. Even though you were typically working late to 
cover your study expenses. Every day you were motivated in the lab, willing to learn 
new reactions. And it paid off! Good luck with your PhD in the Homkat group at the 
UvA. Sjaak, over jou zou ik een hele thesis vol kunnen schrijven, die minstens even 
omvangrijk is als deze.. Het was niet alleen een mooie tijd omdat we een hoop 
nieuwe (converteerbare) chemie hebben geleerd, maar ook op het gebied van 
muziek, (nutteloze) weetjes en de Nederlandse taal zijn we een hoop wijzer 
geworden van elkaar. Ik ben ook erg blij dat je mij bijstaat tijdens de verdediging als 
één van mijn paranimfen. Martin, als mijn eerste HLO student had je de lat meteen 
erg hoog gelegd. Daarnaast was je een goede toevoeging aan de groep als actieve 
borrelaar! Zeker ook je eigen ‘tapas’-borrel zal niet snel vergeten worden. Timo, ik 
heb altijd heel erg genoten van alle ochtendjes als jij weer met een nieuw ideetje 
kwam voor een van onze projecten (of zelfs een project van iemand anders). Jouw 
onuitputbare chemische creativiteit heeft het argatroban project een heel eind 
vooruit geholpen. Ik ben ook erg blij dat je deze master stage (na een kleine 
vertraging) toch succesvol hebt afgerond! Jasper B., tijdens één van mijn eerste 
organische chemie practica had ik jou al gescout als een potentiele topstudent (wat 
je gelukkig ook hebt kunnen bewijzen) en dat heeft ertoe geleid dat ik je maar liefst 
aan drie (!) verschillende projecten bij mij hebt gewerkt. Ik ben erg blij om te zien 
dat je nu je eigen PhD plek hebt gevonden op de UvA! Jasper K., jij was een van de 
uitzonderlijke studenten die (bijna) net zo vroeg op het lab aanwezig was als ik. 
Jouw positieve instelling en goede muzieksmaak (top 2000!) waren een welkome 
toevoeging aan labje N364. Kelly K., jij was mijn eerste student in het nieuwe O2 
gebouw. Ook al liep toen nog niet alles op rolletjes, toch is het jou gelukt om in die 
paar maanden een hele belangrijke bijdrage te leveren voor zowel hoofdstuk 5 als 
een deel van hoofdstuk 6! Dionne, in het begin van jouw stage was alles nog erg 
spannend en onwennig, maar ondanks het lastige project kwam daar al snel 
verandering in! Vond het erg leuk dat je er vaak bij was met de borrels en zelfs voor 
een paar sessies Rock ‘n’ Roll. Sandesh, koning der vastzittende stopjes en 
koelkasten. Door jouw enthousiasme, motivatie en gezelligheid vlogen de laatste 
maanden voorbij! Sinds deze maanden heb ik ook spontaan een voorliefde 
gekregen voor kip en vreugdedansjes. 
Ook buiten het lab heb ik het voorrecht gehad om een aantal studenten te mogen 
begeleiden in de vorm van een literatuur stage. Dit is zeker niet het makkelijkste 
onderdeel van de studie, maar toch hebben jullie het allemaal erg netjes afgerond! 
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Marieke, Daan, Micheal, Peter en Kelly A. erg bedankt voor jullie inzet en positieve 
reacties op alle feedback. Ik wil met name Micheal en Peter bedanken voor dit 
onderdeel, aangezien ik veel van jullie werk heb kunnen gebruiken voor het 
schrijven van mijn introductie.   
Naast alle belangrijke chemische reacties is er ook heel veel werk verricht op de 
achtergrond. Elwin, ik wil jou heel erg bedanken voor al het werk wat jij voor onze 
groep doet. Jouw rechtvaardige lab-bewind heeft ervoor gezorgd dat er altijd veilig 
en professioneel gewerkt wordt op het lab. Daarnaast heb ik je ook erg 
gewaardeerd als actief lid van de groep. Onze maandag-ochtend-weekend-
bespreek gesprekken waren altijd het perfecte begin van de week. Zeker als er 
weer een bekende van de groep je dromen onveilig had gemaakt. Ook de rest van 
het ondersteunde personeel, Miep, Roald, Christophe, Hans en Andreas wil ik erg 
bedanken voor hun onmisbare bijdrages.   
Uiteraard wil ik heel graag de hele SyBOrCh groep bedanken! Naar mijn mening is 
dit echt de perfecte groep waar iedereen het goed met elkaar kan vinden en vooral 
ook alles voor elkaar over heeft. Alle gesprekken, discussies en nuttige suggesties 
zijn heel erg belangrijk geweest voor de totstandkoming van dit boekje! Guido, 
Tjøstil, Sanne, Corien, Matthijs, Esther en Jeroen ik wil jullie heel erg bedanken 
voor de talloze suggesties en natuurlijk alle gezelligheid bij de borrels en andere 
gelegenheden.  
Art, vanaf de eerste dag op de VU hebben we samen een kantoor gedeeld en dat 
beviel meteen goed! Mede dankzij jou is mijn ‘lichte’ interesse in bier uitgegroeid 
tot een heuse hobby. Mocht je ooit nog je eigen brouwerij gaan beginnen en je 
zoekt nog personeel, dan weet je me te vinden! Voor nu natuurlijk heel veel succes 
met de laatste loodjes van het boekje, want ik verwacht er uiteraard binnenkort 
eentje op de deurmat.  
Razvan, I was very lucky with you as a direct colleague on the CHEM21 project. You 
were always there to help out and think along if there were some difficult 
chemistry problems. Besides, I enjoyed all our little adventures through Europe for 
the CHEM21 meetings! 
Vero, I loved it how we ruled lab N364 in the old building, as a ship with the perfect 
crew! I will miss our long talks about everything and nothing, which sometimes 
made it hard to put in some reactions in the mornings (worth it!). I wish you all the 
best with finding a new job and of course with Frank and Theo.  
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En dan natuurlijk de 3 J’s, John, Jordy en Jurriën. Op het moment dat de groep 
langzaam een beetje begon leeg te lopen, zeker bij de pauzes en de borrels, 
kwamen jullie in de groep om de boel weer nieuw leven in te blazen. John, IT-
Johnny, Guitar John, (en nog een heel aantal bijnamen die ik hier niet zal 
neerzetten). Al deze namen geven eigenlijk al aan hoeveel je voor deze groep 
betekent. Het is altijd prettig om een collega te hebben waar je altijd bij terecht 
kunt en ik ben daarom ook erg blij dat je mij bijstaat tijdens de verdediging. Erg 
bedankt voor alle leuke tijden buiten en in(between) het lab. We moeten de 
sporadische (speciaal) bier proeverijtjes zeker in stand gaan houden.  
Jordy, jij was de ideale kandidaat voor het overnemen van de ‘borrelpot’. Door 
jouw uitstekende organisatorische kwaliteiten waren de borrels, cadeautjes, uitjes, 
barbecues en natuurlijk het lab altijd een groot succes. Ik verwacht dat jij en de rest 
van ‘team-Jordy’ ervoor gaan zorgen dat je PhD in no-time afkomt. En mocht je er 
behoefte aan hebben ben je natuurlijk altijd welkom in Nijmegen voor een lekker 
broodje slavink tijdens een aflevering van ‘the O.C.’! 
Jurriën, ik weet dat jij erg graag bedankt wilde worden voor het meten van de 
massa samples, dus bij deze: heel erg bedankt voor het meten van alle samples van 
mij en mijn studenten. Als ‘mede-gebruiker’ van ons stukje bureau-eiland heb ik erg 
genoten van jouw onuitputbare chemische creativiteit en vele ideeën die op het 
‘whiteboard’ verschenen. Ben ook erg benieuwd hoe je Vlaamse avontuur in 
Antwerpen gaat bevallen! 
Mark, erg goed om te zien dat je weer bent teruggekeerd naar de VU! Jouw 
onuitputbare bron aan (geregeld foute) humor zijn een welkome toevoeging bij alle 
borrels en (koffie)pauzes. Vond het ook erg leuk om je in deze laatste paar 
maanden in de SyBOrCh groep een stuk beter te leren kennen dan in de jaren 
ervoor. 
Matteo, I am very happy to see that a motivated and enthusiastic person like you 
has joined the group. I am sure you will have a great time at the VU and a very 
successful PhD! 
Giulia, even though we were only colleagues for a short time it was definitely 
noteworthy. Thanks for all the great conversations during lunch about important 
topics like ‘fruit’ (pronounced as ‘froo-it’) and of course for the delicious lasagna!  
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Barry, je was strikt gesproken geen collega, maar je hebt ongeveer net zolang bij de 
groep rondgelopen als ik, dus voelt het wel een beetje zo. Naast alle ongegeneerde 
opmerkingen tijdens de lunch heb ik voornamelijk ook erg genoten van de ‘eerlijke 
en oprechte’ Barry die tevoorschijn kwam tijdens de rookpauzes van de borrels.   
Natuurlijk was er niet alleen de SyBOrCh groep, maar ik wil ook graag iedereen van 
de andere onderzoeksgroepen bedanken waar we mee hebben samengewerkt of 
geborreld. De fosfor groep, de medicinale chemie groep, de analytische chemie 
groep en sinds de verhuizing uiteraard ook de ‘Grossman’-groep (I am still not sure 
what the exact name of your group is...). Tom, Saskia, Sven, Marta, Kerstin, Caro, 
Matthias, Niall and Kisi you were a very welcome addition to our floor, especially 
for all the social events and of course for adopting me as part of your group during 
your group outings. Marta, thanks again for all the (confidence boosting) chats and 
support, which were very valuable to me within and outside my PhD. And Kerstin, 
learning to dance Rock & Roll with you was definitely one of the highlights of my 
PhD! I will miss our lessons (both the regular lessons and the ‘lab’-lessons from 
Imme), but I’m sure we will still go to some dance festivities every now and then. 
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